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ABSTRACT 
Studies in animal models and lupus patients suggest several mechanisms driving the loss of B 
cell regulation in Systemic Lupus Erythematosus (SLE). The first mechanism involves the 
overexpression of B cell activating factor and the second is driven by follicular T helper 
(Tfh) cells. Monocytes have been implicated in the pathogenesis of SLE through recognition 
of immune complexes containing TLR-binding self-antigens. The overall decrease of NK 
cells and increase of CD56briCD16- NK cells could further promote immune dysregulation in 
SLE. Our aim was to determine whether these abnormalities co-exist within each patient, or 
if human SLE can be subcategorised depending on the immune process driving the disease. 
We found that NK cells, CD4+ T cells and Tfh cells were decreased and lymphocytes, 
atypical memory B cells and CD56briCD16- NK cells were increased in SLE. Analysis with 
the complete data set showed no individual signatures of SLE but we could distinguish SLE 
patients from those without SLE based on the variables measured in the study. We developed 
models for predicting if an individual has SLE, if an SLE patient has renal involvement and 
predicting SLE Disease Activity Index, forming the basis for improved diagnosis and 
assessment of SLE in the future. 
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CHAPTER 1:  INTRODUCTION 
1.1  Systemic Lupus Erythematosus 
Systemic lupus erythematosus (SLE) is an antibody-mediated autoimmune disease that 
affects multiple organ systems. Although the exact aetiology of SLE has not yet been 
established, numerous genetic, hormonal and environmental factors have been associated 
with the disease. These factors combine to perpetuate the dysregulation of the immune 
system, manifested as T cell dysfunction, improper B cell activation and increased cytokine 
production. The resulting breakdown of self tolerance leads to the production of antibodies 
against self tissue and deposition of immune complexes, ultimately generating the vast array 
of clinical manifestations of SLE (Kasper and Harrison, 2005, Lahita, 2004).  
 
1.1.1  Clinical Manifestations 
The production of pathogenic autoantibodies results in the damage to multiple organ systems 
in SLE. The more common manifestations of SLE are listed in Table 1.1. Some of the signs 
and symptoms are more specific to SLE, for example, the classic “butterfly” rash, which is a 
photosensitive, slightly raised malar erythema. Other symptoms, such as fatigue, fever, 
arthritis, are common to many autoimmune diseases (Kasper and Harrison, 2005, Mills, 
1994). 
 
A set of criteria was introduced in 1971 by the American Rheumatism Association to 
establish a system for the diagnosis of a disease as heterogeneous as SLE (Cohen, 1971). 
This system consisted of a list of 14 possible manifestations of SLE, and a diagnosis of SLE 
Table 1.1. Common clinical manifestations of SLE. 
 
Organ system Manifestations 
Systemic Fatigue 
 Fever 
 Weight loss 
Musculoskeletal Polyarthritis 
 Myalgia, arthalgia 
Cutaneous Photosensitivity 
 Malar rash 
 Oral ulcers 
 Alopecia 
Renal Nephritis 
 Haematuria, proteinuria 
Neurologic Cognitive dysfunction 
 Mood disorder 
 Headaches 
 Seizures 
Cardiopulmonary Pleuritis, pericarditis, effusions 
 Myocarditis, endocarditis 
Haematologic Anaemia 
 Leukopaenia 
 Lymphopaenia 
Gastrointestinal Nausea, vomiting, diarrhoea 
 Abnormal liver enzymes 
Ocular Sicca syndrome 
 Conjunctivitis 
 
Table adapted from Kasper & Harrison, 2005. 
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was made if a patient had at least four of the manifestations (Table 1.2). The SLE diagnostic 
criteria were revised in 1982 by the American College of Rheumatology (ACR) (Table 1.3) 
(Tan et al., 1982). Most of the criteria introduced in 1971 were included with the exception of 
alopecia and Raynaud’s phenomenon. Additional immunological criteria, such as the 
detection of anti-nuclear antibodies (ANAs) and antibodies against double-stranded DNA 
(dsDNA) and Smith (Sm) autoantigen, were introduced to reflect the advances in laboratory 
technique to measure these autoantibodies. Patients were diagnosed with SLE if they fulfilled 
4 of the 11 criteria on the list. The use of the 1982 revision in the diagnosis of SLE was 
validated by studies in the United States, Japan and Iran (Levin et al., 1984, Passas et al., 
1985, Yokohari and Tsunematsu, 1985, Davatchi et al., 1985). A slight revision was made to 
the 1982 criteria in 1997 by Hochberg (Table 1.4) (Hochberg, 1997). Positive lupus 
erythematosus (LE) cell preparation was removed and replaced with positive finding of 
antiphospholipid antibodies.  
 
The most recent revision of the SLE diagnostic criteria was made and validated in 2012 (Petri 
et al., 2012) and is what is now known as the Systemic Lupus International Collaborating 
Clinics (SLICC) Classification Criteria (Table 1.5). The 2012 revision was necessary because 
the use of the 1997 revised criteria had not been validated and much more is understood 
about SLE, especially the immunological aspects of the disease. Each criterion in the 2012 
revision is much more descriptive and specific, and clinical and immunologic criteria are 
categorised separately. One of the criteria from the 1971 list which was excluded in the 1982 
revision has now been reintroduced in the 2012 list. Low complement and direct Coomb’s 
Table 1.2. “Preliminary Criteria for the Classification of Systemic Lupus Erythematosus” as 
proposed by the American Rheumatism Association in 1971. 
 
1. Facial erythema (butterfly rash) 
2. Discoid lupus erythematosus 
3. Raynaud phenomenon 
4. Alopecia 
5. Photosensitivity 
6. Oral or nasopharyngeal ulceration 
7. Arthritis without deformity 
8. Lupus erythematosus cells 
9. Chronic false-positive serologic test for syphilis 
10. Profuse proteinuria 
11. Cellular casts 
12. Pleuritis or pericarditis 
13. Psychosis or convulsions 
14. Hemolytic anemia or leukopenia or thrombocytopenia 
 
A diagnosis of SLE is made when any four of the items are present. Table adapted from 
Cohen et al., 1971. 
Table 1.3. The 1982 American College of Rheumatology Revised Criteria for the 
Classification of Systemic Lupus Erythematosus. 
 
Criterion Definition 
1. Malar rash Fixed erythema, flat or raised, over the malar eminences, tending to 
spare the nasolabial folds 
2. Discoid rash Erythematous raised patches with adherent keratotic scaling and 
follicular plugging; atrophic scarring may occur in older lesions 
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history 
or physician observation 
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by 
physician 
5. Arthritis Nonerosive arthritis involving 2 or more peripheral joints, 
characterized by tenderness, swelling, or effusion 
6. Serositis a) Pleuritis--convincing history of pleuritic pain or rubbing heard by a 
physician or evidence of pleural effusion 
OR 
b) Pericarditis--documented by ECG or rub or evidence of pericardial 
effusion 
7. Renal disorder a) Persistent proteinuria greater than 0.5 grams per day or grater than 
3+ if quantitation not performed 
OR 
b) Cellular casts--may be red cell, hemoglobin, granular, tubular, or 
mixed 
8. Neurologic 
disorder 
a) Seizures--in the absence of offending drugs or known metabolic 
derangements; e.g., uremia, ketoacidosis, or electrolyte imbalance 
OR 
b) Psychosis--in the absence of offending drugs or known metabolic 
derangements, e.g., uremia, ketoacidosis, or electrolyte imbalance 
9. Hematologic 
disorder 
a) Hemolytic anemia--with reticulocytosis 
OR 
b) Leukopenia--less than 4,000/mm3 total on 2 or more occasions 
OR 
c) Lyphopenia--less than 1,500/mm3 on 2 or more occasions 
OR 
d) Thrombocytopenia--less than 100,000/mm3 in the absence of 
offending drugs 
10. Immunologic 
disorder 
a) Positive LE cell preparation 
OR 
b) Anti-DNA: antibody to native DNA in abnormal titer 
OR 
c) Anti-Sm: presence of antibody to Sm nuclear antigen 
OR 
d) False positive serologic test for syphilis known to be positive for at 
least 6 months and confirmed by Treponema pallidum immobilization 
Criterion Definition 
or fluorescent treponemal antibody absorption test 
11. Antinuclear 
antibody 
An abnormal titer of antinuclear antibody by immunofluorescence or 
an equivalent assay at any point in time and in the absence of drugs 
known to be associated with "drug-induced lupus" syndrome 
 
 
The proposed classification is based on 11 criteria. For the purpose of identifying patients in 
clinical studies, a person shall be said to have systemic lupus erythematosus if any 4 or more 
of the 11 criteria are present, serially or simultaneously, during any interval of observation. 
 
ECG – electrocardiogram; LE – lupus erythematosus; Sm – Smith antigen. Table adapted 
from Tan et al., 1982. 
Table 1.4. 1997 update of the 1982 American College of Rheumatology Revised Criteria for 
Classification of Systemic Lupus Erythematosus. 
 
Criterion Definition 
1. Malar rash Fixed erythema, flat or raised, over the malar eminences, tending to 
spare the nasolabial folds 
2. Discoid rash Erythematous raised patches with adherent keratotic scaling and 
follicular plugging; atrophic scarring may occur in older lesions 
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history 
or physician observation 
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by 
physician 
5. Nonerosive 
arthritis 
Involving 2 or more peripheral joints, characterized by tenderness, 
swelling, or effusion 
6. Pleuritis or 
pericarditis 
a) Pleuritis--convincing history of pleuritic pain or rubbing heard by a 
physician or evidence of pleural effusion 
OR 
b) Pericarditis--documented by ECG or rub or evidence of pericardial 
effusion 
7. Renal disorder a) Persistent proteinuria > 0.5 grams per day or > 3+ if quantitation 
not performed 
OR 
b) Cellular casts--may be red cell, hemoglobin, granular, tubular, or 
mixed 
8. Neurologic 
disorder 
a) Seizures--in the absence of offending drugs or known metabolic 
derangements; e.g., uremia, ketoacidosis, or electrolyte imbalance 
OR 
b) Psychosis--in the absence of offending drugs or known metabolic 
derangements, e.g., uremia, ketoacidosis, or electrolyte imbalance 
9. Hematologic 
disorder 
1. Hemolytic anemia--with reticulocytosis 
OR 
2. Leukopenia--< 4,000/mm3 on ≥ 2 occasions 
OR 
3. Lyphopenia--< 1,500/ mm3 on ≥ 2 occasions 
OR 
4. Thrombocytopenia--<100,000/ mm3 in the absence of offending 
drugs 
10. Immunologic 
disorder 
1. Anti-DNA: antibody to native DNA in abnormal titer 
OR 
2. Anti-Sm: presence of antibody to Sm nuclear antigen 
OR 
3. Positive finding of antiphospholipid antibodies on:  
1. an abnormal serum level of IgG or IgM anticardiolipin 
antibodies,  
2. a positive test result for lupus anticoagulant using a 
Criterion Definition 
standard method, or  
3. a false-positive test result for at least 6 months confirmed 
by Treponema pallidum immobilization or fluorescent 
treponemal antibody absorption test  
11. Positive 
antinuclear 
antibody 
An abnormal titer of antinuclear antibody by immunofluorescence or 
an equivalent assay at any point in time and in the absence of drugs 
 
The proposed classification is based on 11 criteria. For the purpose of identifying patients in 
clinical studies, a person shall be said to have systemic lupus erythematosus if any 4 or more 
of the 11 criteria are present, serially or simultaneously, during any interval of observation. 
 
ECG – electrocardiogram; Sm – Smith antigen. Table adapted from American College of 
Rheumatology. 
Table 1.5. Clinical and Immunologic Criteria Used in the SLICC Classification Criteria. 
 
Clinical criteria 
1. Acute cutaneous lupus 
including lupus malar rash (do not count if malar discoid) 
bullous lupus 
toxic epidermal necrolysis variant of SLE 
maculopapular lupus rash 
photosensitive lupus rash 
in the absence of dermatomyositis 
OR subacute cutaneous lupus  
(nonindurated psoriaform and/or annular polycyclic lesions that resolve 
without scarring, although occasionally with postinflammatory 
dyspigmentation or telangiectasias) 
 
2. Chronic cutaneous lupus 
including classic discoid rash 
localized (above the neck) 
generalized (above and below the neck) 
hypertrophic (verrucous) lupus 
lupus panniculitis (profundus) 
mucosal lupus 
lupus erythematosus tumidus 
chillblains lupus 
discoid lupus/lichen planus overlap 
 
3. Oral ulcers:  
palate 
buccal 
tongue 
OR nasal ulcers 
in the absence of other causes, such as vasculitis, Behçet's disease, 
infection (herpes), inflammatory bowel disease, reactive arthritis, and acidic 
foods 
 
4. Nonscarring alopecia (diffuse thinning or hair fragility with visible broken hairs) 
in the absence of other causes such as alopecia areata, drugs, iron deficiency, and 
androgenic alopecia 
 
5. Synovitis involving 2 or more joints, characterized by swelling or effusion OR tenderness in 
2 or more joints and at least 30 minutes of morning stiffness 
 
6. Serositis 
typical pleurisy for more than 1 day 
OR pleural effusions 
OR pleural rub 
typical pericardial pain (pain with recumbency improved by sitting forward) for more 
than 1 day 
OR pericardial effusion 
OR pericardial rub 
OR pericarditis by electrocardiography 
in the absence of other causes, such as infection, uremia, and 
Dressler's pericarditis 
 
7. Renal 
urine protein/creatinine ratio (or 24-hour urine protein) representing 500 mg 
protein/24 hours 
OR red blood cell casts 
 
8. Neurologic 
seizures 
psychosis 
mononeuritis multiplex 
in the absence of other known causes such as primary vasculitis 
myelitis 
peripheral or cranial neuropathy 
in the absence of other known causes such as primary vasculitis, infection, 
and diabetes mellitus 
acute confusional state 
in the absence of other causes, including toxic/metabolic, uremia, drugs 
 
9. Hemolytic anemia 
 
10. Leukopenia (<4,000/mm3 at least once) 
in the absence of other known causes such as Felty's syndrome, drugs, and 
portal hypertension 
OR 
Lymphopenia (<1,000/mm3 at least once) 
in the absence of other known causes such as corticosteroids, drugs, and 
infection 
 11. Thrombocytopenia (<100,000/mm3) at least once 
in the absence of other known causes such as drugs, portal hypertension, and 
thrombotic thrombocytopenic purpura 
 
Immunologic criteria 
1. ANA level above laboratory reference range 
 
2. Anti-dsDNA antibody level above laboratory reference range (or >2-fold the reference 
range if tested by ELISA) 
 
3. Anti-Sm: presence of antibody to Sm nuclear antigen 
 
4. Antiphospholipid antibody positivity: any of the following 
lupus anticoagulant 
false-positive test result for RPR 
medium or high titer anticardiolipin antibody level (IgA, IgG, or IgM) 
anti–β2-glycoprotein I (IgA, IgG, or IgM) 
 
5. Low complement 
low C3 
low C4 
low CH50 
 
6. Direct Coombs' test in the absence of hemolytic anemia 
 
The criteria do not need to be present concurrently. The proposed classification rule is as 
follows: classify a patient as having SLE if he or she satisfies 4 of the clinical and 
immunologic criteria used in the SLICC classification criteria, including at least one clinical 
criterion and one immunologic criterion, OR if he or she has biopsy-proven nephritis 
compatible with SLE in the presence of ANAs or anti-dsDNA antibodies. 
 
ANA – anti-nuclear antibody; CH50 – 50% haemolytic complement; dsDNA – double-
stranded DNA; RPR – rapid plasma reagin; SLICC – Systemic Lupus International 
Collaborating Clinics; Sm – Smith antigen. Table adapted from Petri et al., 2012. 
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test have been added to the immunologic criteria. Patients were diagnosed with SLE if they 
fulfilled a minimum of four of the criteria on the 2012 list, but of the four criteria at least one 
needed to be clinical and one immunologic. Additionally, a patient could be diagnosed with 
SLE without using the SLICC Classification Criteria by biopsy-proven nephritis compatible 
with SLE and either ANA or anti-dsDNA antibody positivity (Petri et al., 2012). 
 
Clinical presentations and severity of SLE vary between patients and within the same patient 
over the course of the disease. The SLICC/ACR Damage Index (Table 1.6) was developed in 
1996 and assesses the long-term, irreversible damage to different organ systems since the 
onset of SLE (Gladman et al., 1996). A number of different measures have been developed 
for the assessment of disease activity. These measures include SLE Disease Activity Index 
(SLEDAI) (Bombardier et al., 1992) and SLEDAI Safety of Estrogen in Lupus 
Erythematosus National Assessment (SELENA) modification (Figure 1.1) (American 
College of Rheumatology, 1997), British Isles Lupus Assessment Group (BILAG) index 
2004 (Figure 1.2) (Isenberg et al., 2005), SLE Activity Measure (SLAM) (Figure 1.3) (Liang 
et al., 1989) and European Consensus Lupus Activity Measurement (ECLAM) (Table 1.7) 
(Mosca et al., 2000). Each of the methods used for the measurement of disease activity 
involves assessing the clinical and immunological manifestations at the time of or 2 to 4 
weeks prior to the patient’s visit to the clinic. The methods differ in the manifestations 
included in the assessment, for example, SLAM and ECLAM take into account 
gastrointestinal manifestations while the other methods do not, and SELENA-SLEDAI and 
SLAM also include the physician’s global assessment (PGA) of disease activity. The 
Table 1.6. SLICC/ACR Damage Index for SLE. 
 
Item Score 
Ocular (either eye, by clinical assessment)  
Any cataract ever 1 
Retinal change or optic atrophy 1 
Neuropsychiatric  
Cognitive impairment (e.g., memory deficit, difficulty with calculation, poor 
concentration, difficulty in spoken or written language, impaired 
performance level) or major psychosis 
 
Seizures requiring therapy for 6 months 1 
Cerebrovascular accident ever (score 2 if >1) 1 (2) 
Cranial or peripheral neuropathy (excluding optic) 1 
Transverse myelitis 1 
Renal  
Estimated or measured glomerular filtration rate <50% 1 
Proteinuria greater or equal to 3.5 gm/24 hours 1 
Or End-stage renal disease (regardless of dialysis or transplantation) 3 
Pulmonary  
Pulmonary hypertension (right ventricular prominence, or loud P2) 1 
Pulmonary fibrosis (physical and radiograph) 1 
Shrinking lung (radiograph) 1 
Pleural fibrosis (radiograph) 1 
Pulmonary infarction (radiograph) 1 
Cardiovascular  
Angina or coronary artery bypass 1 
Myocardial infarction ever (score 2 if >1) 1 (2) 
Cardiomyopathy (ventricular dysfunction) 1 
Valvular disease (diastolic, murmur, or systolic murmur >3/6) 1 
Pericarditis for 6 months, or pericardiectomy 1 
Peripheral vascular  
Claudication for 6 months 1 
Minor tissue loss (pulp space) 1 
Significant tissue loss ever (e.g., loss of digit or limb) (score 2 if >1 site) 1 (2) 
Venous thrombosis with swelling, ulceration, or venous stasis 1 
Gastrointestinal  
Infarction or resection of bowel below duodenum, spleen, liver, or gall 
bladder ever, for cause any (score 2 if >1 site) 
1 (2) 
Mesenteric insufficiency 1 
Chronic peritonitis 1 
Stricture or upper gastrointestinal tract surgery ever 1 
Musculoskeletal  
Muscle atrophy or weakness 1 
Deforming or erosive arthritis (including reducible deformities, excluding 
avascular necrosis) 
1 
Osteoporosis with fracture or vertebral collapse (excluding avascular 
necrosis) 
1 
Avascular necrosis (score 2 if >1) 1 (2) 
Osteomyelitis 1 
Skin  
Scarring chronic alopecia 1 
Extensive scarring or panniculum other than scalp and pulp space 1 
Skin ulceration (excluding thrombosis) for >6 months 1 
Premature gonadal failure 1 
Diabetes (regardless of treatment) 1 
Malignancy (exclude dysplasia) (score 2 if >1 site) 1 (2) 
 
Damage (nonreversible change, not related to active inflammation) occurring since onset of 
lupus, ascertained by clinical assessment and present for at least 6 months unless otherwise 
stated. Repeat episodes must occur at least 6 months apart to score 2. The same lesion 
cannot be scored twice. 
 
ACR – American College of Rheumatology; SLE – systemic lupus erythematosus; SLICC – 
Systemic Lupus International Collaborating Clinics. Table adapted from Gladman et al., 1996. 
 
 
 
 
 
Figure 1.1. Systemic Lupus Erythematosus Disease Activity Index Safety of Estrogen in 
Lupus Erythematosus National Assessment modification (SELENA-SLEDAI) (American 
College of Rheumatology, 1997). CH50 - 50% haemolytic complement; CVA – 
cerevrovascular accident; Hb – haemoglobin; NSAID – non-steroidal anti-inflammatory drug; 
PGA – physicians global assessment. 
 
 
Figure 1.2. British Isles Lupus Assessment Group (BILAG) index 2004 revision (Isenberg et 
al., 2005). GFR – glomerular filtration rate; IC – intracranial. 
  Date of Assessment:                              Date of Birth:                              Name/ID: 
Revision: 12/Apr/2004 
 
 
 
 
 Scoring for features:   1    Improving 
       2    Same 
       3    Worse 
       4    New 
       Yes/No   (where indicated) 
        value      (where indicated) 
          indicat e if f eature not due to lupus 
    (default is 0 = not present) 
CONSTITUTIONAL 
1. Pyrexia (documented)   ( ) 
2. Weight loss - unintentional > 5%  ( ) 
3. Lymphadenopathy/splenomegaly  ( ) 
4. Fatigue/malaise/lethargy   ( ) 
5. Anorexia    ( ) 
 
MUCOCUTANEOUS 
6. Skin eruption - severe   ( ) 
7. Skin eruption - mild   ( ) 
8. Angio-oedema    ( ) 
9. Mucosal ulceration - severe  ( ) 
10. Mucosal ulceration - mild   ( ) 
11. Panniculitis - severe   ( ) 
12. Panniculitis - mild   ( ) 
13. Cutaneous vasculitis/thrombosis  ( ) 
14. Digital infarcts/nodular vasculitis  ( ) 
15. Alopecia - severe   ( ) 
16. Alopecia - mild    ( ) 
17. Peri-ungual erythema/chilblains  ( ) 
18. Splinter haemorrhages   ( ) 
 
NEUROPSYCHIATRIC 
19. Aseptic meningitis   ( ) 
20. Cerebral vasculitis   ( ) 
21. Demyelinating syndrome   ( ) 
22. Myelopathy    ( ) 
23. Acute confusional state   ( ) 
24. Psychosis    ( ) 
25. Acute inflammatory demyelinating  ( ) 
       polyradiculoneuropathy 
26. Mononeuropathy (single/multiplex)  ( ) 
27. Cranial neuropathy   ( ) 
28. Plexopathy    ( ) 
29. Polyneuropathy    ( ) 
30. Seizure disorder   ( ) 
31. Status epilepticus   ( ) 
32. Cerebrovascular disease (not due to vasculitis)( )  
33. Cognitive dysfunction   ( ) 
34. Movement disorder   ( ) 
35. Autonomic disorder   ( ) 
36. Cerebellar ataxia   ( ) 
37. Headache, severe, unremitting   ( ) 
38. Migraine with/without aura  ( ) 
39. Tension headache   ( ) 
40. Cluster headache   ( ) 
41. Headache from IC hypertension  ( ) 
42. Mood disorder (depression/mania)  ( ) 
43. Anxiety disorder   ( ) 
 
MUSCULOSKELETAL 
44. Definite myositis (Bohan & Peter)  ( ) 
45. Myositis with incomplete criteria  ( ) 
46. Severe polyarthritis   ( ) 
47. Arthritis/Tendonitis   ( ) 
48. Arthralgia/Myalgia   ( ) 
 
 
 
 
 
BILAG2004 INDEX ASSESSMENT 
Only features attributable to SLE are to be recorded and refer to the last 4 weeks compared with the 
previous 4 weeks. 
CARDIORESPIRATORY 
49. Myocarditis - mild   ( ) 
50. Cardiac failure    ( ) 
51. Arrhythmia     ( ) 
52. New valvular dysfunction   ( ) 
53. Serositis (pleuro-pericardial pain) - mild ( ) 
54. Cardiac tamponade   ( ) 
55. Pleural effusion with dyspnoea  ( ) 
56. Pulmonary haemorrhage/vasculitis  ( ) 
57. Interstitial alveolitis/pneumonitis  ( ) 
58. Shrinking lung syndrome   ( ) 
59. Aortitis    ( ) 
60. Coronary vasculitis   ( ) 
 
GASTROINTESTINAL 
61. Peritonitis    ( ) 
62. Abdominal serositis or ascites  ( ) 
63. Lupus enteritis/colitis   ( ) 
64. Malabsorption    ( ) 
65. Protein losing enteropathy  ( ) 
66. Intestinal pseudo-obstruction  ( ) 
67. Hepatitis    ( ) 
68. Acute cholecystitis   ( ) 
69. Acute pancreatitis   ( ) 
 
OPHTHALMIC 
70. Orbital inflammation with myositis and/or ( ) 
      extra ocular muscle swelling and/or proptosis 
71. Keratitis - severe   ( ) 
72. Keratitis - mild    ( ) 
73. Anterior uveitis    ( ) 
74. Posterior uveitis/retinal vasculitis - severe ( ) 
75. Posterior uveitis/retinal vasculitis - mild ( ) 
76. Episcleritis    ( ) 
77. Scleritis - severe   ( ) 
78. Scleritis - mild    ( ) 
79. Retinal/choroidal vaso-occlusive disease ( ) 
80. Isolated cotton-wool spots (cytoid bodies) ( ) 
81. Optic neuritis    ( ) 
82. Anterior ischaemic optic neuropathy ( ) 
 
RENAL  
83. Systolic blood pressure (mm Hg)   value ( )   
84. Diastolic blood pressure (mm Hg)   value ( )   
85. Accelerated hypertension                   Yes/No ( )   
86. Urine dipstick          (-=0,+=1, ++=2, +++=3) ( )   
87. Urine albumin-creatinine ratio         mg/mmol ( )   
88. Urine protein-creatinine ratio           mg/mmol ( )   
89. 24 hour urine protein (g)    value ( )   
90. Nephrotic syndrome     Yes/No ( )   
91. Creatinine (plasma/serum)   Pmol/l ( )   
92. GFR (calculated)                                 ml/min  ( )   
93. Active urinary sediment                     Yes/No ( )   
94. Histological evidence of active nephritis ( )   
       (within 3 months) (Yes/No) 
 
HAEMATOLOGY 
95. Haemoglobin (g/dl)    value ( )   
96. Total white cell count (x 109/l)   value ( )   
97. Neutrophils (x 109/l)    value ( )   
98. Lymphocytes (x 109/l)    value ( )   
99. Platelets (x 109/l)    value ( )   
100. Evidence of active haemolysis         Yes/No ( ) 
101. Coombs’ test positive (isolated)   Yes/No ( ) 
Weight (kg):  Serum urea (mmol/l): 
Black (Yes/No):  Serum albumin (g/dl): 
 
 
 
 
 
 
Figure 1.3. Systemic Lupus Activity Measure (SLAM) (Liang et al., 1989). 24° - 24 hours; Δ – 
change; CrCl – creatinine clearance; diast. – diastolic blood pressure; EKG – 
electrocardiogram; ESR – erythrocyte sedimentation rate; hpf – high power field; RBC – red 
blood cells; SLE – systemic lupus erythematosus; sx – symptoms; T – thousand; WBC – 
white blood cells. 
Table 1.7. European Consensus Lupus Activity Measurement (ECLAM). 
 
1. Generalised manifestations Any of the following: 0.5 
Fever Documented basal morning temperature of 37.5°C 
not due to an infective process. 
 
Fatigue A subjective feeling of extraordinary tiredness.  
2. Articular manifestations Any of the following: 1 
Arthritis Non-erosive arthritis involving at least 2 peripheral 
joints (wrist, metacarpophalangeal or proximal, 
interphalangeal joints). 
 
Evolving arthralgia New onset or worsening of specific localized pain 
without objective symptoms in at least two 
peripheral joints. 
 
3a. Active muco-cutaneous 
manifestations 
Any of the following: 0.5 
Malar rash Fixed erythema, flat or raised over the malar 
eminences, and tending to spare the naso-labial 
folds. 
 
Generalised rash A maculo-papular rash not induced by drugs, that 
may be located anywhere on the body, and that is 
not strictly dependent on sun exposure. 
 
Discoid rash Erythematosus, raised patches with adherent 
keratotic sealing and follicular plugging. 
 
Skin vasculitis Including digital ulcers, purpura, urticaria, bullous 
lesions. 
 
Oral ulcers Oral or naso-pharyngeal ulcers, usually painless, 
observed by a physician. 
 
3b. Evolving muco-cutaneous 
manifestations 
If any of the above muco-cutaneous manifestations 
are new or have worsened since the last 
observation, add 1 point. 
1 
4. Myositis* Confirmed by raised muscle enzymes and/or EMG 
examination and or histology. 
2 
5. Pericarditis Documented by ECG or rub or evidence of 
pericardial effusion on ultrasound. 
1 
6. Intestinal manifestations Any of the following: 2 
Intestinal vasculitis Evidence of acute intestinal vasculitis  
Sterile peritonitis Evidence of abdominal effusion in the absence of 
infective processes. 
 
7. Pulmonary manifestations Any of the following: 1 
Pleurisy Clinical or radiological evidence of pleural effusion  
in the absence of infective processes. 
Pneumonitis Single or multiple lung opacities on chest X-ray 
thought to reflect active disease not due to an 
infective process. 
 
Ingravescent dyspnoea Due to an evolving interstitial involvement.  
8. Evolving neuropsychiatric 
manifestations* 
New appearance or worsening of any of the 
following: 
2 
Headache/migraine Recently developed, persistent or recurrent. Poorly 
responsive to the most commonly used drugs, but 
partially or totally responsive to corticosteroids. 
 
Seizures Grand mal or petit mal seizures, Jacksonian fits, 
temporal lobe seizures, or choreic syndrome, in the 
absence of offending drugs or known metabolic 
derangements (eg uremia, ketoacidosis or 
electrolyte imbalance). 
 
Stroke Cerebral infarction or haemorrhage, instrumentally 
confirmed. 
 
Organic brain disease Impairment of memory, orientation, perception, and 
ability to calculate. 
 
Psychosis Dissociative features in the absence of offending 
drugs or known metabolic derangements, eg 
uremia, ketoacidosis or electrolyte imbalance. 
 
9a. Renal manifestations* # Any of the following: 0.5 
Proteinuria At least 500mg/d  
Urinary casts Red cells, haemoglobin, granular, tubular or mixed 
casts. 
 
Haematuria Microscopic or macroscopic.  
Raised serum creatinine 
or reduced creatinine 
clearance 
  
9b. Evolving renal manifestations If any of the above renal manifestations are new or 
have worsened since the last 2 observations, add 2 
points. 
 
10. Haematologic features Any of the following: 1 
Non-haemolytic anaemia A Coombs-negative normocytic hypochromic or 
normochromic anaemia without reticulocytosis. 
 
Haemolytic anaemia A Coombs-positive haemolytic anaemia, with 
reticulocytosis and elevated LDH, in the absence of 
offending drugs. 
 
Leukopenia (or Less than 3500mm3 WBC (or 1500mm3  
lymphopenia) lymphocytes) in the absence of offending drugs. 
Thrombocytopenia Less than 100,000mm3 in the absence of offending 
drugs. 
 
11. Erythrocyte sedimentation 
rate 
 1 
Raised ESR Above 25mm/h by Westergren or compatable 
methods, not due to other concomitant pathological 
process. 
 
12a. Hypocomplementaemia Reduced plasma level or any of the following: 1 
C3 By radial immunodiffusion or laser nephelometer.  
CH50 By standardised haemolytic methods.  
12b. Evolving 
hypocomplementaemia 
Significantly reduced level of any of the items 
mentioned above (plus C4) with respect to the last 
observation. 
1 
FINAL SCORE^   
 
* If this system (or manifestation) is the only involvement present from among items 1-10, add 
2 more points. 
# Excluding patients with end-stage chronic renal disease. 
^ If the final total score is not an integer number, round off to the lower integer for values <6 
and to the higher integer for values >6. If the final total score is >10, round off to 10. 
 
CH50 – 50% haemolytic complement; ECG – electrocardiogram; EMG – electromyography; 
LDH – lactate dehydrogenase; WBC – white blood cell. Table adapted from Mosca et al., 
2000. 
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different measures of disease activity allow the severity and progression of SLE to be 
conducted in a quantifiable manner. 
 
1.1.2  Epidemiology of SLE 
The majority of epidemiological studies on SLE were conducted in North America and 
Europe. Globally, the highest incidence rates of SLE were in women greater than 40 years of 
age (Stahl-Hallengren et al., 2000, Somers et al., 2007, Gudmundsson and Steinsson, 1990), 
however, studies in the US have reported that the group with the greatest risk of developing 
SLE was African American women of reproductive age (Hochberg, 1985, McCarty et al., 
1995). Indeed, most studies in the world have found that SLE was more frequent and severe 
in ethnic minority populations, but poorer disease prognosis was more likely due to poorer 
socioeconomic status of these populations than their ethnicity (Samanta et al., 1991, Pons-
Estel et al., 2004, Ward and Studenski, 1990, Bastian et al., 2002, Alarcon et al., 1998, 
Alarcon et al., 2002, Alarcon et al., 1999, Alarcon et al., 2006). 
 
Most of the epidemiological studies conducted in Australia explored the differences in 
prevalence and disease manifestations among populations in remote regions. SLE was more 
prevalent among Aboriginal populations than in Caucasians (Anstey et al., 1993, 
Bossingham, 2003, Segasothy and Phillips, 2001), in line with other studies around the 
world. The disease was also more severe in Aboriginal populations (Anstey et al., 1993, 
Bossingham, 2003). Anstey et al. (Anstey et al., 1993) reported higher rates of renal disease 
and mortality in among an Aboriginal population in the top end of the Northern Territory, but 
the study conducted by Bossingham (Bossingham, 2003) found that disease manifestations 
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were similar between indigenous and non-indigenous populations in far north Queensland. In 
contrast, rates of renal disease and mortality were found to be low in both Aboriginal and 
Caucasian populations in central Australia (Segasothy and Phillips, 2001). More recently, an 
observational study conducted in an urban setting in Melbourne reported that SLE patients of 
Asian ethnicity had more severe disease, with higher SLEDAI scores, and were more likely 
to present with renal disease and autoantibody positivity to dsDNA, Sm, ribonucleoprotein 
(RNP), Ro and La (Golder et al., 2013). 
 
1.1.3  Genetic Factors 
The influence of genetics on SLE was first suggested by studies examining the risk of 
developing the disease amongst family members of SLE patients. Concordance of SLE is 
higher in monozygotic twins (24%) than dizygotic twins (2%) (Deapen et al., 1992). A strong 
familial clustering (λs = >15) reflects an increased risk of developing SLE in siblings and 
first degree relatives of patients (Wakeland et al., 2001). Although a single susceptibility 
gene may be sufficient for SLE in approximately 5% of patients (Mok and Lau, 2003), the 
majority of patients require at least four genes for the development of the disease (Schur, 
1995). Most of the susceptibility genes implicated in SLE contribute to deficiencies and 
dysregulation of mechanisms of the immune system, resulting in the clinical manifestations 
of SLE. A summary of these genes is listed in Table 1.8. 
 
Human leukocyte antigen (HLA) genes are the most studied of the SLE susceptibility genes. 
Although different HLA genes are associated with SLE in different ethnic groups, HLA-DR2 
and -DR3 are most strongly associated with an increased risk of developing SLE, regardless 
Table 1.8. Susceptibility genes implicated in SLE. 
 
 Genes Comments 
HLA genes DR2, DR3 Relative risk of developing SLE = 2-5 
 DR2, DR3, DR7, DQw1, DQw2, DQA1, DQB1, B8 Presence of anti-Ro antibody 
 DR3, DR8, DRw12 Presence of anti-La antibody 
 DR2, DR3, DR7, DQB1 Presence of anti-DNA antibody 
 DR2, DR4, DQw5, DQw8, DQA1, DQB1 Presence of anti-U1 ribonuclear protein 
 DR2, DR4, DR7, DQw6, B61 Presence of anti-Sm antibody 
 DR4, DR7, DQ6, DQ7, DQw7, DQw8, DQw9 Presence of anticardiolipin antibody or lupus coagulant 
 C2, C4, C1q Complement genes 
Non-HLA genes Mannose binding lectin polymorphisms  
 TNF-α  
 T cell receptor  
 IL-6  
 CR1  
 Ig Gm and Km  
 FcγRIIA IgG Fc receptor 
 FcγRIIIA IgG Fc receptor 
 Poly-ADP ribose polymerase  
 HSP-70  
 Humhr 3005  
 
ADP – adenosine diphosphate; CR1 – complement receptor 1; HLA – human leukocyte antigen; HSP-70 – heat shock protein 70; Ig – immunoglobulin; IL-6 – 
interleukin-6; Sm – Smith antigen; TNF-α - tumour necrosis factor α. Table adapted from Mok & Lau, 2003. 
Chapter 1: Introduction  6 
 
of ethnicity (Mok and Lau, 2003). Some HLA class II genes are also associated more 
generally with the presence of autoantibodies, some of which are specific to SLE (see Table 
1.8) (Schur, 1995). However, there are also HLA genes associated with a decreased 
susceptibility for SLE, such as HLA-B40 in an Australian population (Whittingham et al., 
1983) and DR4 in a Japanese population (Kameda et al., 1982). 
 
Deficiencies in complement components, some of which are encoded by HLA class III genes, 
have also been associated with increased risk of SLE, as the complement system plays an 
important role in opsonization and immune complex clearance (Kelly et al., 2002, Mok and 
Lau, 2003). Onset of SLE at an early age, renal disease and the presence of anti-Ro 
autoantibodies are seen in patients with C4 deficiency (Kelly et al., 2002). SLE patients 
deficient in C2 are more likely to present with cutaneous manifestations, photosensitivity and 
anti-Ro autoantibodies, but milder pleuropericardial, neurologic or renal symptoms (Lipsker 
et al., 2000, Provost et al., 1983). Patients with C1q deficiency develop particularly severe 
SLE, often with central nervous system or renal involvement, and also have the highest risk 
of developing the disease (Bowness et al., 1994). 
 
Furthermore, non-HLA genes have also been implicated in the development of SLE, 
including those that encode for mannose binding lectin, interleukin (IL)-10 and Fcγ receptors 
(see Table 1.8) (Kelly et al., 2002). These indicate the importance of the regulation of the 
adaptive immune system. 
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1.1.4  Hormonal Factors 
Hormones were thought to be an important influence on the development of SLE as the 
disease has a female preponderance and patients rarely present with the disease before 
puberty or after menopause. A study of 1,000 patients with SLE from 12 study centres in 
Europe in 1980-1990 found that 86% of patients were diagnosed between 14 to 50 years of 
age, with a female to male ratio of 10:1, which steadily declined with age to a ratio of 5:1 for 
patients diagnosed after 50 years of age, and the ratio was also lower at 7:1 in patients 
diagnosed before 14 years of age (Cervera et al., 1993). Similar numbers were reported in 
studies of SLE patients in the USA (Masi and Kaslow, 1978). A number of hormones have 
been implicated in SLE, of which oestrogen and its effects on the immune system have been 
the best characterized.  
 
In vitro studies have shown that oestrogen was able to induce B cell differentiation (Sthoeger 
et al., 1988) and decrease apoptosis of peripheral blood mononuclear cells (PBMCs), and 
also lower production of tumour necrosis factor (TNF) of PBMCs from lupus patients (Evans 
et al., 1997). Oestrogen inhibited the production of interleukin (IL)-2 and therefore T cell 
proliferation (McMurray et al., 2001), but promoted the expression of CD40 ligand (CD40L) 
on T cells in SLE patients (Rider et al., 2001), skewing towards a T helper type 2 (Th2) 
response. The production of Th2 cytokines was thought to result in B cell hyperactivity and 
increased autoantibody production, including anti-dsDNA antibodies (Kanda and Tamaki, 
1999, Kanda et al., 1999). 
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1.1.5  Environmental Factors 
In addition to predisposing genetic and hormonal factors, it has been suggested that a range 
of environmental factors may be required for the onset of disease in SLE patients. A list of 
possible environmental factors that may influence the development of SLE is listed in Table 
1.9. However, evidence for the involvement of these factors in SLE has yet to be consistently 
demonstrated, with the exception of exposure to ultraviolet (UV) light. UVB light in 
particular has various effects on the skin, including triggering the apoptosis of keratinocytes 
(Casciola-Rosen et al., 1994), which is consistent with photosensitivity being one of the 
criteria in the diagnosis of SLE. In vitro and in vivo studies have demonstrated an increased 
binding of antibody to autoantigens such as Ro, La, RNP and Sm (see 1.2.6 Autoantibodies 
in SLE) on the surface of keratinocytes irradiated with UVB light (LeFeber et al., 1984, 
Golan et al., 1992, Furukawa et al., 1990). 
 
Infection with Epstein-Barr Virus (EBV) was also suggested to be a predisposing factor for 
the development of SLE. Studies of sera from paediatric and adult-onset SLE patients found 
that almost all patients have had previous exposure to EBV (James et al., 2001, McClain et 
al., 2006). There have been reports of cross-reactivity between Epstein-Barr virus Nuclear 
Antigen 1 (EBNA-1) and several lupus autoantigens. An epitope in the middle of the EBNA-
1 protein was found to temporarily cross-react with the Sm autoantigen (McClain et al., 
2003). The first epitope of Ro could cross-react with EBNA-1, and mice treated with either 
the first Ro epitope or EBNA-1 developed a lupus-like illness with autoantibody production, 
leukopenia, thrombocytopenia and renal involvement (McClain et al., 2005).  
 
Table 1.9. Environmental factors which may influence SLE. 
 
 Factors 
Chemical/physical factors Aromatic amines 
 Hydrazines 
 Drugs – procainamide, hydralozine, chlorpromazine, isoniazid, phenytoin, penicillamine 
 Tobacco smoke 
 Hair dyes 
 Ultraviolet light 
Dietary factors L-canavanine (alfalfa sprouts) 
 High intake of saturated fats 
Infectious agents Bacterial DNA and endotoxins 
 Retroviruses 
Hormones and environmental oestrogens Hormonal replacement therapy 
 Oral contraceptive pills 
 Pre-natal exposure to oestrogens 
 
Table adapted from Mok & Lau, 2003. 
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1.2  The Role of B Cells in SLE 
1.2.1  B Cell Development and Maturation 
B cells are developed in the bone marrow from haemopoietic stem cells. The earliest cell 
type committed to the B cell lineage is the pro-B cell (Defrance et al., 2002). Pro-B cells 
express CD19, a cell surface glycoprotein of the immunoglobulin superfamily that is 
expressed only on B cells throughout their development (Haas and Tedder, 2005). 
Immunoglobulin genes of pro-B cells are in a germline configuration. As the pro-B cell 
develops into a pre-B cell, immunoglobulin heavy chain genes undergo somatic 
recombination and results in a µ heavy chain, which together with the invariable surrogate 
light chains λ5 and Vpre-B9 forms the pre-B B-cell receptor (BCR) on the surface of the pre-
B cell (Karasuyama et al., 1993, Karasuyama et al., 1990). Upon receiving signals for the 
proliferation and maturation of the pre-B cell through the pre-B BCR, immunoglobulin light 
chains are rearranged, resulting in the expression of IgM on the surface of the immature B 
cell (Defrance et al., 2002). 
 
Immature B cells exit the bone marrow and transit through the peripheral blood to secondary 
lymphoid organs for their next phase of maturation. Transitional B cells have an intact BCR 
and express surface IgD as they enter B cell follicles in secondary lymphoid organs (Loder et 
al., 1999). In humans, three subsets of transitional B cells, T1, T2 and T3, have been 
identified based on increasing maturation and gradations in cell surface marker expression 
including CD10, CD24 and CD38 (Palanichamy et al., 2009). Finally, B cell maturation is 
complete when transitional B cells develop into mature naïve B cells in response to BCR-
Chapter 1: Introduction  10 
 
mediated signalling (Loder et al., 1999, Petro et al., 2002). Mature naïve B cells can give rise 
to follicular B2 B cells or marginal zone (MZ) B cells (Pillai and Cariappa, 2009). 
 
1.2.2  Activation of Follicular B Cells 
In a typical B cell response, the recognition of protein antigen by antigen-specific follicular 
B2 B cells in secondary lymphoid follicles, followed by secondary signalling events triggered 
by the clustering of BCR, leads to the upregulation of costimulatory molecules and cytokine 
receptors on B cells. Upon homing to secondary lymphoid organs along a chemokine 
gradient, helper T cells and naïve B cells first interact at the border of the T cell and B cell 
zones (Okada et al., 2005, Garside et al., 1998). Antigen presented on the BCR is recognised 
by helper T cells and B7 molecules on B cells bind to CD28 on T cells (Lenschow et al., 
1993, Hathcock et al., 1994, Freeman et al., 1993). Further interaction between B and T cells 
via CD40-CD40L and the secretion of cytokines by T cells results in the activation of B cells 
(Garside et al., 1998, Noelle et al., 1992). Some B cells may move to extrafollicular areas and 
differentiate immediately into short-lived plasma cells that secrete low-affinity antibody 
(Jacob et al., 1991a, Paus et al., 2006).  
 
Other B cells migrate with T cells to the B cell follicle to initiate the germinal centre (GC) 
reaction (Jacob et al., 1991a, Paus et al., 2006), where processes such as affinity maturation 
(Jacob et al., 1991b, Berek et al., 1991) and isotype switching (Liu et al., 1996) occur. A 
specialised subset of T cells, follicular T helper (Tfh) cells, provides help to B cells in the GC 
reaction (see 1.3.1.1 Follicular T Helper Cells). Affinity maturation is initiated by somatic 
hypermutation of rapidly proliferating B cells in the dark zone of the GC. Somatically 
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mutated B cells are then repeatedly exposed to the same antigen presented on follicular 
dendritic cells (FDC) in the light zone, followed by the selection of B cells that recognise 
antigen presented by FDCs with high affinity (MacLennan, 1994). Some B cells after 
encountering antigen undergo immunoglobulin heavy chain class switching from IgM/IgD to 
IgG, IgA or IgE (Liu et al., 1996), a process mediated by CD40-CD40L interaction and 
cytokines secreted by helper T cells (Jabara et al., 1990, Armitage et al., 1992, Rousset et al., 
1991, Korthauer et al., 1993, Allen et al., 1993, Breitfeld et al., 2000). GC B cells with high 
affinity to the antigen presented on FDCs differentiate into long-lived plasma cells, which 
secrete high-affinity antibody in extrafollicular areas of secondary lymphoid organs or reside 
in bone marrow (Phan et al., 2006). Plasma cells circulating in peripheral blood are known as 
plasmablasts, precursors of plasma cells which are smaller, have proliferative capacity and do 
not yet express CD138. Both plasmablasts and terminally differentiated plasma cells in 
humans express high levels of CD27 and CD38 (Kaminski et al., 2012). 
 
GC B cells with intermediate affinity to antigen presented on FDCs differentiate into memory 
B cells, which recirculate between lymphoid organs through peripheral blood (Phan et al., 
2006). Memory B cells do not secrete antibody but have an enhanced ability to respond to 
antigen compared to naïve B cells (Good et al., 2009). A number of memory B cell 
populations have been characterised. Most memory B cell subsets express CD27 (Klein et al., 
1998), including switched or conventional (IgD-IgM-) and non-switched or MZ-like 
(IgD+IgM+) (discussed later in 1.2.3 Marginal Zone B Cells) memory B cells which account 
for 30-40% of the total peripheral blood B cell population (Weill et al., 2009). Switched 
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memory B cells have undergone somatic hypermutation and class switch recombination in 
the GC, and respond upon re-exposure to T-dependent antigen by proliferating and 
differentiating into long-lived plasma cells (McHeyzer-Williams and McHeyzer-Williams, 
2005). More recently it has been shown that switched memory B cells were capable of 
forming secondary GCs, whereby the re-diversification of memory BCR repertoires takes 
place in response to antigen re-exposure (McHeyzer-Williams et al., 2015). 
 
IgM-only (IgM+IgD-) and IgD-only (IgM-IgD+) memory B cells have been described, but 
little is known about these rare subsets. The IgD-only memory B subset represents a small 
fraction of the isotype-switched memory B cells and was reportedly increased in 
autoreactivity (Zheng et al., 2004). Some groups regard IgM-only memory B cells as a 
portion of the IgM+IgD+ memory B cell population because most IgM+ memory cells are 
IgDlo/+ (Weller et al., 2004, Shi et al., 2003, Kruetzmann et al., 2003, Carsetti et al., 2004). 
However, a study investigating the ability of CD27+ memory B cell populations to undergo 
isotype switching found that IgD+IgM+ cells were able to switch as much as naïve B cells, 
but IgM-only cells had a limited ability to class switch (Werner-Favre et al., 2001). In 
another study, patients with primary Sjögren’s Syndrome had a significant increase in the 
frequency of IgM-only memory B cells and a reduction of the IgD+IgM+ memory subsets 
compared with healthy controls (Abdulahad et al., 2011). The findings from these two studies 
suggest that IgM-only and MZ-like memory B cells could indeed be two different memory 
cell subsets. CD27-IgD- memory B cells, also referred to as atypical or double negative 
memory B cells, do not express CD27 or IgD but do exhibit bona fide features of CD27+ 
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switched memory B cells including somatically mutated genes, ability to isotype switch and 
increased expression of costimulatory molecules compared with naïve B cells (Fecteau et al., 
2006, Wei et al., 2007a). 
 
1.2.3  Marginal Zone B Cells 
Mature naïve B cells of the B2 lineage give rise to either follicular B cells or MZ B cells 
(Vinuesa et al., 2003). In the mouse, the MZ is located at the junction between the red pulp 
and the white pulp in the spleen. MZ B cells express high levels of IgM and CD21 and low 
levels of IgD and CD23 on their cell surface (Oliver et al., 1997). MZ B cells can be induced 
by blood-borne pathogens and T-independent antigen such as bacterial polysaccharides to 
proliferate and differentiate into short-lived plasma cells that secrete polyreactive natural IgM 
antibody without a germinal centre reaction (Oliver et al., 1999, Oliver et al., 1997, Snapper 
et al., 1993, Vinuesa et al., 2003, Chen et al., 1997, Ochsenbein et al., 1999, Zhou et al., 
2007). MZ B cells can be induced to class switch in vitro and preferentially switch to IgA 
(Snapper et al., 1993, Kaminski and Stavnezer, 2006). Their low threshold for activation 
enables MZ B cells to rapidly respond to invading encapsulated bacterial species (Oliver et 
al., 1999). MZ B cells are also able to carry immune complexes containing bacterial or viral 
antigen to B cell follicles to trigger T-dependent responses (Ferguson et al., 2004). 
 
Human IgM+IgD+CD27+ B cells have been referred to as either non-switched memory B 
cells or MZ B cells. Human IgM+IgD+CD27+ B cells can be detected in the spleen and 
peripheral blood, and have a similar cell surface phenotype to mouse MZ B cells, expressing 
high levels of surface IgM and CD21 but low levels of IgD and no CD23 (Weller et al., 
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2004). Patients with hyper-IgM syndrome do not have class-switched or IgM-only memory B 
cells because GC reactions cannot occur due to a genetic deficiency of CD40 or CD40L. 
However, IgM+IgD+CD27+ B cells were found in the peripheral blood of hyper-IgM patients, 
which suggests that IgM+IgD+CD27+ B cells develop outside of the GC in a T-independent 
manner, just as with mouse MZ B cells (Agematsu et al., 1998, Weller et al., 2001). Asplenic 
and splenectomised patients, children under 2 years of age and patients with conditions such 
as common variable immunodeficiency (CVID) were more susceptible to infections with 
encapsulated bacteria, and were found to have very few IgM+IgD+CD27+ B cells 
(Kruetzmann et al., 2003). The work by Kruetzmann et al. (Kruetzmann et al., 2003) suggests 
a role for IgM+IgD+CD27+ B cells in the protection against T-independent antigen such as 
bacterial polysaccharides as seen in mouse MZ B cells, and that the spleen is necessary for 
the development of IgM+IgD+CD27+ B cells. Further study of IgM+IgD+CD27+ B cells 
including phenotypic analysis, complementarity-determining region 3 (CDR3) spectratyping 
during T-independent vaccination and gene expression profiling showed that 
IgM+IgD+CD27+ B cells corresponded with the circulating splenic MZ B cell subset (Weller 
et al., 2004).  
 
Additionally, human IgM+IgD+CD27+ B cells resemble switched memory B cells in several 
ways. Clonally expanded B cells were found in the MZ and GC in histological sections of 
spleen and lymph nodes, although fewer proliferating cells were found in the MZ. However, 
no clones were shared between B cells in the MZ and adjacent GCs (Dunn-Walters et al., 
1995, Tierens et al., 1999). IgM+IgD+CD27+ B cells from hyper-IgM patients, who do not 
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have switched or IgM-only memory B cells as described above, were found to be somatically 
mutated (Weller et al., 2001). Somatic hypermutation was also observed in IgM+IgD+CD27+ 
B cells in a study by Tian et al. (Tian et al., 2007) but at a lower mutational frequency 
compared to switched memory B cells. The data from all these different studies indicates that 
IgM+IgD+CD27+ B cells could consist of at least two subpopulations based on functional 
characteristics, and shows why these cells are sometimes referred to as non-switched memory 
B cells (as a lack of IgD implies isotype switching has occurred), or were defined as MZ-like 
B cells by other groups. 
 
1.2.4  B1 B Cells 
Our understanding of the characteristics and function of B1 B cells were mostly from 
observations in mice until the recent discovery of a small population of B cells in human 
blood resembling mouse B1 B cells. A rare Lin-CD45Rlo/-CD19+ population that was initially 
detected in adult bone marrow (Montecino-Rodriguez et al., 2001) was found to be the 
progenitor of mouse B1 B cells (Montecino-Rodriguez et al., 2006). Most B1 B cells reside 
in the peritoneal cavity (Hayakawa et al., 1985). B1 B cells can be divided into two subsets 
based on CD5 expression – CD5+ B1a and CD5- B1b cells (Kantor et al., 1992). Lin-
CD45Rlo/-CD19+ progenitor cells from the fetal liver mainly give rise to B1a cells, while 
those isolated from adult bone marrow mostly developed into B1b cells (Montecino-
Rodriguez et al., 2006). Funtionally, B1a cells are involved in the innate response to invading 
encapsulated bacteria and viruses by secreting natural IgM, which are low affinity, 
polyreactive (Haas et al., 2005, Martin et al., 2001, Baumgarth et al., 2000, Ochsenbein et al., 
1999, Zhou et al., 2007) and encoded by unmutated, germline sequences (Hardy et al., 1989, 
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Pennell et al., 1989, Forster et al., 1988, Kantor et al., 1997). However, B1 cells can be 
induced to class switch in vitro and preferentially switch to IgA (Kaminski and Stavnezer, 
2006, Tarlinton et al., 1995). B1b cells are responsible for long-term protection of the host to 
T-independent antigen and secrete antibody after antigen exposure (Alugupalli et al., 2004, 
Haas et al., 2005). B1 cells are capable of tonic intracellular signalling without specific 
stimulation in their resting state (Holodick et al., 2009, Karras et al., 1997, Wong et al., 2002) 
and can efficiently present antigen to T cells (Zhong et al., 2007). 
 
These functional properties were all present in a small population of B cells detected in 
human umbilical cord and adult peripheral blood, which was subsequently referred to as 
human B1 B cells (Griffin et al., 2011). Human B1 cells are larger in size compared to most 
lymphocyte populations (Descatoire et al., 2011) and express CD20, CD27 and CD43 
(Griffin et al., 2011). There are also two subsets of B1 cells in humans which differ in their 
expression of CD5, just as in mice, although Griffin et al. (Griffin and Rothstein, 2011) 
subdivided B1 cells based on their differential expression of CD11b. The majority of human 
B1 cells are CD11b- and the two subsets differ in both phenotype and function. CD11b- B1 
cells are not precursors to their CD11b+ counterpart as CD11b expression could not be 
induced in CD11b- B1 cells. CD11b- B1 cells express surface CD5 but not CD14 and CD11c 
and are mostly IgD-, but CD11b+ B1 cells express CD14, CD11c and IgD but not CD5. The 
larger size and cell surface marker expression (CD14+, CD11b+ and CD11c+) of CD11b+ B1 
cells were reminiscent of monocytes, but CD11b+ B1 cells were classed as true B cells based 
on their expression of IgD. Functionally, CD11b- B1 cells exhibited higher levels of 
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spontaneous IgM secretion whereas CD11b+ B1 cells were more efficient at stimulating 
allogeneic CD4+ T cell expansion (Griffin and Rothstein, 2011). 
 
A recent study by Covens et al. (Covens et al., 2013) demonstrated that CD20+CD27+CD43+ 
B cells could actually be pre-plasmablasts of B2 cell lineage, and not B1 cells as suggested 
by Griffin et al. (Griffin et al., 2011). Covens et al. (Covens et al., 2013) found that 
CD20+CD27+CD43+ B cells were able to spontaneously secrete antibody of different 
isotypes, and could be induced to secrete IgG specific for tetanus toxoid, a T-dependent 
antigen, upon re-exposure. Isotype switching and memory are features of follicular B cells 
which have undergone a GC reaction, but not of B1 cells. The gene expression profile of 
CD20+CD27+CD43+ B cells was most similar to that of plasmablasts than other B cell 
subsets, and CD20+CD27+CD43+ B cells could be differentiated into CD20- plasmablasts and 
plasma cells in vitro, all of which support the view that CD20+CD27+CD43+ B cells are 
precursors of plasmablasts. It appears that CD20+CD27+CD43+ B cells may represent a 
heterogenous population which includes both pre-plasmablasts and B1 cells, and more 
research is needed to fully characterise this population. 
 
1.2.5  B Cell Tolerance and Loss of B Cell Regulation 
Several mechanisms ensure that self-reactive B cells are prohibited from entering the 
periphery. Should immature B cells bind to self antigen in the bone marrow with high 
affinity, these B cells will be removed by apoptosis, become anergic, or undergo receptor 
editing so that the BCR will no longer recognise self antigen (Hartley et al., 1993, Nemazee 
and Burki, 1989, Goodnow et al., 1988, Tiegs et al., 1993, Retter and Nemazee, 1998, Radic 
Chapter 1: Introduction  18 
 
et al., 1993, Gay et al., 1993, Chen et al., 1994). If self-reactive B cells are able to evade 
these mechanisms and seed to the periphery, there are additional measures for their 
elimination. Highly self-reactive mature B cells are deleted from the periphery (Russell et al., 
1991). BCRs that bind to self-antigen with high affinity may be produced during somatic 
hypermutation (Tiller et al., 2007, Mietzner et al., 2008, Armengol et al., 2001, Salomonsson 
et al., 2003). Should these B cells with self-reactive BCRs not be rendered functionally 
inactive or undergo negative selection, they may compete with normal B cells for survival 
factors (Goodnow et al., 1995), leading to the production of autoantibodies by these self-
reactive B cells. 
 
Additionally, cytokine production by T cells in SLE patients is Th2-skewed, resulting in the 
enhanced secretion of B helper cytokines such as IL-10, and fewer T cell cytokines such as 
IL-2. The cytokine imbalance further promotes B cell activation and antibody production. 
Lupus T cells secreted lower levels of IL-2 and were less responsive to IL-2 stimulation 
compared with control T cells in vitro (Alcocer-Varela and Alarcon-Segovia, 1982, Linker-
Israeli et al., 1983). SLE patients had increased levels of soluble CD30, which is expressed 
on cells producing Th2 cytokines, and this increase correlated with disease activity 
(Caligaris-Cappio et al., 1995). Peripheral blood B cells and monocytes from SLE patients 
produced significantly higher levels of IL-10 compared to those from control subjects 
(Llorente et al., 1994), and an elevated ratio of IL-10- to interferon (IFN)-γ-secreting cells in 
SLE patients correlated with disease activity (Hagiwara et al., 1996). Patients with SLE had 
higher levels of serum IL-10 compared to controls, and IL-10 levels correlated with clinical 
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and serological activity and anti-DNA antibody levels (Houssiau et al., 1995, Grondal et al., 
2000). IL-10 stimulated the production of anti-DNA antibodies from PBMCs from SLE 
patients but the addition of IL-12 halted antibody production (Tyrrell-Price et al., 2001, 
Houssiau et al., 1997). In addition, the production of IL-12 in vitro was impaired in PBMCs 
from SLE patients compared with those from matched controls (Horwitz et al., 1998, Liu and 
Jones, 1998). IL-12 has been shown to have an inhibitory effect on humoral responses 
(Trinchieri, 1994), and it appears that IL-12 may have a role in controlling B cell 
hyperactivity in SLE.  
 
1.2.6  Autoantibodies in SLE 
Autoantibodies mediate pathogenesis in SLE in several different ways. Immune complexes 
are formed when autoantibodies combine with circulating antigen or antigen at the site of 
target organs, causing inflammation and resulting in manifestations including nephritis and 
vasculitis (Lahita, 2004). The depletion of certain cell types in haematologic manifestations 
such as anaemia, thrombocytopenia and leukopenia is caused by autoantibodies binding to 
antigens on the surface of target cells or less specific antigens, leading to the death of these 
cells or their removal by phagocytosis (Lahita, 2004). Autoantibodies may also cause damage 
by disrupting the normal function of cells, for example, by penetrating into and promoting 
the apoptosis of these cells (Alarcon-Segovia et al., 1996). 
 
The autoantibodies implicated in SLE are listed in Table 1.10. The presence of anti-dsDNA 
and anti-Sm antibodies is specific to SLE. Anti-dsDNA antibodies target a conserved nucleic 
determinant on DNA while anti-Sm antibodies bind to a small nuclear ribonucleoprotein 
Table 1.10. Autoantibodies implicated in SLE 
 
Antibody Antigen recognised Comments 
ANA Multiple nuclear  
Anti-dsDNA dsDNA Specific for SLE 
Anti-Sm Protein complexed to 6 species of nuclear U1 RNA Specifc for SLE, most patients also have anti-RNP 
Anti-RNP Protein complexed to U1 RNAγ Not specific for SLE 
Anti-SS-A 60kDa and 52kDa protein complexed to hY RNA Not specific for SLE 
Anti-SS-B 47kDa protein complexed to hY RNA Usually associated with anti-Ro 
Anti-histone Histones associated with DNA More frequent in drug-induced lupus 
Anti-phospholipid Phospholipids, β2 glycoprotein 1 co-factor, prothrombin  
Anti-erythrocyte Erythrocyte membrane  
Anti-platelet Surface and altered cytoplasmic antigens in platelets  
Anti-neuronal Neuronal and lymphocyte surface antigens  
Anti-ribosomal P Protein in ribosomes  
 
ANA – anti-nuclear antibodies; dsDNA – double-stranded DNA; RNP – ribonucleoprotein; SS-A – Sjögren’s syndrome A; SS-B – Sjögren’s syndrome B; Sm – 
Smith antigen. Table adapted from Kasper & Harrison, 2005. 
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(Pisetsky, 2000). Another difference between anti-dsDNA and anti-Sm antibodies is that anti-
Sm antibody titres do not vary whereas anti-dsDNA antibody titres may fluctuate during the 
course of the disease (Pisetsky, 1998).  
 
Interestingly, not all anti-DNA antibodies are pathogenic such as low affinity anti-DNA 
natural IgM antibody. Processes such as class switching to IgG and somatic hypermutation 
may result in the formation of high affinity anti-DNA autoantibodies that have been 
attributed to manifestations in SLE (Taki et al., 1992, Diamond et al., 1992). Numerous 
studies have demonstrated the involvement of anti-DNA autoantibodies in lupus 
glomerulonephritis. Anti-DNA antibodies were present in the glomerular eluates of patients 
with active lupus nephritis (Winfield et al., 1977). The administration of anti-DNA mAb 
from lupus-prone mice to non-autoimmune mice and anti-DNA mAb from lupus nephritis 
patients to SCID mice resulted in the deposition of anti-DNA antibody to glomeruli and other 
organs and the development of proteinuria (Vlahakos et al., 1992, Ehrenstein et al., 1995). 
Anti-DNA antibodies can bind directly to both DNA and non-DNA antigenic targets on the 
glomerular basement membrane or form immune complexes with autoantigen prior to 
deposition on glomeruli (Termaat et al., 1992, Madaio et al., 1987, Faaber et al., 1986, 
Lefkowith et al., 1996, Kramers et al., 1994, Morioka et al., 1994). 
 
1.2.7  Peripheral Blood B Cell Abnormalities in SLE Patients 
Studies on human PBMC samples have revealed a number of B cell abnormalities unique to 
patients with SLE. The findings of these studies are summarised on Table 1.11. Frequency of 
transitional B cells were found to be significantly higher in the peripheral blood of SLE 
Table 1.11. Perturbations of B cell subsets in human SLE. 
 
B cell population Phenotype Patient group Associations with features of SLE References 
Increased transitional 
(immature T1) B cells 
CD27- CD38hi IgD+ CD20hi Active and inactive 
SLE 
Inversely correlated with total lymphocyte count 
Did not correlate with SLEDAI, autoantibody levels, 
ESR, CRP or complement levels 
(Sims et al., 
2005) 
 CD38hi IgD+ IgMhi CD24hi Active and inactive 
SLE 
 (Wehr et al., 
2004) 
     
Increased pre-naïve B 
cells 
CD27- CD38int IgD+ Active SLE  (Lee et al., 2009) 
     
Decreased naïve B cells CD27- IgD+ Active SLE  (Anolik et al., 
2004) 
 CD27- CD20+ Active SLE Inversely correlated with disease duration (Jacobi et al., 
2003) 
     
Increased atypical 
memory B cells 
CD27- IgD- CD95+ Active SLE  (Jacobi et al., 
2008) 
 CD27- IgD- Active SLE  (Anolik et al., 
2004) 
 CD27- IgD- Active SLE Associated with increased disease severity, history of 
nephritis and presence of SLE autoantibodies 
(Wei et al., 2007) 
     
Decreased IgM+ non-
switched memory B cells 
IgM+ CD27+ Patients with SLE 
and connective 
tissue diseases 
 (Wehr et al., 
2004) 
     
Increased plasmablasts 
or plasma cells 
CD27hi CD38+ CD19dim 
surface Iglo CD20- CD138+ 
Active SLE  (Odendahl et al., 
2000) 
 CD27hi IgD-, 
CD38hi CD19lo CD20-, or 
CD38hi IgD- CD20- 
Active SLE  (Anolik et al., 
2004) 
 CD27hi CD20- Active SLE Correlated significantly with increased SLEDAI or 
ECLAM, anti-dsDNA antibody titre and disease duration 
(Jacobi et al., 
2003) 
 HLA-DRhi CD27hi CD20- 
CD19dim (plasmablasts) 
Active SLE Correlated significantly with increased SLEDAI and 
anti-dsDNA antibody titre 
(Jacobi et al., 
2010) 
     
Increased CD19hiCD21lo 
B cells 
CD19hi CD21lo Active and inactive 
SLE 
 (Wehr et al., 
2004) 
     
Increased CD11b+ B1 B 
cells 
CD11b+ CD20+ CD27+ 
CD43+ 
Active and inactive 
SLE 
 (Griffin and 
Rothstein, 2011) 
 
CD – cluster of differentiation; CRP – C-reactive protein; dsDNA – double stranded DNA; ECLAM – European Consensus Lupus Activity Measurement; ESR 
– erythrocyte sedimentation rate; HLA – human leukocyte antigen; Ig – immunoglobulin; SLE – systemic lupus erythematosus; SLEDAI – SLE Disease 
Activity Index. 
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patients compared with healthy controls (Sims et al., 2005, Wehr et al., 2004) and correlated 
inversely with the total lymphocyte count (Sims et al., 2005). The investigation of pre-naïve 
B cells by Lee et al. (Lee et al., 2009) described an increased proportion of this subset in 
active SLE patients, while Anolik et al. (Anolik et al., 2004) and Jacobi et al. (Jacobi et al., 
2003) reported a reduction of naïve B cells in active lupus. Most studies have demonstrated 
an increase in the number and frequency of CD27hi plasmablasts or plasma cells in patients 
with active SLE (Odendahl et al., 2000, Anolik et al., 2004, Jacobi et al., 2003, Jacobi et al., 
2010). The number and frequency of plasmablasts or plasma cells correlated significantly 
with SLEDAI scores, anti-dsDNA antibody titre and duration of disease (Jacobi et al., 2003, 
Jacobi et al., 2010). Of the memory B cell subsets, atypical CD27-IgD- memory B cells have 
been reported to be expanded in active SLE patients (Jacobi et al., 2008b, Anolik et al., 2004) 
and the increase of this subset was associated with increased disease severity, a history of 
nephritis and autoantibodies specific to SLE (Wei et al., 2007a). Wehr et al. (Wehr et al., 
2004) found a decreased number of IgM+ non-switched memory B cells in patients with SLE 
and connective tissue diseases. They also reported an increase in a previously uncharacterised 
population, CD19hiCD21lo B cells, in patients with SLE. More recently, studies on human B1 
B cells reported a four-fold increase in the frequency of CD11b+ B1 cells in lupus patients 
compared with age- and gender-matched normal controls, with minimal differences in other 
B cell populations including naïve, memory and CD11b- B1 B cells. CD11b+ B1 cells from 
lupus patients exhibited an increased ability to stimulate T cells in vitro compared with 
CD11b+ B1 cells from normal controls (Griffin and Rothstein, 2011). 
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1.3  T Cell-Dependent Mechanisms 
1.3.1  The Role of Follicular T Helper Cells in SLE 
1.3.1.1  Follicular T Helper Cells 
Follicular T helper (Tfh) cells are a specialised subset of CD4+ helper T cells that provide 
help to B cells in GC reactions (Breitfeld et al., 2000, Schaerli et al., 2000, Kim et al., 
2001b). The phenotypic and functional properties of Tfh cells were characterised in both 
human tonsillar and mouse Tfh cells, which are highly similar between the two species 
(Chtanova et al., 2004, Vinuesa et al., 2005, Rasheed et al., 2006, Nurieva et al., 2008, Ma et 
al., 2009, Yusuf et al., 2010). Expression of B cell lymphoma-6 (Bcl-6), the master 
transcriptional regulator for Tfh cells, is required for the differentiation of CD4+ T cells into 
Tfh cells (Yu et al., 2009, Johnston et al., 2009, Nurieva et al., 2009). T cells are first 
activated by antigen presented on dendritic cells (DC), and then upregulation of Bcl-6 on T 
cells occurs prior to antigen presentation by B cells (Choi et al., 2011, Kerfoot et al., 2011, 
Kitano et al., 2011, Goenka et al., 2011). The upregulation of Bcl-6 results in the expression 
of CXCR5 on Tfh cells, as well as a number of other surface molecules and cytokines 
important to their function in providing B cell help (Nurieva et al., 2009, Kroenke et al., 
2012). The downregulation of CCR7 and upregulation of CXCR5 on Tfh cells allows homing 
to the border of the T and B cell zones of secondary lymphoid follicles, where the ligand for 
CXCR5, CXCL13, is expressed by reticular cells and blood vessels (Schaerli et al., 2000). 
 
The upregulation of CXCR5 is sufficient for Tfh cells to localise to the T-B border but not 
enter the follicle (Ansel et al., 1999, Haynes et al., 2007). Inducible costimulator (ICOS), a 
CD28 family costimulatory molecule, is highly expressed on Tfh cells (Hutloff et al., 1999) 
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and enables Tfh cells to successfully enter the follicle. ICOS induces Bcl-6 expression, 
leading to the upregulation of CXCR5 on Tfh cells to initiate the homing process (Choi et al., 
2011). Tfh cells then move from the T-B border to the follicle when the ICOS expressed on 
Tfh cells binds to ICOS-L expressed on bystander B cells in the follicle (Xu et al., 2013). 
 
ICOS also has a role in the expression of molecules and secretion of cytokines that promote 
humoral immunity. ICOS was able to promote the long-term expression of CD40L on CD4+ 
T cells in vitro (Kaminski et al., 2009). CD40L is highly expressed on all activated CD4+ T 
cells and binds to CD40 on B cells (Noelle et al., 1992). CD40-CD40L interaction is crucial 
for GC formation and facets of the GC reaction (Foy et al., 1994, van Essen et al., 1995, Liu 
et al., 1989, Choe et al., 1996, Arpin et al., 1995). Furthermore, CD40-CD40L binding is also 
necessary for the maintenance of T cell helper functions (Grewal et al., 1995, Whitmire et al., 
1999). 
 
ICOS is also necessary for the optimal production of IL-21 by Tfh cells (Vogelzang et al., 
2008). Although Tfh cells express high levels of IL-21 (Vinuesa et al., 2005, Chtanova et al., 
2004, Nurieva et al., 2008, Rasheed et al., 2006, Yusuf et al., 2010) other CD4+ T cell 
populations are able to produce IL-21 as well, such as Th17 cells (Wei et al., 2007b, Nurieva 
et al., 2007). IL-21 modulates the expression of CXCR5 and CCR7 and acts as an autocrine 
growth factor for Tfh cells (Vogelzang et al., 2008). IL-21 also maintains Bcl-6 expression in 
GC B cells and promotes B cell activation (Linterman et al., 2010, Zotos et al., 2010, Pene et 
al., 2004, Ettinger et al., 2005, Kuchen et al., 2007, Ozaki et al., 2004, Bryant et al., 2007).  
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Another molecule that is highly expressed by Tfh cells is programmed cell death-1 (PD-1), 
one of the CD28 family co-inhibitory receptors (Ishida et al., 1992, Chtanova et al., 2004, 
Haynes et al., 2007). PD-1 is also expressed on other T and B cell populations (Agata et al., 
1996, Barber et al., 2006, Blackburn et al., 2009, Vibhakar et al., 1997, Kasagi et al., 2010). 
Ligation of the T or B cell receptor induces the expression of PD-1 (Agata et al., 1996). PD-1 
and its ligands PDL1 and PDL2 are crucial for the maintenance of peripheral tolerance. 
Development of autoimmunity has been demonstrated in blockade of PD-1 or its ligands and 
PD-1-/- animal models (Nishimura et al., 1999, Nishimura et al., 2001, Kasagi et al., 2010, 
Fife et al., 2009). The interaction of PD-1 with PDL1 or PDL2 resulted in the inhibition of 
TCR-mediated proliferation, cytokine production and suboptimal levels of CD28-mediated 
costimulation (Freeman et al., 2000, Latchman et al., 2001). The mechanism by which PD-1 
and its ligands maintain peripheral tolerance is by sending inhibitory signals to limit 
interactions between T cells and DCs (Fife et al., 2009). PD-1 may also have a role as a 
regulator of B cells responses such as B cell proliferation and class-switching (Nishimura et 
al., 1998). PDL1 and PDL2 were shown recently to be expressed on GC B cells. Signalling 
via PD-1 and its ligands may be involved in the regulation of GC Tfh and B cell survival and 
plasma cell affinity (Good-Jacobson et al., 2010). 
 
Two subsets of Tfh cells exist based on follicular localisation. Tfh (or pre-Tfh) cells are those 
outside the GC and those in the GC are referred to as GC Tfh cells (Crotty, 2011). In human 
tonsils, CXCR5intICOSint and CXCR5hiICOShi Tfh cells correspond to mouse Tfh and GC 
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Tfh cells respectively (Rasheed et al., 2006, Ma et al., 2009). More recently, there is growing 
interest in the investigation of a human peripheral blood Tfh subset, because of its potential 
as a biomarker for a number of autoimmune conditions, including SLE (Simpson et al., 2010, 
Terrier et al., 2012, Dolff et al., 2011, Feng et al., 2012). Blood Tfh cells resemble tonsillar 
Tfh cells in that they are CXCR5+ CD4+ T cells with an increased propensity to provide B 
cell help and produce IL-21 compared to CXCR5- CD4+ T cells (Morita et al., 2011, 
Chevalier et al., 2011). Expression of other molecules differs between different populations 
of Tfh cells. CD84 is expressed on tonsillar but not on blood Tfh cells (Chtanova et al., 2004) 
and surprisingly, blood Tfh cells do not express Bcl-6 (Simpson et al., 2010, Morita et al., 
2011, Chevalier et al., 2011). Blood Tfh cells also express moderate to high levels of ICOS 
and/or PD-1, but the definition of blood Tfh cells is still unclear as different research groups 
use different combinations of markers to identify this population (see 1.3.1.3 Evidence for 
Increased Tfh Cells in SLE Patients). Another suggestion was that CXCR5+CD4+ blood 
Tfh cells may represent a heterogeneous population. Morita et al. (Morita et al., 2011) 
defined three subsets of CXCR5+CD4+ blood Tfh cells based on chemokine receptor 
expression, transcription factors and cytokine production. CXCR3+CCR6- Th1 Tfh cells 
expressed TBX21 and secreted IFNγ, CXCR3-CCR6- Th2 Tfh expressed GATA3 and secreted 
IL-4, IL-5 and IL-13, and CCR3-CCR6+ Th17 Tfh expressed RORC and secreted IL-17A and 
IL-22. Th2 and Th17 but not Th1 Tfh cells were able to induce B cell differentiation via IL-
21, and blood Tfh cells were skewed towards the Th2 and Th17 subsets in patients with 
juvenile dermatomyositis. 
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1.3.1.2  Evidence for T Cell-Dependent Mechanisms in Animal Models of Lupus 
The first of the spontaneous models of murine lupus was the NZB/W F1 mice, the F1 
progeny of the New Zealand Black (NZB) and New Zealand White (NZW) strains (Helyer 
and Howie, 1963). NZB mice develop a mild SLE-like disease whereas NZW mice have a 
non-autoimmune background, but disease in NZB/W F1 mice occurs earlier and is more 
severe than in NZB mice (Furukawa and Yoshimasu, 2005). NZB/W F1 mice initially have 
an abnormal B cell compartment characterised by hyperresponsive B cells and polyclonal B 
cell activation but later develop a dysregulated T-dependent response, accumulating class-
switched and somatically mutated autoantibodies that deposit in the kidneys at 4 to 5 months 
of age, resulting in proliferative glomerulonephritis and early mortality (50% mortalitiy rate 
at 8 to 9 months of age) (Lambert and Dixon, 1968, Hurd and Ziff, 1977). Both plasmablasts 
and plasma cells were found to accumulate in the spleens of NZB/W F1 mice (Hoyer et al., 
2004), which secrete IgG to single- and double-stranded DNA, histones and phospholipids 
(Andrews et al., 1978). The lupus-like illness of NZB/W F1 mice has a female preponderance 
as seen in human SLE (Melez et al., 1978). Treatment of NZB/W F1 mice with 17β-estradiol, 
an active metabolite of oestogen, led to the worsening of the disease (Roubinian et al., 1979). 
 
Another strain of mice used to explore the mechanisms of murine lupus is the BXSB strain, a 
recombinant inbred strain derived from C57BL/6 female and SB/Le male mice (Murphy and 
Roths, 1979). The introduction of the Y chromosome-linked Yaa mutation to BXSB mice 
results in accelerated disease in male mice due to the overexpression of toll like receptor 
(TLR)-7 (Pisitkun et al., 2006, Subramanian et al., 2006). TLR-7 is involved in the 
recognition of RNA fragments that have been internalised by the BCR, leading to the 
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proliferation and activation of these B cells (Lau et al., 2005). The lupus-like disease in 
BXSB mice is caused by the dysregulation of the B cell compartment. Spontaneous 
polyclonal B cell activation in BXSB mice has been reported (Izui et al., 1978), as well as the 
proliferation of B cells in the spleen and lymph nodes of male BXSB mice as the disease 
progresses (Theofilopoulos et al., 1979). B cells, but not T cells, were hyperproliferated in 
BXSB-Yaa mice when stimulated in vitro (DesJardin et al., 1996). However, the 
development and expansion of MZ B cells were impaired in vivo in these mice, which 
suggests that follicular B cells are more likely to be involved in the pathogensis of lupus in 
BXSB-Yaa mice (Amano et al., 2003). Autoantibodies to single- and double-stranded DNA, 
erythrocytes and platelets are present in BXSB mice, which develop fatal immune complex-
mediated glomerulonephritis (70% mortality rate at 40 weeks of age) (Andrews et al., 1978). 
Serum IL-21 and IL-21 mRNA levels were found to be increased in BXSB-Yaa mice (Ozaki 
et al., 2004). BXSB-Yaa mice deficient in the receptor for IL-21 did not develop the lupus-
like disease or immunopathology characteristic of this strain, implicating a role for IL-21 in 
SLE. Interestingly, not only CXCR5+ Tfh cells, but all splenic CD4+ T cells expressing ICOS 
contributed to the enhanced IL-21 levels in these mice (Bubier et al., 2009). 
 
Researchers have crossed two strains of lupus-prone mice, NZW and BXSB-Yaa, to study the 
mechanisms of lupus and antiphospholipid syndrome. NZW/BXSB F1 mice exhibit 
symptoms of both conditions such as anti-cardiolipin and anti-RNP antibodies, progressive 
immune thrombocytopenia, glomerulonephritis and thrombotic vasculopathy (Hang et al., 
1981). Autoimmune disease in the NZW/BXSB F1 strain is accelerated in male mice, as seen 
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in BXSB mice (Hang et al., 1981), and is dependent on B cells and CD4+ T cells. 
NZW/BXSB F1 mice treated with anti-CD4 monoclonal antibody (mAb) at 7 weeks of age 
had an improved survival rate and less severe disease, however mice succumbed to disease 
more quickly when treated with anti-CD8 mAb (Adachi et al., 1998). Transplantation of T 
cell-depleted bone marrow prevented disease in NZW/BXSB F1 mice (Kirzner et al., 2000). 
Treatment of NZW/BXSB F1 mice with cytotoxic lymphocyte-associated antigen 4 (CTLA-
4) immunoglobulin (Ig) before the appearance of anti-cardiolipin antibodies prevented B cell 
expansion and activation and perpetuation of disease, but CTLA-4 Ig was ineffective in 
preventing disease when administered after the appearance of autoantibodies (Akkerman et 
al., 2004). A subset of highly activated T cells, which resemble Tfh cells in that they express 
ICOS and secrete IL-21, has been reported in NZW/BXSB F1 mice. These mice formed 
spontaneous GCs, had few MZ B cells but an expansion of follicular B cells that increased 
with age, all of which are characteristic of an overabundant T-dependent immune response 
(Ramanujam and Davidson, 2008). The findings from these studies suggest that initiation of 
autoimmunity in NZW/BXSB F1 mice is driven by dysregulated T-dependent B cell 
activation. 
 
The sanroque mouse strain was developed from breeding male C57BL/6 mice with single-
base substitutions to homozygosity and screening them for autoimmunity. This strain was 
found to have elevated numbers of Tfh cells which express surface markers such as ICOS, 
CXCR5 and PD-1, and formed spontaneous GCs and developed severe autoimmune disease 
with features characteristic of human SLE, such as high titres of anti-dsDNA antibodies and 
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glomerulonephritis with immune complex deposition (Vinuesa et al., 2005). Roquin is a 
RING-type ubiquitin ligase (Vinuesa et al., 2005) that acts as a repressor of ICOS by 
promoting the degradation of ICOS mRNA (Yu et al., 2007). ICOS is essential for the 
development and survival of Tfh cells (Akiba et al., 2005, Bossaller et al., 2006, Nurieva et 
al., 2008). The homozygous M199R mutation in the ROQ domain of Roquin (Rc3h1) drives 
the overexpression of ICOS, resulting in excessive numbers of Tfh cells (Vinuesa et al., 
2005). Spontaneous GC formation and the subsequent overproduction of autoantibody was 
shown to be a direct result of the expansion of Tfh cells, demonstrating that the Roquin 
M199R mutation is responsible for the lupus-like disease in sanroque mice (Linterman et al., 
2009). 
 
Disease in MRL/lymph proliferation (lpr) mice arises from a defect in the Fas gene, leading 
to excessive proliferation of double negative (CD3+CD4-CD8-) T cells in secondary 
lymphoid organs due to defective apoptosis (Watanabe-Fukunaga et al., 1992a, Wofsy et al., 
1984a). These mice also develop macroscopic skin lesions that were not seen in NZB/W F1 
or BXSB mice (Furukawa et al., 1984). Another difference with MRL/lpr mice compared to 
NZB/W F1 and BXSB mice is that females succumb to disease earlier and more rapidly than 
males (Furukawa and Yoshimasu, 2005). Treatment of MRL/lpr mice with 17β-estradiol led 
to the worsening of the disease (Carlsten et al., 1990). Elevated levels of anti-dsDNA, anti-
histone, anti-Sm, anti-Ro and anti-La antibodies are present in the serum of MRL/lpr mice at 
2 to 3 months of age, and mice develop glomerulonephritis with a 50% mortality rate by 5 to 
6 months of age (Andrews et al., 1978). MRL/lpr mice expressing the mutant transgene 
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mIgMTg, rendering B cells unable to secrete antibody, still developed nephritis and vasculitis 
despite the lack of serum autoantibody (Chan et al., 1999). In B cell-deficient MRL/lpr mice, 
memory T cells could not be activated or proliferate due to the lack of B cells, and these mice 
did not develop the lupus-like illness seen in the wildtype strain (Shlomchik et al., 1994, 
Chan and Shlomchik, 1998). Levels of activated memory T cells were also diminished in 
CD40L-deficient MRL/lpr mice, which have an impaired CD40-CD40L B-T cell 
costimulation (Ma et al., 1996). These mice did not present with glomerulonephritis and did 
not have increased levels of anti-dsDNA antibody. All the data from these studies with 
MRL/lpr mice suggest that in addition to autoantibody production, B cells play a crucial role 
in driving the autoimmune dysregulation in murine lupus by activating the autoreactive T 
cells responsible for the disease in these mice. 
 
1.3.1.3  Evidence for Increased Tfh Cells in SLE Patients 
Most studies have found an increase in Tfh or Tfh-like cells in patients with SLE, which are 
summarised in Table 1.12. Earlier studies reported an increased expression of ICOS on T 
cells in patients with SLE. The expression of ICOS was increased on CD4+ and CD8+ T cells 
but ICOS-L expression was decreased on memory B cells in patients with SLE compared 
with healthy controls. ICOS expression did not correlate with SLE activity (Hutloff et al., 
2004). Yang et al. (Yang et al., 2005) also found significantly expanded populations of 
ICOS-expressing CD4+ and CD8+ T cells in SLE patients, compared with rheumatoid 
arthritis (RA) patients and healthy controls. ICOS expression was significantly enhanced on 
CD4+ T cells in active SLE patients compared with inactive patients and healthy controls, 
and the in vitro costimulation of T cells from both active and inactive SLE patients resulted 
Table 1.12. Evidence for increased Tfh cells in human SLE. 
 
Population Phenotype Patient group Associations with features of SLE References 
Increased ICOS expression on 
CD4+ and CD8+ T cells 
 Active and 
inactive SLE 
 (Hutloff et al., 
2004) 
     
Increase in ICOS+ T cells ICOS+ and CD4+ or CD8+ Active and 
inactive SLE 
 (Yang et al., 
2005) 
 ICOS+ CD45RO+ and CD4+ 
or CD8+ 
Active SLE  (Kawamoto et al., 
2006) 
     
Increase in IL-21+ T cells IL-21+ and CD4+ or CD8+ Active and 
inactive SLE 
 (Dolff et al., 
2011) 
 IL-21+ CD4+ 
IL-21+ CD4+ CXCR5+ Bcl-6+ 
Active and 
inactive SLE 
 (Terrier et al., 
2012) 
     
Increase in Tfh cells CD4+ CXCR5+ Bcl-6- and 
ICOShi or PD-1hi 
Active SLE Correlated significantly with increased autoantibody 
titre and severity of end-organ damage 
(Simpson et al., 
2010) 
 CD4+ CXCR5+ PD-1+ Active and 
inactive SLE 
Correlated with increased frequency of plasma cells, 
serum ANA levels and disease activity 
Tfh cells decreased significantly after 
methylprednisone treatment 
(Feng et al., 
2012) 
 
ANA – anti-nuclear antibody; Bcl-6 – B cell lymphoma-6; CD – cluster of differentiation; ICOS – inducible costimulator; IL – interleukin; PD-1 – programmed 
cell death-1; SLE – systemic lupus erythematosus; Tfh – follicular T helper cell. 
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in the production of IFNγ and IgG anti-dsDNA antibody by autologous B cells (Kawamoto et 
al., 2006). 
 
Based on the findings on studies investigating the role of Tfh cells in the sanroque mouse 
model (described above in 1.3.1.2 Evidence for T Cell-Dependent Mechanisms in Animal 
Models of Lupus), the first study examining the role of Tfh cells in human SLE 
demonstrated an increase in the number of circulating Tfh (cTfh) cells in a subset of active 
SLE patients (14 of 46). The number of cTfh cells correlated with autoantibody titre and 
severity of end-organ damage. Serum IL-21 levels were increased in a subset of SLE patients 
but did not correlate with cTfh levels. cTfh cells in SLE patients resembled Tfh cells in 
sanroque mice in that they were CXCR5+ CD4+ T cells with high expression of ICOS or PD-
1, but CXCR5+ICOShi cTfh cells did not express Bcl-6, a transcriptional repressor that was 
expressed on tonsillar Tfh cells. In addition, CD57 expression was lower on CXCR5+ICOShi 
cTfh cells compared with tonsillar Tfh cells (Simpson et al., 2010).  
 
Subsequent studies of human SLE defined cTfh cells using varying combinations of markers 
associated with Tfh cells. Dolff et al. (Dolff et al., 2011) reported significantly expanded 
populations of IL-21-expressing CD4+ and CD8+ T cells in SLE patients compared with 
healthy controls, but the level of expression of Bcl-6 on T cells and IL-21R on B cells was 
similar between the two groups. Terrier et al. (Terrier et al., 2012) also found an increase in 
CD4+ T cells producing IL-21 in SLE patients, and this population of IL-21+ CD4+ T cells 
included both CXCR5+ and CXCR5- cells. Interestingly, the IL-21+ CXCR5+CD4+ T cells 
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were mostly circulating Bcl-6+CXCR5+CD4+ Tfh cells, and these Bcl-6+ cTfh cells were 
increased in SLE patients. This is in contrast to what was reported by Simpson et al. 
(Simpson et al., 2010), that cTfh cells did not express Bcl-6. The frequency of Tfh cells, 
defined as CXCR5+PD-1+ CD4+ T cells, was increased in SLE patients and correlated with 
the frequency of plasma cells, serum ANA levels and disease activity (Feng et al., 2012). 
Feng and co-workers also investigated the effect of corticosteroids on Tfh cells and found 
that the percentage and absolute number of Tfh cells decreased significantly after 
methylprednisone treatment, and dexamethasone reversed the in vitro expansion of Tfh cells 
from IL-21 stimulation.  
 
1.3.2  The Role of Regulatory T Cells in SLE 
1.3.2.1  Regulatory T Cells 
Regulatory T cells (Tregs) were first shown to have an important role in maintaining self-
tolerance in mice by Sakaguchi et al. (Sakaguchi et al., 1995). The CD4+CD25+ T cells 
described by Sakaguchi in 1995 are now termed natural Tregs, as they are derived from 
precursors in the thymus (Asano et al., 1996, Itoh et al., 1999), in contrast to other subsets 
such as T regulatory 1 (Tr1) and T helper 3 (Th3) cells, which are induced from non-
regulatory CD4+CD25- T cells in the periphery. Although Tregs need to be activated via the 
TCR in order to suppress self-reactive T cells, they do not proliferate upon TCR ligation 
(Takahashi et al., 1998, Thornton and Shevach, 2000). Murine Tregs express CD25, the α-
chain of the IL-2 receptor, and the forkhead box P3 transcription factor (FoxP3), a master 
regulator for the development and function of Tregs (Hori et al., 2003, Sakaguchi et al., 1995, 
Fontenot et al., 2003). The importance of FoxP3 in the regulation of Tregs was demonstrated 
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in studies with Scurfy mice, a strain that spontaneously develops a fatal systemic 
autoimmune lymphoproliferative disease due to a deficiency in and functional impairment of 
CD4+CD25+ Tregs, resulting from a mutation in the Foxp3 gene (Brunkow et al., 2001, 
Fontenot et al., 2003). 
 
Similarly, mutations in the FOXP3 gene in humans, the ortholog of the Foxp3 gene in mice, 
led to the development of immune dysregulation, polyendocrinopathy, enteropathy, X-linked 
(IPEX) syndrome, which is characterised by autoimmune disease in endocrine organs, allergy 
and irritable bowel disease (Wildin et al., 2001, Bennett et al., 2001). CD4+CD25+ T cells 
were isolated from human peripheral blood and were demonstrated to have many 
characteristics in common with murine Tregs. Human CD4+CD25+ Tregs did not proliferate 
upon TCR stimulation, were able to suppress conventional CD4+CD25- and CD8+ T cell 
proliferation and cytokine production in vitro in a cell-cell contact dependent manner, and 
produced IL-10 and transforming growth factor (TGF)-β but little or no IFNγ, IL-2 and IL-4 
(Baecher-Allan et al., 2001, Levings et al., 2001, Ng et al., 2001, Jonuleit et al., 2001, 
Dieckmann et al., 2001). The anergic state of human Tregs could be partially reversed by IL-
2, IL-4 or IL-15 (Dieckmann et al., 2001, Jonuleit et al., 2001, Ng et al., 2001). Tregs were 
once considered to be anergic as they did not proliferate after TCR stimulation in vitro (Itoh 
et al., 1999, Takahashi et al., 1998). However, Treg proliferation was later demonstrated in 
vivo after adoptive transfer to lymphopenic hosts (Annacker et al., 2001, Almeida et al., 
2002), and also in non-lymphopenic hosts when animals were challenged with immunised 
antigen (Walker et al., 2003, Klein et al., 2003), antigen-pulsed DCs (Yamazaki et al., 2003) 
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or antigen expressed transgenically on peripheral tissue (Walker et al., 2003, Fisson et al., 
2003). The anergic state of human Tregs could be partially reversed by IL-2, IL-4 or IL-15 
(Dieckmann et al., 2001, Jonuleit et al., 2001, Ng et al., 2001). 
 
Human Tregs express CD45RO (Baecher-Allan et al., 2001, Jonuleit et al., 2001, Dieckmann 
et al., 2001), and constitutively express low levels of surface CTLA-4 (Levings et al., 2001, 
Jonuleit et al., 2001, Dieckmann et al., 2001). One of the pioneer studies of human Tregs 
found that Tregs with a higher level of expression of CD25 (i.e. CD4+CD25hi) had a greater 
suppressive capability than CD4+CD25+ Tregs (Baecher-Allan et al., 2001). It was 
subsequently shown that most CD4+CD25hi Tregs expressed FoxP3 but a much smaller 
percentage of CD4+CD25int Tregs expressed FoxP3, suggesting that FoxP3 expression is 
indicative of regulatory activity (Roncador et al., 2005). Thus, it appeared that human Tregs 
shared a similar phenotype to murine Tregs, i.e. CD4+ T cells that express FoxP3 and 
intermediate to high levels of CD25.  
 
However, the expression of FoxP3 was also observed in human activated non-regulatory 
CD25- CD4+ and CD8+ T cells. Expression of FoxP3 on conventional T cell subsets was 
induced following in vitro stimulation but did not confer regulatory activity (Roncador et al., 
2005, Gavin et al., 2006, Morgan et al., 2005, Allan et al., 2007, Wang et al., 2007). FoxP3 
was expressed at lower levels and transiently on non-regulatory T cells compared with 
CD4+CD25+ Tregs (Wang et al., 2007, Allan et al., 2007, Seddiki et al., 2006b, Miyara et al., 
2009). Furthermore, human activated conventional CD4+ T cells express intermediate levels 
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of CD25, as an expansion of the CD4+CD25int population was observed in adult peripheral 
blood but not cord blood, and this was not seen in mouse peripheral blood (Seddiki et al., 
2006b). Expression of CD127, the α-chain of the IL-7 receptor, was subsequently 
demonstrated to reliably distinguish between conventional and regulatory T cells. A low level 
of expression of CD127 inversely correlated with the expression of FoxP3 and clearly 
identified Tregs within the CD4+CD25+ T cell population. These CD4+CD25+CD127lo Tregs 
were anergic and demonstrated suppressive function in vitro, which was not seen in 
conventional CD4+CD25+CD127hi T cells (Seddiki et al., 2006a, Liu et al., 2006). 
 
The human Treg population can be divided into naïve (or resting) and effector/memory (or 
activated) subsets. The earlier investigations that were discussed in previous paragraphs 
mostly described effector/memory Tregs, which are the CD4+CD25+/hi(CD127lo) Tregs that 
express FoxP3 and CD45RO. Naïve Tregs express CD45RA but not CD45RO, and had 
slightly lower levels of expression of CD25 and FoxP3 (Seddiki et al., 2006b, Valmori et al., 
2005, Miyara et al., 2009). Cord blood consisted mostly of naïve Tregs, and the ratio naïve to 
effector/memory Tregs reaches approximately 50:50 in adulthood, before declining with age 
with the total naïve CD4+ cell population (Seddiki et al., 2006b, Valmori et al., 2005, Miyara 
et al., 2009, Fritzsching et al., 2006). Both naïve and effector/memory Tregs exhibited cell-
cell contact dependent suppressive activity in vitro (Seddiki et al., 2006b, Valmori et al., 
2005, Miyara et al., 2009). Effector/memory Tregs are terminally differentiated cells that 
express high levels of Fas and are more sensitive to apoptosis (Fritzsching et al., 2006, 
Miyara et al., 2009). In contrast, naïve Tregs express low levels of Fas and are therefore more 
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resistant to apoptosis (Fritzsching et al., 2006). Naïve Tregs proliferate and upregulate Fas 
and other memory T cell markers in response to TCR-mediated stimulation with IL-2 or 
responder cells and differentiate into effector/memory Tregs (Fritzsching et al., 2006, Miyara 
et al., 2009, Valmori et al., 2005). 
 
Tregs are able to exert their suppressive effects not only on non-regulatory CD4+ and CD8+ T 
cells, but also B cells, DCs and monocytes. Mechanisms of suppression by Tregs fall broadly 
under two categories – cell-contact dependent mechanisms and cytokine-mediated 
mechanisms. Murine Tregs and human CD4+CD25hi Tregs inhibited the proliferation and IL-
2 production of activated responder CD4+CD25- T cells in vitro, which was dependent on 
contact between the Tregs and responder T cells and not mediated by cytokines (Baecher-
Allan et al., 2001, Thornton and Shevach, 1998, Takahashi et al., 1998). A number of 
molecules have been implicated in the contact dependent mechanisms of suppression by 
Tregs. CTLA-4, which binds B7 molecules, is upregulated on conventional T cells after 
activation but is constitutively expressed on Tregs (Linsley et al., 1992, Read et al., 2000). 
The ligation of CTLA-4 on Tregs with B7 on conventional CD4+CD25- T cells results in the 
inhibition of the conventional T cell response (Paust et al., 2004). In addition to the 
suppression of conventional T cells, human CD4+CD25+ Tregs reduced the proliferation and 
impaired the antigen presenting capacity of monocyte-derived DCs in vitro via a contact-
dependent mechanism (Misra et al., 2004). CTLA-4 expressed on Tregs mediated the 
downregulation of B7 on DCs, and it was suggested that the diminished antigen-presenting 
capacity of DCs would in turn limit the activation of conventional T cells (Wing et al., 2008). 
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Human CD4+CD25+ Tregs also suppressed the activation and antigen presenting capacity of 
monocytes in vitro, as shown by the inhibition of proinflammatory cytokine production and 
decreased expression of costimulatory molecules of monocytes (Taams et al., 2005).  
 
Lymphocyte activation gene 3 (LAG3), which is expressed on activated Tregs, binds to MHC 
class II molecules. Furthermore, the ectopic expression of LAG3 limited the proliferation and 
induced the suppressive activity of naïve CD4+CD25- T cells. LAG3+ Tregs therefore have 
the capacity to mediate the suppression of any cell that expresses MHC class II molecules, 
such as DCs, monocytes, B cells and activated conventional T cells (Huang et al., 2004).  
 
Fas is widely expressed on activated cells, including activated T cells (Watanabe-Fukunaga 
et al., 1992b, Klas et al., 1993), whereas the expression of Fas ligand (FasL) is induced when 
previously activated T cells are stimulated (Suda et al., 1993, Alderson et al., 1995). The 
binding of FasL to Fas results in the apoptosis of the Fas+ T cells, a process known as 
activation induced cell death (AICD), which is one of the mechanisms in which peripheral T 
cell tolerance is maintained (Alderson et al., 1995, Brunner et al., 1995, Ju et al., 1995). In 
this way, human CD4+CD25hiFoxP3+ Tregs suppressed the proliferation of responder CD8+ 
cytotoxic T lymphocytes (CTLs) via Fas-mediated apoptosis, but the suppression of 
responder CD4+CD25- T cells by Tregs was independent of the Fas/FasL pathway. 
Interestingly, although Tregs from both cancer patients and healthy controls expressed Fas, 
only Tregs from cancer patients expressed FasL (Strauss et al., 2009). In addition to 
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responder T cells, Tregs could also downregulate the immune response by killing antigen-
presenting B cells via Fas-induced apoptosis (Janssens et al., 2003). 
 
Another contact dependent mechanism through which Tregs exert their suppressive function 
is by the release of granzymes. In mice, effector CD4+CD25- T cells were lysed by Tregs 
through the release of granzyme B, but not perforin (Gondek et al., 2005). A subset of murine 
FoxP3+ Tregs that expressed granzyme B at increased levels was able to kill CTLs and NK 
cells with granzyme B and perforin in a tumour environment (Cao et al., 2007). The killing of 
target cells through the perforin/granzyme B pathway was also demonstrated with human Tr1 
cells, but natural Tregs lyse target cells with granzyme A in a perforin-dependent manner 
(Grossman et al., 2004b, Grossman et al., 2004a). Antibody production and class-switching 
of B cells were directly suppressed by FoxP3+ Tregs at the T-B border and in GCs of human 
tonsils (Lim et al., 2005). Antigen-presenting B cells were killed in a cell-contact dependent 
manner by perforin and granzymes released by Tregs (Zhao et al., 2006).  
 
Another mechanism through which Tregs may suppress conventional T cells is by cytokine 
adsorption. IL-2 is necessary for the activation and proliferation of conventional T cells, but 
not for Tregs (Takahashi et al., 1998, Thornton and Shevach, 1998). It was shown in vitro 
and in vivo in a mouse model of inflammatory bowel disease that CD4+CD25+FoxP3+ Tregs 
induced the apoptosis of CD4+ effector T cells. The high levels of expression of CD25 on 
Tregs could consume the IL-2 required for the proliferation of CD4+ effector T cells, leading 
to their apoptosis (Pandiyan et al., 2007). 
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Although a number of mechanisms of suppression by Tregs have been suggested, the 
majority of these mechanisms were demonstrated in vitro with human or mouse Tregs, and 
some of these mechanisms were observed in specific disease settings in vivo. However, it is 
still not clear if some of the mechanisms observed in vitro would apply in vivo, or if a 
mechanism shown in one disease setting would also be seen in other disease models, and 
why Tregs suppress different cell populations with different mechanisms. 
 
1.3.2.2  Follicular Regulatory T cells 
Recently, a population of T cells with suppressive capacity and features of both Tregs and 
Tfh cells was identified within the GC, and was therefore referred to as follicular regulatory 
T (Tfr) cells (Chung et al., 2011, Linterman et al., 2011, Wollenberg et al., 2011). Tfr cells 
express CXCR5, PD-1, ICOS and Bcl-6, which are markers expressed on Tfh cells (Chung et 
al., 2011, Linterman et al., 2011). However, Tfr cells do not express CD40L or the cytokines 
IL-21 and IL-4 (Linterman et al., 2011). Tfr cells also express Treg markers such as FoxP3, 
CD25 and CTLA-4 (Chung et al., 2011, Linterman et al., 2011). Tfr cells derive from nTregs 
and not Tfh cells or any other FoxP3- T cell population (Chung et al., 2011, Linterman et al., 
2011), and Tfh could not be induced to express FoxP3 in vitro (Wollenberg et al., 2011). As 
Tfr cells have a key role in suppressing B cell responses, which was demonstrated in vivo by 
three different groups (Chung et al., 2011, Linterman et al., 2011, Wollenberg et al., 2011), it 
seems plausible that any aberrations in Tfr cell number or function may result in humoral 
autoimmunity. However, the mechanisms of suppression by Tfr cells and their involvement 
Chapter 1: Introduction  40 
 
in different disease settings, including human autoimmune conditions, remain to be fully 
elucidated. 
 
1.3.2.3  Reduced Tregs in Animal Models of Lupus 
Studies in lupus-prone mice suggest an important role for Tregs in controlling disease 
progression. (SWR x New Zealand Black)F1 (SNF1) is a cross between the non-autoimmune 
SWR strain and NZB mice that develop a mild lupus-like illness. Disease in SNF1 mice is 
characterised by the production of autoantibodies directed towards DNA and immune 
complex deposition in the kidney resulting in fatal glomerulonephritis (Datta et al., 1978). 
NZB/W F1 and SNF1 mice were found to have a lower frequency of CD4+CD25+ Tregs 
compared with non-autoimmune strains (Wu and Staines, 2004, Hsu et al., 2006). Tregs from 
NZB/W F1 mice had increased IL-10 but normal levels of FoxP3 and TGFβ mRNA 
expression, and exerted suppressive activity in vitro (Hsu et al., 2006). The depletion of 
Tregs from non-autoimmune mice with tolerance disrupted with apoptotic-cell pulsed DCs 
resulted in the production of anti-dsDNA antibodies (Hsu et al., 2006). Although the 
depletion of Tregs from SNF1 mice by thymectomy led to an increase in autoantibody 
production and frequency of activated CD4+ T cells, thymectomised SNF1 mice did not 
develop glomerulonephritis (Bagavant et al., 2002).  
 
NZB/W F1 mice have fewer lymph node and splenic Tregs compared with age-matched non-
autoimmune mice, and the adoptive transfer of exogenously expanded CD4+CD25+CD62Lhi 
Tregs resulted in a lower rate of disease progression and mortality in NZB/W F1 mice 
(Scalapino et al., 2006). Disease in the lupus-prone recombinant inbred strain New Zealand 
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Mixed 2328 (NZM2328) is characterised by the production of autoantibodies to dsDNA and 
the development of severe proteinuria and glomerulonephritis, which affects three times as 
many females as males at 12 months of age (Rudofsky et al., 1993, Waters et al., 2001). 
Interestingly, the transfer of Tregs from asymptomatic, young NZM2328 mice prevented the 
production of anti-dsDNA antibodies and development of organ-specific autoimmunity but 
not lupus glomerulonephritis and sialoadenitis in thymectomised NZM2328 mice (Bagavant 
and Tung, 2005). Treatment of NZB/W F1 mice with cyclophosphamide, a cytostatic agent, 
inhibited the proliferation of conventional and regulatory T cells, with a reduced number of 
CD4+CD25+FoxP3+ Tregs in lymphoid organs. The adoptive transfer of purified splenic and 
lymph node Tregs to NZB/W F1 mice after cyclophosphamide infusion therapy replenished 
the Treg pool, resulting in the increased survival and a longer remission period in these mice 
(Weigert et al., 2013). A recent study found that CD4+CD25+FoxP3+ Tregs were able to 
suppress the production of autoantibodies in NZB/W F1 mice through the induction of B cell 
anergy (Liu et al., 2014). It is possible that Tregs could bind to B7 on B cells via CTLA-4, 
thereby sending inhibitory signals and inducing anergy in B cells, further implicating a role 
for Tregs in controlling the development of autoimmunity. 
 
MRL/Mp mice, the background strain of MRL/lpr mice, are Fas-intact lupus-prone mice that 
develop disease much later age than MRL/lpr mice (Theofilopoulos and Dixon, 1981). 
Although Tregs from MRL/Mp mice had only mild aberrations in suppressive function, 
conventional T cells from MRL/Mp mice were significantly less sensitive to suppression in 
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vitro by Tregs from non-autoimmune mice (Monk et al., 2005), suggesting another 
mechanism in which peripheral tolerance can be disrupted in autoimmunity. 
 
1.3.2.4  Tregs in SLE Patients 
There are conflicting data from studies that compare frequency and absolute numbers of 
Tregs between SLE patients and healthy controls. The findings from these studies are 
summarised in Table 1.13. Most studies showed that CD4+CD25+/hi (Crispin et al., 2003, Liu 
et al., 2004a, Miyara et al., 2005, Mellor-Pita et al., 2006, Lee et al., 2006, Barath et al., 
2007a, Bonelli et al., 2008a, Bonelli et al., 2008b, Lee et al., 2008, Zhang et al., 2008a, 
Barreto et al., 2009, Habibagahi et al., 2011, Vargas-Rojas et al., 2008) or 
CD4+CD25+/hiFoxP3+ (Yan et al., 2008, Barath et al., 2007b, Suen et al., 2009, Kim et al., 
2012, Ma et al., 2013) Tregs were decreased in SLE patients with active disease compared 
with patients with inactive SLE and/or healthy controls. Some of these studies also found that 
Treg number and frequency inversely correlated with disease activity (Mellor-Pita et al., 
2006, Lee et al., 2006, Miyara et al., 2005, Bonelli et al., 2008a, Barreto et al., 2009, 
Habibagahi et al., 2011, Ma et al., 2013) and anti-dsDNA antibody titre (Lee et al., 2008, Lee 
et al., 2006, Barreto et al., 2009). However, no correlation was found between frequency and 
number of Tregs and disease activity in the studies conducted by Liu et al. (Liu et al., 2004a) 
and Barath et al. (Barath et al., 2007a). The studies conducted by Alvarado-Sanchez et al. 
(Alvarado-Sanchez et al., 2006) and Vargas-Rojas et al. (Vargas-Rojas et al., 2008) found no 
significant difference in levels of Tregs (defined as CD4+CD25+, CD4+CD25bright or 
CD4+FoxP3+) between SLE patients and healthy controls. Yates et al. (Yates et al., 2008) 
also found that the frequency of CD4+CD25hi Tregs was similar between SLE patients and 
Table 1.13. Perturbations of Tregs in human SLE. 
 
Treg population Phenotype Patient group Associations with features of SLE References 
Decreased Tregs CD4+ CD25+/hi Active SLE  (Crispin et al., 2003, Bonelli et al., 2008b, 
Zhang et al., 2008a, Vargas-Rojas et al., 2008) 
 CD4+ CD25+/hi Active SLE Inversely correlated with disease 
activity 
(Miyara et al., 2005, Mellor-Pita et al., 2006, 
Lee et al., 2006, Bonelli et al., 2008a, Barreto 
et al., 2009, Habibagahi et al., 2011) 
 CD4+ CD25+/hi Active SLE Inversely correlated with anti-
dsDNA antibody titre 
(Lee et al., 2006, Lee et al., 2008, Barreto et 
al., 2009) 
 CD4+ CD25+/hi Active SLE No correlation with disease activity (Liu et al., 2004, Barath et al., 2007a) 
 CD4+ CD25+/hi 
FoxP3+ 
Active SLE  (Yan et al., 2008, Barath et al., 2007b, Suen et 
al., 2009, Kim et al., 2012) 
 CD4+ CD25+/hi 
FoxP3+ 
Active SLE Inversely correlated with disease 
activity 
(Ma et al., 2013) 
     
No difference in Tregs CD4+ CD25+/bri/hi Active and 
inactive SLE 
 (Alvarado-Sanchez et al., 2006, Yates et al., 
2008) 
 CD4+ FoxP3+ Active and 
inactive SLE 
 (Alvarado-Sanchez et al., 2006, Vargas-Rojas 
et al., 2008) 
 CD4+ CD25+/hi 
FoxP3+ 
Active and 
inactive SLE 
 (Venigalla et al., 2008, Zhang et al., 2008b, 
Prado et al., 2013) 
 CD4+ CD25+/hi 
CD127lo FoxP3+ 
Active and 
inactive SLE 
 (Mesquita et al., 2011) 
     
Increased Tregs CD4+ CD25+/hi Active and 
inactive SLE 
Increase or recovery of Tregs with 
glucocorticoid treatment 
(Suarez et al., 2006, Azab et al., 2008, Zhang 
et al., 2008a) 
 CD4+ CD25bri Active and 
inactive SLE 
Increase or recovery of Tregs with 
rituximab treatment 
(Vigna-Perez et al., 2006) 
 CD4+ CD25+/hi Active and 
inactive SLE 
Correlated with increased SLEDAI (Azab et al., 2008) 
 CD4+ CD25+ FoxP3+ Active SLE  (Yan et al., 2008) 
 CD4+ CD25+ FoxP3+ Active and 
inactive SLE 
Increase or recovery of Tregs with 
glucocorticoid treatment 
(Cepika et al., 2007, Ma et al., 2013) 
 CD4+ CD25bri 
FoxP3+ 
Active and 
inactive SLE 
Increase or recovery of Tregs with 
rituximab treatment 
(Vallerskog et al., 2007) 
 CD4+ CD25+ FoxP3+ Active SLE Correlated with increased SLEDAI (Lin et al., 2007) 
     
Increased naïve Tregs Naïve: CD45RA+ 
FoxP3lo 
Activated: CD45RA- 
FoxP3hi 
Active SLE  (Miyara et al., 2009) 
 Naïve: CD45RA+ 
FoxP3lo 
Activated: CD45RA- 
FoxP3hi 
Active SLE Correlated with increased SLEDAI 
and anti-dsDNA antibody titre 
(Pan et al., 2012) 
     
No difference in ratio of 
naïve and activated 
Tregs 
Naïve: CD4+ CD25++ 
CD45RA+ 
Activated: CD4+ 
CD25+++ CD45RA- 
Active and 
inactive SLE 
 (Kim et al., 2012) 
     
Functionally defective 
Tregs 
CD4+ CD25+/hi Active SLE  (Valencia et al., 2007) 
 CD4+ CD25+/hi Active SLE Treg suppressive capability 
inversely correlated with disease 
activity 
(Alvarado-Sanchez et al., 2006) 
 CD4+ CD25+/hi Active and 
inactive SLE 
Treg suppressive capability 
inversely correlated with disease 
activity 
(Bonelli et al., 2008a) 
     
Functionally defective 
naïve Tregs 
Naïve: CD45RA+ 
FoxP3lo 
Activated: CD45RA- 
FoxP3hi 
Active SLE  (Pan et al., 2012) 
     
Functionally intact 
Tregs 
CD4+ CD25hi 
CD127lo/- 
Active and 
inactive SLE 
 (Venigalla et al., 2008) 
 CD4+ FoxP3+ Active and 
inactive SLE 
 (Vargas-Rojas et al., 2008) 
 CD4+ CD25+/hi 
FoxP3+ 
Active and 
inactive SLE 
 (Zhang et al., 2008b, Suen et al., 2009) 
 
CD – cluster of differentiation; dsDNA – double stranded DNA; FoxP3 – forkhead box P3 transcription factor; SLE – systemic lupus erythematosus; SLEDAI – 
SLE Disease Activity Index; Treg – regulatory T cell.  
 
Chapter 1: Introduction  43 
 
controls, but active disease was associated with the expansion of the CD4+CD25+ population. 
Several other studies also reported that levels of CD4+CD25+/hiFoxP3+ or 
CD4+CD25+/hiCD127loFoxP3+ Tregs were similar between SLE patients and control subjects 
(Venigalla et al., 2008, Zhang et al., 2008b, Mesquita et al., 2011, Prado et al., 2013). 
 
On the other end of the spectrum, several studies reported an increase of CD4+CD25+/hi Tregs 
in SLE patients compared with healthy controls (Azab et al., 2008, Suarez et al., 2006), while 
other groups found that active SLE patients had elevated levels of CD4+CD25+FoxP3+ Tregs 
compared with patients with inactive SLE and healthy controls (Lin et al., 2007a, Yan et al., 
2008). Some of these studies found a positive correlation between levels of Tregs and 
SLEDAI scores (Azab et al., 2008, Lin et al., 2007a). It is possible that therapeutic regimens 
that include glucocorticoids (Azab et al., 2008, Suarez et al., 2006, Zhang et al., 2008a, 
Cepika et al., 2007, Ma et al., 2013) or rituximab (Vigna-Perez et al., 2006, Vallerskog et al., 
2007) may be responsible for the increase or recovery of Tregs seen in some SLE patients. 
When Tregs were divided into naïve or resting (CD45RA+FoxP3lo) and activated (CD45RA-
FoxP3hi) subsets, active SLE patients had an increased proportion of naïve Tregs compared to 
that of inactive SLE patients and healthy controls (Miyara et al., 2009, Pan et al., 2012), and 
the higher percentage of naïve Tregs correlated with higher SLEDAI scores and serum anti-
dsDNA antibody positivity (Pan et al., 2012). However, Kim et al. (Kim et al., 2012) found 
that the ratio of resting (CD25+CD45RA+) to activated (CD25hiCD45RA-) Tregs did not 
differ significantly between SLE patients and controls. 
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Several studies reported that CD4+CD25+/hi Tregs from some SLE patients were functionally 
impaired, as measured by their reduced capacity to inhibit the proliferation of CD4+CD25- 
responder T cells in vitro, and the suppressive function of Tregs was inversely correlated 
with disease activity (Alvarado-Sanchez et al., 2006, Bonelli et al., 2008a). In addition to 
defective inhibition of T cell proliferation, Tregs from active SLE patients were also 
impaired in their ability to suppress cytokine production by effector T cells compared to 
Tregs from patients with inactive SLE and healthy controls (Valencia et al., 2007). When 
Tregs were subfractionated into naïve and activated subsets, defective suppressive activity 
was seen in naïve Tregs from SLE patients (Pan et al., 2012). In contrast, the suppressive 
function of Tregs was not defective in SLE patients in the studies conducted by Zhang et al. 
(Zhang et al., 2008b) and Suen et al. (Suen et al., 2009). Although a reduction of T cell 
proliferation was seen in SLE patients in the studies by Venigalla et al. (Venigalla et al., 
2008) and Vargas-Rojas et al. (Vargas-Rojas et al., 2008), this was attributed to conventional 
T cells from SLE patients having a decreased sensitivity to suppression rather than defective 
Treg function, which was observed previously in MRL/Mp mice (Monk et al., 2005). Tregs 
from SLE patients, defined as CD4+CD25hiCD127-/lo by Venigalla et al. (Venigalla et al., 
2008) and CD4+FoxP3+ by Vargas-Rojas et al. (Vargas-Rojas et al., 2008), exhibited normal 
suppressive activity. 
 
1.4  T Cell-Independent Mechanisms 
1.4.1  B Cell Activating Factor 
B cell activating factor belonging to tumour necrosis factor family (BAFF) (Schneider et al., 
1999), also known also as B lymphocyte stimulator (BLyS) (Moore et al., 1999) or TNF and 
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apoptosis ligand-related leukocyte-expressed ligand 1 (TALL-1) (Shu et al., 1999), is an 
important survival factor for B cells. BAFF is a member of the tumour necrosis factor family 
and can exist as a type II transmembrane protein or a soluble homotrimeric form (Schneider 
et al., 1999). It is constitutively expressed by myeloid cells such as monocytes, macrophages 
and DCs (Nardelli et al., 2001). BAFF is also expressed to a lesser extent by neutrophils 
(Scapini et al., 2003, Assi et al., 2007), T cells (Schneider et al., 1999, Huard et al., 2004, 
Yoshimoto et al., 2006, Morimoto et al., 2007), activated B cells (Chu et al., 2007) and B-cell 
chronic lymphocytic leukemia cells (Novak et al., 2002). The expression of BAFF can be 
upregulated by IFNγ and IL-10 (Nardelli et al., 2001), TNF (Assi et al., 2007), granulocyte 
colony stimulating factor (Scapini et al., 2003) and the activation of TLR-9 by immune 
complexes containing chromatin (Boule et al., 2004).  
 
BAFF has three transmembrane receptors, each with a different cell distribution. B-cell 
maturation antigen (BCMA) can be found on plasma cells in the tonsils, spleen and bone 
marrow, memory B cells in the tonsil and GC B cells (Darce et al., 2007, Ng et al., 2004). 
Transmembrane activator and calcium modulator, and cyclophilin ligand interactor (TACI) is 
expressed on CD27+ memory B cells, plasma cells in the tonsils and bone marrow, activated 
CD27- non-GC B cells, a subset of naïve B cells in the blood and tonsils (Darce et al., 2007, 
Ng et al., 2004, Groom et al., 2007), monocytes (Chang et al., 2006) and DCs (Chang et al., 
2008). BAFF-receptor (BAFF-R) is expressed on all B cells except bone marrow plasma 
cells (Darce et al., 2007, Ng et al., 2004), activated T cells and Tregs (Ye et al., 2004).  
 
Chapter 1: Introduction  46 
 
A major role of BAFF is to promote the survival of B cells (Gross et al., 2000, Mackay et al., 
1999, Khare et al., 2000, Batten et al., 2000). Altering the expression of BAFF in animal 
models indicated that BAFF was not required for B1 cells, B2 cell development in the bone 
marrow or survival of B2 cells prior to the transitional T1 stage of development, but 
necessary for survival and development for transitional T2, mature and MZ B cells 
(Schneider et al., 2001, Schiemann et al., 2001, Gross et al., 2001, Hsu et al., 2002, Batten et 
al., 2000, Gorelik et al., 2003). Interestingly, memory B cells were the only mature B2 subset 
that did not depend on BAFF for its survival and function (Benson et al., 2008). BAFF in 
conjunction with its receptors control various aspects of humoral immunity. The interaction 
of BAFF and BAFF-R, which is expressed on most mature B cell subsets but downregulated 
on immature, T1 and most T2/T3 B cells upon BCR crosslinking, promotes the survival of 
B2 cells beyond the T1 stage and maintenance of B cell homeostasis (Hsu et al., 2002, 
Tussiwand et al., 2012). BCMA is critical for the survival of long-lived plasma cells in the 
bone marrow (O'Connor et al., 2004). TACI is required for the survival of activated B cells 
and plasma cells and responses to T-independent antigen (Mantchev et al., 2007, Bossen et 
al., 2008, von Bulow et al., 2001). TACI can also act as a negative regulator of the humoral 
response by suppressing antibody production enhanced by BAFF-R and CD40 (Sakurai et al., 
2007). 
 
BAFF also rescues self-reactive B cells targeted for negative selection, which may lead to the 
overproduction of autoantibody and autoimmunity (Lesley et al., 2004, Thien et al., 2004, 
Mackay et al., 1999, Khare et al., 2000). In addition, high levels of BAFF can contribute 
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towards T cell-independent autoantibody production via a positive feedback loop involving 
the TLRs, which are involved in the recognition of T-independent antigens. BAFF increases 
expression of TLR-7 and 9, which when ligated increase the responsiveness of B cells to 
BAFF by upregulating the expression of TACI, further increasing the production of 
autoantibodies. This feedback loop has been postulated as sufficient for the maintenance of 
SLE pathogenesis (Groom et al., 2007). 
 
More recently, however, it has been suggested that BAFF may also modulate the B cell 
response through the regulation of Tfh cell responses. Coquery et al. (Coquery et al., 2015) 
found that in autoimmune-prone mice with T cells deficient in BCMA had increased Tfh 
cells, GC formation, autoantibody production and IFN-γ production by Tfh cells, and patients 
with SLE had increased percentages of CXCR5+ CD4+ Tfh-like cells that express BAFF-R 
(but not BCMA) which correlated with increased serum BAFF and IFN-γ levels. Their 
findings suggest that uncontrolled BAFF/BAFF-R interactions may contribute to 
autoimmunity in a T-dependent manner. 
 
1.4.2  Evidence for T Cell-Independent Mechanisms in Animal Models of Lupus 
Serum BAFF levels were increased nine-fold in NZB/W F1 mice with increased anti-dsDNA 
antibody titres and proteinuria, compared with before the onset of disease. However, BAFF 
levels were not increased in healthy control mice, even as they aged (Gross et al., 2000). 
Treatment of NZB/W F1 mice with IFNα, which induced the overexpression of circulating 
BAFF levels in vivo, resulted in accelerated disease (Mathian et al., 2005). Disease activity 
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was decreased when NZB/W F1 mice were treated with TACI-Fc (Gross et al., 2000) or 
BAFF-R-Fc (Kayagaki et al., 2002). 
 
As well as the presence of Tfh-like cells, serum BAFF levels were elevated in NZW/BXSB 
F1 mice, and were found to increase with age. Blockade of BAFF with BAFF-R-Ig or TACI-
Ig led to an improvement in these mice, including smaller spleens, reduction of B cells, and 
significantly less nephritis and myocardial infarcts compared with untreated mice. However, 
BAFF blockade had limited effect on the formation of anti-cardiolipin and anti-platelet 
autoantibodies (Kahn et al., 2008). 
 
Serum BAFF levels were also increased in MRL/lpr mice (Gross et al., 2000). However, 
BAFF blockade with adeno-encoded soluble TACI (AdTACI) or BAFF-R mutation did not 
completely prevent the development of autoimmunity in MRL/lpr mice. Treatment of 
MRL/lpr mice with AdTACI led to a reduction of disease manifestations such as 
glomerulonephritis and proteinuria, but not T cell infiltration and interstitial nephritis (Liu et 
al., 2004b). The development of immature, mature and MZ B cells was impaired in BAFF-R 
deficient MRL/lpr mice, but there was no reduction in autoantibody production, 
hypergammaglobulinemia or glomerulonephritis (Ju et al., 2007). These results suggest that 
the blockade of BAFF by removing or interfering with only one of its receptors is not 
sufficient for the prevention of disease in MRL/lpr mice. In addition, both T-dependent and 
independent mechanisms are involved in autoimmunity in MRL/lpr mice, and removing both 
arms of the immune response is necessary to completely ameliorate the disease. 
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BAFF-/- mice were made by targeted inactivation of the BAFF gene. These BAFF-deficient 
mice had a severe depletion of follicular and MZ B cells, with almost no B2 B cells present 
beyond the transitional T1 stage. However, populations of immature B cells in the bone 
marrow and peritoneal B1 B cells were normal in number and phenotype in BAFF-/- mice. 
The findings in studies of BAFF-/- mice suggest that BAFF has a direct role at the transitional 
T1 to T2 stage of development of B2 B cells, but is not necessary in the development of B1 B 
cells (Gross et al., 2001, Schiemann et al., 2001). 
 
BAFF-transgenic (Tg) mice have an increased number of mature B cells, enlarged secondary 
lymphoid organs and hypergammaglobulinaemia. They present with features of SLE 
including autoantibodies to nuclear antigens, circulating immune complexes, and immune 
complex deposits in the kidneys. It was in these mice that BAFF was originally identified as 
a possible mediator of autoimmune disease (Mackay et al., 1999, Khare et al., 2000). 
 
By examining the fate of hen egg lysozyme (HEL)+ self-reactive B cells in BAFF-Tg mice, 
Thien at al. (Thien et al., 2004) demonstrated the importance of BAFF in promoting the 
survival of self-reactive B cells beyond the transitional T1 stage of development. In addition, 
self-reactive B cells rescued from the overproduction of BAFF allows them to migrate to 
normally forbidden follicular and marginal zones, where they are more likely to be 
inappropriately activated and mediate autoimmunity. 
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Furthermore, different B cell subsets could contribute to autoimmune disease at different 
anatomical sites.  Both BAFF-Tg mice and lymphotoxin-β (LTβ)-deficient BAFF-Tg mice, 
which lack MZ B cells, develop a lupus-like disease. However, disease in BAFF-Tg mice 
correlates with the increase of MZ and MZ-like B cells in the blood and lymph nodes, 
whereas disease is associated with B1 B cells and mainly affects the kidneys in LTβ-deficient 
BAFF-Tg mice (Fletcher et al., 2006). 
 
It has been suggested that BAFF-mediated autoantibody production in SLE could occur via a 
T-independent pathway. BAFF-Tg mice lacking TNF, despite having an impaired T-
dependent immune response, developed autoimmune disease that correlated with the increase 
of transitional T2 and MZ B cells, as seen in BAFF-Tg mice (Batten et al., 2004). T cell-
deficient BAFF-Tg mice also developed a lupus-like disease resembling that of BAFF-Tg 
mice (Groom et al., 2007). The study by Groom and colleagues (Groom et al., 2007) also 
revealed a role for BAFF in the production of autoantibody. BAFF upregulated the 
expression of TLR-7/9 on B cells and the activation of TLR-7/9 increased the expression of 
TACI, all of which are important in B cell responses and T cell-independent antibody 
production. 
 
BAFF overexpression, however, is not the sole mediator of SLE. Severe glomerular 
pathology developed in autoimmune-prone B6.Sle1 and B6.Nba2 BAFF-Tg mice but not in 
age-matched BAFF-Tg mice with no genetic predisposition to SLE, even though both groups 
of mice exhibited similar increases in B cells and immunoglobulin production and renal 
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immune complex deposition (Stohl et al., 2005). This suggests that an increase of BAFF, in 
combination with other factors such as genetic susceptibility, is necessary for the 
development of SLE. 
 
1.4.3  Increased BAFF in SLE Patients 
Studies examining the role of BAFF in human SLE have investigated serum BAFF levels, 
BAFF receptor expression and peripheral blood BAFF mRNA expression in relation to 
clinical and laboratory measures of the disease, including disease activity and anti-dsDNA 
antibody titre. The findings of these studies are summarised below in Table 1.14. 
 
Most studies have demonstrated an increase in serum BAFF levels, either in all SLE patients 
(Lin et al., 2007b, Pers et al., 2005, Zhang et al., 2001) or in a subset of patients (Cheema et 
al., 2001, Stohl et al., 2003) compared to healthy control subjects. Serum BAFF levels in 
patients with SLE positively correlated with elevated anti-dsDNA antibody titres in most 
studies (Lin et al., 2007b, Pers et al., 2005, Zhang et al., 2001, Cheema et al., 2001, Stohl et 
al., 2003), but did not correlate with disease activity (Zhang et al., 2001, Stohl et al., 2003). 
In contrast, Becker-Merok et al. (Becker-Merok et al., 2006) found that serum BAFF levels 
correlated with SLEDAI scores but not anti-dsDNA antibody levels. In addition, serum 
BAFF levels were found to correlate positively with serum IgG levels (Cheema et al., 2001, 
Lin et al., 2007b). High-dose corticosteroid treatment reduced serum BAFF levels but 
treatment with cytotoxics had no affect on BAFF levels in SLE patients (Lin et al., 2007b, 
Stohl et al., 2003, Ju et al., 2006). Stohl et al. (Lin et al., 2007b, Stohl et al., 2003, Ju et al., 
2006) also found no correlation between serum BAFF levels and organ involvement. Blood 
Table 1.14. Evidence for increased BAFF in human SLE. 
 
Form of BAFF Patient group Associations with features of SLE References 
Increased serum 
BAFF 
Active and 
inactive SLE 
Correlated with elevated anti-dsDNA antibody titre 
but not disease activity 
(Lin et al., 2007, Pers et al., 2005, Zhang et al., 2001, Cheema 
et al., 2001, Stohl et al., 2003) 
  Correlated with increased disease activity but not 
anti-dsDNA antibody titre 
(Becker-Merok et al., 2006) 
  Correlated with increased serum IgG levels (Cheema et al., 2001, Lin et al., 2007) 
  Treatment with corticosteroids reduced serum 
BAFF, treatment with cytotoxics had no effect on 
BAFF 
No correlation with organ involvement 
(Stohl et al., 2003) 
    
Increased blood 
BAFF mRNA 
Active and 
inactive SLE 
 (Ju et al., 2006, Lin et al., 2007, Stohl et al., 2003) 
 
BAFF – B cell activating factor belonging to the tumour necrosis factor family; dsDNA – double stranded DNA; SLE – systemic lupus erythematosus. 
 
Chapter 1: Introduction  52 
 
BAFF mRNA (Lin et al., 2007b, Stohl et al., 2003, Ju et al., 2006) and BAFF receptor 
mRNA (Ju et al., 2006) expression in peripheral blood mononuclear cells were increased in 
patients with SLE compared with healthy control subjects. The expression of BAFF-R on B 
cells was decreased in patients with SLE and correlated with changes in SLEDAI (Sellam et 
al., 2007). However, Carter et al. (Carter et al., 2005) found that total available BAFF-R, but 
not total surface expression of BAFF-R on B cells, was decreased in patients with SLE 
compared to healthy control subjects. 
 
1.4.4  Belimumab 
Belimumab, marketed as Benlysta (Adis R&D Profile, 2010) was approved for the treatment 
of SLE in the United States and the European Union in 2011 (Vincent et al., 2012). 
Belimumab is a recombinant fully human monoclonal IgG1 antibody directed against BAFF 
(Baker et al., 2003) and is administered to patients intravenously (Adis R&D Profile, 2010). 
The mechanism by which belimumab impairs the function of BAFF is to bind to soluble 
BAFF with high affinity, rendering it unable to bind to its receptors TACI, BCMA and 
BAFF-R. This in turn lowers the amount of BAFF available for the survival of autoreactive B 
cells that cause disease in SLE (Mackay and Schneider, 2009, Cancro et al., 2009). Human 
Genome Sciences first identified BAFF as a target for SLE therapy in 2001, and the 
development of belimumab for the treatment of SLE was fast-tracked in the United States 
following the conclusion of Phase I clinical trials in 2003. Human Genome Sciences together 
with GlaxoSmithKline further developed belimumab and conducted Phase II and III trials, 
which ended in 2010 (Adis R&D Profile, 2010). Both Phase III trials, BLISS-52 (Furie et al., 
2011) and BLISS-76 (Navarra et al., 2011), achieved their primary efficacy endpoint as 
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evaluated by the SLE Responder Index (SRI) at week 52 of the trial. The SRI was defined as 
a reduction of at least 4 points in SELENA-SLEDAI score, no new BILAG A organ domain 
score and no more than 1 new BILAG B score, and no worsening of PGA score versus 
baseline (an increase of <0.3) (Furie et al., 2011). The SRI rates were higher in the group 
treated with 10mg/kg of belimumab compared with the placebo group in both BLISS-52 and 
BLISS-76 (Furie et al., 2011, Navarra et al., 2011). SRI rate of patients treated with 1mg/kg 
was higher compared to that of patients who were administered placebo in BLISS-52 only. 
Treatment with belimumab was associated with increased complement levels and decreased 
anti-dsDNA antibody concentration, hyper-gammaglobulinaemia and new flares of disease in 
BLISS-52 (Furie et al., 2011). In BLISS-76, patients treated with belimumab plus standard 
treatment (prednisone, or non-steroidal anti-inflammatory, anti-malarial or 
immunosuppressive drugs which fulfill the inclusion criteria of the trial) had higher response 
rates at week 76 than patients treated with placebo and standard treatment, but this difference 
was not significant (Navarra et al., 2011). The findings in both Phase III trials led to the 
approval for the use of belimumab in the treatment of SLE in 2011. 
 
1.5  The Role of Monocytes in SLE 
1.5.1  Monocyte Development and Activation 
Monocytes derive from myeloid precursor cells in the fetal liver and bone marrow (Ginhoux 
and Jung, 2014). The monocyte-macrophage and DC precursor has lost its ability to develop 
into granulocytes and can give rise to two separate downstream precursors for monocytes and 
macrophages, and several DC subsets (Auffray et al., 2009, Fogg et al., 2006, Varol et al., 
2007). As their names suggest, the common monocyte progenitor is a bone marrow precursor 
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for monocytes and monocyte-derived macrophages (Hettinger et al., 2013), while the 
common DC progenitor can develop into conventional or plasmacytoid DCs (Onai et al., 
2007, Naik et al., 2007, Liu et al., 2009). It was long believed that monocytes were a 
transitory population which circulated in the blood for 1 to 2 days before differentiating into 
macrophages in various tissues (van Furth and Cohn, 1968). However, recent studies have 
shown that many adult tissue macrophages do not develop from bone marrow-derived 
monocytes but from embryonic precursors that have colonised various tissues before birth, 
and the maintenance of the macrophage pool does not rely on monocyte output (Yona et al., 
2013, Hashimoto et al., 2013, Schulz et al., 2012). Further to the paradigm shift is that 
monocytes are no longer considered as simply transitory cells, as they can traffic to non-
inflamed tissues without differentiating into macrophages or DCs and have effector functions 
of their own (Jakubzick et al., 2013). 
 
In mice, Ly6Chi/Gr1+ monocytes are classical monocytes and were once referred to as 
inflammatory monocytes (Geissmann et al., 2003). Classical monocytes, which are 
CX3CR1lo, are recruited to sites of inflammation (Geissmann et al., 2003, Sunderkotter et al., 
2004, Nahrendorf et al., 2007) where they can differentiate into macrophages or DCs 
(Ginhoux et al., 2006, Landsman and Jung, 2007, Varol et al., 2007). Ly6Clo/Gr1- monocytes, 
which express high levels of CX3CR1, crawl along and maintain the integrity of the 
endothelium that expresses the ligand for CX3CR1, fractalkine, and were therefore referred 
to as resident or patrolling monocytes (Auffray et al., 2007, Carlin et al., 2013, Geissmann et 
al., 2003). In addition, Ly6Clo/Gr1- monocytes are responsible for initiating the early, 
Chapter 1: Introduction  55 
 
transient inflammatory response during infection, in contrast to the longer-lasting 
inflammatory response elicited by Ly6Chi/Gr1+ monocytes that are recruited later to the sites 
of damage (Auffray et al., 2007). A developmental relationship exists between the two 
subsets, where Ly6Chi/Gr1+ monocytes can differentiate into Ly6Clo/Gr1- monocytes in the 
absence of inflammation or insufficient levels of the growth factor, macrophage colony-
stimulating factor (M-CSF) (Yona et al., 2013, Varol et al., 2007). 
 
Monocytes account for 10% of all leukocytes in human peripheral blood (Ginhoux and Jung, 
2014). The current consensus in the field is that there are three functional subsets of 
monocytes in humans: CD14+CD16- (CD14++CD16-) classical, CD14+CD16+ 
(CD14++CD16+) intermediate and CD14dim (CD14+CD16++) non-classical monocytes 
(Ziegler-Heitbrock et al., 2010, Cros et al., 2010). Classical and intermediate monocytes 
resemble murine Ly6Chi/Gr1+ monocytes based on gene expression profiling and functional 
studies, and respond to bacterial signals such as lipopolysaccharide (LPS) via TLR-1, 2 and 4 
by secreting inflammatory cytokines. Conversely, non-classical monocytes are more similar 
to Ly6Clo/Gr1- monocytes in mice. CD14dim monocytes respond poorly to bacterial signals, 
but secrete inflammatory cytokines in response to viral nucleic acids via TLR-7 and 8, and 
for this reason, this subset has been implicated in lupus nephritis (Cros et al., 2010).  
However, genome wide analyses performed by other groups have found that intermediate and 
non-classical monocytes were more closely related, and that classical monocytes resembled 
mouse Ly6Chi/Gr1+ monocytes while the two subsets expressing CD16 resembled 
Ly6Clo/Gr1- monocytes (Ingersoll et al., 2010, Wong et al., 2011, Zawada et al., 2011).  
Chapter 1: Introduction  56 
 
 
Controversy also exists with regards to cytokine production. Cros et al. (Cros et al., 2010) 
found that classical monocytes secrete IL-6, IL-8, CCL2 and CCL3 while intermediate 
monocytes produce mainly IL-1β and TNF, and both subsets produce little IL-10 in response 
to LPS. Non-classical monocytes secreted higher levels of IL-10 in response to bacterial 
signals than the other two subsets (Cros et al., 2010). In agreement with Cros et al. (Cros et 
al., 2010), Rossol et al. (Rossol et al., 2012) found that intermediate monocytes from RA 
patients produced the highest levels of IL-1β and TNF when stimulated by LPS in vitro, but 
the CD14+ subsets produced similar levels of IL-10, IL-6 and IL-8, which were higher than 
those produced by the CD14dim subset. Wong et al. (Wong et al., 2011) also found that IL-6 
and IL-8 production was similar in all monocyte subsets, but the non-classical monocytes had 
the highest levels of IL-1β and TNF production and the classical monocytes secreted the 
most IL-10 in response to LPS, in contrast to findings reported by Cros et al. (Cros et al., 
2010). Another study also found that the CD14dim monocytes produced the highest levels of 
TNF compared to the other two subsets in response to LPS but CD14+CD16+ monocytes 
produced the highest levels of IL-10 (Skrzeczynska-Moncznik et al., 2008). 
 
Functionally, classical monocytes have an enhanced phagocytic ability compared with 
intermediate monocytes as they produce high levels of reactive oxygen species and increased 
mRNA expression for myeloperoxidase and lysozyme in response to bacterial antigen (Cros 
et al., 2010). Intermediate monocytes were shown to be proficient antigen presenting cells 
(APC) with their increased expression of genes associated with antigen processing and 
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presentation, as well as surface markers involved with antigen presentation to T cells, such as 
CD40 and CD54 (Wong et al., 2011, Zawada et al., 2011). Intermediate monocytes have also 
been implicated in angiogenesis (Zawada et al., 2011). Human non-classical monocytes, 
which express CX3CR1 like their mouse counterpart, were shown to attach to and crawl 
along mouse endothelium after intravenous transfer, one of the key functions of mouse 
Ly6Clo/Gr1- monocytes (Cros et al., 2010). Studies of gene expression also revealed the 
increased expression of genes associated with cell motility on non-classical monocytes 
(Wong et al., 2011, Zawada et al., 2011). 
 
The majority of monocytes in human peripheral blood are classical monocytes, up to 90% of 
all monocytes in the steady state, with the two subsets expressing CD16 accounting for the 
remaining 10% (Ziegler-Heitbrock et al., 1993). These proportions can change in different 
circumstances, for example, CD16+ monocytes were expanded during various infections and 
inflammatory conditions (Ziegler-Heitbrock, 2007), and glucocorticoid treatment resulted in 
the depletion of CD16+ monocytes (Fingerle-Rowson et al., 1998) and lower CD14 
expression (Sumegi et al., 2005). A developmental relationship also appears to exist between 
human monocyte subsets. In a clinical trial of anti-M-CSF mnonclonal antibody for the 
treatment of RA, the administration of anti-M-CSF led to the immediate depletion of 
intermediate and non-classical monocytes. This effect was not seen in the patient who was 
given placebo. In the patient treated with anti-M-CSF, there was a gradual recovery of the 
intermediate monocytes prior to the non-classical monocytes (Korkosz et al., 2012). Non-
human primates have a similar system of monocyte subsets compared to that of humans 
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(Ziegler-Heitbrock, 2014). In model of viral infection where rhesus macaques were injected 
with R-848, a ligand for TLR-7/8, there was an immediate increase on day 1 of the 
intermediate monocytes, followed by an increase of non-classical monocytes on day 2 
(Kwissa et al., 2012). The data from these two studies suggest a sequential development of 
monocytes in both human and non-human primates from classical through intermediate to 
non-classical monocytes. 
 
1.5.2  Increased Ly6Clo/Gr1- Monocytes in Animal Models of Lupus 
Monocytosis is a unique feature of the BXSB murine model of lupus as it is not seen in 
NZB/W F1 or MRL/lpr mice. The expansion of the monocyte population began at 2 months 
of age in male BXSB mice and progressively increased with age, with 50 to 90% of PBMC 
being monocytes by 6 months of age (Wofsy et al., 1984b). Monocytosis in mice bearing the 
Yaa mutation correlated with autoantibody production and the development of lethal lupus 
nephritis (Kikuchi et al., 2006). Ly6Clo/Gr1- monocytes have been implicated in murine 
lupus. Amano et al. (Amano et al., 2005) demonstrated an increase in circulating Ly6Clo/Gr1- 
monocytes compared with Ly6Chi/Gr1+ monocytes in 8-month-old BXSB-Yaa male mice but 
not in younger BXSB-Yaa mice, old BXSB mice without the Yaa mutation or B6-Yaa mice. 
Furthermore, the in vivo activation of TLR-7 or 9 resulted in monocytosis and promoted the 
differentiation of Ly6Chi/Gr1+ monocytes to Ly6Clo/Gr1- monocytes (Santiago-Raber et al., 
2011). Although most of the work by Santiago-Raber et al. (Santiago-Raber et al., 2011) was 
performed on C57Bl/6 mice, it was suggested that a more dramatic increase in monocytes 
and differentiation to the Ly6Clo/Gr1- subset would be present in BXSB-Yaa mice because 
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the Yaa mutation confers an overexpression of TLR-7 (Pisitkun et al., 2006, Subramanian et 
al., 2006). 
 
An increase in fractalkine expression and accumulation of CD16+ monocytes in glomerular 
lesions of C.B-17/Inc-scid/scid severe combined immunodeficiency (SCID) lupus mice 
injected with IgG3-producing hybridoma clones from MRL/lpr mice has been reported by 
Nakatani et al. (Nakatani et al., 2010). However, it is unclear which monocyte population 
Nakatani and colleagues were referring to because both Ly6Chi/Gr1+ and Ly6Clo/Gr1- 
monocytes in mice express CD16 (Geissmann et al., 2003), and the differential expression of 
CD16 is therefore not generally used to distinguish monocyte subsets in mice. 
 
1.5.3  Monocyte Subset Abnormalities in Human SLE 
Overall, different studies have reported different findings with regards to variations in 
monocyte subsets in patients with SLE. This could be due to differences in gating strategy, 
and earlier studies have included intermediate and non-classical monocytes as a single 
population. The findings from these studies are summarised in Table 1.15. Cairns et al. 
(Cairns et al., 2002) studied the changes in CD14++CD16- (classical) and CD14+CD16+ 
(intermediate and non-classical together) monocytes in the peripheral blood of RA and SLE 
patients. A reduction of CD14+CD16+ monocytes was seen in RA patients but not SLE 
patients compared to healthy controls, and the percentage of CD14+CD16+ monocytes did not 
correlate with SLAM or BILAG scores in SLE patients. Also, the frequency of CD14+CD16+ 
monocytes did not differ significantly between SLE and RA patients who were on 
Table 1.15. Perturbations of monocyte subsets in human SLE. 
 
Monocyte subsets Phenotype Patient group Associations with features of SLE References 
Increased intermediate and non-
classical monocytes 
Classical: CD14hi CD16- 
Intermediate and non-
classical: CD14dim CD16+ 
Active and 
inactive SLE 
Glucocorticoid treatment of SLE patients 
resulted in the decrease of CD14dim CD16+ and 
increase of CD14hi CD16- monocytes 
(Sumegi et al., 
2005) 
 Classical: CD16- 
Intermediate and non-
classical: CD16+ 
Active lupus 
nephritis 
Infiltration of CD16+ monocytes in glomerular 
vessels 
(Yoshimoto et 
al., 2007) 
     
No difference in intermediate and non-
classical monocytes 
Classical: CD14++ CD16- 
Intermediate and non-
classical: CD14+ CD16+ 
Active and 
inactive SLE 
Frequency of CD14+ CD16+ monocytes did not 
correlate with disease activity or dosage of 
corticosteroids 
(Cairns et al., 
2002) 
     
Increased classical, decreased non-
classical and no difference in 
intermediate monocytes 
Classical: CD14++ CD16- 
Intermediate: CD14++ CD16+ 
Non-classical: CD14+ 
CD16++ 
Active SLE  (Burbano et al., 
2014) 
     
Decreased expression of CD16 on 
non-classical monocytes 
Classical: CD14++ CD16- 
Intermediate: CD14++ CD16+ 
Non-classical: CD14+ 
CD16++ 
Active SLE  (Burbano et al., 
2014) 
     
Decreased expression of CD14 on 
classical monocytes 
Classical: CD14hi CD16- 
Intermediate and non-
classical: CD14dim CD16+ 
Active and 
inactive SLE 
Glucocorticoid treatment resulted in dose-
dependent reduction of CD14 expression on 
classical monocytes 
(Sumegi et al., 
2005) 
 Classical: CD14++ CD16- 
Intermediate: CD14++ CD16+ 
Non-classical: CD14+ 
CD16++ 
Active and 
inactive SLE 
 (Burbano et al., 
2014) 
 
CD – cluster of differentiation; SLE – systemic lupus erythematosus. 
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corticosteroid treatment versus those who were not, and did not correlate with the dosage of 
corticosteroids in both conditions.  
 
In contrast, another study which investigated the effects of glucocorticoids on CD14hiCD16- 
(classical) and CD14dimCD16+ (in this case, intermediate and non-classical) monocytes, 
Sumegi et al. (Sumegi et al., 2005) reported that the frequency and absolute number of 
CD14dimCD16+ monocytes were significantly increased in untreated SLE patients compared 
with healthy controls and glucocorticoid treatment resulted in the reduction of this subset. 
Absolute number of CD14hiCD16- monocytes increased with glucocorticoid treatment but not 
significantly compared with SLE patients on low dose steroid treatment, untreated patients or 
healthy controls. Glucocorticoid treatment also led to the dose-dependent reduction of CD14 
expression on CD14hiCD16- monocytes, but CD14 expression was similar on CD14dimCD16+ 
monocytes regardless of glucocorticoid dosage. 
 
More recently, Burbano et al. (Burbano et al., 2014) studied the numbers of all three 
monocyte subsets (classical CD14++CD16-, intermediate CD14++CD16+ and non-classical 
CD14+CD16++) in SLE patients. The frequency of classical monocytes was increased in 
patients with active SLE compared with inactive SLE and controls, and the frequency and 
absolute number of non-classical monocytes were lower in active SLE compared to the other 
groups. The absolute number of intermediate monocytes did not differ between SLE patients 
and healthy controls. CD14 expression was decreased on classical monocytes in SLE patients 
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compared with healthy controls, and CD16 expression was lower on non-classical monocytes 
in active versus inactive SLE. 
 
Several studies have implicated the involvement of the CD16-expressing monocyte subsets in 
human lupus nephritis. Yoshimoto et al. (Yoshimoto et al., 2007) found an infiltration of 
CD16+ monocytes (both intermediate and non-classical monocytes) with increased 
expression of CX3CR1 in the glomerular vessels of patients with proliferative lupus 
nephritis. Cros et al. (Cros et al., 2010) demonstrated the secretion of TNF and CCL3 by 
CD14dim monocytes activated by sera from lupus patients and by anti-RNP antibodies. They 
suggested a role for CD14dim monocytes in the pathogenesis of SLE, whereby immune 
complexes containing RNPs activate monocytes via their expression of TLR-7/8, leading to 
secretion of inflammatory cytokines.  
 
1.6  The Role of NK Cells in SLE 
1.6.1  Human NK Cell Development and Maturation 
NK cells are considered innate lymphoid cells as they morphologically resemble 
lymphocytes but do not undergo antigen receptor rearrangement unlike B and T cells (Spits 
and Cupedo, 2012), but NK cells also have a role in enhancing adaptive immune responses 
(discussed later in this section). The development of the NK cell occurs mainly in the bone 
marrow, where hematopoietic stem cells give rise to the common lymphoid progenitor (Yu et 
al., 2013). In mice, NK cell maturation occurs in four stages based on differential expression 
of CD27 and CD11b (Chiossone et al., 2009). Different stages of human NK cell maturation 
was demonstrated in secondary lymphoid tissue, beginning with the IL-15-independent NK 
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cell progenitor, followed by the pre-NK cell and the immature NK cell stages that respond to 
IL-15 to initiate their development but do not yet express CD56 or CD16. Expression of 
CD56 begins in the fourth stage with the appearance of the mature CD56bri NK cell subset 
(Freud et al., 2006). 
 
Five human peripheral blood NK cell populations have been identified based on differential 
expression of CD56 and CD16. The majority of NK cells in the peripheral blood are the 
mature CD56dimCD16+ subset, accounting for 90% of all circulating NK cells (Cooper et al., 
2001a). CD56bri NK cells account for most of the remaining 10% of circulating NK cells 
(Cooper et al., 2001a) and consist of two subsets, mostly CD56briCD16- and less than 50% 
are CD56briCD16dim, which are often considered together as a single population in studies 
(Poli et al., 2009). CD56bri NK cells are found mostly in secondary lymphoid organs, except 
for the spleen where most of the NK cells are of the CD56dimCD16+ subset (Ferlazzo et al., 
2004). The abundance of the CD56bri subset in secondary lymphoid sites indicated that NK 
cell maturation could occur outside of the bone marrow, with studies demonstrating that 
CD56bri NK cells can give rise to the more mature CD56dimCD16+ subset, which is 
considered to be the fifth stage of NK cell development (Romagnani et al., 2007, Chan et al., 
2007). CD56dimCD16- NK cells are rare in the peripheral blood of healthy individuals and 
little is known about this subset (Poli et al., 2009). CD56- NK cells are also rare in healthy 
individuals but are expanded in patients with chronic human immunodeficiency (HIV)-1 and 
hepatitis C (HCV) (Hu et al., 1995, Gonzalez et al., 2009, Gonzalez et al., 2008, Eller et al., 
2009, Mavilio et al., 2005). 
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In addition to expression of CD56 and CD16, NK cell subsets also differ in their expression 
of cell surface inhibitory and activating receptors. Killer Ig-like receptors (KIRs) that 
recognise classical MHC class I ligands (Colonna and Samaridis, 1995, D'Andrea et al., 
1995, Wagtmann et al., 1995a, Wagtmann et al., 1995b) and the CD94/NKG2A complex that 
recognises the non-classical HLA-E (Braud et al., 1998, Borrego et al., 1998, Lee et al., 
1998) are two well-characterised types of inhibitory receptors. Many KIRs have two 
immunoreceptor tyrosine-based inhibitory motifs (ITIM) in their cytoplasmic domains 
(Olcese et al., 1996, Burshtyn et al., 1996, Fry et al., 1996). CD94 has a short cytoplasmic 
domain that lacks a signalling function and acts as a chaperone molecule for the inhibitory 
receptor NKG2A, which also has two ITIMs in its cytoplasmic domain (Carretero et al., 
1998, Le Drean et al., 1998). CD56dimCD16+ NK cells express higher levels of KIRs but the 
CD56briCD16- subset expresses more CD94/NKG2A (Jacobs et al., 2001, Andre et al., 2000, 
Voss et al., 1998). There are activating isoforms of KIRs that recognise the same ligands as 
their inhibitory counterparts, but at a lower affinity (Moretta et al., 1995, Biassoni et al., 
1996, Bottino et al., 1996, Biassoni et al., 1997, Stewart et al., 2005). Activating KIRs do not 
have ITIMs and they associate with DAP12, an adaptor protein that has an immunoreceptor 
tyrosine-based activation motif (ITAM), to enable activatory signalling (Bottino et al., 1996, 
Campbell et al., 1998, Lanier et al., 1998b). NKG2C is the activatory isoform of NKG2A and 
also recognises HLA-E (Houchins et al., 1997). As with activating KIRs, NKG2C needs to 
associate with DAP12 for activatory signalling to occur (Lanier et al., 1998a).  
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Inhibitory and activatory receptors on NK cells form an NK synapse with ligands on target 
cells. Whether the target cell is lysed or not by the NK cell is largely determined by the 
balance of inhibitory and activatory signalling within the NK synapse (Davis et al., 1999, 
Lou et al., 2000, Vyas et al., 2001). NK cells are prevented from lysing healthy cells under 
normal circumstances due to the recognition of self-MHC class I molecules expressed on 
healthy cells by inhibitory receptors on NK cells. In general, stressed, infected or tumour 
cells lower their expression of self-MHC class I molecules to avoid attack by cytotoxic T 
lymphocytes. It was initially believed that NK cells would no longer be inhibited from 
activation by such cells due to their reduced expression self-MHC class I ligands, and these 
susuceptible target cells will be lysed by activated NK cells. This was referred to as the 
“missing-self hypothesis” (Karre et al., 1986, Ljunggren and Karre, 1990). However, this 
theory was disproven because MHC class I-deficient individuals did not develop NK cell-
mediated autoimmunity despite their NK cells being fully functional (Furukawa et al., 1999, 
Vitale et al., 2002, Zimmer et al., 1998). It was subsequently shown that in order for NK cells 
to become responsive from stimulation through their activating receptors, NK cells needed to 
have been “educated” or “licensed” by previous self-MHC class I recognition through their 
inhibitory receptors (Kim et al., 2005, Kim et al., 2008, Anfossi et al., 2006). When the 
signalling through the activating KIRs or NKG2C in association with DAP12 is stronger than 
inhibitory signals, this results in the lysis of the target cell and IFNγ production by the 
activated NK cell (Bottino et al., 1996, Campbell et al., 1998, Mandelboim et al., 1998). The 
expression of the activating KIR, KIR3DS1, and its ligand had a protective effect on patients 
with acute HIV-1 including a delayed progression to AIDS, inhibition of HIV-1 replication 
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and an increased level of degranulation of HIV-infected target cells (Martin et al., 2002, Alter 
et al., 2007). 
 
NK cells also express activating receptors that recognise non-MHC class I molecules. 
NKG2D is expressed on all NK cells and in association with the adaptor protein DAP10 
binds to ligands including the MHC class I-like MIC proteins and UL16-binding protiens 
(Bauer et al., 1999, Chalupny et al., 2003, Cosman et al., 2001, Wu et al., 1999). Ligands for 
NKG2D are not expressed on healthy cells but are upregulated on stressed, transformed or 
virally infected cells, which are then killed by NK cells through perforin-dependent 
cytotoxicity when activatory signalling through NKG2D/DAP10 are stronger than inhibitory 
signals (Bauer et al., 1999, Wu et al., 1999, Hayakawa et al., 2002, Gasser et al., 2005). 
 
Natural cytotoxicity receptors (NCRs) are another type of activating receptor that binds to 
non-MHC class I ligands. Two of the NCRs, NKp46 and NKp30, are constitutively 
expressed on all NK cells (Pende et al., 1999, Pessino et al., 1998, Sivori et al., 1997). 
NKp46, postulated to be the mammalian pan-NK cell marker (Walzer et al., 2007), is 
expressed at higher levels on CD56briCD16- than CD56dimCD16+ NK cells (Caligiuri, 2008). 
Both NKp46 and NKp30 have cytoplasmic tails that lack a signalling motif and therefore are 
required to bind adaptor proteins, CD3ζ and FcRγ, for the activation of the NK cell (Vitale et 
al., 1998, Pende et al., 1999). Several splice variants of NKp30 exist. The engagement of 
NKp30a or NKp30b results in the production of high levels of IFNγ but engagement of 
NKp30c leads to the secretion of IL-10 (Delahaye et al., 2011). NKp44 is expressed on 
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activated but not resting NK cells and associates with DAP12 to enable NK cell activation 
(Cantoni et al., 1999, Vitale et al., 1998). The role of NCRs was first uncovered by their 
involvement in the killing of tumour cells (Pende et al., 1999, Pessino et al., 1998, Sivori et 
al., 1999, Fauriat et al., 2007). However, ligands for NCRs have only been identified in 
recent years (reviewed in (Kruse et al., 2014)), including heparin and heparan sulfate on 
animal cells (Hecht et al., 2009), viral haemagglutinins (Arnon et al., 2004, Mandelboim et 
al., 2001, Jarahian et al., 2011), B7-H6 on tumour cells recognised by NKp30 (Brandt et al., 
2009) and also proliferating cell nuclear antigen (PCNA) on tumour cells recognized by 
NKp44 (Rosental et al., 2011). The binding of NCRs to their ligands mostly results in 
cytotoxicity or cytokine production by the NK cell, but in some cases may lead to inhibitory 
responses, for example, NKp30 interactions with PCNA (Rosental et al., 2011). 
 
Adhesion molecule and chemokine receptor expression also differs between the two major 
NK cell subsets, which determines their homing capabilities. CD56briCD16- NK cells express 
higher levels of CD62L and other adhesion molecules involved in leukocyte extravasation 
into tissues than the CD56dimCD16+ subset, but a small population of CD56dimCD16+ NK 
cells have an elevated expression of CD11a (Frey et al., 1998, Poli et al., 2009). 
CD56dimCD16+ NK cells express CXCR1 and CX3CR1 and localise to acute inflammatory 
sites but CD56briCD16- NK cells, which are mostly found in secondary lymphoid organs, 
express CCR7 and higher levels of CXCR3 than the CD56dimCD16+ subset (Campbell et al., 
2001). Functionally, CD56dimCD16+ NK cells are more efficient at killing target cells due to 
their increased expression of perforin, granzyme and cytolytic granules (Nagler et al., 1989, 
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Jacobs et al., 2001). The expression of CD16 on CD56dimCD16+ NK cells confers on them 
the ability to perform antibody-dependent cellular cytotoxicity (ADCC) (Nagler et al., 1989, 
Leibson, 1997). In contrast, CD56briCD16- NK cells are more efficient at cytokine secretion, 
mainly secreting IFNγ and also TNF, GM-CSF, IL-10 and IL-13 (Cooper et al., 2001b, 
Fehniger et al., 1999, Jacobs et al., 2001). However, cytolytic activity can be induced on 
CD56briCD16- NK cells when stimulated in vitro (Nagler et al., 1990, Robertson et al., 1992). 
CD56briCD16- NK cells have been referred to as regulatory NK cells due to their ability to 
secrete IL-10 (Deniz et al., 2008) and regulate the function of other immune cells. 
CD56briCD16- NK cells were shown to be involved in the generation, maturation and 
cytokine production of DCs (Gerosa et al., 2002, Piccioli et al., 2002, Della Chiesa et al., 
2003), enhance the function of CD4+ T cells and promote Th1 responses (Roncarolo et al., 
1991, Zingoni et al., 2004, Hanna et al., 2004, Byrne et al., 2004, Morandi et al., 2006, 
Martin-Fontecha et al., 2004). CD56briCD16- NK cells also have a role in maintaining 
tolerance by the killing of over-stimulated DCs, activated B and T cells (Della Chiesa et al., 
2003, Takeda and Dennert, 1993, Lu et al., 2007) and the inhibition of autoreactive T cell 
responses (Trivedi et al., 2005, Deniz et al., 2008, Yu et al., 2006). Thus, it is conceivable 
that any disruption to the number or function of CD56briCD16- NK cells could result in 
autoimmunity due to ineffective regulation of other cell populations. In addition, it has been 
suggested that the dysregulation of CD56briCD16- NK cells could drive the development of 
autoimmunity by promoting B cell responses via CD40-CD40L interactions (Blanca et al., 
2001). 
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An increase in CD56- NK cells has been seen in patients with chronic HCV (Gonzalez et al., 
2009, Gonzalez et al., 2008) and chronic HIV-1, but not in patients with acute HIV-1 (Hu et 
al., 1995, Brunetta et al., 2009, Mavilio et al., 2003, Mavilio et al., 2005, Alter et al., 2005, 
Eller et al., 2009). Because CD56- NK cells are rare in healthy individuals (Hu et al., 1995), 
the characterisation of this subset has mostly been from cells isolated from patients with 
HIV-1 or HCV. CD56- NK cells express CD16 (Hu et al., 1995, Mavilio et al., 2005) but 
have a lower expression of perforin compared with CD56dimCD16+ NK cells (Alter et al., 
2006, Gonzalez et al., 2009, Gonzalez et al., 2008). Regarding inhibitory receptor expression, 
CD56- NK cells from patients with chronic HIV and HCV express low levels of 
CD94/NKG2A (Mavilio et al., 2005, Eller et al., 2009, Gonzalez et al., 2008). Of the KIRs, 
Mavilio et al. (Mavilio et al., 2005) reported that CD56- NK cells had a higher expression of 
KIR2DL2, KIR2DL3 and LILRB1 than CD56+ NK cells in patients with HIV-1, but 
KIR2DL1 expression was found to be decreased on both CD56- and CD56dim NK cells in 
HIV-1 patients in the study by Eller et al. (Eller et al., 2009). Activating NK cell receptor 
expression varies in different infections. CD56- NK cells from HIV-1 patients express lower 
levels of NKp30 and NKp46 than CD56dimCD16+ NK cells but this difference was not seen 
in NK cells from HCV patients (Mavilio et al., 2005, Eller et al., 2009, Gonzalez et al., 
2008). Expression of NKG2D is similar in both CD56- and CD56dimCD16+ NK subsets in 
both HIV-1 and HCV (Mavilio et al., 2005, Gonzalez et al., 2008). Furthermore, it appears 
that CD56- NK cells are functionally impaired. Compared with CD56dimCD16+ NK cells, 
CD56- NK cells from patients with chronic viral infections had a decreased ability to 
degranulate and mediate ADCC, and produced lower levels of cytokines including IFNγ (Hu 
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et al., 1995, Alter et al., 2005, Eller et al., 2009, Gonzalez et al., 2008). The cell surface 
phenotype and reduced functional capabilities of CD56- NK cells suggest that CD56- NK 
cells are closely related to and may have developed from CD56dimCD16+ NK cells, but 
further research is required to determine the origin of CD56- NK cells. 
 
1.6.2  NK Cell Dysregulation in Animal Models of Lupus 
Functional impairment of NK cells has been reported in different mouse strains bearing the 
lpr gene. C57Bl/6, C3H and MRL mice with the lpr mutation spontaneously develop mild, 
moderate and severe lupus-like illness respectively, and were found to have splenic and bone 
marrow NK cells with defective lytic activity from 2 months of age, which was further 
reduced as the mice aged (Pan et al., 1986). Takeda and Dennert (Takeda and Dennert, 1993) 
found that the age-dependent reduction of NK and NKT cells was associated with the 
development of autoimmunity in B6.lpr mice and demonstrated that the depletion of NK 
cells in B6.lpr mice resulted in the expansion of B cells that secreted autoantibody against 
dsDNA, but autoantibody production was delayed in B6.lpr mice with the adoptive transfer 
of NK cells. In contrast, Magilavy et al (Magilavy et al., 1987) found an age-dependent 
increase of NK cell activity in the liver but not in the spleen or peripheral blood of MRL/lpr 
and NZB/W F1 mice, and these mice had extremely high levels of hepatic NK cell activity by 
the onset of clinical disease. More recently, a subset of NK cells expressing the activating 
receptor CD226 (DNAX accessory molecule-1) that had an enhanced cytotoxic ability were 
found to infiltrate the kidneys of MRL/lpr mice prior to the development of clinical 
manifestations (Huang et al., 2011). 
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1.6.3  NK Cell Dysregulation in Human SLE 
The findings from various studies investigating NK cell dysregulation in human SLE are 
summarised in Table 1.16. Most studies have reported a decrease in the absolute number 
(Hervier et al., 2011, Henriques et al., 2013, Erkeller-Yusel et al., 1993, Park et al., 2009, 
Schleinitz et al., 2009, Riccieri et al., 2000) and frequency (Erkeller-Yusel et al., 1993, Park 
et al., 2009, Schleinitz et al., 2009, Puxeddu et al., 2012, Riccieri et al., 2000) of peripheral 
blood NK cells in patients with SLE compared with healthy controls, but proportions of the 
two major NK cell subsets (CD56dimCD16+ and CD56briCD16-) were similar in SLE patients 
and controls (Hervier et al., 2011, Henriques et al., 2013, Schleinitz et al., 2009). Some of 
these studies found a greater reduction of NK cells in patients with active SLE compared to 
those with inactive disease (Erkeller-Yusel et al., 1993, Huang et al., 2011, Henriques et al., 
2013). SLE patients with renal involvement had fewer NK cells than patients with non-renal 
manifestations (Park et al., 2009, Erkeller-Yuksel et al., 1997), and the number and 
percentage of NK cells inversely correlated with renal system activity as assessed by the 
BILAG index (Erkeller-Yuksel et al., 1997). Park and colleagues (Park et al., 2009) 
suggested that the decrease in NK cells could be due to the reduced proliferative capacity of 
haematopoietic stem cells (HSC) and differentiation of NK cells from HSCs in SLE patients. 
Interestingly, NK cell deficiency was more pronounced in SLE patients treated with steroids 
and azathioprine than untreated patients (Erkeller-Yusel et al., 1993). In contrast, Schepis et 
al. (Schepis et al., 2009) found a significant increase in CD56briCD16- NK cells in patients 
with SLE but the frequency of the total NK cell population did not vary between SLE and 
controls. The expansion of the CD56briCD16- NK cell subset was not related to the 
Table 1.16. Perturbations of NK cell subsets in human SLE. 
 
NK cell population Phenotype Patient group Associations with features of SLE References 
Decreased total NK 
cells 
NK cells: CD3- CD56+  Active and 
inactive SLE 
 (Hervier et al., 2011, Henriques 
et al., 2013, Schleinitz et al., 
2009, Puxeddu et al., 2012) 
 NK cells: CD3- CD56+  Active and 
inactive SLE 
Patients with renal involvement had fewer NK cells 
than patients with non-renal manifestations 
(Park et al., 2009) 
 NK cells: CD3- CD56+ 
CD16+  
Active and 
inactive SLE 
 (Riccieri et al., 2000) 
 NK cells: CD3- CD56+ 
CD16+  
Active and 
inactive SLE 
Inversely correlated with renal system activity, 
patients with renal involvement had fewer NK cells 
than patients with non-renal manifestations 
(Erkeller-Yuksel et al., 1997) 
 NK cells: CD3- CD56+ 
CD16+  
Active and 
inactive SLE 
NK cell deficiency more pronounced in patients 
treated with steroids and azathioprine 
(Erkeller-Yusel et al., 1993) 
     
No difference in 
proportion of NK cell 
subsets 
NK cells: CD3- CD56+ 
Subsets: CD56bri and 
CD56dim  
Active and 
inactive SLE 
 (Hervier et al., 2011, Henriques 
et al., 2013, Schleinitz et al., 
2009) 
     
Increased CD56bri NK 
cells, no difference in 
total NK cells 
NK cells: CD3- CD56+ 
Subsets: CD56bri (CD3- 
CD56+ CD16-) and CD56dim 
Active and 
inactive SLE 
Not related to development of lupus nephritis, anti-
dsDNA titre or treatment 
(Schepis et al., 2009) 
     
Decreased expression 
of CD16 on NK cells 
NK cells: CD3- CD56+ Active and 
inactive SLE 
 (Schleinitz et al., 2009) 
     
Decreased expression 
of CD16 on CD56dim 
NK cells 
NK cells: CD3- CD56+ 
Subsets: CD56bri and 
CD56dim 
Active SLE  (Hervier et al., 2011) 
     
Increased expression 
of NKp46 on CD56dim 
NK cells 
NK cells: CD3- CD56+ 
Subsets: CD56bri (CD3- 
CD56+ CD16-) and CD56dim 
Active and 
inactive SLE 
 (Schepis et al., 2009) 
     
No difference in 
expression of NKp46 
on NK cells 
NK cells: CD3- CD56+ Active and 
inactive SLE 
 (Schleinitz et al., 2009, 
Puxeddu et al., 2012) 
 
CD – cluster of differentiation; dsDNA – double stranded DNA; SLE – systemic lupus erythematosus.  
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development of lupus nephritis, anti-dsDNA antibody levels or treatment (Schepis et al., 
2009).  
 
It is important to note that the markers used to identify NK cells varied among different 
groups. NK cells were defined as CD3-CD56+ cells in most studies (Park et al., 2009, Hervier 
et al., 2011, Henriques et al., 2013, Schleinitz et al., 2009, Puxeddu et al., 2012, Huang et al., 
2011, Schepis et al., 2009) but some studies also included the expression of CD16 and 
defined NK cells as CD3-CD56+CD16+ cells (Erkeller-Yuksel et al., 1997, Riccieri et al., 
2000). CD56dimCD16+ and CD56briCD16- NK cell subsets were identified based on 
differential expression of CD56 on CD3-CD56+ cells (Schleinitz et al., 2009, Hervier et al., 
2011, Henriques et al., 2013) but Schepis et al. (Schepis et al., 2009) defined CD56briCD16- 
NK cells as CD3-CD56+CD16- cells. 
 
The expression of some of the NK cell surface markers is also altered in SLE. Schleinitz et 
al. (Schleinitz et al., 2009) found that NK cells from SLE patients had lower levels of CD16 
expression compared to those from healthy controls, and Hervier et al. (Hervier et al., 2011) 
reported a decrease of CD16 expression on CD56dim NK cells from active SLE patients. The 
expression of NKp46 but not NKp30 or NKp44 was slightly higher on CD56dim NK cells 
from SLE patients compared with controls in the study by Schepis and co-workers (Schepis 
et al., 2009), but other studies found that the expression of natural cytotoxicity receptors 
including NKp46 did not differ between SLE patients and healthy controls (Schleinitz et al., 
2009, Puxeddu et al., 2012). 
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1.7  Project Aims 
Studies in animal models and lupus patients suggest several mechanisms driving the loss of B 
cell regulation and the resultant production of pathogenic autoantibodies in SLE. The first 
mechanism involves overexpression of BAFF and operates in a T-independent manner. The 
second is driven by Tfh cells and does not require an increase in BAFF. In addition, studies 
have shown a decrease in Tregs in lupus-prone mice. There is some evidence of a correlation 
between disease severity and both increased serum BAFF levels and increased cTfh cells in 
patients with SLE. Furthermore, there is evidence suggesting a role for monocytes in the 
pathogenesis of SLE through enhanced recognition of immune complexes containing TLR-
binding self antigens. The overall decrease of NK cells and a proportional increase of the 
CD56briCD16- NK cell subset could further promote immune dysregulation in patients with 
SLE. Finally, a number of B cell abnormalities have been reported in SLE, at least some of 
which are believed to correlate with disease severity. It remains unclear whether all of these 
abnormalities co-exist within each patient, or if human SLE can be divided into subcategories 
depending on the particular immune process driving the disease. 
 
In this project, I will investigate the contributions of BAFF, B cells, Tfh cells, Tregs, 
monocytes and NK cells to human SLE. The first aim is to subtype SLE on the basis of 
multi-parameter flow cytometric analysis of peripheral blood cells from SLE patients. The 
second aim is to ascertain whether the frequencies of B cell, Tfh cell, Treg, monocyte and 
NK cell populations correlate with each other, serum BAFF levels and other measures of 
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SLE, including anti-dsDNA antibody titre, disease activity and clinical history. A better 
understanding of relationships between these parameters will give insights into the 
pathophysiology of SLE and thus improve diagnosis and therapeutic options. 
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CHAPTER 2:  MATERIALS AND METHODS 
2.1  Patient and Control Samples 
2.1.1  Recruitment of SLE Patients 
144 blood samples were collected from 65 individual patients with SLE, who were recruited 
from the Department of Clinical Immunology, Royal Prince Alfred Hospital (Sydney). 123 
samples were from 57 female SLE patients (mean age 39.9 years, range 20-66 years) and 21 
samples were from 8 male SLE patients (mean age 38.8 years, range 27-50 years). Patients 
recruited in this study fulfilled the American College of Rheumatology criteria for the 
diagnosis of SLE and their clinical activity was determined by the SELENA-SLEDAI 
(Figure 1.1). We aimed to collect as many samples as we could, especially samples from SLE 
patients with more highly active disease. Samples were not included or excluded based on 
treatment. The only reason a sample would have been rejected from our study was poor 
sample quality. The majority of patients had inactive SLE (n=81) while 57 patients were 
assessed as having lupus flares at the time of blood collection. Three of the patients were 
diagnosed by renal biopsy and were not assessed with the SELENA-SLEDAI. One sample 
was collected from a patient with chronic renal failure therefore disease activity could not be 
determined. Demographic, clinical and therapeutic details of SLE patients are summarised in 
Table 2.1. Written informed consent was obtained from all patients. Ethics approval was 
obtained from the Human Research Ethics Committee of the University of Sydney. 
 
Table 2.1. Demographic, clinical and therapeutic characteristics of SLE patients, disease 
control and healthy control subjects and samples included in study. 
 
 SLE Disease 
control 
Healthy 
Subjects 65 23 68 
Samples 144 28 68 
Age, mean years 39.9 54.9 41.2 
Female, no. of subjects (%) 57 (88%) 19 (83%) 58 (85%) 
Female age, mean years 39.9 54.4 41.2 
Male, no. of subjects (%) 8 (12%) 4 (17%) 10 (15%) 
Male age, mean years 38.8 57.2 41.2 
SLE disease activity, no. of samples    
Active (%) 58 (40%) - - 
Severe 15 - - 
Moderate 18 - - 
Mild 25 - - 
Inactive (%) 81 (56%) - - 
Not assessed by SELENA-SLEDAI 5 (3%) - - 
SLE manifestations, no. of samples    
Neurologic 6 - - 
Musculoskeletal 34 - - 
Renal 34 - - 
Cutaneous 18 - - 
Cardiopulmonary 4 - - 
Systemic 3 - - 
Haematologic 3 - - 
Disease control conditions, no. of subjects    
Antiphospholipid syndrome - 2 - 
Drug-induced lupus - 1 - 
Lupus-like illness, undifferentiated autoimmune 
disease 
- 5 - 
Rheumatoid arthritis - 4 - 
Scleroderma - 1 - 
Sjögren’s syndrome - 9 - 
Vasculitis - 1 - 
Therapy, no. of samples    
Azathioprine 31 5 - 
Cyclophosphamide 5 1 - 
Cyclosporin 1 1 - 
Hydroxychloroquine 83 10 - 
IVIG 3 0 - 
Methotrexate 5 5 - 
Mycophenolate 20 0 - 
Prednisone 101 13 - 
Rituximab 1 0 - 
Tacrolimus 1 0 - 
  
IVIG – intravenous immunoglobulin; SELENA – Safety of Estrogen in Lupus Erythematosus 
National Assessment; SLE – systemic lupus erythematosus; SLEDAI – SLE Disease Activity 
Index. 
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2.1.2  Recruitment of Disease Control Subjects 
In addition, 28 blood samples were obtained from 23 individual patients with autoimmune 
conditions other than SLE as disease control subjects. These patients were recruited from the 
Department of Clinical Immunology, Royal Prince Alfred Hospital (Sydney). Samples were 
not included or excluded based on treatment. The non-SLE disease controls were considered 
as one whole group; we did not segregate the non-SLE group into subgroups of diseases 
because that was not the goal of our study here. We collected whatever was made available to 
us. The only reason a sample would have been rejected from our study was poor sample 
quality. Autoimmune conditions in this population included antiphospholipid syndrome 
(n=2), drug-induced lupus (n=1), lupus-like illness or undifferentiated autoimmune condition 
(n=5), rheumatoid arthritis (n=4), scleroderma (n=1), Sjögren’s Syndrome (n=9) and 
vasculitis (n=1). The disease control group consisted of 19 women (mean age 54.4 years, 
range 34-84 years) and 4 men (mean age 57.2 years, range 23-74 years), and their 
demographic, clinical and therapeutic details are summarised in Table 2.1. Written informed 
consent was obtained from all subjects. Ethics approval was obtained from the Human 
Research Ethics Committee of the University of Sydney. 
 
2.1.3  Recruitment of Healthy Control Subjects 
68 age- and sex-matched healthy control subjects with no known autoimmune condition were 
recruited in Sydney. The healthy control population consisted of 58 women (mean age 41.2 
years, range 22-65 years) and 10 men (mean age 41.2 years, range 27-73 years). 
Demographic details are summarised in Table 2.1. Written informed consent was obtained 
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from all subjects. Ethics approval was obtained from the Human Research Ethics Committee 
of the University of Sydney. 
 
2.1.4  Sample Collection 
2.1.4.1  Peripheral Blood 
10-15ml of blood was collected into tubes containing lithium heparin (Greiner Bio-One) for 
the isolation of PBMC for flow cytometry analysis. In addition, 5ml of blood was collected 
into a Vacuette® serum tube (Greiner Bio-One) for the measurement of serum BAFF 
concentration. 
 
2.1.4.2  Lymph Nodes 
Human lymph node samples, which were collected for a separate study in the lab, were used 
in the optimisation of the antibody panel for the identification of Tfh cells. Lymph nodes 
within fresh operative colon samples were obtained from patients undergoing surgery for 
cancer or incontinence at the Royal Prince Alfred Hospital. Lymph nodes were identified by 
palpation and dissected away from the bowel wall using fine scissors and forceps. 
 
2.2  Reagents 
2.2.1  Phosphate Buffered Saline (PBS) 
Sterile 10x Dulbecco PBS (DKSH) was diluted with triple distilled water to make 1x PBS. 
PBS was stored at room temperature. 
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2.2.2  Tissue Culture Medium (TCM) 
RPMI Medium 1640 with L-glutamine and HEPES buffer (Invitrogen) was supplemented 
with 10% heat inactivated foetal calf serum (FCS) (JHR Biosciences). 100 units/ml of 
penicillin (Gibco) and 100ug/ml of streptomycin (Gibco) were added to minimise organism 
contamination. TCM was kept sterile and stored at 4ºC. 
 
2.2.3  Freezing Medium 
2x Freezing Medium consisted of RPMI Medium 1640 and 20% Dimethyl sulfoxide 
(DMSO) (Sigma) filtered through a 0.22µm sterile filter (Millipore) with 40% FCS added 
after filtration. 2x Freezing Medium was kept sterile and stored at 4ºC. 
 
2.2.4  DC FACS Wash 
DC fluorescent-activated cell sorting (FACS) wash was used in the washing and 
resuspension steps associated with antibody labelling for flow cytometry. FACS wash 
consisted of 5% FCS in PBS filtered through a 0.22µm sterile filter (Millipore) with 0.05M 
sodium azide and 5mM ethylenediaminetetraacetic acid (EDTA) added. DC FACS wash was 
stored at 4ºC. 
 
2.2.5  FACS Fixing Buffer 
FACS fixing buffer was used to fix all samples analysed by flow cytometry, with the 
exception of cells that were fixed for intracellular Bcl-6 staining (see 2.4.6 Bcl-6 
Intracellular Immuno-Staining). FACS fixing buffer consisted of 1% paraformaldehyde 
(BDH Laboratory Supplies) in PBS and was stored at 4ºC. 
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2.2.6  0.1M Glycine at pH 2.8 
3.75g of glycine was added to 1L deionised water and pH was adjusted to 2.8 with 1.4ml 
HCl. 0.1M glycine was stored at room temperature. 
 
2.2.7  1M Tris 
141.1g of Tris base was added to 1L with deionised water and was stored at room 
temperature. 
 
2.3  Purification of PBMCs, Preparation of Lymph Node Samples and 
Serum Collection 
2.3.1  Purification of PBMCs by Density Gradient Centrifugation 
60µl of peripheral blood was transferred from a lithium heparin tube into a 1.5ml 
microcentrifuge tube for the enumeration of white blood cells, lymphocytes and monocytes 
on a Sysmex XS-1000i automated haematology analyser (Sysmex Corporation, Kobe, Japan). 
Peripheral blood was transferred from the lithium heparin tube into a sterile 50ml tube and 
diluted two-fold with an equal volume of sterile PBS, and an equal volume of Ficoll-Paque 
PLUS (GE Healthcare Bio-Sciences AB) was gently layered underneath the diluted blood. 
The tube was centrifuged at 1600 rpm without braking for 30 minutes at 23ºC. 
 
The PBMC layer was transferred into two sterile 15ml tubes that were then filled to the top 
with sterile PBS. When transferring the PBMC layer, some of the plasma and Ficoll-Paque 
will unintentionally be transferred as well, no matter how careful this is done. We therefore 
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transferred into two 15ml tubes to ensure we had a high enough ratio of PBS to 
PBMC/plasma/Ficoll-Paque suspension to thoroughly wash off the Ficoll-Paque. The tubes 
were centrifuged at 1200rpm with the brake on for 10 minutes at 23ºC. 
 
The supernatant was then discarded and the cell pellets were resuspended. The two cell 
suspensions were combined into one 15ml tube and then diluted in 2ml sterile PBS. 60µl of 
the cell suspension was transferred into a 1.5ml microcentrifuge tube for the enumeration of 
white blood cells, lymphocytes and monocytes on the Sysmex automated haematology 
analyser. The 15ml tube containing the cell suspension was filled with sterile PBS and 
centrifuged at 1200rpm with the brake on for 10 minutes at 23ºC. The supernatant was 
discarded and the cell pellet was resuspended. PBMCs to be stained for cell surface markers 
immediately were transferred to a round-bottom FACS plate. 
 
For PBMCs to be stored in liquid nitrogen, 50% RPMI+10% FCS and 50% 2x freezing 
medium were added to the cell suspension before being transferred to multiple 1ml cryovials 
containing approximately 2-4 million cells each. The cryovials were placed in a cryo-freezing 
container (Nalgene) allowing cells to be frozen at 1ºC per minute prior to storage at -180ºC in 
liquid nitrogen. 
 
2.3.2  Purification of PBMCs by Red Blood Cell Lysis 
60µl of peripheral blood was transferred from a lithium heparin tube into a 1.5ml 
microcentrifuge tube for the enumeration of white blood cells, lymphocytes and monocytes 
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on the Sysmex automated haematology analyzer. A second aliquot of 100µl of peripheral 
blood was transferred from the lithium heparin tube into another microcentrifuge tube for the 
purification of PBMC. 2ml of 1x FACS lysing solution (BD) was added to the peripheral 
blood. After incubating in the dark at 23ºC temperature for 10 minutes, the tube was 
microcentrifuged at 8000rpm for 3 minutes. Supernatant was removed and the cell pellet was 
washed with 2ml DC FACS wash. The cell pellet was resuspended in 100µl DC FACS wash 
and transferred to a round-bottom FACS plate, ready for staining for cell surface markers. 
 
2.3.3  Preparation of Lymph Node Samples 
Single cell suspensions of lymph nodes were prepared by slicing the tissue and teasing it 
through an 80 gauge metal mesh sieve, then washing twice before cryopreservation in liquid 
nitrogen in the same manner as for PBMCs (described above in 2.3.1 Purification of 
PBMCs by Density Gradient Centrifugation). 
 
2.3.4  Serum Collection 
Blood was allowed to stand for 30 minutes at room temperature. The serum tube was then 
centrifuged at 2000g for 10 minutes at 20ºC for the separation of serum from whole blood. 
Serum was transferred to a sterile 2ml or 5ml tube and stored at -30ºC. 
 
2.4  Flow Cytometry Staining and Analysis 
2.4.1  Thawing and Culturing of Anti-Human CD3 (OKT3) Hybridoma Cells 
Anti-human CD3 (OKT3) hybridoma cells cryopreserved in liquid nitrogen were thawed in a 
37ºC water bath and transferred sterile to 13ml of pre-warmed 37ºC TCM. Cells were 
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centrifuged at 1000rpm for 10 minutes at 23ºC. The supernatant was removed and the cell 
pellet was resuspended and washed once in pre-warmed TCM. Cells were then resuspended 
in 2.2ml pre-warmed TCM and transferred to a 24-well tissue culture plate where a 1 in 10 
serial dilution of the cells were performed. Cells were then transferred to a 25cm2 flask and 
incubated in 10ml TCM at 37ºC with 5% CO2 and passaged twice over two weeks before 
growth of cells was stopped. Supernatant and cells from the flasks were transferred to 50ml 
tubes and centrifuged at 2000rpm for 30 minutes at room temperature. The supernatant was 
filtered and collected into sterile glass bottles prior to protein G purification. 
 
2.4.2  Protein G Purification of Anti-CD3 (OKT3) mAb 
The protein G column (Pharmacia Biotech) was prepared by washing twice with sterile 1X 
PBS. Anti-CD3 antibody was purified from the supernatant on the protein G column. The 
anti-CD3 antibody was eluted with 10ml of 0.1M Glycine and the pH was neutralized with 
1ml 0.1M Tris. The antibody was dialysed at 4ºC against 1X PBS at 500 times the sample 
volume and then concentrated in a protein concentration column (Millipore). The final 
concentration of the antibody was measured on the NanoDrop micro-volume 
spectrophotometer (Thermo Scientific) and aliquots were stored at 4ºC. 
 
2.4.3  Biotinylation of Anti-CD3 (OKT3) mAb 
Purified anti-CD3 (OKT3) antibody was prepared at 2mg/ml and adjusted to pH 8.3 with 
0.1M NaHCO3 (Sigma). NHS-LC-Biotin (Invitrogen) was warmed to room temperature 
before being dissolved 1mg/ml in anhydrous DMSO (Sigma). Biotin was added to the 
antibody at a concentration of 100µl biotin per 1mg of antibody. The biotin and antibody 
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mixture was incubated for 2 hours in the dark at room temperature with constant rotation. 1M 
NH4Cl (Sigma) was added to the biotinylated antibody at a concentration of 10µl per 1ml of 
antibody and incubated for 20 minutes in the dark at room temperature with constant rotation. 
The biotinylated antibody was dialysed overnight in 1X PBS at 4ºC. 0.02% sodium azide and 
albumin (Sigma) were added to the biotinylated antibody at the concentration of 1mg per 
1mg antibody prior to long-term storage at 4ºC. 
 
2.4.4  Thawing PBMCs After Cryopreservation 
PBMC samples cryopreserved in liquid nitrogen were thawed in a 37ºC water bath and 
transferred to 13ml of pre-warmed 37ºC RPMI+10% FCS. Cells were centrifuged at 
1000rpm for 10 minutes at 23ºC. The supernatant was removed and the cell pellet was 
resuspended in 2ml cold DC FACS wash. 60µl of the cell suspension was transferred into a 
1.5ml microcentrifuge tube for the enumeration of white blood cells on the Sysmex 
automated haematology analyser. Cells were centrifuged at 1500rpm for 5 minutes at 4ºC. 
The supernatant was removed and the cell pellet was resuspended in 100µl DC FACS wash. 
Cell samples were transferred to a round-bottom FACS plate with approximately 1 million 
white blood cells per well, ready for staining for cell surface markers. 
 
2.4.5  Staining for Cell Surface Markers 
Cells were then washed in the plate by centrifugation at 1500rpm for 3 minutes at 4ºC. 
Supernatant from each well was removed and cell pellets were resuspended in 100µl DC 
FACS wash. Cells were washed again then resuspended in 100µl of a pre-diluted first layer 
antibody mix. For antibody panels with a biotin-conjugated mAb, this layer consists of the 
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biotin-conjugated mAb only. Otherwise, this layer includes all the mAb in the antibody 
panel. For the analysis of Tfh cells using anti-PD-1 (NAT) (see 3.5.2 Comparison of Two 
Different Clones of Anti-PD-1 mAb), this layer consists of unconjugated anti-PD-1 mAb 
only. 
 
After incubating on ice for 30 minutes, cells were washed twice then resuspended in 100µl of 
a pre-diluted second layer antibody mix, if necessary. For antibody panels with a biotin-
conjugated mAb, this second layer includes all the other mAb in the panel and streptavidin 
conjugated to Pacific Orange, but not the biotin-conjugated mAb. 0.5µl of LIVE-DEAD® 
Fixable Near-IR were then added to all cell samples. For the analysis of Tfh cells using anti-
PD-1 (NAT), this layer consists of PE-conjugated anti-mouse IgG (H+L). 
 
After incubating on ice for 30 minutes, cells were washed twice more. For the analysis of Tfh 
cells using anti-PD-1 (NAT), cells were resuspended and 20µl of mouse serum was added. 
After incubating on ice for 10 minutes, a pre-diluted mix of other antibodies required for the 
analysis of Tfh cells were added. 0.5µl of LIVE-DEAD® Fixable Near-IR were then added 
to all cell samples. 
 
After incubating on ice for 30 minutes, cells were washed twice then resuspended in 150µl 
FACS fixing buffer. After incubating on ice for 10 minutes, cells were washed then 
resuspended in 150µl DC FACS wash. Cell suspensions were filtered through a 70µm nylon 
mesh into a 5ml round-bottom tube prior to data acquisition on a flow cytometer. 
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2.4.6  Bcl-6 Intracellular Immuno-Staining 
PBMC or lymph node samples to be analysed for Tfh cells were transferred from wells of a 
round-bottom FACS plate to 1.5ml microcentrifuge tubes after staining for cell surface 
markers. 1ml of 1x FOXP3 Fix/Perm buffer (BioLegend) were added to cell suspensions and 
incubated for 20 minutes in the dark at room temperature. Cell suspensions were centrifuged 
at 1500rpm for 5 minutes at room temperature and the supernatant was removed. Cells were 
then washed in 200µl DC FACS wash and then washed again in 1ml FOXP3 Perm buffer 
(BioLegend) before being resuspended in 1ml FOXP3 Perm buffer. After incubating for 15 
minutes in the dark at room temperature, cells were centrifuged at 1500rpm for 5 minutes at 
room temperature. The supernatant was removed and 100µl of FOXP3 Perm buffer and 5µl 
of PE-conjugated anti-Bcl-6 antibody were added to the cells. After incubating for 30 
minutes in the dark at room temperature, cells were washed twice in 200µl DC FACS wash. 
Cells were finally resuspended in 150µl DC FACS wash and filtered through a 70µm nylon 
mesh into a 5ml round-bottom tube prior to data acquisition on a flow cytometer. 
 
2.4.7  Preparation of Compensation Beads 
For each fluorochrome-conjugated mouse (or rat) antibody used for the staining of cell 
surface markers, 1µl of fluorochrome-conjugated mouse (or rat) anti-human mAb was diluted 
in 50µl FW in a 5ml FACS tube. Approximately 60µl of CompBeads Anti-Mouse (or Anti-
Rat) Ig (BD) was added to the tube, which was then incubated for 10 minutes in the dark 
prior to data acquisition on a flow cytometer. 60µl of CompBeads Anti-Mouse (or Anti-Rat) 
Ig (BD) added to 50µl FW was used as a negative control. 
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2.4.8  Flow Cytometry Acquisition and Analysis 
Data was acquired on a FACSCanto II flow cytometer (Becton Dickinson, Franklin Lakes, 
NJ, USA) and collected in an uncompensated digital FCS3 file format using FACSDiva 
software (Becton Dickinson, Franklin Lakes, NJ, USA). Approximately 10,000 events were 
collected for compensation beads and 200,000 events were collected for the analysis of 
PBMC samples. FlowJo 9.8.2 (Tree Star Inc., San Carlos, CA, USA) was used for the 
calculation of a compensation matrix, which was applied to all samples, and for the analysis 
of mononuclear cell subsets. 
 
2.5  Measurement of Serum BAFF Concentration 
Serum BAFF concentration was determined using the Quantikine® Human 
BAFF/BLyS/TNFSF13B Immunoassay (R&D Systems, Inc. Minneapolis, MN, USA), 
following the recommendations of the manufacturer throughout the procedure. Serum 
samples were thawed and allowed to warm to room temperature. Serum samples diluted five-
fold with calibrator diluent were added to individual wells of a microplate pre-coated with 
monoclonal antibody specific for BAFF. After incubation for three hours at room 
temperature on a horizontal orbital microplate shaker at 500rpm, substances non-specifically 
bound to the BAFF monoclonal antibody were removed in a wash step. Polyclonal antibody 
conjugated to horseradish peroxidase specific for BAFF was added to the microplate and 
incubated for one hour at room temperature on a horizontal orbital microplate shaker at 
500rpm, followed by another wash step to remove any unbound BAFF polyclonal antibody. 
Substrate solution was added to the microplate and incubated away from light for 30 minutes 
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at room temperature, allowing colour development, which is proportional to the amount of 
BAFF present in each well.  After stop solution was added to the microplate, the intensity of 
colour of each well was measured using a POLARstar Omega microplate reader (BMG 
LABTECH GmbH, Ortenberg, Germany) at 540nm with wavelength correction at 450nm. 
Standard curves were derived from serial dilutions of 40ng of NS0-expressed recombinant 
human BAFF. All standards and patient and control samples were run in duplicate with the 
results averaged. 
 
2.6  Statistical Analysis 
2.6.1  Analysis of Peripheral Blood Cell Populations and Serum BAFF Concentration in 
SLE 
Statistical analysis for was performed using Prism 6 (GraphPad Software, Inc., La Jolla, CA, 
USA). The Kruskal-Wallis test followed by Dunn’s multiple comparison was used to 
compare differences between four groups (active SLE, inactive SLE, disease control and 
healthy control samples), with p-values <0.05 considered significantly different. Disease 
activity (i.e. active or inactive SLE) was determined by the Physician’s Global Assessment 
(PGA) (Figure 1.1). The non-parametric Spearman method was used to calculate correlation 
coefficients. For SLE patients and disease control subjects who have contributed multiples 
samples to the study, only one sample per subject, selected at random, was included in the 
analysis. 
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2.6.2  Development of Models for the Immune Profiling of SLE 
Statistical analysis of the complete data set and the development of models for the immune 
profiling of SLE were performed with the assistance of Dr. John Ormerod from the School of 
Mathematics and Statistics, University of Sydney. Analysis was performed using the R 
statistical computing package (R Foundation for Statistical Computing, Vienna, Austria). 
 
2.6.2.1  Summary of Data Prior to Data Cleaning and Imputation 
The number of SLE, disease control and healthy control subjects and samples are 
summarised in Table 2.2. Four SLE samples were excluded prior to data cleaning and 
imputation. Three of the samples were from patients who were diagnosed by renal biopsy and 
one sample was from a patient who had chronic renal failure. Overall, a total of 236 samples 
from 154 subjects were included in the analysis and of these, 200 samples were from female 
subjects and 36 samples from male subjects. The age of subjects at the time of blood sample 
collection as well as the age at onset and duration of disease for patients with SLE and other 
autoimmune conditions are summarised in Table 2.3. The 96 missing values for age at onset 
and duration of disease correspond to healthy control subjects and SLE patients and disease 
control subjects from which information on age at onset or duration of disease could not be 
obtained. 
 
Disease severity of SLE patients was determined using the SELENA-SLEDAI, as described 
in 2.1.1 Recruitment of SLE Patients. SLEDAI scores of SLE patients at the time of blood 
sample collection are summarised in Table 2.4. Information on symptoms of SLE patients 
was collected as part of the process of calculating patient SLEDAI scores, as shown in Figure 
Table 2.2. Counts of SLE, disease control and healthy control samples included in the 
statistical analysis of the complete data set prior to data cleaning. 
 
 Samples 
Total samples (all time points) 236 
Female 200 
Male 36 
Total samples (first time point only) 154 
SLE 140 
Severe 15 
Moderate 18 
Mild 25 
Inactive 81 
Disease control 28 
Healthy control 68 
 
 
Table 2.3. Summary of age at time of sample collection, age at onset of SLE and duration of 
SLE of all samples included in the statistical analysis of the complete data set prior to data 
cleaning. 
 
Variable Min 1st 
quartile 
Median Mean 3rd 
quartile 
Max Number 
missing 
Age at sample 
collection, years 
20.00 33.75 41.50 42.08 49.00 84.00  
Age at onset of 
SLE, years 
7.00 21.00 29.00 31.36 40.00 82.00 96 
Duration of SLE, 
years 
0.00 3.00 7.00 9.84 13.00 52.00 96 
 
 
Table 2.4. Summary of SLEDAI scores for all SLE samples included in the statistical analysis 
of the complete data set prior to data cleaning. 
 
Min 1st quartile Median Mean 3rd quartile Max 
0.00 2.00 4.00 5.83 8.00 30.00 
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1.1. In our study, some of the symptoms were also considered together according to organ 
system. Neurologic symptoms included psychosis, organic brain syndrome, visual 
disturbance, cranial nerve disorder and lupus headache. Arthritis and myositis were 
considered together as musculoskeletal symptoms. Renal symptoms included the presence of 
urinary casts, hematuria, proteinuria and pyuria. Cutaneous symptoms included new rash, 
alopecia and mucosal ulcers. Table 2.5 lists the symptoms of the SLE patients in this study. 
 
SLE patients included in the present study were on different combinations of the following 
medications specifically for the treatment of SLE symptoms: azathioprine, 
cyclophosphamide, cyclosporin, methotrexate, mycophenolate, hydroxychloroquine, 
prednisone, tacrolimus, intravenous immunoglobulin and rituximab. Of these, patients were 
most commonly treated with azathioprine, prednisone, mycophenolate and 
hydroxychloroquine, and the numbers of patients treated with these medications are 
summarised in Table 2.6. 
 
2.6.2.2  Data Cleaning 
Data cleaning was performed on the data we collected to ensure methods used for analysis 
would work and reliable results could be obtained. Samples in which SLE disease activity 
was not assessed by SELENA-SLEDAI or where this information could not be obtained were 
removed. For SLE patients and disease control subjects who provided more than one sample 
to the study, the first of their samples included in the study was selected in analyses including 
only a single sample from each subject. 
 
Table 2.5. Summary of symptoms of SLE patients included in the statistical analysis of the 
complete data set prior to data cleaning. 
 
Symptom Samples from 
all time points 
% Sample from 
first time point 
only 
% 
Seizure 0 0.00 0 0.00 
Psychosis 2 1.43 0 0.00 
Organic brain syndrome 2 1.43 1 1.59 
Visual disturbance 0 0.00 0 0.00 
Cranial nerve disorder 0 0.00 0 0.00 
Lupus headache 2 1.43 1 1.59 
CVA 1 0.71 1 1.59 
Vasculitis 0 0.00 0 0.00 
Arthritis 34 24.29 13 20.63 
Myositis 4 2.86 1 1.59 
Urinary casts 10 7.14 4 6.35 
Hematuria 19 13.57 6 9.52 
Proteinuria 29 20.71 9 14.29 
Pyuria 6 4.29 1 1.59 
New rash 6 4.29 4 6.35 
Alopecia 14 10.00 7 11.11 
Mucosal ulcers 8 5.71 2 3.17 
Pleurisy 4 2.86 0 0.00 
Pericarditis 0 0.00 0 0.00 
Low complement 63 45.00 28 44.44 
Increased DNA binding 77 55.00 35 55.56 
Fever 3 2.14 1 1.59 
Thrombocytopenia 0 0.00 0 0.00 
Leukopenia 3 2.14 1 1.59 
Neurologic 6 4.29 2 3.17 
Musculoskeletal 34 24.29 13 20.63 
Renal 34 24.29 10 15.87 
Cutaneous 18 12.86 8 12.70 
 
 
Table 2.6. Summary of treatment data for SLE samples included in the statistical analysis of 
the complete data set prior to data cleaning. 
 
 AZA PRED MMF HCQ 
Samples from all time points     
Count 31 100 20 83 
% 22.14 71.43 14.29 59.06 
Sample from first time point only     
Count 8 44 5 27 
% 12.70 69.84 7.94 42.86 
 
AZA – azathioprine; HCQ – hydroxychloroquine; MMF – mycophenolate; PRED – prednisone. 
Chapter 2: Materials and Methods  89 
 
SLE symptoms were considered together according to organ system. The symptom variable 
Neurologic is derived from the symptoms psychosis, organic brain syndrome, visual 
disturbance, cranial nerve disorder and lupus headache. If a subject had any of the five 
symptoms it was recorded as an occurrence, and non-occurrence otherwise. Missing values 
were also considered as non-occurrences. Similarly, Musculoskeletal was derived from 
arthritis and myositis, Renal from urinary casts, hematuria, proteinuria and pyuria, and 
Cutaneous from new rash, alopecia and mucosal ulcers. 
 
Therapy details were recorded either as a numerical dosage (“15mg” or “10mg/week”) or in 
the form of “yes/no”. In our analyses we have included the four most commonly used 
medications – azathioprine, prednisone, mycophenolate and hydroxychloroquine. Due to the 
non-uniformity of dosages, “1” was recorded if a patient was on a particular medication and 
“0” otherwise. 
 
An exact SLEDAI score could not be obtained for some patients because anti-dsDNA 
antibody titre or complement levels or both were not measured. Therefore the SLEDAI 
scores for these patients were recorded as “at least 10” or “likely 0”, for example. Such 
formats were changed to a numerical value only (e.g. “10” or “0”, respectively) to ensure 
uniformity for the purpose of analysis. 
 
Outlier samples were removed from the analysis so that samples with unusually large or 
small values for particular observations compared to others in the cohort do not have an 
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overly large effect on fitted models. Including outliers would be undesirable because we 
aimed to develop models that are generalisable, and a few isolated outlier values do not 
usually constitute a reliable pattern of observations. 
 
The values of all measurements were then log-transformed and all numeric variables were 
standardised to have a mean of 0 and variance of 1. 
 
2.6.2.3  Missing Data Imputation 
Most analytical methods require complete data. To overcome the problem of having high 
percentages of samples and variables with missing data in our study, we performed single 
imputation using the R package spaceExt (Peng et al., 2009) and the tuning parameter was 
selected using a Bayesian Information Criterion (BIC) (Yuan and Lin, 2007). Single 
imputation was performed by fitting the data to a large multivariate normal distribution so 
that small correlations between variables were treated as zero. 
 
2.6.2.4  Potential Response Variables 
Some of the questions we hoped to answer in our data analysis were if any of the variables 
that were measured (frequency and number of cells determined by flow cytometry, serum 
BAFF concentration, blood counts and markers of SLE such as anti-dsDNA antibody and 
complement levels, ESR, CRP) could predict disease activity and SLEDAI score, if any of 
the measurements differed significantly between patients with SLE from healthy individuals, 
and if any of the measurements were associated with neurologic, musculoskeletal, renal or 
cutaneous symptoms. The potential response types and class numbers are summarised in 
Chapter 2: Materials and Methods  91 
 
Table 2.7. It is important to note that most of the response types have moderate to severe 
class imbalance, or one of the classes has a small number of samples. Therefore some of the 
potential response types were not investigated further because a reliable analysis would not 
possible. 
 
2.6.2.5  Calculating Measurement Error 
The measurement error, which includes sample-to-sample variability (samples collected at 
different time points from a single subject) and the within sample variability in our flow 
cytometry data, was calculated using the random intercept model (McCulloch et al., 2008). 
The measurement error was calculated to ascertain whether or not there was problem in the 
experimental process. Four peripheral blood samples were obtained from a single healthy 
subject at different time points over two years. We included one of the samples from this 
healthy subject as an inter-assay control each time we performed an assay with SLE patient 
samples, disease control and other healthy control samples. 
 
2.6.2.6  Methods Used for Data Analysis 
To determine the effect of various treatments in SLE patients on variables measured by flow 
cytometry, serum BAFF concentration, blood counts and markers of SLE such as anti-
dsDNA antibody and complement levels, ESR and CRP, a linear model was fitted of the 
form 
variable = constant + α x COND1error 
if the effect of one medication (e.g. with prednisone vs. no prednisone) was to be analysed, 
where the error term is normally distributed. A linear model was fitted of the form 
Table 2.7. Potential response variables and their class sizes to be investigated with our 
complete data set. 
 
Potential response variables Class size 
n = 
Class size 
n1 = 
Class size 
n0 = 
SLEDAI    
Samples from all time points 136 - - 
Sample from first time point only 61 - - 
    
SLE (n1) vs healthy (n0)    
Samples from all time points - 136 68 
Sample from first time point only - 61 68 
    
Severe, moderate, mild SLE (n1) vs inactive SLE (n0)    
Samples from all time points - 54 81 
Sample from first time point only - 20 40 
    
Cutaneous involvement: yes (n1) vs no (n0)    
Samples from all time points - 14 122 
Sample from first time point only * - 8 55 
    
Renal involvement: yes (n1) vs no (n0)    
Samples from all time points - 30 106 
Sample from first time point only * - 8 53 
    
Neurologic involvement: yes (n1) vs no (n0)    
Samples from all time points * - 6 130 
Sample from first time point only * - 2 59 
    
Musculoskeletal involvement: yes (n1) vs no (n0)    
Samples from all time points - 31 105 
Sample from first time point only * - 12 49 
 
* Reliable analysis deemed not possible due to severe class imbalance and/or one of the 
classes has a small number of samples. 
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variable = constant + α x COND1 + β x COND2 + γ x COND1 x COND2 + error 
if the effect of a combination of two medications was to be analysed, where the error term is 
normally distributed. COND1 and COND2 are two conditions, e.g. COND1 is the condition 
that the patient was treated with azathioprine and COND2 is the condition that the patient 
was treated with prednisone. The effects of the four most commonly used medications, 
prednisone, azathioprine, hydroxychloroquine and mycophenolate, were analysed, and the 
effects of these four medications in active SLE patients and inactive SLE patients were 
compared. Outliers were removed and all of the continuous variables were log-transformed 
and standardised. A medication or combination of medications was considered to have 
significant effects on a variable if the F-test of the model was statistically significant at the 
5% level after a Bonferroni correction for multiple testing. 
 
Principal component analysis (PCA) was performed on the cleaned, imputed data to 
determine if any of the variables measured by flow cytometry, serum BAFF concentration, 
blood counts or other markers of SLE such as anti-dsDNA antibody and complement levels, 
ESR and CRP could separate the response types listed on Table 2.7.  
 
A complete case analysis, i.e. using the cleaned, imputed data, was used to determine 
associations of individual variables (variables measured by flow cytometry, serum BAFF 
concentration, blood counts or other markers of SLE such as anti-dsDNA antibody and 
complement levels, ESR and CRP) against SLEDAI, and also variable associations with 
binary variables – whether variables measured associated with SLE patients, patients with 
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other autoimmune conditions or healthy controls, and if variables measured associated with 
renal, cutaneous, neurologic or musculoskeletal symptoms. For variable associations with 
SLEDAI the rococo package in R was used, and the different transformations “classical”, 
“linear”, “exp”, “epstol” and “gauss” were used to search for non-linear associations. For 
variable associations with binary variables, a logistic regression model was fitted for each 
variable and the p-value was determined by the glm function in R. A standard two-sample t-
test was then applied to test for a significant difference in means for each group (e.g. SLE 
patients and healthy controls). p-values were then adjusted with multiple testing correction 
using the p.adjust ( ) function and method=“fdr”. 
 
Penalised regression was used to select the model for predicting SLEDAI with the previously 
identified associated variables. Penalised logistic regression was used to select the models for 
predicting response types with previously identified associated variables – if associated 
variables were able to classify whether an individual had SLE, another autoimmune condition 
or no autoimmune disease, and if associated variables could classify SLE patients as having 
renal, cutaneous, neurologic or musculoskeletal symptoms. AIC (Akaike, 1973) and BIC 
(Schwarz, 1978) criterion were applied for model selection. Performance of the selected 
models was then assessed by cross-validation. 
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CHAPTER 3:  ANTIBODY PANEL DEVELOPMENT AND 
OPTIMISATION 
3.1  B Cell Panel Development 
The development of the antibody panel for the detection of peripheral B cell subsets was 
based on previous studies of human peripheral B cells as well as investigations of B cell 
abnormalities in patients with SLE and other autoimmune conditions. 
 
3.1.1  Detection of Core B Cell Populations and Pre-Naïve and CD19hiCD21lo B Cells 
All human peripheral B cells express CD19 (Haas and Tedder, 2005). Most commonly found 
in peripheral blood are transitional, naïve and memory B cells. Using CD27, CD38, IgD and 
IgM, we were able to clearly identify these cell populations using flow cytometry. 
Transitional and naïve B cells were identified within the CD19+ population based on their 
expression of IgD but not CD27, and transitional B cells were distinguished from naïve B 
cells based on their higher expression of CD38 (Sims et al., 2005). Several memory B cell 
subsets exist in human peripheral blood. CD27 has long been used as a memory B cell 
marker (Klein et al., 1998) until the discovery of atypical or double negative memory B cells, 
so-called because they express neither CD27 nor IgD but exhibit features found in CD27+ 
memory B cells (Fecteau et al., 2006, Wei et al., 2007a). Studies of B cell populations in 
lupus patients have shown an increase in atypical memory B cells in patients with active SLE 
(Jacobi et al., 2008b, Anolik et al., 2004, Wei et al., 2007a). IgD and IgM were used to 
further sub-fractionate CD27+ memory B cells. Switched memory B cells have switched 
immunoglobulin isotypes and therefore no longer express IgD and IgM (McHeyzer-Williams 
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and McHeyzer-Williams, 2005). The nomenclature for the other CD27+ memory B cell 
subsets varies between different research groups. IgD+ IgM+ memory B cells have been 
described by numerous groups and are otherwise known as non-switched or marginal zone-
like memory B cells in the literature (Weill et al., 2009). One group has identified a small 
population of isotype-switched IgD-only memory B cell population which expresses IgD but 
not IgM (Zheng et al., 2004). In addition, a few groups have described a small CD27+ 
memory B cell population which expresses IgM but not IgD. IgM-only memory B cells were 
often regarded as a portion of the IgM+IgD+ memory B cells because most IgM+ memory 
cells express at least a low level of IgD (Weller et al., 2004, Shi et al., 2003, Kruetzmann et 
al., 2003, Carsetti et al., 2004). 
 
Plasma cells are the B cells that secrete antibody while plasmablasts are their precusors. 
Plasmablasts transit in the periphery for a very short amount of time before differentiating 
into plasma cells, which reside in the bone marrow. Plasma cells and plasmablasts are 
characterised by their larger size compared to other B cell populations, their high expression 
of CD27 and CD38, lower levels of CD19 and no IgD expression (Anolik et al., 2004, 
Kaminski et al., 2012). Although plasma cells are mostly found in the bone marrow, many 
studies have reported an increase in plasma cells and/or plasmablasts in the blood of active 
SLE patients (Odendahl et al., 2000, Anolik et al., 2004, Jacobi et al., 2003, Jacobi et al., 
2010). 
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3.1.2  Antibody Panel for the Detection of B Cell Populations Including Pre-Naïve and 
CD19hiCD21lo B Cells 
In summary, a minimum of five markers, CD19, CD27, CD38, IgD and IgM, are necessary 
for the identification of the core B cell populations in human peripheral blood. Including a 
dead cell exclusion marker, this left two more channels available on an eight-colour flow 
cytometry panel. 
 
In addition to aberrations found in the core B cell subsets, several groups have described 
increases in other B cell populations in the blood of SLE patients, which were not seen in 
healthy individuals. Lee et al. (Lee et al., 2009) reported an increased proportion of pre-naïve 
or intermediate B cells in active SLE patients. As with transitional and naïve B cells, pre-
naïve B cells express IgD but not CD27. Of the markers tested in the study by Lee et al. 
(2009), CD10 appeared to most clearly distinguish between the phenotypically similar 
transitional, pre-naïve and naïve B cell subsets. Wehr et al. (Wehr et al., 2004) described an 
increase in the proportion of CD19hiCD21lo B cells in patients with SLE and other 
autoimmune conditions. 
 
CD10 and CD21 were therefore added to complete the first eight-colour antibody panel for 
the detection of peripheral B cells. The antibodies used for this B cell panel are listed in 
Table 3.1. The detection fluorochromes selected for each marker depended on the 
commercial availability of the monoclonal antibody (mAb)-fluorochrome combination, and 
the level of expression of the molecule on the cell population to be detected. Dimmer 
fluorochromes were selected for molecules that are highly expressed on B cells, e.g. V450 for 
Table 3.1. Summary of monoclonal antibodies used in the first B cell panel. 
 
Source Fluorochrome mAb/Stain Clone Dilution 
Southern Biotech Biotinylated Mouse IgG1, antihuman IgM SA-DA4 1:50 
Life Technologies Pacific Orange Streptavidin - 1:200 
BD Horizon V450 Mouse IgG1 κ, antihuman CD19 HIB19 1:640 
Southern Biotech FITC Mouse IgG2a κ, antihuman IgD IADB6 1:400 
BD Pharmingen PE Mouse IgG1 κ, antihuman CD27 M-T271 1:10 
BD Pharmingen PerCP Cy5.5 Mouse IgG1 κ, antihuman CD38 HIT2 1:40 
BD Biosciences PE Cy7 Mouse IgG1 κ, antihuman CD10 HI10a 1:40 
BD Pharmingen APC Mouse IgG1 κ, antihuman CD21 B-ly4 1:5 
Life Technologies - LIVE-DEAD® Fixable Near-IR - 1:200 
 
APC – Allophycocyanin; CD – Cluster of differentiation; Cy – Cyanine; FITC – Fluorescein 
isothiocyanate; IR – infra red; mAb – monoclonal antibody; PE – R-Phycoerythrin; PerCP – 
Peridinin chlorophyll-a protein. 
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CD19. The amount of spillover to adjacent fluorescence channels was also considered, e.g. 
the signal from an APC-conjugated molecule spills over significantly into the adjacent 
channel, which detects APC-Cy7 (or similar)-conjugated molecules. Therefore, molecules 
that are highly expressed on B cells were not selected for such channels with a high level of 
spillover to avoid interfering with detection in adjacent channels, and vice versa. In the 
present B cell panel, APC was selected for CD21, a marker that is expressed at low to 
intermediate levels on some B cell subsets, while the dead cell exclusion dye LIVE-DEAD® 
Fixable Dead Cell Stain, which reacts mostly with free cellular amines within cells with a 
permeated membrane, was to be detected in the adjacent channel, Near-IR. 
 
This B cell panel for the detection of B cell populations including pre-naïve and 
CD19hiCD21lo B cells (Table 3.1) was used in two test studies. For our test cohorts, we chose 
samples from patients with the greatest number of PBMCs collected for the test stains so that 
we would have enough PBMCs left for our final stains once all the panels were optimised. 
For each cohort, we selected samples from whatever we had collected at the time of testing. 
We made sure for each test that we did we included samples from patients with active SLE 
because these patients would most likely have or have the highest number of the unusual 
populations associated with SLE. Nine PBMC samples from 6 female patients with SLE 
were selected in the first study (Cohort 1). Four of the samples were collected from a single 
patient over a period of 11 weeks. Patients in Cohort 1 were selected with no restrictions on 
age, sex, medication or clinical or laboratory measures of SLE, and had a mean age of 42 
years. Six healthy control subjects were included in the first study of B cell populations. 
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There were no restrictions on age or sex in the selection of healthy control subjects. The 
mean age of the healthy control group was 39 years. Four of the control subjects are female. 
Demographic characteristics and disease activity of Cohort 1 are summarised in Table 3.2. 
 
In the second study, 11 PBMC samples from 8 SLE patients were selected (Cohort 2). Four 
of the samples were collected from a single patient over a period of 13 months. Patients in 
Cohort 2 were selected with no restrictions on sex, medication or clinical or laboratory 
measures of SLE. This cohort consisted of 7 females and 1 male (mean age 38.7 years). A 
female patient (aged 51 years) with Sjögren’s Syndrome was included as a disease control 
subject. Eleven age-matched healthy control subjects (mean age 39.2 years) were included in 
Cohort 2. The healthy control group consisted of 8 females and 3 males. Demographic 
characteristics and disease activity of Cohort 2 are summarised in Table 3.3. 
 
3.1.3  Gating Strategy for the Detection of B Cell Populations Including Pre-Naïve and 
CD19hiCD21lo B Cells 
The gating strategy for the identification of B cell populations including pre-naïve and 
CD19hiCD21lo B cells is summarised in Figure 3.1. Doublets (A-B) and non-viable cells (C) 
were excluded from the analysis. Lymphocytes were identified based on forward and side 
scatter properties (D). The expression of CD19 and CD27 were compared for the detection of 
CD27hi plasmablasts or plasma cells (E). Also, the expression of CD19 and CD21 were 
compared for the identification of CD19hiCD21lo B cells (F). B cells were identified by the 
expression of CD19 (G). Naïve and transitional B cells were identified in the CD19+ 
population based on their expression of IgD but not CD27 (H). Transitional B cells were 
Table 3.2. Demographic characteristics and disease activity of SLE patients, disease control 
and healthy control subjects included in Cohort 1. 
 
 SLE Healthy 
Number of subjects 6 6 
Age, mean years 42 39 
Female (%) 6 (100%) 4 (67%) 
Male (%) 0 (0%) 2 (33%) 
Number of samples 9 6 
SLE disease activity   
Active (%) 5 (56%) - 
Moderate 2 - 
Mild 3 - 
Inactive (%) 4 (44%) - 
  
 
Table 3.3. Demographic characteristics and disease activity of SLE patients, disease control 
and healthy control subjects included in Cohort 2. 
 
 SLE Disease control Healthy 
Number of subjects 8 1 11 
Age, mean years 40.1 51 39.2 
Female (%) 7 (88%) 1 (100%) 8 (73%) 
Male (%) 1 (12%) 0 (0%) 3 (27%) 
Number of samples 11 1 11 
SLE disease activity    
Active (%) 3 (27%) - - 
Moderate 1 - - 
Mild 2 - - 
Inactive (%) 8 (73%) - - 
Disease control conditions    
Sjögren’s syndrome - 1 - 
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Figure 3.1. Standard gating strategy of B cell populations using the initial B cell panel. (A-B) 
Sequential height vs. area gates for forward and side scatter were applied to exclude any 
doublets. (C) LIVE-DEAD® Fixable Near-IR dead cell exclusion stain was used to exclude 
dead cells. (D) Lymphocytes were identified based on forward and side scatter profiles. (E) 
Expression of CD19 and CD27 were compared on lymphocytes to identify CD27hi 
plasmablasts or plasma cells. (F) Expression of CD19 and CD21 were compared on 
lymphocytes to identify CD19hiCD21lo B cells. (G) B cells were identified by the expression of 
CD19. (H) Expression of CD27 and IgD were compared in CD19+ cells to identify transitional 
and naïve B cells (upper left), CD27+IgD+ (upper right), CD27+IgD- (lower right) and CD27-IgD- 
atypical memory (lower left) B cells. (I) CD38 expression was used to distinguish naïve (left) 
and transitional (right) B cells. (J) CD27+IgD- memory B cells were either switched (IgM-, left) 
or non-switched (IgM+, right). Numbers represent percentage of cells within the gate. 
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distinguished from naïve B cells based on their higher expression of CD38 (I). We were 
unable to clearly identify pre-naïve B cells from transitional and naïve B cells whether we 
compared the expression levels of CD10 or CD38, and the latter proved to be better at 
differentiating between naïve and transitional B cells (Figure 3.2). Three memory B cell 
subsets were identified based on the expression levels of CD27 and IgD: CD27+IgD+, 
CD27+IgD- and CD27-IgD- atypical memory B cells (H). CD27+IgD- memory B cells were 
either class-switched (IgM-) or non-switched (IgM+) (J). While the signal for IgM was very 
bright, the background fluorescence for IgM was also very high. Despite the high background 
fluorescence, two distinct populations with different levels of expression of IgM could be 
clearly seen, and the gates for the IgM+ and IgM- populations were set further to the right 
than for other markers based on these observations. While the signal for IgM was very bright, 
the background fluorescence for IgM was also very high. Despite the high background 
fluorescence, two distinct populations with different levels of expression of IgM could be 
clearly seen, and the gates for the IgM+ and IgM- populations were set further to the right than 
for other markers based on these observations. 
 
3.1.4  Detection of Core B Cell Populations and B1 B Cells 
Recently, research conducted by Rothstein’s group (Griffin et al., 2011) has revealed a subset 
of B cells expressing CD27 and CD43 which phenotypically and functionally resemble 
mouse B1 B cells, although other research groups argue that these CD27+CD43+ B cells are 
more likely to be pre-plasmablasts (Covens et al., 2013) (see 1.2.4 B1 B Cells). Two subsets 
of B1 cells exist based on CD11b expression, with the majority of peripheral B1 cells being 
CD11b- (Griffin and Rothstein, 2011). Interestingly, CD11b+ B1 cells have features similar to 
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monocytes, e.g. larger than lymphocytes (Descatoire et al., 2011), express markers such as 
CD14, CD11b and CD11c, but they express surface IgD and are therefore classified as B 
cells (Griffin and Rothstein, 2011). Griffin and Rothstein (Griffin and Rothstein, 2011) found 
a four-fold increase in relative cell number of CD11b+ (but not CD11b-) B1 cells in a cohort 
of mostly inactive lupus patients. 
 
3.1.5  Antibody Panel for the Detection of B Cell Populations Including B1 B Cells 
Regardless of whether these CD27+CD43+ B cells are B1 B cells or pre-plasmablasts, it 
would still be of interest to investigate if numbers of this B cell population differs between 
SLE patients and healthy individuals. Our first B cell panel was optimal for the study of core 
B cell populations. However, we found that CD10 was no better at distinguishing between 
transitional, pre-naïve and naïve B cells than CD38, as shown in Figure 3.2 (A). We also did 
not identify any CD19hiCD21lo B cells in either of the test studies, as shown in Figure 3.2 
(B), and little has been published regarding this B cell subset in SLE since the work of Wehr 
et al. in 2004 (Wehr et al., 2004). In light of these findings in the testing of our first B cell 
panel, we replaced CD10 and CD21 with CD43 and CD11b for the detection of B1 cells in 
peripheral blood. The antibodies used for this modified B cell panel are listed in Table 3.4.  
 
The modified antibody panel for the detection of B cell populations including B1 cells was 
tested on a third cohort of SLE patients (Cohort 3). Thirty-two PBMC samples from 16 SLE 
patients were chosen. Patients in Cohort 3 were selected with no restrictions on sex, 
medication or clinical or laboratory measures of SLE, and consisted of 15 female and one 
male SLE patients (mean age 36.3 years). Thirteen PBMC samples from 9 patients with other 
 
 
Figure 3.2. CD10 and CD21 no longer necessary for the flow cytometric detection of B cell 
populations. (A) Naïve and transitional B cells identified by the difference in expression level 
of CD38 on CD27-IgD+ B cells (left panel). Numbers represent percentage of cells within the 
gate. Naïve, transitional and/or pre-naïve B cells could not be identified based on CD10 
expression (middle panel). Comparison of CD10 expression on IgD+CD38+ naïve and 
IgD+CD38hi transitional B cells (right panel). (B) Representative plots depicting CD21 vs. 
CD19 expression of lymphocytes from active SLE, inactive SLE, disease control and healthy 
control samples. No CD19hiCD21lo B cells were detected. 
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Table 3.4. Summary of monoclonal antibodies used in the final B cell panel. 
 
Source Fluorochrome mAb/Stain Clone Dilution 
Southern Biotech Biotinylated Mouse IgG1, antihuman IgM SA-
DA4 
1:50 
Life 
Technologies 
Pacific Orange Streptavidin - 1:200 
BD Horizon V450 Mouse IgG1 κ, antihuman CD19 HIB19 1:640 
Southern Biotech FITC Mouse IgG2a κ, antihuman IgD IADB6 1:400 
BD Pharmingen PE Mouse IgG1 κ, antihuman CD27 M-T271 1:10 
BD Pharmingen PerCP Cy5.5 Mouse IgG1 κ, antihuman CD38 HIT2 1:20-
1:40* 
BD Pharmingen PE Cy7 Mouse IgG1 κ, antihuman 
CD11b 
ICRF44 1:20 
BD Pharmingen APC Mouse IgG1 κ, antihuman CD43 1G10 1:5-1:10* 
Life 
Technologies 
- LIVE-DEAD® Fixable Near-IR - 1:200 
 
* Optimal working dilutions differed between different lots of the same antibody as determined 
by antibody titration. 
 
APC – Allophycocyanin; CD – Cluster of differentiation; Cy – Cyanine; FITC – Fluorescein 
isothiocyanate; IR – infra red; mAb – monoclonal antibody; PE – R-Phycoerythrin; PerCP – 
Peridinin chlorophyll-a protein. 
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autoimmune conditions (Sjögren’s Syndrome n=5, antiphospholipid syndrome n=1, 
rheumatoid arthritis n=1, vasculitis n=1 and one patient with a lupus-like illness but did not 
fulfil the ACR criteria for SLE) were included as disease controls. Eight females and one 
male (mean age 54.2 years) were in the disease control group. Twelve age-matched healthy 
control subjects (mean age 36.8 years) were included in the testing of the modified B cell 
panel. The healthy control group consisted of 8 females and 4 males. Demographic 
characteristics and disease activity of Cohort 3 are summarised in Table 3.5. 
 
3.1.6  Gating Strategy for the Detection of B Cell Populations Including B1 B Cells 
The gating strategy for the identification of B cell populations including B1 cells is 
summarised in Figure 3.3. Doublets (A-B) and non-viable cells (C) were excluded from the 
analysis. Instead of gating only for lymphocytes as in the previous gating strategy (Figure 
3.1), we have modified the gate to include cells with larger forward and side scatter to ensure 
we have included the larger CD11b+ B1 cells in our analysis (D). The expression of CD19 
and CD27 (E) and CD38 and IgD (F) were compared for the detection of 
CD19loCD27hiCD38hiIgD- plasmablasts and plasma cells. B cells were identified by the 
expression of CD19 (G). B1 cells were identified within the CD19+ population based on their 
expression of CD27 and CD43 (H). Two B1 cell subsets were identified based on CD11b 
expression (I). Naïve and transitional B cells were identified within the CD43- population 
based on their expression of IgD but not CD27 (J). Transitional B cells were distinguished 
from naïve B cells by their higher expression of CD38 (K).  
 
Table 3.5. Demographic characteristics and disease activity of SLE patients, disease control 
and healthy control subjects included in Cohort 3. 
 
 SLE Disease control Healthy 
Number of subjects 16 9 12 
Age, mean years 36.3 54.2 36.8 
Female (%) 15 (94%) 8 (89%) 8 (67%) 
Male (%) 1 (6%) 1 (11%) 4 (33%) 
Number of samples 32 13 12 
SLE disease activity    
Active (%) 16 (50%) - - 
Severe 4 - - 
Moderate 5 - - 
Mild 7 - - 
Inactive (%) 16 (50%) - - 
Disease control conditions    
Antiphospholipid syndrome - 4  - 
Lupus-like illness - 1 - 
Rheumatoid arthritis - 1 - 
Sjögren’s syndrome - 5 - 
Vasculitis - 2  - 
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Figure 3.3. Standard gating strategy of B cell populations including B1 cells using the final B 
cell panel. (A-B) Sequential height vs. area gates for forward and side scatter were applied to 
exclude any doublets. (C) LIVE-DEAD® Fixable Near-IR dead cell exclusion stain was used 
to exclude dead cells. (D) PBMCs were identified based on forward and side scatter profiles. 
Expression of CD19 and CD27 (E) and CD38 and IgD (F) were compared on PBMCs to 
identify CD19loCD27hiCD38hiIgD- plasmablasts and plasma cells. (G) B cells were identified 
by the expression of CD19. (H) B1 cells were identified based on the expression of CD27 and 
CD43. (I) Two subsets of B1 cells were identified based on CD11b expression. (J) Expression 
of CD27 and IgD were compared in CD43- B cells to identify transitional and naïve B cells 
(upper left), CD27-IgD- atypical memory B cells (lower left) and CD27+ memory B cells (right). 
(K) CD38 expression was used to distinguish naïve (left) and transitional (right) B cells. (L) 
Expression of IgD and IgM were compared to identify switched (IgD-IgM-, bottom) and MZ or 
non-switched (IgD+IgM+, top) memory B cells. Numbers represent percentage of cells within 
the gate. 
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Also within the CD43- gate are CD27-IgD- atypical memory B cells and CD27+ memory B 
cells (J). In our previous gating strategy (Figure 3.1), two CD27+ memory B cell populations 
were identified by their expression of CD27 and IgD, before sub-fractionating these memory 
B cells based on IgM expression. As shown in Figure 3.4, it was discovered that firstly, all 
CD27+IgD+ memory B cells in the samples (both patient and control groups) we have 
analysed express IgM (A-B). Furthermore, memory B cell subsets were more clearly 
distinguishable when comparing IgD and IgM expression after gating for CD27+ cells (E-G), 
which suggested that the small population of IgM+ CD27+IgD- memory B cells present in 
some of the samples (C) could be part of the CD27+IgD+ gate (H). Our gating strategy shown 
in Figure 3.3 was therefore modified to identify IgD-IgM- switched and IgD+IgM+ MZ or 
non-switched memory B cells (L) after gating for CD27+ cells (J). 
 
3.1.7  Final B Cell Panel and Gating Strategy for SLE Study 
We extended our investigation of B cell populations using the antibody panel shown in Table 
3.4 to the rest of the SLE, disease control and healthy control samples we collected for our 
study (Table 2.1). However, we discovered that for some patient samples, we did not have a 
sufficient number of cells for the investigation of all the populations we were interested in, 
namely B cells, monocytes, NK cells, Tregs and Tfh cells. We subsequently developed a 
combined B cell-monocyte-NK antibody panel for the flow cytometric analysis of samples 
with insufficient cell numbers (discussed below in 3.4 Combined B cell/Monocyte/NK cell 
Panel Development). A limitation of using this combined panel was that we had to reduce 
the number of markers for the investigation of each cell type, keeping only the markers 
necessary for the identification of core cell subsets. Therefore, only CD19, CD27, CD38, IgD 
 
H 
 Original gating Modified gating 
 CD27+IgD+ CD27+IgD- 
IgM- 
CD27+IgD- 
IgM+ 
CD27+IgD-IgM- CD27+IgD+IgM+ 
As % live 1.21 2.96 0.42 2.97 1.6 
As % total B 
cells 
9.13 22.3 3.18 22.3 12.1 
 
Figure 3.4. Gating for CD27+ memory B cell populations. (A) CD27+IgD+ (upper right) and 
CD27+IgD- (lower right) memory B cells were identified within the CD19+ cell population using 
the original gating strategy. (B) All CD27+IgD+ memory B cells express IgM. (C) Most 
CD27+IgD- memory B cells are IgM- (left) but a small proportion is IgM+ (right). (D) 
Comparison of IgD and IgM expression of the entire CD27+ B cell population suggested that 
the fraction of CD27+IgD- memory B cells expressing IgM could be part of the CD27+IgD+ 
population. (E) CD27+ memory B cells were identified within the CD19+ cell population using 
the modified gating strategy. (F) IgD+IgM+ (right) and IgD-IgM- (left) memory B cells were 
identified within the CD27+ B cell population. (G) IgD+IgM+ and IgD-IgM- memory B cells could 
not be clearly distinguished by comparing the expression of CD27 and IgD only. Numbers 
represent percentage of cells within the gate. (H) Table depicting frequencies of the different 
CD27+ memory B subsets expressed as a percentage of total B cells or live cells. The sum of 
the frequencies of CD27+IgD- IgM+ cells and CD27+IgD+ cells from the original gating strategy 
is equivalent to that of CD27+IgD+IgM+ cells in the modified gating strategy. Frequency of 
CD27+IgD- IgM- cells from the original gating strategy is equivalent to that of CD27+IgD-IgM- 
cells in the modified gating strategy. 
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and IgM were used in the final analysis of B cell populations, and the gating strategy for 
samples stained using the full B cell panel as listed on Table 3.4 was changed slightly. As 
there were very few B1 B cells detected in any of the patient or control samples in Cohort 3, 
as shown in Figure 3.5, we believed that it was more important to analyse the core B cell 
populations. For the purposes of our study, we were more interested in determining how 
different cell populations changed relative to each other and over time, rather than focus on 
the increase or decrease of a specific subset on its own. 
 
The gating strategy for the identification of core B cell populations using the full B cell panel 
is summarised in Figure 3.6. Doublets (A-B) and non-viable cells (C) were excluded from the 
analysis, and mononuclear cells were identified based on forward and side scatter properties 
(D). The expression of CD19 and CD27 (E) and CD38 and IgD (F) were compared for the 
detection of CD19loCD27hiCD38hiIgD- plasmablasts and plasma cells. B cells were identified 
in the mononuclear cell gate by the expression of CD19 (G). Naïve and transitional B cells 
were identified within the CD19+ population based on their expression of IgD but not CD27 
(H). Also within the CD19+ gate are CD27-IgD- atypical and CD27+ memory B cells (H). 
Expression of IgD and IgM were compared on CD27+ memory B cells to identify IgD-IgM- 
switched and IgD+IgM+ marginal zone or non-switched memory B subsets (I). Finally, 
transitional B cells were distinguished from naïve B cells by their higher expression of CD38 
(J). 
 
 
 
Figure 3.5. Few B1 B cells were found in any of the patient or control samples. (A) 
Representative plots depicting CD27 vs. CD43 expression by flow cytometry of active SLE, 
inactive SLE, disease control and healthy control samples. CD19+ B cells were further gated 
for B1 B cells, which express CD27 and CD43. (B) Representative plots depicting CD11b vs. 
SSC-A expression by flow cytometry of active SLE, inactive SLE, disease control and healthy 
control samples. Two B1 B cell subsets exist based on differential expression of CD11b. 
Percentages of cells within each gate are shown in (A) and (B). 
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Figure 3.6. Standard gating strategy of core B cell populations using the final B cell panel. (A-
B) Sequential height vs. area gates for forward and side scatter were applied to exclude any 
doublets. (C) LIVE-DEAD® Fixable Near-IR dead cell exclusion stain was used to exclude 
dead cells. (D) PBMCs were identified based on forward and side scatter profiles. Expression 
of CD19 and CD27 (E) and CD38 and IgD (F) were compared on PBMCs to identify 
CD19loCD27hiCD38hiIgD- plasmablasts and plasma cells. (G) B cells were identified by the 
expression of CD19. (H) Expression of CD27 and IgD were compared in CD19+ cells to 
identify transitional and naïve B cells (upper left), CD27-IgD- atypical memory B cells (lower 
left) and CD27+ memory B cells (right). (I) Expression of IgD and IgM were compared to 
identify switched (IgD-IgM-, bottom) and MZ or non-switched (IgD+IgM+, top) memory B cells. 
(J) CD38 expression was used to distinguish naïve (left) and transitional (right) B cells. 
Numbers represent percentage of cells within the gate. 
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3.2  Monocyte Panel Development 
3.2.1  Detection of the Total Monocyte Population Based on Forward and Side Scatter 
Profile 
While performing the analysis of B cell populations of Cohort 1 for the first test study (see 
3.1.3 Gating Strategy for the Detection of B Cell Populations Including Pre-Naïve and 
CD19hiCD21lo Cells), we observed that monocytes, identified based on forward and side 
scatter properties, were increased in active SLE patients compared to inactive patients and 
healthy controls, as shown in Figure 3.7. The frequency, but not the absolute number, of 
monocytes was significantly increased in active patients (mean 26.1% p<0.05) compared to 
healthy controls (mean 13.9%) (B). The frequency of monocytes was also higher in active 
compared with inactive patients (mean 14.63%), but this increase was not significant. The 
findings in the first test study demonstrated that monocytosis may be an important marker in 
the diagnosis of active SLE, and warranted further investigation of subsets of monocytes with 
monocyte-specific cell surface markers. 
 
3.2.2  Antibody Panel for the Detection of Monocyte Subsets 
Three monocyte populations have been identified in human peripheral blood. The majority of 
monocytes in the blood are the classical monocytes which express CD14 but not CD16, and 
intermediate monocytes express both CD14 and CD16 and are of similar size to classical 
monocytes (Ziegler-Heitbrock et al., 1993, Ziegler-Heitbrock et al., 2010). Most recently 
characterised are the non-classical or CD14dim monocytes, which express CD16 and a low 
level of CD14 and are smaller than classical and intermediate monocytes (Cros et al., 2010, 
Ziegler-Heitbrock et al., 2010). In addition to size and phenotypic differences, the three 
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Figure 3.7. Comparison of lymphocytes and monocytes in SLE patients and healthy controls. 
(A) Representative plots depicting viable lymphocytes (lower gate) and monocytes (upper 
gate) based on FSC-A vs. SSC-A expression by flow cytometry from active SLE, inactive SLE 
and healthy control samples. Percentages of cells within each gate are shown. (B) Absolute 
number and frequency of monocytes were compared between active SLE, inactive SLE and 
healthy control samples. Samples collected from a single patient at different time points are 
indicated by green squares. The horizontal bar represents the mean of each group. Statistical 
analysis of differences between patient and control groups was determined using the Kruskal-
Wallis test. * denotes p<0.05. (C) Four blood samples from a single SLE patient were 
collected over an 11 week period. Representative plots depicting viable lymphocytes (lower 
gate) and monocytes (upper gate) based on FSC-A vs. SSC-A expression by flow cytometry 
at 4 different time points. Percentages of cells within each gate are shown. (D) Frequency of 
lymphocytes and monocytes at 4 different time points from a single SLE patient were 
compared. 
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subsets represent different development stages of monocytes, increasing in maturity from 
classical through intermediate to non-classical monocytes (Korkosz et al., 2012, Kwissa et 
al., 2012). However, it is sometimes difficult to clearly distinguish the monocyte populations, 
especially the intermediate CD14+CD16+ and non-classical CD14dim subsets which have 
sometimes been considered together as CD16+ monocytes (Ziegler-Heitbrock et al., 2010). 
 
CD14dim monocytes have been implicated in the immunopathogenesis of lupus nephritis 
(Cros et al., 2010). It was therefore important to include additional cell surface markers in an 
attempt to clearly distinguish between CD14+CD16+ and CD14dim monocytes where 
necessary. The study of monocytes by Cros et al. (2010) included a thorough phenotypic 
analysis of the three monocyte subsets and it was found that the expression of CD11b and 
CD163 differed the most between CD14+CD16+ and CD14dim monocytes. We also included 
CX3CR1 in our analysis of monocytes because of the observation that CD16+ monocytes 
with an increased expression of CX3CR1 home to glomerular vessels of lupus nephritis 
patients (Yoshimoto et al., 2007). 
 
In summary, CD14, CD16, CD11b, CD163 and CX3CR1 were included in our panel for the 
detection of monocyte populations by flow cytometry. Our panel design followed the same 
principles as those for the B cell panel (see 3.1.1 Detection of Core B Cell Populations and 
Pre-Naïve and CD19hiCD21lo Cells). The dimmer flurochromes were selected for the two 
markers expressed in abundance on monocyte subsets, Pacific Blue for CD14 and PE Cy7 for 
CD16. The brightest fluorochromes were then used for the remaining three markers, i.e. 
Chapter 3: Antibody Panel Development and Optimisation 106 
 
CD11b Alexa Fluor 488, CX3CR1 PE and CD163 APC. We used LIVE-DEAD® Fixable 
Near-IR for the exclusion of dead cells. Table 3.6 lists the antibodies used in this panel. This 
monocyte panel was tested on PBMC samples from Cohort 2 (Table 3.3). 
 
3.2.3  Gating Strategy for the Detection of Monocyte Subsets 
Two gating strategies were trialled for the detection of monocyte subsets based on the 
expression of CD14 and CD16, as summarised in Figure 3.8. Doublets (A-B) and non-viable 
cells (C) were excluded from the analysis. The expression of CD14 and CD16 were 
compared on viable cells to identify CD14dim/-CD16+, CD14+CD16+ and CD14+CD16- 
populations and the identification of CD14dim, CD14+CD16+ and CD14+CD16- monocytes 
were confirmed by forward and side scatter profiles (D). As CD14dim monocytes are smaller 
and less granular than CD14+CD16+ and CD14+CD16- monocytes, the gating strategy used in 
(D) did not gate for total monocytes based on forward and side scatter prior to differentiating 
the monocyte subsets to avoid excluding CD14dim monocytes from our analysis 
unintentionally. Alternatively, live cells with a larger forward and side scatter profile were 
identified as monocytes, which were then compared for their expression of CD14 and CD16 
to identify the three subsets, CD14dim, CD14+CD16+ and CD14+CD16- monocytes. The 
gating strategy used in (E) was based largely on the study by Cros et al (Cros et al., 2010). 
The frequency of each monocyte subset expressed as a percentage of live cells was almost 
the same regardless of whether gating strategy (D) or (E) was used, as shown in (F). We 
therefore selected (E) for our final monocyte gating strategy. Strategy (E) has the advantage 
reducing the risk of unintentionally including smaller cell types that express CD16 but not 
Table 3.6. Summary of monoclonal antibodies used for the detection of monocyte subsets. 
 
Source Fluorochrome mAb/Stain Clone Dilution 
BD Pharmingen Pacific Blue Mouse IgG2a κ, antihuman CD14 M5E2 1:40 
BioLegend AF488 Mouse IgG1 κ, antihuman CD11b icrf44 1:80 
BioLegend PE Rat IgG2b κ, antihuman CX3CR1 2A9-1 1:20 
BD Pharmingen PE Cy7 Mouse IgG1 κ, antihuman CD16 3G8 1:80 
BioLegend APC Mouse IgG1 κ, antihuman CD163 gh1/61 1:5 
Invitrogen - LIVE-DEAD® Fixable Near-IR - 1:200 
 
AF – Alexa fluor; APC – Allophycocyanin; CD – Cluster of differentiation; Cy – Cyanine; IR – 
infra red; mAb – monoclonal antibody; PE – R-Phycoerythrin. 
 
F 
 Gating strategy D Gating strategy E 
Monocyte 
population 
CD14+CD16- CD14+CD16+ CD14dim CD14+CD16- CD14+CD16+ CD14dim 
As % live 20.2 2.18 4.79 19.6 2.16 4.82 
 
 
Figure 3.8. Determining the gating strategy to be used for the identification of monocyte 
populations. (A-B) Sequential height vs. area gates for forward and side scatter were applied 
to exclude any doublets. (C) LIVE-DEAD® Fixable Near-IR dead cell exclusion stain was 
used to exclude dead cells. (D) Live cells were compared for their expression of CD14 and 
CD16 (upper left) prior to comparing forward and side scatter properties to identify 3 
monocyte populations, CD14+CD16+ intermediate (upper right), CD14+CD16- classical (lower 
right) and CD14dim non-classical (lower left) monocytes. (E) Live cells with a larger forward 
and side scatter profile were identified as monocytes (top), which were then compared for 
their expression of CD14 and CD16 to identify 3 subpopulations, CD14+CD16+, CD14+CD16- 
and CD14dim monocytes (bottom). Numbers represent percentage of cells within the gate. (F) 
Table depicting frequencies of the 3 monocyte populations identified by the two different 
gating strategies expressed as a percentage of live cells. 
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CD14 from the analysis of CD14dim monocytes, e.g. CD56- NK cells (Hu et al., 1995, 
Gonzalez et al., 2009, Gonzalez et al., 2008, Eller et al., 2009, Mavilio et al., 2005). 
 
The final gating strategy for the detection of monocyte populations is shown in Figure 3.9. 
Doublets (A-B) and non-viable cells (C) were excluded from the analysis, and monocytes 
were identified based on forward and side scatter properties (D). Expression of CD14 and 
CD16 were compared for the identification of 3 monocyte populations, CD14+CD16-, 
CD14+CD16+ and CD14dim monocytes (E). In samples where CD14+CD16+ and CD14dim 
monocytes could not be distinguished, monocytes were gated for CD14+CD16- and CD16+ 
subsets only (F). The expression of CD11b, CX3CR1 and CD163 were compared in all 
subsets of monocytes (G). 
 
3.2.4  Considerations for the Detection of Monocytes by Flow Cytometry 
3.2.4.1  Monocytes Purified by RBC Lysis Have Lower Forward Scatter 
Recommendations have pushed for the use of RBC lysis instead of density gradient 
centrifugation for the purification of PBMCs for immunophenotyping. Nguyen et al. 
(Nguyen, 2007) believe the purification of PBMCs by RBC lysis has less of an effect on cells 
than with other methods, including density gradient centrifugation. Cros et al. (Cros et al., 
2010) opted for RBC lysis as Ficoll density centrifugation may cause monocytes to become 
activated. 
 
To compare the effects on monocytes purified by RBC lysis or density gradient 
centrifugation, two whole blood samples were collected from a healthy control subject at the 
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same time. PBMCs from one sample were purified by RBC lysis while PBMCs from the 
other sample were purified by density gradient centrifugation on Ficoll-Paque (see 2.3 
Purification of PBMCs and Serum Colletion). PBMCs were stained immediately after 
purification for the analysis of monocyte subsets. 
 
As shown in Figure 3.10, different purification methods have yielded monocytes with 
different forward and side scatter properties. It is important to note that to allow for an 
objective comparison, CST settings on the flow cytometer were not changed between the 
analysis of monocytes purified by RBC lysis and monocytes obtained by Ficoll density 
centrifugation. While the mean fluorescence intensity (MFI) of side scatter was almost the 
same between monocytes purified by either method (MFI SSC-A RBC lysis 58201, Ficoll 
63954), the MFI of forward scatter of monocytes purified by RBC lysis (MFI FSC-A 53949) 
was almost half that of monocytes purified by density gradient centrifugation (MFI FSC-A 
98204) (C), indicating that the RBC lysis buffer may cause monocytes to shrink in size. 
Therefore, our findings are in contrast to suggestions by Nguyen et al. (Nguyen, 2007) that 
PBMC purification methods other than RBC lysis cause greater disturbance to the cells. 
 
The RBC lysis buffer also seemed to affect CD16 (but not CD14) expression on monocytes, 
increasing the background expression of CD16, especially on the CD14+CD16- classical 
monocyte subset (MFI CD16 RBC lysis 1581, Ficoll 590) (B, C). As CD16 is indicative of 
monocyte activation (Autissier et al., 2010, Saha and Geissmann, 2011), it appears that Ficoll 
density centrifugation did not lead to the activation of monocytes, as monocytes purified by 
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Figure 3.10. The effects of RBC lysis, density gradient centrifugation on Ficoll-Paque (“Ficoll”) 
and cryopreservation on monocytes. (A) Representative plots depicting viable monocytes based 
on FSC-A vs. SSC-A expression by flow cytometry from PBMCs purified by RBC lysis (left), by 
Ficoll (middle) and PBMCs which were purified by Ficoll two years earlier and cryopreserved 
(right). Percentages of cells within each gate are shown. (B) Representative plots depicting 
differential expression of CD14 and CD16 on monocytes by flow cytometry from PBMCs purified 
by RBC lysis (left), by Ficoll (middle) and PBMCs which were purified by Ficoll two years earlier 
and cryopreserved (right). Percentages of cells within each gate are shown. (C) Comparison of 
forward and side scatter properties (MFI) of monocytes and level of CD16 expression (MFI) of 
monocyte subsets from PBMCs purified by RBC lysis, by Ficoll and PBMCs which were purified 
by Ficoll at two years earlier and cryopreserved. 
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this method expressed lower levels of CD16. This was in contrast to what was suggested by 
Cros et al. (Cros et al., 2010). Based on these findings, density gradient centrifugation on 
Ficoll-Paque was the preferred method for the purification of PBMCs for flow cytometric 
analysis in our study. 
 
3.2.4.2  Cryopreservation Did Not Adversely Alter Properties of Monocytes Purified by 
Density Gradient Centrifugation 
Further to the optimisation of the monocyte cell surface staining protocol, we investigated the 
effects of cryopreservation on monocytes purified by Ficoll density centrifugation. PBMCs 
from a healthy control subject were purified by density gradient centrifugation on Ficoll-
Paque (see 2.3.1 Purification of PBMCs by Density Gradient Centrifugation). At the 
same time, cryopreserved PBMCs collected from the same subject by density gradient 
centrifugation on Ficoll-Paque two years earlier were thawed. Both PBMC samples were 
stained simultaneously for the analysis of monocyte subsets. 
 
As shown in Figure 3.10 (A), cryopreservation did not alter the forward and side scatter 
profile of monocytes. The forward and side scatter MFI of monocytes that had been 
cryopreserved (MFI FSC-A 95079, SSC-A 60456) was only slightly lower than that of 
monocytes stained immediately after Ficoll density centrifugation (MFI FSC-A 98204, SSC-
A 63954) (C). Although CD16 (but not CD14) expression was lower on monocytes that had 
been cryopreserved, more notably in the CD14+CD16+ (MFI CD16 not cryopreserved 33523, 
cryopreserved 16659) and CD14dim subsets (MFI CD16 not cryopreserved 72874, 
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cryopreserved 54362), the extent to which cryopreserved monocytes were affected was 
minimal with respect to the immunophenotyping of these cells (B, C). 
 
As cryopreservation did not drastically alter forward and side scatter properties or CD14 and 
CD16 expression levels of monocytes, it does not matter whether these cells are analysed by 
flow cytometry on the day the PBMC sample was obtained or at a later date after storage in 
liquid nitrogen. Logistically, the cryopreservation of PBMCs obtained by Ficoll density 
centrifugation offers several advantages. As there is no fixed schedule of when whole blood 
samples are collected from SLE patients, cryopreservation enables a number of patient 
PBMC samples to be stored and analysed together at a later date to avoid inter-assay 
variation, such as variations in staining protocols and inconsistent flow cytometer settings. In 
addition, cryopreservation allows for the investigation of more subsets of cells or other 
analyses of the PBMC samples in the future. 
 
3.3  Monocyte and NK Cell Panel Development 
3.3.1  CD14dim Monocytes are Phenotypically Similar to CD56- NK Cells 
Concerns were raised over the possibility of including CD56- NK cells in the CD14dim 
monocyte gate. CD56- NK cells are rarely found in the peripheral blood of healthy 
individuals (Hu et al., 1995) but were found to be increased in chronic HIV-1 and HCV 
patients (Hu et al., 1995, Gonzalez et al., 2008, Gonzalez et al., 2009, Eller et al., 2009, 
Mavilio et al., 2005). NK cells are lymphocytes, and CD14dim monocytes are a smaller subset 
of monocytes and therefore could be similar in size to CD56- NK cells. CD14dim monocytes 
and CD56- NK cells both express CD16 but CD56- NK cells do not express CD14 (Cros et 
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al., 2010, Hu et al., 1995). Although CD14dim monocytes do express a certain level of CD14, 
it is possible that in some PBMC samples the level of CD14 expression is so low that it may 
be interpreted as CD14- on a two-dimensional flow cytometry plot. For these reasons we 
decided to include cell surface markers specific to NK cells in our monocyte antibody panel. 
 
3.3.2  Antibody Panel for the Detection of Monocyte and NK Cell Subsets 
The two main subsets of NK cells in peripheral blood are CD56dimCD16+ and CD56briCD16- 
NK cells. The majority of NK cells in the blood are the CD56dimCD16+ subset while 
CD56briCD16- NK cells are mostly found in secondary lymphoid tissue (Cooper et al., 2001a, 
Ferlazzo et al., 2004). Other rare peripheral blood NK cell populations based on CD16 and 
CD56 expression include CD56dimCD16- and CD56briCD16dim NK cells (Poli et al., 2009), as 
well as the CD56- population mentioned above. 
 
NKp46 is one of the natural cytotoxicity receptors expressed by all NK cells and is thought to 
be the mammalian pan-NK cell marker (Pende et al., 1999, Pessino et al., 1998, Sivori et al., 
1997, Walzer et al., 2007). Both CD56dimCD16+ and CD56briCD16- NK cells express NKp46. 
CD56- NK cells from HIV-1 but not HCV patients express NKp46 at lower levels (Mavilio et 
al., 2005, Eller et al., 2009, Gonzalez et al., 2008). Cros et al (Cros et al., 2010) included 
NKp46 in their antibody panel to exclude NK cells from their analysis of monocytes. 
 
We therefore added CD56 and NKp46 to our monocyte antibody panel, not only to exclude 
NK cells from the analysis of monocytes, but also to investigate NK cell subsets in the 
peripheral blood of SLE patients. CD3 was included as a pan-T cell exclusion marker, which 
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will exclude NKT cells from the analysis of NK cells as NKT cells express CD3 and may 
express NK markers including CD16 and CD56 (Berzins et al., 2011). Also, CD19 was 
included as a pan-B cell exclusion marker to exclude CD11b+ B1 B cells from the analysis of 
monocytes, because this subset of B1 cell has a similar cell surface phenotype (CD11b+, 
CD14+, CD11c+) and size to CD14+ monocyte subsets (Griffin and Rothstein, 2011). 
 
One of the monocyte markers from the original monocyte antibody panel (Table 3.6) had to 
be removed in order to add the new NK and exclusion markers to the panel. Of the three non-
core monocyte markers, CD11b, CX3CR1 and CD163, we decided to exclude CD163. 
Although CX3CR1 was not the best marker to distinguish between CD14+CD16+ and 
CD14dim monocytes (Figure 3.9 (G)), CX3CR1 expression has been implicated in the 
immunopathogenesis of lupus nephritis and we believed analysis of its expression levels on 
the monocyte subsets to be vital to our study. Both CD11b and CD163 could be used to 
distinguish CD14+CD16+ monocytes from the CD14dim subset (Figure 3.9 (G)) so having 
both markers in our panel would be redundant. Furthermore, Moniuszko et al (Moniuszko et 
al., 2006) reported that CD163 expression on CD14+ monocytes was significantly lower in 
blood treated with heparin compared with other anticoagulants used in their study (EDTA 
and citrate). Almost all of the blood samples we have collected in our study were collected in 
tubes containing lithium heparin so any finding in our study based on CD163 expression 
would not be reliable. 
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Table 3.7 lists the antibodies used in the present panel used for the detection of monocyte and 
NK cell populations. CD3 and CD19 were exclusion markers and therefore were to be 
detected in the dimmer Pacific Orange channel. We were already using CD11b conjugated to 
PE Cy7 in our second B cell panel (Table 3.4) and so we decided to use the same antibody in 
the monocyte/NK cell panel as well. CD16 was moved to the moderately bright PerCP Cy5.5 
channel. We selected NKp46 conjugated to PE and CX3CR1 to FITC based on commercial 
availability. The last free channel remaining was APC, which is a bright channel, and was 
selected for CD56 as it is expressed at lower levels on the main NK subset CD56dimCD16+ 
NK cells. The dead cell exclusion marker used was once again LIVE-DEAD® Fixable Near-
IR. The monocyte/NK cell panel was tested on PBMC samples from Cohort 3 (Table 3.5). 
 
3.3.3  Gating Strategy for the Detection of Monocyte and NK Cell Subsets 
The gating strategy for the identification of monocyte and NK cell populations is shown in 
Figure 3.11. Doublets (A-B) and non-viable cells (C) were excluded from the analysis. 
Instead of gating only for monocytes and lymphocytes based on forward and side scatter 
properties, we gated for mononuclear cells (D). This was to ensure we did not include 
granulocytes which could express marker found on monocytes (CD11b and CD16), and 
monocytes and NK cells will be distinguished using NKp46 instead of by size. CD3+ and 
CD19+ cells were gated out to ensure NKT cells (which express CD3 and CD56) and B1 B 
cells (CD11b+ B1 B cells are similar in size and phenotype to monocytes) were excluded 
from our analysis (E). CD3- CD19- cells were compared for their size and expression of 
NKp46 (F). NK cells express NKp46, while monocytes will be found in the NKp46- gate. 
CD16 and CD56 expression were compared on NKp46+ cells to identify 3 populations of NK 
Table 3.7. Summary of monoclonal antibodies used for the detection of monocyte and NK cell 
subsets. 
 
Source Fluorochrome mAb/Stain Clone Dilution 
BD 
Pharmingen 
Pacific Blue Mouse IgG2a κ, antihuman CD14 M5E2 1:40 
Centenary 
Institute 
Biotinylated Mouse IgG2a κ, antihuman CD3 OKT3 1:320 
BD 
Pharmingen 
Biotinylated Mouse IgG1 κ, antihuman CD19 HIB19 1:10 
Life 
Technologies 
Pacific Orange Streptavidin - 1:200 
BioLegend FITC Rat IgG2b κ, antihuman CX3CR1 2A9-1 1:40 
BD 
Pharmingen 
PE Mouse IgG1 κ, antihuman NKp46 9E2 1:5-
1:10* 
BD 
Biosciences 
PerCP Cy5.5 Mouse IgG1 κ, antihuman CD16 3G8 1:20 
BD 
Pharmingen 
PE Cy7 Mouse IgG1 κ, antihuman CD11b ICRF44 1:20 
BD 
Biosciences 
APC Mouse IgG2b κ, antihuman CD56 NCAM16.2 1:40-
1:80* 
Invitrogen - LIVE-DEAD® Fixable Near-IR - 1:200 
 
* Optimal working dilutions differed between different lots of the same antibody as determined 
by antibody titration. 
 
APC – Allophycocyanin; CD – Cluster of differentiation; Cy – Cyanine; FITC – Fluorescein 
isothiocyanate; IR – infra red; mAb – monoclonal antibody; PE – R-Phycoerythrin; PerCP – 
Peridinin chlorophyll-a protein. 
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Figure 3.11. Standard gating strategy for the detection of monocyte and NK cell populations. 
(A-B) Sequential height vs. area gates for forward and side scatter were applied to exclude 
any doublets. (C) LIVE-DEAD® Fixable Near-IR dead cell exclusion stain was used to 
exclude dead cells. (D) PBMCs were identified based on forward and side scatter profiles. (E) 
CD3+ and CD19+ cells were gated out to ensure NKT cells and B1 B cells were excluded from 
analysis. (F) CD3- CD19- cells were compared for their expression of NKp46. (G) CD16 and 
CD56 expression were compared on NKp46+ cells to identify 3 populations of NK cells, 
namely CD56briCD16-, CD56dimCD16+ and CD56- NK cells. (H) CD14 and CD16 expression 
were compared on NKp46- cells to identify 2 populations of monocytes, namely CD14+CD16- 
classical and CD16+ monocytes. (I) A third population of monocytes, the CD14dim non-
classical monocytes, exists in some individuals as a subset of CD16+ monocytes. (J) 
CX3CR1 and CD11b expression were compared in all subsets of monocytes. Numbers 
represent percentage of cells within the gate. 
Chapter 3: Antibody Panel Development and Optimisation 114 
 
cells, CD56briCD16-, CD56dimCD16+ and CD56- NK cells (G). CD14 and CD16 expression 
were compared on NKp46- cells to identify CD14+CD16- and CD16+ monocytes (H). 
CD14dim monocytes exist in some individuals as a subset of CD16+ monocytes (I). To unify 
our downstream analysis of monocyte populations, we calculated frequencies and numbers of 
CD14+CD16- and CD16+ monocytes for all samples. Additional analysis was performed for 
samples with CD14dim monocytes. CX3CR1 and CD11b expression were compared in all 
subsets of monocytes for all samples (J). 
 
We were fortunate that we had a sample in Cohort 3 which had an unusually increased CD56- 
NK population and a clearly identifiable CD14dim monocyte population, as shown in Figure 
3.12. This PBMC sample was from a patient diagnosed with Sjögren’s Syndrome. When the 
expression of CD16 and CD56 were compared, we were able to see from this sample that 
CD14dim monocytes have a higher expression of CD16 than CD56- NK cells (in green, C). 
The CD14-/dim population with a slightly lower expression of CD16 than CD14dim monocytes 
(in orange, B) appeared to be CD56dimCD16+ and CD56- NK cells (in orange, C). Although 
CD14dim monocytes (in green, D) were smaller than CD14+CD16- (in red, D) and 
CD14+CD16+ (in blue, D) monocytes, CD14dim monocytes were well within the total 
monocyte gate. CD56- NK cells (in black, G) were among the smaller NK cells and therefore 
less likely to be the same size as CD14dim monocytes, as clearly shown in (H). The NKp46+ 
cells which expressed CD16 at a higher level than CD56- NK cells (in purple, E) appeared to 
be CD14dim monocytes (in purple, F) when comparing CD14 and CD16 expression. Once 
again, it can be seen that CD56- NK cells express CD16 at lower levels than CD14dim 
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Figure 3.12. CD14dim monocytes and CD56- NK cells differ in CD16 expression and forward 
and side scatter profiles. (A) Monocytes and NK cells were identified from CD3-CD19- cells 
based on NKp46 expression and forward scatter. (B) CD14+CD16-, CD14+CD16+ and 
CD14dim monocytes and a CD14-CD16+ population were identified from larger NKp46- cells. 
(C) Expression of CD16 and CD56 were compared for CD14dim monocytes and the CD14-
CD16+ population. The CD14-CD16+ cells have similar CD16 and CD56 expression to 
CD56dimCD16+ and CD56- NK cells, whereas the CD14dim monocytes have a higher CD16 
expression. (D) Forward and side scatter properties were compared for the 3 monocyte 
subsets. (E) CD56briCD16-, CD56dimCD16+ and CD56- NK cells and a CD56-CD16hi population 
were identified from smaller NKp46+/- cells. (F) Expression of CD14 and CD16 were 
compared for CD56- NK cells and the CD56-CD16hi population. The CD56-CD16hi cells have 
similar CD14 and CD16 expression to CD14dim monocytes whereas the CD56- NK cells did 
not express CD14. (G) Forward and side scatter properties were compared for the 3 NK cell 
subsets. (H) Forward and side scatter properties were compared for CD14dim monocytes and 
CD56- NK cells. Numbers represent percentage of cells within the gate. 
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monocytes (in black, F). Our observations in this sample enabled us to understand the 
differences between two similar populations of cells, CD14dim monocytes and CD56- NK 
cells, and how to gate for them more accurately. 
 
3.3.4  Final Monocyte/NK Cell Panel and Gating Strategy for SLE Study 
As with the analysis of B cell populations, we extended our investigation of monocytes and 
NK cell populations to the rest of the SLE, disease control and healthy control samples we 
collected for our study (as described in 2.1 Patient and Control Samples) using the 
antibody panel shown in Table 3.7. As explained previously, we did not have sufficient 
numbers of cells for some of the patient samples and as a consequence we had to limit our 
analysis to core populations of cells using a minimal number of cell surface markers. Only 
CD14, CD16, CD56 and NKp46 were required for the identification of monocyte and NK 
cell subsets, and the gating strategy for samples stained using the full monocyte/NK cell 
panel (Table 3.7) was altered slightly. It was no longer necessary to gate out CD3 and CD19 
prior to identifying monocytes and NK cells. There are generally very low levels of NKT 
cells, ranging from 0.01-0.5% of all peripheral blood cells (Berzins et al., 2011). Also, results 
from our test study using samples from Cohort 3 indicated that there are very few B1 B cells 
in peripheral blood, as shown in Figure 3.12, with most of them the smaller CD11b- B1 cells 
and not the larger CD11b+ B1 cells which resemble monocytes in terms of size and marker 
expression. 
 
Our final gating strategy involved first distinguishing monocytes and lymphocytes, which 
includes NK cells, based on differences in forward and side scatter. The main concern for not 
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gating for monocytes and lymphocytes in this manner previously (Figure 3.11) was because 
we could have unintentionally excluded the smaller CD14dim monocytes or included some 
larger NK cells from our total monocyte gate, and vice versa within the lymphocyte gate. As 
shown in Figure 3.13, we measured the proportion of NK cells included in the monocyte gate 
(C) and monocytes in the lymphocyte gate (G), expressed as a percentage of live cells, in 12 
PBMC samples. In general, there were 1% or less of monocytes in the lymphocyte gate 
(mean 0.56%) and less than 0.3% of NK cells were found in the monocyte gate (mean 
0.13%) (H).  
 
We therefore used the method of identifying monocytes and lymphocytes based on forward 
and side scatter properties in our final gating strategy for the detection of monocyte and NK 
cell subsets, summarised in Figure 3.14. Briefly, doublets (A-B) and non-viable cells (C) 
were excluded from the analysis. Monocytes and lymphocytes were identified based on 
forward and side scatter properties (D). NKp46+ cells were excluded from the analysis of 
monocyte populations (E). CD14 and CD16 expression were compared on NKp46- cells to 
identify CD14+CD16- and CD16+ monocytes (F). CD14dim monocytes exist in some 
individuals as a subset of CD16+ monocytes (G). NK cells were identified in the lymphocyte 
population based on NKp46 expression (H). CD16 and CD56 expression were compared on 
NKp46+ cells to identify CD56briCD16-, CD56dimCD16+ and CD56- NK cells (I). 
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Figure 3.13. Few NK cells were found in the monocyte gate and few monocytes found in the 
NK cell gate. (A) Live cells were gated for monocytes and lymphocytes based on forward and 
side scatter properties. (B) The expression of NKp46 was compared for cells within the 
monocyte gate. (C) NKp46+ cells within the monocyte gate were compared for their 
expression of CD16 and CD56 to identify NK cell subsets. (D) NKp46- cells within the 
monocyte gate were compared for their expression of CD14 and CD16 to identify monocyte 
subsets, which is how we identify monocytes in our usual monocyte/NK gating strategy. (E) 
The expression of NKp46 was compared for cells within the lymphocyte gate. (F) NKp46+ 
cells within the lymphocyte gate were compared for their expression of CD16 and CD56 to 
identify NK cell subsets, which is how we identify NK cells in our usual monocyte/NK gating 
strategy. (G) NKp46- cells within the lymphocyte gate were compared for their expression of 
CD14 and CD16 to identify monocyte subsets. Numbers represent percentage of cells within 
the gate. (H) Proportions of monocytes in the lymphocyte gate (in purple) and NK cells in the 
monocyte gate (in orange), expressed as a percentage of live cells. 
 0 50K 100K 150K 200K 250K
0
50K
100K
150K
200K
250K
80.7
17.6
FSC-A
S
S
C
-A
0 50K 100K 150K 200K 250K
0
102
103
104
105
99.4
N
K
p4
6 
P
E
FSC-A
0 50K 100K 150K 200K 250K
0
102
103
104
105
11.3
N
K
p4
6 
P
E
FSC-A
0 102 103 104 105
0
102
103
104
105
86.8
7.39
CD14 PB
C
D
16
 P
er
C
P 
C
y5
.5
0 102 103 104 105
0
102
103
104
105
1.2
6.98
88.1
CD16 PerCP Cy5.5
C
D
56
 A
P
C
0 102 103 104 105
0
102
103
104
105
87.1
4.85 6.71
CD14 PB
C
D
16
 P
er
C
P 
C
y5
.5
OR
0 50K 100K 150K 200K 250K
0
50K
100K
150K
200K
250K
91.9
0 50K 100K 150K 200K 250K
0
50K
100K
150K
200K
250K
99.9
0 50K 100K 150K 200K 250K
0
102
103
104
105
91.2
FSC-A
FS
C
-H
SSC-A
S
S
C
-H
FSC-A
Li
ve
-D
ea
d 
N
ea
r-
IR
A B C
D E F G
H I
Figure 3.14. Standard gating strategy for the detection of core monocyte and NK cell populations. (A-B) Sequential height vs. area gates for forward and side 
scatter were applied to exclude any doublets. (C) LIVE-DEAD® Fixable Near-IR dead cell exclusion stain was used to exclude dead cells. (D) Lymphocytes 
and monocytes were identified based on forward and side scatter profiles. (E) NKp46+ cells were excluded to ensure no NK cells were included in the 
analysis of monocytes. (F) CD14 and CD16 expression were compared on NKp46- cells to identify 2 populations of monocytes, namely CD14+CD16- classical 
and CD16+ monocytes. (G) A third population of monocytes, the CD14dim non-classical monocytes, exists in some individuals as a subset of CD16+ 
monocytes. (H) NK cells were identified in the lymphocyte population based on NKp46 expression. (I) CD16 and CD56 expression were compared on NKp46+ 
cells to identify 3 populations of NK cells, namely CD56briCD16-, CD56dimCD16+ and CD56- NK cells. Numbers represent percentage of cells within the gate. 
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3.4  Combined B Cell/Monocyte/NK Cell Panel Development 
Once we had finalised the B cell and monocyte/NK antibody panels, we were ready to extend 
our investigation to the rest of the samples we had collected for our study. As mentioned 
above, some of the patient samples we had collected did not have sufficient cell numbers for 
the study of not only B cells, monocytes and NK cells, but also Tregs and Tfh cells 
(discussed below in 3.6 Treg and Tfh Cell Panel Development). We typically stain one 
million cells with one of the eight-colour antibody panels in our study, meaning we would 
ideally like to have 3 to 4 million PBMCs per patient or control sample. Unfortunately we 
had less than 2 million PBMCs for some of our patient samples, due to reasons such as the 
patient being leukopenic at the time of blood collection, or Ficoll density centrifugation was 
performed following a lengthy delay after venepuncture leading to a lower yield of PBMCs. 
Thus, a new combined antibody panel was developed so that the investigation of all the cell 
populations we were interested in would be possible even in samples with fewer PBMCs. 
 
The cell surface markers that have been used in our various antibody panels for the detection 
B cells, monocytes, NK cells, Tregs and Tfh cells were compared on Table 3.8. The cell 
types with the most mutually exclusive markers were to be combined in an eight-colour 
antibody panel. Although the ten laser LSR-9 flow cytometer (BD) would allow us to detect 
more than eight markers simultaneously, we preferred to continue using the Canto-II flow 
cytometer because of its more stable fluidics system.  
 
Table 3.8. Expression of cell surface markers used in our study on B cells, monocytes, NK 
cells and Tregs and Tfh cells. 
 
  B cells Tregs and Tfh Monocytes NK cells 
CD19 + - - - 
IgM + - - - 
IgD + - - - 
CD27 + + - + 
CD38 + + + + 
CD11b CD11b+ B1 cells + + + 
CD43 + + + + 
CD4 - + low - 
CD25 + + + - 
CD127 - + - - 
CD45RO + + + - 
CXCR5 + + - - 
CXCR3 - + - + 
PD-1 + + + - 
CD14 CD11b+ B1 cells - + - 
CD16 - - + + 
CD56 - NKT cells some CD14+ Mo + 
NKp46 - - - + 
CX3CR1 - + + + 
CD3 - + low - 
 
CD – cluster of differentiation; Mo – monocytes; PD-1 – programmed cell death-1; Tfh – 
follicular helper T cell. 
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B cells, monocytes and NK cells have the most mutually exclusive markers and were 
therefore combined in an eight-colour antibody panel. We had to restrict the number of cell 
surface markers for the detection of core cell populations only as we were limited to eight 
detection channels on the Canto-II flow cytometer. CD43 and CD11b from the full B cell 
panel (Table 3.4) were excluded and CX3CR1 and CD11b were excluded from the full 
monocyte/NK panel (Table 3.7). CD3 and IgM were to be detected in one channel as IgM is 
only expressed on B cells and B cells do not express the pan-T cell marker CD3. Similarly, 
IgD and CD16 were to be detected in a single channel because IgD is only expressed on B 
cells and B cells do not express CD16. CD14 and CD27 were to be detected in a single 
channel as monocytes do not express CD27. Of the cell populations we were interested in, 
only CD11b+ B1 B cells express CD14 other than monocytes, but we would gate out all 
CD19+ cells prior to detection of monocyte subsets in our gating strategy. Thus, we were able 
to detect 10 cell surface markers in our eight-colour antibody panel. The first combined 
B/monocyte/NK panel was developed building on the knowledge we had gained from the 
separate B cell and monocyte/NK panels. The same marker-fluorochrome combinations we 
had from our separate B cell and monocyte/NK panels were used as much as possible in our 
combined panel. The new monoclonal antibodies we used in the combined panel were CD14 
and CD27 conjugated to FITC and IgD conjugated to PE Cy7. Table 3.9 lists the antibodies 
that were used in the first combined panel. 
 
The gating strategy for the detection of B cell, monocyte and NK cell populations using the 
combined panel, summarised in Figure 3.15, was based on the strategies developed using the 
Table 3.9. Summary of monoclonal antibodies used in the first combined B cell/monocyte/NK 
cell panel. 
 
Source Fluorochrome mAb/Stain Clone Dilution 
Centenary 
Institute 
Biotinylated Mouse IgG2a κ, antihuman 
CD3 
OKT3 1:320 
Southern Biotech Biotinylated Mouse IgG1, antihuman IgM SA-DA4 1:50 
Life Technologies Pacific Orange Streptavidin - 1:200 
BD Horizon V450 Mouse IgG1 κ, antihuman 
CD19 
HIB19 1:640 
BD Pharmingen FITC Mouse IgG2a κ, antihuman 
CD14 
M5E2 1:5 
BD Pharmingen FITC Mouse IgG1 κ, antihuman 
CD27 
M-T271 1:5 
BD Pharmingen PE Mouse IgG1 κ, antihuman 
NKp46 
9E2 1:10 
BD Pharmingen PerCP Cy5.5 Mouse IgG1 κ, antihuman 
CD38 
HIT2 1:40 
BD Pharmingen PE Cy7 Mouse IgG1 κ, antihuman 
CD16 
3G8 1:80 
BD Pharmingen PE Cy7 Mouse IgG2a κ, antihuman 
IgD 
IA6-2 1:40 
BD Biosciences APC Mouse IgG2b κ, antihuman 
CD56 
NCAM16.2 1:80 
Life Technologies - LIVE-DEAD® Fixable Near-IR - 1:200 
 
APC – Allophycocyanin; CD – Cluster of differentiation; Cy – Cyanine; FITC – Fluorescein 
isothiocyanate; IR – infra red; mAb – monoclonal antibody; PE – R-Phycoerythrin; PerCP – 
Peridinin chlorophyll-a protein. 
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Figure 3.15. Standard gating strategy for the detection of B cell, monocyte and NK cell 
populations using the first combined panel. (A-B) Sequential height vs. area gates for forward 
and side scatter were applied to exclude any doublets. (C) LIVE-DEAD® Fixable Near-IR 
dead cell exclusion stain was used to exclude dead cells. (D) PBMCs were identified based 
on forward and side scatter profiles. (E) B cells were identified by the expression of CD19. (F) 
Expression of CD27 and IgD were compared on CD19+ cells to identify transitional and naïve 
B cells (upper left), atypical memory B cells (lower left) and CD27+ memory B cells (right). (G) 
Expression of IgD and IgM were compared on CD27+ B cells to identify switched (IgD-IgM-, 
bottom) and MZ or non-switched (IgD+IgM+, top) memory B cells. Expression of CD19 and 
CD27 (H) and CD38 and IgD (J) were compared to identify CD19loCD27hiCD38hiIgD- 
plasmablasts and plasma cells. (I) CD38 expression was used to distinguish naïve (left) and 
transitional (right) B cells. (K) CD3+ cells were excluded from the CD19- population. (L) CD3- 
CD19- cells were compared for their size and expression of NKp46. (M) CD14 and CD16 
expression were compared on NKp46- cells to identify CD14+CD16- classical and CD16+ 
monocytes. (N) CD16 and CD56 expression were compared on NKp46+ cells to identify 
CD56briCD16-, CD56dimCD16+ and CD56- NK cells. Numbers represent percentage of cells 
within the gate. 
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separate B cell (Figure 3.6) and monocyte/NK panels (Figure 3.14). Doublets (A-B) and non-
viable cells (C) were excluded from the analysis. Mononuclear cells were identified based on 
forward and side scatter profile (D). B cells were identified in the mononuclear cell gate by 
the expression of CD19 (E). Naïve and transitional B cells were identified within the CD19+ 
population based on their expression of IgD but not CD27 (F). Also within the CD19+ gate 
are CD27-IgD- atypical and CD27+ memory B cells (F). Expression of IgD and IgM were 
compared on CD27+ memory B cells to identify IgD-IgM- switched and IgD+IgM+ marginal 
zone or non-switched memory B subsets (G). The expression of CD19 and CD27 (H) and 
CD38 and IgD (J) were compared for the detection of CD19loCD27hiCD38hiIgD- 
plasmablasts and plasma cells. Transitional B cells were distinguished from naïve B cells by 
their higher expression of CD38 (I). CD3+ cells were excluded from the population of CD19- 
cells to ensure NKT cells were not included in our analysis of NK cells (K). CD3- CD19- 
cells were compared for their size and expression of NKp46 (L). CD14 and CD16 expression 
were compared on NKp46- cells to identify CD14+CD16- and CD16+ monocytes (M). The 
sample we used to test our first combined panel did not have a clearly identifiable CD14dim 
monocyte population. CD16 and CD56 expression were compared on NKp46+ cells to 
identify CD56briCD16-, CD56dimCD16+ and CD56- NK cells (N). 
 
The sample we used to test the combined panel was also stained with the separate B cell and 
monocyte/NK panels simultaneously. Frequencies of B cell, monocyte and NK cell 
populations using the three different panels are listed in Table 3.10. The frequencies of the B 
cell populations, expressed as a percentage of total B cells or live cells, were almost identical 
Table 3.10. Frequencies of B cell, monocyte and NK cell populations of a single sample using 
the first combined panel compared with the separate B cell and monocyte/NK panels. 
 
    Combined B Mo/NK 
Total B (%live) 7.32 7.11  
Plasmablasts and plasma cells (%live) 0.04 0.06  
Switched memory (%CD19+) 11.1 10.7  
Switched memory (%live) 0.81 0.76  
MZ or non-switched memory (%CD19+) 40 37.4  
MZ or non-switched memory (%live) 2.93 2.66  
Atypical memory (%CD19+) 1.21 1.93  
Atypical memory (%live) 0.088 0.14  
Naïve (%CD19+) 43 47.3  
Naïve (%live) 3.15 3.36  
Transitional (%CD19+) 1.72 1.88  
B cells 
Transitional (%live) 0.13 0.13  
Total Mo (%live) 12.7  15.1 
CD14+CD16- (%Mo) 72.7  70.7 
CD14+CD16- (%live) 9.21  10.7 
CD16+ (%Mo) 10.7  11.1 
Monocytes 
CD16+ (%live) 1.35  1.67 
Total NK (%live) 35.8  35.9 
CD56briCD16- (%NK) 1.02  1.73 
CD56briCD16- (%live) 0.37  0.62 
CD56dimCD16+ (%NK) 94  94.1 
CD56dimCD16+ (%live) 33.7  33.8 
CD56- (%NK) 1.01  0.7 
NK cells 
CD56- (%live) 0.36  0.25 
 
CD – cluster of differentiation; Mo – monocytes; MZ – marginal zone. 
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for most B cell subsets when using either the separate B cell or the combined panel. 
However, the anti-CD27-FITC antibody used in the combined panel had a lower signal-to-
noise ratio than the anti-CD27-PE antibody used in the separate B cell panel (MFI CD27-
FITC+ 1369, CD27-FITC- 180, CD27-PE+ 3116, CD27-PE- 69.1), as shown in Figure 3.16 
(A-C). This could explain the difference in the frequency of naïve and MZ or non-switched 
memory B cells because the two populations could not be clearly separated using anti-CD27-
FITC. There were 50% less CD56briCD16- NK cells detected using the combined panel 
compared with the separate monocyte/NK panel, which we attributed to problems with 
compensation as CD56 and CD16 were detected on adjacent channels (APC and PE Cy7, 
respectively) (D-E). There were also fewer monocytes detected using the combined panel 
compared with the separate monocyte/NK panel. We subsequently observed that the 
background fluorescence of IgM (MFI 2556) is at a similar level to the CD3/CD19 positive 
signal (MFI 3947) (F-I). 
 
Three issues had to be resolved. We reverted back to the anti-CD27-PE antibody for the 
identification of B cell subsets. Therefore, CD14 would also be detected in the PE channel. 
This would not be ideal in a monocyte-only panel because CD14 is highly expressed on most 
monocytes, but our options were limited to combining mutually exclusive markers and 
availability of antibody-fluorochrome combinations for the other markers in the panel. CD56 
would now be detected in the FITC channel, away from the channel detecting CD16 PE Cy7. 
NKp46 would now be detected in the APC channel. Table 3.11 lists the antibodies used in 
the final combined panel for the analysis of B cells, monocytes and NK cells. We decided not 
 
 
Figure 3.16. Problems encountered using the first combined B cell/monocyte/NK cell panel. 
(A) B cells were compared for their expression of CD27 and IgD using the combined panel. 
(B) B cells were compared for their expression of CD27 and IgD using the separate B cell 
panel. (C) Signal and background expression (MFI) of CD27 of B cells from a sample stained 
with anti-CD27-FITC (combined panel) or anti-CD27-PE (B cell panel). (D) NKp46+ cells were 
compared for their expression of CD16 and CD56 using the combined panel. (E) NKp46+ 
cells were compared for their expression of CD16 and CD56 using the separate monocyte/NK 
panel. (F) CD3 and IgM expression were compared on mononuclear cells using the combined 
panel. (G) CD3 and CD19 expression were compared on mononuclear cells using the 
monocyte/NK panel. (H) IgM and IgD expression were compared on CD27+ B cells using the 
B cell panel. (I) Signal and background expression (MFI) of CD3 and CD19 of mononuclear 
cells of a sample stained with the monocyte/NK panel, and of IgM of CD27+ B cells of the 
same sample stained with the B cell panel. 
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Table 3.11. Summary of monoclonal antibodies used in the final combined B 
cell/monocyte/NK cell panel. 
 
Source Fluorochrome mAb/Stain Clone Dilution 
Southern 
Biotech 
Biotinylated Mouse IgG1, antihuman IgM SA-DA4 1:50 
Life 
Technologies 
Pacific Orange Streptavidin - 1:200 
BD Horizon V450 Mouse IgG1 κ, antihuman 
CD19 
HIB19 1:640 
BD Biosciences FITC Mouse IgG2b κ, antihuman 
CD56 
NCAM16.2 1:40 
BioLegend PE Mouse IgG2a κ, antihuman 
CD14 
M5E2 1:20 
BD Pharmingen PE Mouse IgG1 κ, antihuman 
CD27 
M-T271 1:10 
BD Pharmingen PerCP Cy5.5 Mouse IgG1 κ, antihuman 
CD38 
HIT2 1:20-
1:40* 
BD Pharmingen PE Cy7 Mouse IgG1 κ, antihuman 
CD16 
3G8 1:80 
BD Pharmingen PE Cy7 Mouse IgG2a κ, antihuman 
IgD 
IA6-2 1:40 
BD Pharmingen APC Mouse IgG1 κ, antihuman 
NKp46 
9E2 1:20 
Life 
Technologies 
- LIVE-DEAD® Fixable Near-IR - 1:200 
 
* Optimal working dilutions differed between different lots of the same antibody as determined 
by antibody titration. 
 
APC – Allophycocyanin; CD – Cluster of differentiation; Cy – Cyanine; FITC – Fluorescein 
isothiocyanate; IR – infra red; mAb – monoclonal antibody; PE – R-Phycoerythrin; PerCP – 
Peridinin chlorophyll-a protein. 
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to include CD3 as an exclusion marker because there are few NKT cells in peripheral blood 
(Berzins et al., 2011). It was because of the problem with CD3 signal being similar to the 
background fluorescence of IgM here that we decided to change the gating strategy for 
monocytes and NK cells when using the separate monocyte/NK panel, i.e. first identifying 
the total monocyte and lymphocyte populations by forward and side scatter properties 
(Figure 3.14).  
 
We therefore modified the gating strategy for the detection of B cell, monocyte and NK cell 
populations using our final combined antibody panel, summarised in Figure 3.17. Doublets 
(A-B) and non-viable cells (C) were excluded from the analysis. Mononuclear cells were 
identified based on forward and side scatter profile (D). B cells were identified in the 
mononuclear cell gate by the expression of CD19 (E). Naïve and transitional B cells were 
identified within the CD19+ population based on their expression of IgD but not CD27 (F). 
Also within the CD19+ gate are CD27-IgD- atypical and CD27+ memory B cells (F). 
Expression of IgD and IgM were compared on CD27+ memory B cells to identify IgD-IgM- 
switched and IgD+IgM+ marginal zone or non-switched memory B subsets (G). The 
expression of CD19 and CD27 (H) and CD38 and IgD (J) were compared for the detection of 
CD19loCD27hiCD38hiIgD- plasmablasts and plasma cells. Transitional B cells were 
distinguished from naïve B cells by their higher expression of CD38 (I). Monocytes and 
lymphocytes were identified based on forward and side scatter properties (K). NKp46+ cells 
were excluded from the analysis of monocyte populations (L). CD14 and CD16 expression 
were compared on NKp46- cells to identify CD14+CD16- and CD16+ monocytes (M). 
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Figure 3.17. Standard gating strategy for the detection of B cell, monocyte and NK cell 
populations using the final combined panel. (A-B) Sequential height vs. area gates for 
forward and side scatter were applied to exclude any doublets. (C) LIVE-DEAD® Fixable 
Near-IR dead cell exclusion stain was used to exclude dead cells. (D) PBMCs were identified 
based on forward and side scatter profiles. (E) B cells were identified by the expression of 
CD19. (F) Expression of CD27 and IgD were compared on CD19+ cells to identify transitional 
and naïve B cells (upper left), atypical memory B cells (lower left) and CD27+ memory B cells 
(right). (G) Expression of IgD and IgM were compared on CD27+ B cells to identify switched 
(IgD-IgM-, bottom) and MZ or non-switched (IgD+IgM+, top) memory B cells. Expression of 
CD19 and CD27 (H) and CD38 and IgD (J) were compared to identify 
CD19loCD27hiCD38hiIgD- plasmablasts and plasma cells. (I) CD38 expression was used to 
distinguish naïve (left) and transitional (right) B cells. (K) Monocytes and lymphocytes within 
the CD19- gate were identified based on forward and side scatter properties. (L) NKp46+ cells 
were excluded to ensure no NK cells were included in the analysis of monocytes. (M) CD14 
and CD16 expression were compared on NKp46- cells to identify CD14+CD16- classical and 
CD16+ monocytes. (N) A third population of monocytes, the CD14dim non-classical 
monocytes, exists in some individuals as a subset of CD16+ monocytes. (O) NK cells were 
identified in the lymphocyte population based on NKp46 expression. (P) CD16 and CD56 
expression were compared on NKp46+ cells to identify CD56briCD16-, CD56dimCD16+ and 
CD56- NK cells. Numbers represent percentage of cells within the gate. 
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CD14dim monocytes exist in some individuals as a subset of CD16+ monocytes (N). NK cells 
were identified in the lymphocyte population based on NKp46 expression (O). CD16 and 
CD56 expression were compared on NKp46+ cells to identify CD56briCD16-, CD56dimCD16+ 
and CD56- NK cells (P). 
 
Once again, the sample we used to test the final combined panel was also stained with the 
separate B cell and monocyte/NK panels simultaneously. Frequencies of B cell, monocyte 
and NK cell populations using the three different panels are listed in Table 3.12. The 
frequencies of all cell populations were very similar when using either the final combined 
panel or separate B and monocyte/NK cell panels. 
 
3.5  Tfh Cell Panel Development 
3.5.1  Detection of Tfh Cells in Peripheral Blood Using CXCR5, ICOS, PD-1 and CD200 
Our first panel for the detection of human peripheral blood Tfh cells was based largely on the 
work of Simpson et al. (Simpson et al., 2010). Their study on Tfh cells in the blood of SLE 
patients reported that the expression of PD-1 and ICOS closely correlated with the number of 
Tfh cells in human peripheral blood, which were defined as CD4+CXCR5+. They thus 
concluded that human cTfh cells were ICOShi or PD-1hi CD4+CXCR5+ cells. Based on this, 
we included CD4, CXCR5, ICOS and PD-1 in our Tfh antibody panel. Simpson et al. 
(Simpson et al., 2010) also found that SLE patients with high levels of Tfh cells expressed 
CD200 on a higher proportion of these cells and blood Tfh cells, defined as CXCR5+ICOShi 
CD4+ T cells, could be clearly distinguished from other CD4+ T cell subsets (CXCR5-ICOShi, 
CXCR5+ not ICOShi, CXCR5- not ICOShi) using CD200. We therefore also included CD200 
Table 3.12. Frequencies of B cell, monocyte and NK cell populations of a single sample using 
the final combined panel compared with the separate B cell and monocyte/NK panels. 
 
   Combined B Mo/NK 
Total B (%live) 26.4 26.5  
Plasmablasts and plasma cells (%live) 0.14 0.14  
Switched memory (%CD19+) 12.3 12.2  
Switched memory (%live) 3.25 3.23  
MZ or non-switched memory (%CD19+) 5.86 4.93  
MZ or non-switched memory (%live) 1.55 1.31  
Atypical memory (%CD19+) 3.17 2.7  
Atypical memory (%live) 0.84 0.72  
Naïve (%CD19+) 70.8 72.4  
Naïve (%live) 18.7 19.2  
Transitional (%CD19+) 7.36 7.61  
B cells 
Transitional (%live) 1.94 2.02  
Total Mo (%live) 6.2  6.19 
CD14+CD16- (%Mo) 84.2  83.6 
CD14+CD16- (%live) 5.22  5.17 
CD16+ (%Mo) 15.8  16.4 
Monocytes 
CD16+ (%live) 0.98  1.01 
Total NK (%live) 17.5  18.2 
CD56briCD16- (%NK) 6.26  6.3 
CD56briCD16- (%live) 1.09  1.15 
CD56dimCD16+ (%NK) 92.9  92.8 
CD56dimCD16+ (%live) 16.2  16.9 
CD56- (%NK) 0.84  0.86 
NK cells 
CD56- (%live) 0.15  0.16 
 
CD – cluster of differentiation; Mo – monocytes; MZ – marginal zone. 
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in our Tfh panel. The development of the first Tfh panel was based on the same principles as 
those for the B cell and monocyte/NK panels. Pacific Blue, a dimmer fluorochrome, was 
selected for the highly expressed CD4. The brighter fluorochromes were paired with the Tfh-
specific markers based on commercial availability, namely ICOS-Alexa Fluor 488, CD200-
PE, PD-1-PerCP Cy5.5 and CXCR5-Alexa Fluor 647. LIVE-DEAD® Fixable Near-IR was 
used once again as the dead cell exclusion stain. Table 3.13 lists the antibodies used in our 
first Tfh panel and this panel was tested on samples from Cohort 1 in our first test study 
(Table 3.2). 
 
We have gated for cTfh cells using three different strategies, summarised in Figure 3.18. 
Doublets (A-B) and non-viable cells (C) were excluded from the analysis. Lymphocytes were 
identified based on forward and side scatter profiles (D). The first two strategies gate either 
CXCR5+ICOS+ cells (F) or CXCR5+PD-1+ cells (H) within the CD4+ lymphocyte gate (E). 
According to Simpson et al. (Simpson et al., 2010), both of these gates should identify Tfh 
cells, however, gating on CD4+CXCR5+ cells (J) shows that although some cells in this gate 
are positive for both ICOS and PD-1, few express high levels of both (K). Simpson et al. 
were able to confirm their gating of Tfh cells based on staining of tonsillar lymphocytes. 
Since tonsillar samples were not available in our study, we have performed comparisons 
using all three gating strategies. CD4+ T cells were also gated for ICOS+CD200+ (G) and PD-
1+CD200+ cells (I) for comparison of CD200 expression. Lastly, Simpson et al. identified a 
population of ICOShi CD4+ T cells in 6 of 29 SLE patients so the expression of ICOS on 
CD4+ lymphocytes was included in our analysis (L). 
Table 3.13. Summary of monoclonal antibodies used for the analysis of Tfh cells using 
CXCR5, ICOS, PD-1 and CD200. 
 
Source Fluorochrome mAb/Stain Clone Dilution 
BioLegend Pacific Blue Mouse IgG2b κ, antihuman CD4 OKT4 1:640 
BioLegend AF488 Armenian hamster IgG antihuman 
ICOS 
C398.4A 1:200 
BioLegend PE Mouse IgG1 κ, antihuman CD200 OX-104 1:5 
BioLegend PerCP Cy5.5 Mouse IgG1 κ, antihuman PD-1 EH12.2H7 1:20 
BD 
Pharmingen 
AF647 Rat IgG2b κ, antihuman CXCR5 RF8B2 1:640 
Invitrogen - LIVE-DEAD® Fixable Near-IR - 1:200 
 
AF – Alexa fluor; CD – Cluster of differentiation; Cy – Cyanine; IR – infra red; mAb – 
monoclonal antibody; PE – R-Phycoerythrin; PerCP – Peridinin chlorophyll-a protein. 
 
 
Figure 3.18. Gating strategy for the detection of Tfh cells using CXCR5, ICOS, PD-1 and 
CD200. (A-B) Sequential height vs. area gates for forward and side scatter were applied to 
exclude any doublets. (C) LIVE-DEAD® Fixable Near-IR dead cell exclusion stain was used 
to exclude dead cells. (D) Lymphocytes were identified based on forward and side scatter 
profiles. (E) CD4+ T lymphocytes were identified among live cells. (F) Tfh cells were identified 
as CXCR5+ICOS+ CD4+ cells. (G) Tfh cells were identified as CD200+ICOS+ CD4+ cells. (H) 
Tfh cells were identified as CXCR5+PD-1+ CD4+ cells. (I) Tfh cells were identified as 
CD200+PD-1+ CD4+ cells.  (J) CD4+ T cells were gated for CXCR5+ cells. (K) Tfh cells were 
identified as ICOS+PD-1hi CXCR5+ cells. (L) Lymphocytes were gated for ICOS+ or ICOShi 
CD4+ T cells. Numbers represent percentage of cells within the gate. 
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As shown in Figure 3.19 (A), the expression of ICOS on CD4+ cells appears to be increased 
in active SLE patients compared to inactive SLE and healthy control groups. In contrast, 
active SLE patients had lower CXCR5 and PD-1 expression on CD4+ cells compared to 
healthy controls and inactive SLE patients. This is evident when comparing the frequencies 
of ICOS+ CD4+ cells, CXCR5+ICOS+ CD4+ cells and CXCR5+PD-1+ CD4+ cells between the 
three groups (B). The frequency of ICOS+ CD4+ cells, although variable among active SLE 
patients, was slightly higher in this group (mean 2.94%) compared to inactive patients (mean 
2.79%) and healthy controls (mean 2.5%). Similarly, the frequency of CXCR5+ICOS+ CD4+ 
cells was variable within each group, especially among active patients and healthy controls. 
However, active and inactive SLE patients had a lower proportion of this subset of CD4+ 
cells (mean 0.38% and 0.39%, respectively) compared to healthy controls (mean 0.62%). 
Furthermore, the frequency of CXCR5+PD-1+ CD4+ cells among active and inactive SLE 
patients was also lower (mean 2.23% and 2.86%, respectively) than that of healthy controls 
(mean 3.42%), indicating that the expression of ICOS, but not CXCR5 or PD-1, is elevated in 
active SLE patients. The expression of CD200 did not vary greatly between patient and 
control groups, regardless of which gating strategy was utilised, shown in Figure 3.20. 
 
The findings here suggest that ICOS may be preferable to PD-1 as a marker for the 
identification of Tfh cells in peripheral blood. This is in contrast to findings by Simpson et al. 
(Simpson et al., 2010) where it was reported that a high level of expression of PD-1 on CD4+ 
T cells is enough to identify cTfh cells. 
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Figure 3.19. Comparison of gating strategies for the identification of Tfh cells using CXCR5, ICOS and PD-1. (A) Top panel compares the expression level of 
ICOS on CD4+ cells between active SLE, inactive SLE and healthy control samples. Middle panel compares the differential expression of both CXCR5 and 
ICOS on CD4+ cells. Bottom panel compares the differential expression of both CXCR5 and PD-1 on CD4+ cells. Percentages of cells within each gate are 
shown. (B) Frequencies of ICOS+ and ICOShi CD4+ cells (top), CXCR5+ICOS+ CD4+ cells (middle) and CXCR5+PD-1+ CD4+ cells (bottom) were compared 
between active SLE, inactive SLE and healthy control samples. Samples collected from a single patient at different time points are indicated by green 
squares. The horizontal bar represents the mean of each group. 
 
Figure 3.20. Comparison of CD200 expression between SLE patients and healthy controls. 
(A) Representative plots depicting CD200 vs. ICOS expression on CD4+ cells by flow 
cytometry from active SLE, inactive SLE and healthy control samples. (B) Representative 
plots depicting CD200 vs. PD-1 expression on CD4+ cells by flow cytometry from active SLE, 
inactive SLE and control samples. Percentages of cells within each gate are shown. 
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3.5.2  Comparison of Two Different Clones of Anti-PD-1 mAb 
The lack of CXCR5+PD-1hi CD4+ cells and ICOS+PD-1hi CXCR5+CD4+ cells in the 
peripheral blood of our first cohort of SLE patients prompted us to question whether the high 
expression of PD-1 was a property specific to tonsillar Tfh cells. Alternatively, there may 
have been a problem with the anti-PD-1 mAb used in this study. Through personal 
correspondence with Nick Simpson and Carola Vinuesa (two of the authors from the 
Simpson et al., 2010 study), it was recommended that we use the NAT clone of anti-PD-1 
mAb for the staining of PBMCs. We had been using the EH12.2H7 clone of anti-PD-1 mAb 
in our analysis of cTfh cells. 
 
Three healthy control samples and a sample from a patient with SLE were used for the 
comparison of the two clones of anti-PD-1 mAb. As shown in Figure 3.21, PBMCs stained 
with the anti-PD-1 (NAT) mAb gave a clearer positive PD-1 signal compared to PBMCs 
stained with the anti-PD-1 (EH12.2H7) mAb when gating for CXCR5+PD-1hi CD4+ cells (A) 
and ICOS+PD-1hi CXCR5+CD4+ cells (C). This observation was confirmed by the increased 
mean fluorescence intensity (MFI) of PD-1 in both subsets of Tfh cells when stained with the 
NAT clone versus the EH12.2H7 clone. For CXCR5+PD-1hi CD4+ cells (B), the MFI of PD-1 
of PBMCs stained with NAT was significantly higher (mean 14,814, p<0.05) than when 
stained with EH12.2H7 (mean 9258). Similarly, for ICOS+PD-1hi CXCR5+CD4+ cells (D), 
the MFI of PD-1 of PBMCs stained with NAT was also significantly higher (mean 16,478. 
p<0.05) than when stained with EH12.2H7 (mean 8237).  
 
 
Figure 3.21. Comparison of human PBMCs stained with different clones of anti-PD-1 monoclonal 
antibodies. (A) Representative plots depicting CXCR5 vs. PD-1 expression of CD4+ cells by flow 
cytometry from a sample stained with anti-PD-1 (EH12.2H7) (left) or anti-PD-1 (NAT) (right). (B) 
Expression levels (MFI) of PD-1 of CXCR5+PD-1hi CD4+ cells from samples stained with anti-PD-
1 (EH12.2H7) or anti-PD-1 (NAT). (C) Representative plots depicting ICOS vs. PD-1 expression 
of CXCR5+CD4+ cells by flow cytometry from a sample stained with anti-PD-1 (EH12.2H7) (left) 
or anti-PD-1 (NAT) (right). (D) Expression levels (MFI) of PD-1 of ICOS+PD-1hi CXCR5+CD4+ 
cells from samples stained with anti-PD-1 (EH12.2H7) or anti-PD-1 (NAT). Percentages of cells 
within each gate are shown. The horizontal bar represents the mean of each group. Statistical 
analysis of differences between patient and control groups was determined using the Mann-
Whitney test. * denotes p<0.05. 
0 102 103 104 105
0
102
103
104
105
1.64
0 102 103 104 105
0
102
103
104
105
0.45
0 102 103 104 105
0
102
103
104
105
0.15
0 102 103 104 105
0
102
103
104
105
0.86
CXCR5
P
D
-1
P
D
-1
ICOS
EH12.2H7
EH12.2H7
NAT
NAT
A B
EH12.2H7 NAT
0
5000
10000
15000
20000
EH12.2H7 NAT
8000
10000
12000
14000
16000
C D
*
*
M
FI
M
FI
Chapter 3: Antibody Panel Development and Optimisation 126 
 
3.5.3  Detection of Tfh Cells in Peripheral Blood Using CXCR5, ICOS and PD-1 
We therefore decided to conduct another analysis of Tfh cells in SLE patients and healthy 
controls, using the anti-PD-1 (NAT) mAb. CD200 was no longer necessary for the detection 
of Tfh cells in peripheral blood as its expression did not differ significantly on Tfh cells 
between SLE patients and healthy controls in our first test study (Figure 3.20). This left the 
brightest channel, PE, available for one of the key Tfh markers. PD-1 was moved from the 
moderately bright PerCP Cy5.5 channel to PE for better discrimination of PD-1hi from PD-1+ 
CXCR5+CD4+ cells. This panel of antibodies, listed on Table 3.14, was tested on samples 
from Cohort 2 in our second test study (Table 3.3).  We had available a human lymph node 
sample that was collected for a separate study in the lab (described in 2.1.4.2 Lymph Nodes). 
We included this lymph node sample in our study to confirm that there were no problems 
with the monoclonal antibodies we used for the detection of cTfh cells. 
 
Based on the definition of cTfh cells by Simpson et al. (Simpson et al., 2010) and our first 
test study of Tfh cells in SLE patients and healthy controls, we gated for Tfh cells using three 
different strategies, summarised in Figure 3.22. Doublets (A-B) and non-viable cells (C) were 
excluded from the analysis. The first strategy gated ICOS+PD-1hi cells (F) within the 
CD4+CXCR5+ gate (E). Tfh cells were also gated as either CXCR5+ICOS+ cells (G) or 
CXCR5+PD-1hi cells (H) within the CD4+ gate (D). Regardless of the gating strategy, it 
appeared that using the anti-PD-1 (NAT) mAb could no better identify cTfh cells than the 
anti-PD-1 (EH12.2H7) mAb that was used previously (F-H). 
 
Table 3.14. Summary of monoclonal antibodies used for the analysis of Tfh cells using 
CXCR5, ICOS and PD-1. 
 
Source Fluorochrome mAb/Stain Clone Dilution 
BioLegend Pacific Blue Mouse IgG2b κ, 
antihuman CD4 
OKT4 1:640 
BioLegend AF488 Armenian hamster IgG 
antihuman ICOS 
C398.4A 1:200 
CNIO (Spanish National 
Cancer Research 
Center) 
unconjugated Mouse IgG1 antihuman 
PD-1 
NAT 1:400 
Jackson 
ImmunoResearch 
PE AffiniPure F(ab’)2 
fragment goat 
antimouse IgG (H+L) 
Polyclonal 1:100 
BD Pharmingen AF647 Rat IgG2b κ, antihuman 
CXCR5 
RF8B2 1:640 
Invitrogen - LIVE-DEAD® Fixable 
Near-IR 
- 1:200 
 
AF – Alexa fluor; CD – Cluster of differentiation; H+L – heavy and light chains; IR – infra red; 
mAb – monoclonal antibody; PE – R-Phycoerythrin. 
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Figure 3.22. Gating strategy for the detection of Tfh cells in peripheral blood (PBMC) using CXCR5, ICOS and PD-1. Gating of PBMC was confirmed with the 
gating of Tfh cells from a lymph node (LN) sample. (A-B) Sequential height vs. area gates for forward and side scatter were applied to exclude any doublets. 
(C) LIVE-DEAD® Fixable Near-IR dead cell exclusion stain was used to exclude dead cells. (D) CD4+ T lymphocytes were identified among live cells. (E) 
CD4+ T cells were gated for CXCR5+ cells. (F) Tfh cells were identified as ICOS+PD-1hi CXCR5+ cells. (G) Tfh cells were identified as CXCR5hiICOS+ CD4+ 
cells. (H) Tfh cells were identified as CXCR5hiPD-1hi CD4+ cells. Numbers represent percentage of cells within the gate. 
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3.5.4  Detection of Tfh Cells in Peripheral Blood Using CXCR5, ICOS, PD-1 and Bcl-6 
As we could not clearly identify Tfh cells in any PBMC sample in either of our test studies, 
this led us to hypothesise that perhaps cTfh cells are at a different stage of differentiation 
compared with Tfh cells found in the germinal centres of secondary lymphoid organs. This 
could possibly account for the difference in the level of expression of ICOS and PD-1 on the 
surface of lymph node and peripheral blood cells. Bcl-6, the transcription factor of Tfh cells, 
drives the differentiation of CD4+ T cells into Tfh cells (Yu et al., 2009, Johnston et al., 2009, 
Nurieva et al., 2009), and therefore should be detected in all Tfh cells. Although Simpson et 
al (Simpson et al., 2010) did not find an increase of Bcl-6 expression in CXCR5+ICOS+ cTfh 
cells, there were few other studies at the time reporting similar findings regarding Bcl-6 
expression and thus we believed the use of Bcl-6 as a marker for cTfh cells warranted further 
investigation. As the MFI of PD-1 was markedly improved when we switched to the NAT 
clone, PD-1 was to be detected in the moderately bright PerCP channel, so that Bcl-6, which 
could prove to be vital to our detection of Tfh cells in peripheral blood, could be detected in 
the brightest channel, PE. The latest changes to our Tfh panel are summarised in Table 3.15 
and this panel was tested on samples from Cohort 3 (Table 3.5). We included lymph node 
samples from the same cohort of ulcerative colitis patients each time we stained PBMC 
samples for the detection of Tfh cells, to ensure that there were no problems with the 
antibodies we used and to confirm the gating of Tfh cells in blood. 
 
The gating strategies used here for the detection of Tfh cells, shown in Figure 3.23, were 
based on those we used with our earlier Tfh panels. Doublets (A-B) and non-viable cells (C) 
were excluded from the analysis. After gating for CD4+ T cells (D), CD4+ T cells were gated 
Table 3.15. Summary of monoclonal antibodies used for the analysis of Tfh cells using 
CXCR5, ICOS, PD-1 and Bcl-6. 
 
Source Fluorochrome mAb/Stain Clone Dilution 
BioLegend Pacific Blue Mouse IgG2b κ, 
antihuman CD4 
OKT4 1:640 
BioLegend AF488 Armenian hamster IgG 
antihuman ICOS 
C398.4A 1:200 
BD Pharmingen PE Mouse IgG1 κ, 
antihuman Bcl-6 
K112-91 1:20 
CNIO (Spanish National 
Cancer Research Center) 
unconjugated Mouse IgG1 antihuman 
PD-1 
NAT 1:400 
Jackson 
ImmunoResearch 
PerCP AffiniPure F(ab’)2 
fragment goat 
antimouse IgG (H+L) 
Polyclonal 1:100 
BD Pharmingen AF647 Rat IgG2b κ, antihuman 
CXCR5 
RF8B2 1:640 
Invitrogen - LIVE-DEAD® Fixable 
Near-IR 
- 1:200 
 
AF – Alexa fluor; CD – Cluster of differentiation; H+L – heavy and light chains; IR – infra red; 
mAb – monoclonal antibody; PE – R-Phycoerythrin; PerCP – Peridinin chlorophyll-a protein. 
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Figure 3.23. Gating strategy for the detection of Tfh cells in peripheral blood (PBMC) using CXCR5, ICOS, PD-1 and Bcl-6. Gating of PBMC was confirmed 
with the gating of Tfh cells from a lymph node (LN) sample. (A-B) Sequential height vs. area gates for forward and side scatter were applied to exclude any 
doublets. (C) LIVE-DEAD® Fixable Near-IR dead cell exclusion stain was used to exclude dead cells. (D) CD4+ T lymphocytes were identified among live 
cells. (E) CD4+ T cells were gated for CXCR5+ cells. (F) Tfh cells were identified as ICOS+PD-1hi CXCR5+ cells. (G) ICOS+PD-1hiCXCR5+ Tfh cells in LN 
express Bcl-6 (in blue). (H) Tfh cells were identified as CXCR5hiICOS+ CD4+ cells. (I) Tfh cells were identified as CXCR5hiPD-1hi CD4+ cells. (J) Tfh cells were 
identified as CXCR5hiBcl-6+ CD4+ cells. (K) CXCR5hiBcl-6+ Tfh cells in LN are ICOS+PD-1hi (in blue). Numbers represent percentage of cells within the gate. 
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for CXCR5+ cells (E). Tfh cells were identified as ICOS+PD-1hi CXCR5+ cells (F). 
ICOS+PD-1hi CXCR5+ Tfh cells from the lymph node sample express Bcl-6 (G). 
Alternatively, Tfh cells were identified as CXCR5+ICOS+ CD4+ cells (H), CXCR5+PD-1hi 
CD4+ cells (I) or CXCR5+Bcl-6+ CD4+ cells (J). ICOS and PD-1 are expressed highly on 
CXCR5+Bcl-6+ CD4+ cells from the lymph node sample (K). Once again, we could not 
clearly identify Tfh cells in the peripheral blood of SLE patients or control subjects 
regardless of the gating strategy employed. When comparing PBMC and lymph node 
samples stained simultaneously with the same panel of antibodies, it was becoming apparent 
that GC Tfh cells and cTfh cells are very different phenotypically and we therefore could not 
rely on methods and markers used for the identification of GC Tfh cells to detect cTfh cells. 
 
3.6  Treg and Tfh Cell Panel Development 
A number of research groups have used different combinations and expression levels of 
different markers to identify Tfh cells in human peripheral blood (refer to 1.3.1.3 Evidence 
for Increased Tfh Cells in SLE Patients). More recently, researchers have been referring to 
cTfh cells simply as CXCR5+ CD4+ T cells, and suggested that there are different subsets of 
cTfh cells which are distinguished by the level of expression of known Tfh markers such as 
ICOS and PD-1 and also various chemokine receptors.  
 
Bentebibel et al (Bentebibel et al., 2013) observed an expanded population of CD4+ T cells 
they described as ICOS+CXCR3+CXCR5+ circulating memory Tfh cells 7 days after 
influenza vaccination in healthy adults, which correlated with the increase of blood 
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plasmablasts. ICOS+CXCR3+CXCR5+CD4+ T cells also expressed PD-1 but not Bcl-6. 
Furthermore, ICOS+CXCR3+CXCR5+CD4+ T cells were able to induce memory B cells to 
differentiate into plasma cells ex vivo, which suggested these ICOS+CXCR3+CXCR5+CD4+ 
cells could be a subset of cTfh cells. 
 
Locci et al (Locci et al., 2013) observed in individuals who produced broad-neutralising 
antibodies against HIV an increase in a population of CD4+ T cells they defined as PD-
1+CXCR3-CXCR5+ memory Tfh cells. In addition, Locci et al found that blood PD-
1+CXCR3-CXCR5+ CD4+CD45RO+ T cells were most similar to GC Tfh cells in terms of 
gene expression and functions such as intracellular cytokine expression, in vitro induction of 
memory B cells to plasmablasts and immunoglobulin production compared to CXCR5-, PD-
1+CXCR3+CXCR5+, PD-1-CXCR3-CXCR5+ and PD-1-CXCR3+CXCR5+ CD4+CD45RO+ T 
cells. This is in contrast to the circulating memory Tfh cells described by Bentebibel et al 
(Bentebibel et al., 2013) as expressing CXCR3, further demonstrating that subsets of cTfh 
cells with different marker expression exist. 
 
We kept CD4, CXCR5 and PD-1 in our antibody panel for the detection of cTfh cells. 
Including ICOS in our stain would be redundant because the subset of cTfh cells described 
by Bentebibel et al (Bentebibel et al., 2013), ICOS+CXCR3+CXCR5+CD4+ T cells, also 
expressed PD-1. Bcl-6 was excluded as its expression was not found in Tfh subsets described 
by Simpson et al (Simpson et al., 2010) and Bentebibel et al (Bentebibel et al., 2013), and we 
also did not find Bcl-6 expression on Tfh cells in any of our PBMC samples in Cohort 3 
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regardless of the gating strategy used (Figure 3.23). CD25, CD127 and CD45RO were added 
to the panel for the detection of Tregs, a population we have not yet investigated in our study. 
Tregs could be detected without the use of FoxP3 intracellular staining by the expression of 
CD4, CD25 and lower levels of CD127. This method for the identification of Tregs in human 
peripheral blood was developed and optimised in our laboratory (Seddiki et al., 2006a). 
 
Dimmer fluorochromes were paired with the highly expressed markers in our stain, i.e. CD4 
and PE Cy7, CXCR5 and PerCP Cy5.5, and CD45RO and Pacific Orange. The newly 
available Brilliant Violet 421 was selected for CD127, which is expressed at lower levels on 
Tregs. We reverted back to using the EH12.2H7 clone of PD-1, conjugated to PE, because 
we were no longer detecting PD-1hi Tfh cells, which was based on the phenotype of GC Tfh 
cells. CD25 conjugated to APC and CXCR3 conjugated to Alexa Fluor 488 were chosen 
because they were already available and had been tested in other studies in our lab. The dead 
cell exclusion stain used here was once again LIVE-DEAD® Fixable Near-IR. The 
antibodies used for the detetion of Tregs and Tfh cells are summarised in Table 3.16. The 
Treg/Tfh panel was tested on a sample from a healthy subject one day after influenza 
vaccination, a sample from the same subject 7 days after influenza vaccination, and also a 
sample from a patient with severely active SLE. 
 
The gating strategy for the detection of Tregs and Tfh cells is shown in Figure 3.24. Doublets 
(A-B) and non-viable cells (C) were excluded from the analysis. Mononuclear cells were 
identified based on forward and side scatter properties (D). It is not necessary to gate for 
Table 3.16. Summary of monoclonal antibodies used for the analysis of Tregs and Tfh cells. 
 
Source Fluorochrome mAb/Stain Clone Dilution 
BD Horizon BV 421 Mouse IgG1 κ, antihuman 
CD127 
HIL-7R-
M21 
1:20 
BioLegend Biotinylated Mouse IgG2a κ, 
antihuman CD45RO 
UCHL1 1:100 
Life Technologies Pacific Orange Streptavidin - 1:200 
BD Pharmingen AF 488 Mouse IgG1 κ, antihuman 
CXCR3 
1C6 1:10 
BioLegend PE Mouse IgG1 κ, antihuman 
PD-1 
EH12.2H7 1:10-
1:20* 
BD Pharmingen PerCP Cy5.5 Rat IgG2b κ, antihuman 
CXCR5 
RF8B2 1:40 
BioLegend PE Cy7 Mouse IgG2b κ, 
antihuman CD4 
OKT4 1:40 
BD Biosciences APC Mouse IgG1 κ, antihuman 
CD25 
2A3 1:40 
Invitrogen - LIVE-DEAD® Fixable 
Near-IR 
- 1:200 
 
* Optimal working dilutions differed between different lots of the same antibody as determined 
by antibody titration. 
 
AF – Alexa fluor; APC – Allophycocyanin; BV – Brilliant violet; CD – Cluster of differentiation; 
Cy – Cyanine; IR – infra red; mAb – monoclonal antibody; PE – R-Phycoerythrin; PerCP – 
Peridinin chlorophyll-a protein. 
 
Figure 3.24. Gating strategy for the detection of Tregs and Tfh cells. (A-B) Sequential height 
vs. area gates for forward and side scatter were applied to exclude any doublets. (C) LIVE-
DEAD® Fixable Near-IR dead cell exclusion stain was used to exclude dead cells. (D) 
Mononuclear cells were identified based on forward and side scatter profiles. (E) CD4+ T 
lymphocytes were identified within the mononuclear cell gate. (F) Tregs were identified based 
on expression of CD25 and low expression of CD127 on CD4+ T cells. (G) CD45RO 
expression was compared on Tregs. (H) CD45RO expression was compared on CD4+ T cells. 
(I) Circulating Tfh (cTfh) cells were identified as CXCR5+ CD4+ T cells. (J) CXCR5 and PD-1 
expression were compared on CD4+ T cells. (K) Two subsets of cTfh cells were identified 
among CXCR5+PD-1+CD45RO+ CD4+ cells based on CXCR3 expression. Numbers represent 
percentage of cells within the gate. 
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lymphocytes or mononuclear cells prior to gating for CD4+ cells (E), but this step was 
included so the gating strategy here was consistent with those for the combined and separate 
B cell and monocyte/NK panels. Tregs were identified within the CD4+ population as 
CD25+CD127lo cells (F). CD45RO expression was compared on Tregs (G). CD45RO 
expression was compared on the total CD4+ T cell population (H). The total cTfh population 
was identified based on expression of CD4 and CXCR5 (I). Expression of CXCR5 and PD-1 
was compared on CD4+ T cells (J). Two subsets of CXCR5+PD-1+ Tfh cells were identified 
based on CD45RO and CXCR3 expression (K). 
 
As shown in Figure 3.25, we were able to clearly identify CXCR3+ and CXCR3- 
CXCR5+PD-1+ Tfh cells, as well as Tregs, in the peripheral blood of the SLE patient and the 
healthy subject. The proportion of CXCR3- Tfh cells was higher after vaccination and in 
SLE. We extended our investigation of peripheral blood Tfh cells and Tregs using the present 
antibody panel (Table 3.16) to the rest of the SLE, disease control and healthy control 
samples we have collected. 
 
3.7  Summary 
All healthy control samples and patient samples which had greater than 3 million PBMCs 
were stained with the final B cell panel (Table 3.4 and Figure 3.5), final monocyte/NK panel 
(Table 3.7 and Figure 3.14) and the Treg/Tfh panel (Table 3.16 and Figure 3.24). Patient 
samples with fewer than 3 million PBMCs were stained with the final combined B 
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Figure 3.25. Comparison of Tregs and Tfh cells stained with the Treg/Tfh panel between 
PBMC samples from a healthy subject 1 and 7 days after influenza vaccination and a patient 
with severe SLE. (A) CD4 expression was compared on live PBMCs. (B) Expression of CD25 
and CD127 on CD4+ T cells were compared to identify CD25+CD127lo Tregs. (C) CD45RO 
expression was compared on Tregs. (D) Expression of CXCR5 and PD-1 on CD4+ T cells 
were compared to identify CXCR5+PD1+ cTfh cells. A lymph node (LN) sample from a patient 
with ulcerative colitis (rightmost panel) was stained for the comparison of CXCR5 and PD-1 
expression on GC Tfh and cTfh cells. (E) Expression of CXCR3 and CD45RO were 
compared on CXCR5+PD-1+ cTfh cells in PBMC samples and CXCR5hiPD-1hi GC Tfh cells in 
the LN sample to identify CD45RO+ CXCR3+ and CXCR3- Tfh cell subsets. Numbers 
represent percentage of cells within the gate. 
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cell/monocyte/NK cell panel (Table 3.11 and Figure 3.17) and the Treg/Tfh panel (Table 
3.16 and Figure 3.24). 
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CHAPTER 4:  RESULTS 
4.1  Analysis of Peripheral Blood Cell Populations and Serum BAFF 
Concentration in SLE 
4.1.1  Highly Significant Positive Correlation Between Absolute Number and Frequency 
of Cell Populations Expressed as a Percentage of Live Cells 
PBMCs from SLE patients, patients with other autoimmune conditions and healthy 
individuals were immunostained and analysed by flow cytometry for the detection of B cell, 
monocyte, NK cell, Treg and Tfh cell populations. Proportion of cell subsets, frequency 
expressed as a percentage of live cells and absolute number of each of the cell populations 
were calculated. We found a highly significant positive correlation between the absolute 
number and frequency of cell populations expressed as a percentage of live cells (p<0.0001). 
For example, as illustrated in Figure 4.1, the frequency of naïve B cells expressed as a 
percentage of live cells significantly correlated with the absolute number of naïve B cells 
(R=0.9177, p<0.0001). This was also true for all the populations we measured by flow 
cytometry and the R values of the correlations between absolute number and frequency of 
these populations are listed on Table 4.1. All of the correlations were highly significant with 
p-values less than 0.0001 as measured by the non-parametric Spearman method. For this 
reason, only proportion of subsets and absolute number, but not frequency of cell populations 
expressed as a percentage of live cells, will be shown in figures for the remainder of 4.1 
Analysis of Peripheral Blood Cell Populations and Serum BAFF Concentration in SLE. 
 
 
 
Figure 4.1. Frequency of naïve B cells expressed as a percentage of live cells was compared 
with the absolute number of naïve B cells. The non-parametric Spearman method was used 
to calculate correlation coefficients.  
 
 
Table 4.1. R values of correlations between frequency expressed as a percentage of live 
cells and absolute number of cell populations measured by flow cytometry. 
 
Population R 
Total B cells 0.8321 
Transitional B cells 0.9526 
Naïve B cells 0.9177 
Atypical memory B cells 0.9100 
Switched memory B cells 0.9163 
MZ or non-switched memory B cells 0.9239 
Plasmablasts and plasma cells 0.9332 
Total monocytes 0.8603 
CD14+CD16- monocytes 0.8732 
CD16+ monocytes 0.8801 
CD14dim monocytes 0.9312 
Total NK cells 0.9010 
CD56briCD16- NK cells 0.8771 
CD56dimCD16+ NK cells 0.9140 
CD56-CD16+ NK cells 0.9150 
Total CD4+ cells 0.6958 
CD45RO+ CD4+ cells 0.7992 
CD45RO- CD4+ cells 0.8537 
Tregs 0.7414 
CD45RO+ Tregs 0.7411 
CD45RO- Tregs 0.8944 
CXCR5+ CD4+ cells 0.8924 
CXCR5+ PD-1+ Tfh cells 0.8860 
CXCR3+ Tfh cells 0.9308 
CXCR3- Tfh cells 0.8706 
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4.1.2  Decreased Number of Lymphocytes in SLE Patients 
All of the PBMC samples from SLE patients, disease control and healthy control subjects we 
had recruited, as summarised on Table 2.1, were immunostained and analysed by flow 
cytometry for the detection of B cell, monocyte, NK cell, Treg and Tfh cell populations. 
However, for SLE patients and disease control subjects who had contributed multiple 
samples to the study, only one sample per subject, selected at random, was included in the 
first part of our analysis. The demographic and disease characteristics of the samples 
included in the current analysis are summarised on Table 4.2. Overall, 62 SLE samples, 23 
disease control samples and 68 healthy control samples were included in the analysis of 
peripheral blood cell populations with the exception of CD14dim monocytes (see 4.1.8 
Similar Numbers of Monocytes and Proportions of Monocyte Subsets in SLE Patients 
and Control Subjects) and measurement of serum BAFF concentration (see 4.1.13 Similar 
Levels of Serum BAFF in SLE Patients and Control Subjects). 
 
Whole blood count was performed on all samples prior to PBMC purification, as described in 
Section 2.3.1 Purification of PBMCs by Density Gradient Centrifugation. White cell 
count was similar between SLE patients (active SLE mean 6.99 x 106/ml, inactive SLE mean 
6.36 x 106/ml) and disease control subjects (mean 6.82 x 106/ml) (Figure 4.2 (A)). Healthy 
individuals had fewer white blood cells (mean 5.87 x 106/ml) compared with patients with 
SLE and other autoimmune conditions but this did not reach statistical significance. SLE 
patients had significantly lower numbers of lymphocytes (active SLE mean 1.45 x 106/ml, 
p<0.01, inactive SLE mean 1.63 x 106/ml, p<0.05) compared with healthy individuals (mean 
1.94 x 106/ml) (Figure 4.2 (B)). Lymphocytes were identified based on forward and side 
Table 4.2. Demographic characteristics and disease activity of SLE patient, disease control 
and healthy control samples included in the analysis of peripheral blood cell populations with 
the exception of CD14dim monocytes and measurement of serum BAFF concentration. For 
SLE patients and disease control subjects who have contributed multiples samples to the 
study, only one sample per subject, selected at random, was included in the analysis. 
 
 SLE 
(n = 62) 
Disease control 
(n = 23) 
Healthy 
(n = 68) 
Age, mean years 41.3 54.2 41.2 
Female (%) 55 (89%) 19 (83%) 58 (85%) 
Male (%) 7 (11%) 4 (17%) 10 (15%) 
SLE disease activity    
Active (%) 20 (32%) - - 
Severe 3 - - 
Moderate 6 - - 
Mild 11 - - 
Inactive (%) 42 (68%) - - 
Disease control conditions    
Antiphospholipid syndrome - 2 - 
Drug-induced lupus - 1 - 
Lupus-like illness, undifferentiated 
autoimmune disease 
- 5 - 
Rheumatoid arthritis - 4 - 
Scleroderma - 1 - 
Sjögren’s syndrome - 9 - 
Vasculitis - 1 - 
  
 
 
Figure 4.2. (A) White blood cell count performed before PBMC purification by density 
gradient centrifugation was compared between active SLE, inactive SLE, disease control and 
healthy control samples. (B) Lymphocyte count performed before PBMC purification by 
density gradient centrifugation was compared between active SLE, inactive SLE, disease 
control and healthy control samples. (C) Representative plots depicting FSC-A vs. SSC-A of 
viable PBMCs by flow cytometry from active SLE, inactive SLE, disease control and healthy 
control samples. Lymphocytes are contained within the gate, and the percentage of cells 
within the gate is shown. (D) The absolute number of total lymphocytes, as determined by 
flow cytomtery, was compared between active SLE, inactive SLE, disease control and healthy 
control samples. (E) Absolute numbers of total B cells, total NK cells, total CD4+ T cells, other 
lymphocytes and total monocytes were compared together between active SLE, inactive SLE, 
disease control and healthy control samples. In (A), (B) and (D), the horizontal bar represents 
the mean of each group. Statistical significance was calculated using the Kruskal-Wallis test. 
* denotes p<0.05 and ** denotes p<0.01. 
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scatter profile during flow cytometric analysis (Figure 4.2 (C)) and the absolute number of 
lymphocytes was calculated (Figure 4.2 (D)). Again, active SLE patients had significantly 
fewer lymphocytes (mean 3.65 x 106/ml, p<0.05) compared to healthy controls (mean 4.69 x 
106/ml). Inactive SLE patients also had fewer lymphocytes (mean 4.27 x 106/ml) than healthy 
controls but the difference was not statistically significant. The absolute numbers of total B 
cells, total NK cells, total CD4+ T cells, other lymphocytes and total monocytes were 
compared between SLE patients and control groups, as illustrated in Figure 4.2 (E). At a 
glance, it appears that SLE patients in general have fewer NK cells and CD4+ T cells, 
contributing to the overall decrease in lymphocytes. Comparison of these white blood cell 
populations between SLE and control groups will be discussed in depth below. 
 
4.1.3  Absolute Number of B cells was Similar but Proportion of B cell Subsets Differed 
Between SLE Patients and Control Subjects 
As shown in Figure 4.3 (A), patients with active SLE had greater absolute numbers of B cells 
(mean 0.64 x 106/ml) compared with inactive SLE patients (mean 0.50 x 106/ml), disease 
controls (mean 0.61 x 106/ml) and healthy controls (mean 0.56 x 106/ml), but the difference 
was not statistically significant. Proportion of B cell subsets was compared between the SLE 
patient and control groups, as illustrated in Figure 4.3 (B). The majority of B cells in the 
peripheral blood of all subjects were naïve B cells. Although all subjects had a similar 
number of B cells, the proportions of B cell subsets we detected in our flow cytometric 
analysis, including transitional, naïve, atypical memory, MZ or non-switched memory and 
switched memory B cells, varied between the SLE patient and control groups. Differences in 
frequency and number of B cell subsets will be discussed in depth below. 
 
Figure 4.3. (A) The absolute number of total B cells was compared between active SLE, 
inactive SLE, disease control and healthy control samples. (B) Proportions of B cell subsets 
were compared together between active SLE, inactive SLE, disease control and healthy 
control samples. (C) Representative plots depicting CD38 vs. IgD expression by flow 
cytometry from active SLE, inactive SLE, disease control and healthy control samples. CD27-
IgD+ B cells were further gated for naïve (CD38+) and transitional (CD38hi) B cells. Plots in the 
top row depict samples with clearly identifiable naïve and transitional B cell populations. Plots 
in the bottom row depict samples with naïve B cells and almost no transitional B cells. 
Percentages of cells within each gate are shown. (D) Frequency of naïve B cells was 
compared between active SLE, inactive SLE, disease control and healthy control samples. 
(E) Frequency of transitional B cells was compared between active SLE, inactive SLE, 
disease control and healthy control samples. The horizontal bar represents the mean of each 
group in (A), (D) and (E). 
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4.1.4  Transitional B cells were Increased in a Subset of SLE Patients 
Figure 4.3 (C) shows the comparison of the transitional and naïve B cell subsets as identified 
by the differential expression of CD38 in SLE patients and controls. Some subjects had a 
clearly identifiable population of transitional B cells (top row) while this cell population was 
almost completely absent from other subjects (bottom row). This did not appear to be 
disease-related as both observations were found in both patient and control samples. Overall, 
SLE patients had a lower percentage of naïve B cells (active SLE mean 50.20%, inactive 
SLE mean 54.17%) than disease controls (mean 62.01%) and healthy controls (mean 
54.99%), but the difference was not statistically significant (Figure 4.3 (D)). The proportion 
of transitional B cells was similar across SLE patient (active SLE mean 5.18%, inactive SLE 
mean 5.69%) and control groups (disease control mean 5.54%, healthy control mean 4.42%) 
but four of the SLE patients had a much higher percentage of transitional B cells (23.2%, 
34.8%, 36.9% and 44.3%) compared to all the other subjects (Figure 4.3 (E)). 
 
4.1.5  Atypical Memory B cells were Significantly Increased in Patients with SLE and 
Other Autoimmune Conditions 
Figure 4.4 (A) shows the comparison of memory B cell subsets as identified by differential 
expression of CD27, IgD and IgM in SLE patients and control subjects. Both active and 
inactive SLE patients had significantly increased proportions of CD27-IgD- atypical memory 
B cells (active SLE mean 6.23%, p<0.01, inactive SLE mean 7.43%, p<0.0001) compared 
with healthy controls (mean 2.96%) (Figure 4.4 (B)). Disease control subjects also had a 
significantly greater percentage of atypical memory B cells (mean 5.12%, p<0.05) than 
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Figure 4.4. Comparison of memory B cell subsets in SLE patients and disease control and 
healthy control subjects. (A) Representative plots depicting CD27 vs. IgD expression (top 
row) and IgM vs. IgD expression (bottom row) by flow cytometry of active SLE, inactive SLE, 
disease control and healthy control samples. CD19+ B cells were further gated for CD27-IgD- 
atypical memory B cells (top row). CD27+ B cells were further gated for IgD-IgM- switched and 
IgD+IgM+ MZ or non-switched memory B cells (bottom row). Percentages of cells within each 
gate are shown. (B) Frequency of atypical memory B cells expressed as a percentage of total 
B cells was compared between active SLE, inactive SLE, disease control and healthy control 
samples. (C) Frequency of MZ or non-switched memory B cells expressed as a percentage of 
total B cells was compared between active SLE, inactive SLE, disease control and healthy 
control samples. (D) Frequency of switched memory B cells expressed as a percentage of 
total B cells was compared between active SLE, inactive SLE, disease control and healthy 
control samples. In (B-D), the horizontal bar represents the mean of each group. Statistical 
significance was calculated using the Kruskal-Wallis test. * denotes p<0.05, ** denotes 
p<0.01 and **** denotes p<0.0001. 
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healthy control subjects. Active SLE patients had a similar percentage of CD27+IgD+IgM+ 
MZ or non-switched memory B cells (mean 20.52%) compared with healthy controls (mean 
19.41%), but patients with inactive SLE had a significantly decreased percentage of this cell 
subset (mean 11.49%, p<0.01) compared with healthy controls (Figure 4.4 (C)). Disease 
control subjects also had a smaller percentage of MZ or non-switched memory B cells (mean 
14.54%) but the difference did not reach statistical significance. Overall, patients with active 
SLE had a similar proportion of CD27+IgD-IgM- switched memory B cells (mean 17.08%) 
compared with healthy controls (mean 17.57%) (Figure 4.4 (D)). Inactive SLE patients had a 
significantly increased proportion of switched memory B cells (mean 19.09%, p<0.05), but 
disease control subjects had significantly fewer switched memory B cells (mean 12.32%, 
p<0.05) compared to healthy control subjects. 
 
4.1.6  IgM-only Memory B cells were Detected in Several SLE Samples 
Five of the samples from SLE patients (one with severely active SLE from Patient 71 and 
four with inactive SLE from Patients 4, 19, 53 and 55) had a clearly identifiable IgM-only 
memory B cell population. IgM-only memory B cells could not be detected in the other SLE 
samples or in any of the control samples. Figure 4.5 (A) illustrates the difference in IgM and 
IgD expression between samples from two different SLE patients, one of which had IgM-
only memory B cells (left) and the other did not (right). The proportions of switched, MZ or 
non-switched and IgM-only memory B cells were compared among the five patients with 
IgM-only memory B cells, and proportions of switched and MZ or non-switched memory B 
cells were also compared between these five patients and the other SLE patients who do not 
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Figure 4.5. (A) Representative plots depicting IgM vs. IgD expression of CD27+ memory B 
cells. The plot on the left represents a sample where there is a clearly identifiable population 
of IgM-only memory B cells in addition to switched and MZ or non-switched memory B cells. 
The plot on the right represents a sample where there are only switched and MZ or non-
switched memory B cells. Percentages of cells within each gate are shown. (B) Proportions of 
switched, MZ or non-switched and IgM-only memory B cells expressed as a percentage of 
total B cells of the five samples that have IgM-only memory B cells are shown. Black squares 
depict samples from patients with inactive SLE and the red circle represents a sample from a 
patient with severely active SLE. Black crosses depict the mean proportions and vertical bars 
the standard deviation of switched and MZ or non-switched memory B cells of all the SLE 
patient samples included in the analysis that do not have clearly identifiable IgM-only memory 
B cells. (C) Representative plots depicting CD19 vs. CD27 expression of PBMCs (top row) 
and CD38 vs. IgD expression of CD19loCD27hi cells (bottom row) by flow cytometry from 
active SLE, inactive SLE, disease control and healthy control samples. Plasmablasts and 
plasma cells were identified by the expression of high levels of CD27 and CD38, low levels of 
CD19 but not IgD. Percentages of cells within each gate are shown. (D) Absolute number of 
plasmablasts and plasma cells were compared between active SLE, inactive SLE, disease 
control and healthy control samples. The horizontal bar represents the mean of each group. 
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have IgM-only memory B cells (Figure 4.5 (B)). The percentage of IgM-only memory B 
cells varies greatly among the five patients, ranging from 2.67-16.00%. 
 
4.1.7  Increased Plasmablasts and Plasma Cells in a Subset of SLE Patients 
Figure 4.5 (C) shows the comparison of plasmablasts and plasma cells as identified by the 
high level of expression of CD27 and lower levels of CD19 (top row) and high levels of 
CD38 but not IgD (bottom row) in SLE patients and control subjects. SLE patients had a 
greater absolute number of plasmablasts and plasma cells (active SLE mean 0.010 x 106/ml, 
inactive SLE mean 0.006 x 106/ml) than both disease controls (mean 0.003 x 106/ml) and 
healthy controls (mean 0.004 x 106/ml), but this difference was not statistically significant 
(Figure 4.5 (D)). There appears to be a subset of 8 SLE patients (1 with severely active SLE 
from Patient 71, 2 with moderately active SLE from Patients 57 and 87, 3 with mild SLE 
from Patients 41, 76 and 88, and 2 with inactive SLE from Patients 77 and 84) which had 
much greater numbers of plasmablasts and plasma cells (ranging from 0.014-0.068 x 106/ml) 
compared to the rest of the SLE patients. This subset of SLE patients with greatly expanded 
plasmablasts and plasma cells is almost completely different to the subset of patients with 
IgM-only memory B cells, with the exception of Patient 71. However, it is to be noted that 
the sample from Patient 71 that had IgM-only memory B cells was collected on 10th July 
2008 while the sample from this patient with increased plasmablasts and plasma cells was 
collected almost two months earlier on 13th May 2008. 
 
As plasmablasts and plasma cells were defined as expressing low levels of CD19 in our 
gating strategy, we had not included them as CD19+ B cells in our analysis. As a 
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consequence, we did not calculate the frequency of plasmablasts and plasma cells as a 
percentage of total B cells but only the frequency as a percentage of live cells, which 
correlated with the absolute number (see Table 4.1). 
 
4.1.8  Similar Numbers of Monocytes and Proportions of Monocyte Subsets in SLE 
Patients and Control Subjects 
Patients with SLE and other autoimmune conditions had a greater absolute number of 
monocytes (active SLE mean 1.31 x 106/ml, inactive SLE mean 1.17 x 106/ml, disease 
control mean 1.46 x 106/ml) than healthy subjects (mean 0.87 x 106/ml), but this difference 
was not statistically significant (Figure 4.6 (A)). Figure 4.6 (B) shows the comparison of 
CD14+CD16- classical and CD16+ monocytes in SLE patients and control subjects. 
Approximately half of the samples from both patients and controls did not have a clearly 
identifiable CD14dim non-classical monocyte population, therefore in samples from subjects 
with CD14dim monocytes, CD14+CD16+ intermediate and CD14dim monocyte subsets were 
considered together as CD16+ monocytes. Active SLE patients had a slightly increased 
proportion of CD14+CD16- monocytes (mean 89.17%) compared with inactive SLE patients 
(mean 85.87%), disease controls (mean 85.74%) and healthy controls (mean 85.92%), but 
this increase did not reach statistical significance (Figure 4.6 (C)). Conversely, active SLE 
patients had a smaller percentage of CD16+ monocytes (mean 10.83%) compared with the 
other three groups (inactive SLE mean 14.13%, disease control mean 14.26%, healthy 
control mean 14.08%), and the difference was also not statistically significant (Figure 4.6 
(D)). 
 
 
Figure 4.6. Comparison of monocytes in SLE patients and disease control and healthy 
control subjects. (A) Absolute number of total monocytes was compared between active SLE, 
inactive SLE, disease control and healthy control samples. (B) Representative plots depicting 
CD14 vs. CD16 expression by flow cytometry from active SLE, inactive SLE, disease control 
and healthy control samples that do not have a clearly identifiable CD14dim monocyte 
population. NKp46- PBMCs with larger forward and side scatter properties were further gated 
for CD14+CD16- and CD16+ monocyte subsets. Percentages of cells within each gate are 
shown. (C) Frequency of CD14+CD16- monocytes expressed as a percentage of total 
monocytes was compared between active SLE, inactive SLE, disease control and healthy 
control samples. (D) Frequency of CD16+ monocytes expressed as a percentage of total 
monocytes was compared between active SLE, inactive SLE, disease control and healthy 
control samples. In (A), (C) and (D), the horizontal bar represents the mean of each group. 
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The demographic and disease characteristics of the samples included in the analysis of 
CD14dim monocytes are summarised on Table 4.3. Overall, 25 SLE samples, 14 disease 
control samples and 37 healthy control samples were included, which is approximately 
equivalent to half of the number of samples included in the analysis of the other cell 
populations. Figure 4.7 (A) shows the comparison of CD14+CD16-, CD14+CD16+ and 
CD14dim monocytes in SLE patients and control subjects. Active SLE patients had a slightly 
lower proportion of CD14dim monocytes (mean 7.87%) compared to inactive SLE patients 
(mean 10.16%), disease controls (mean 8.69%) and healthy controls (mean 8.63%), but this 
difference was not statistically significant (Figure 4.7 (B)). 
 
4.1.9  Significantly Decreased Total Number of NK cells and Increased Proportion of 
CD56briCD16- NK cells in SLE 
Figure 4.8 (A) shows the comparison of CD56briCD16-, CD56dimCD16+ and CD56-CD16+ 
NK cells in SLE patients and control subjects. The absolute number of NK cells was 
significantly lower in SLE patients (active SLE mean 0.29 x 106/ml, p<0.0001, inactive SLE 
mean 0.51 x 106/ml, p<0.01) compared with healthy controls (mean 0.59 x 106/ml) (Figure 
4.8 (B)). One of the patients with inactive SLE had a much higher number of NK cells (4.71 
x 106/ml) than all the other subjects in the study, but this increase did not appear to be related 
to SLE. The absolute number of NK cells in active SLE patients was also significantly 
reduced compared with disease control subjects (mean 0.65 x 106/ml, p<0.05). SLE patients 
had a significantly higher proportion of CD56briCD16- NK cells (active SLE mean 18.99%, 
p<0.001, inactive SLE mean 16.23%, p<0.01) than healthy controls (mean 7.28%) (Figure 
4.8 (C)). The proportion of CD56briCD16- NK cells was also significantly increased in active 
Table 4.3. Demographic characteristics and disease activity of SLE patient, disease control 
and healthy control samples included in the analysis of CD14dim monocytes. For SLE patients 
and disease control subjects who have contributed multiples samples to the study, only one 
sample per subject, selected at random, was included in the analysis. 
 
 SLE 
(n = 25) 
Disease control 
(n = 14) 
Healthy 
(n = 37) 
Age, mean years 40.8 56.6 41.3 
Female (%) 22 (88%) 12 (86%) 30 (81%) 
Male (%) 3 (12%) 2 (14%) 7 (19%) 
SLE disease activity    
Active (%) 7 (28%) - - 
Severe 2 - - 
Moderate 2 - - 
Mild 3 - - 
Inactive (%) 18 (72%) - - 
Disease control conditions    
Antiphospholipid syndrome - 1 - 
Lupus-like illness, undifferentiated 
autoimmune condition 
- 2 - 
Rheumatoid arthritis - 2 - 
Scleroderma - 1 - 
Sjögren’s syndrome - 7 - 
Vasculitis - 1 - 
  
 
 
 
Figure 4.7. Comparison of CD14dim monocytes in SLE patients and disease control and 
healthy control subjects. (A) Representative plots depicting CD14 vs. CD16 expression by 
flow cytometry of active SLE, inactive SLE, disease control and healthy control samples that 
have a clearly identifiable CD14dim monocyte population. NKp46- PBMCs with larger forward 
and side scatter properties were further gated for CD14+CD16-, CD16+ and CD14dim 
monocytes. Percentages of cells within each gate are shown. (B) Frequency of CD14dim 
monocytes expressed as a percentage of total monocytes was compared between active 
SLE, inactive SLE, disease control and healthy control samples. The horizontal bar 
represents the mean of each group. 
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Figure 4.8. Comparison of NK cells in SLE patients and disease control and healthy control 
subjects. (A) Representative plots depicting CD16 vs. CD56 expression by flow cytometry 
from active SLE, inactive SLE, disease control and healthy control samples. NKp46+ 
lymphocytes were further gated for CD56dimCD16+, CD56briCD16- and CD56-CD16+ NK cell 
subsets. Percentages of cells within each gate are shown. (B) Absolute number of total NK 
cells was compared between active SLE, inactive SLE, disease control and healthy control 
samples. (C) Frequency of CD56briCD16- NK cells was compared between active SLE, 
inactive SLE, disease control and healthy control samples. (D) Frequency of CD56dimCD16+ 
NK cells was compared between active SLE, inactive SLE, disease control and healthy 
control samples. (E) Frequency of CD56-CD16+ NK cells was compared between active SLE, 
inactive SLE, disease control and healthy control samples. In (B-E), the horizontal bar 
represents the mean of each group. Statistical significance was calculated using the Kruskal-
Wallis test. * denotes p<0.05, ** denotes p<0.01, *** denotes p<0.001 and **** denotes 
p<0.0001. 
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SLE patients compared with disease controls (mean 8.79%, p<0.05). Conversely, SLE 
patients had a significantly lower proportion of CD56dimCD16+ NK cells (active SLE 
78.60%, p<0.001, inactive SLE 81.15%, p<0.01) compared to healthy controls (mean 
87.61%) (Figure 4.8 (D)). Disease controls had a similar percentage of CD56dimCD16+ NK 
cells (mean 87.44%) to healthy controls. The proportion of CD56-CD16+ NK cells was 
similar across all groups (active SLE mean 2.41%, inactive SLE mean 2.61%, disease control 
mean 3.78%, healthy control mean 1.88%) (Figure 4.8 (E)). Interestingly, there were two 
patients with Sjögren’s Syndrome who had a much higher percentage of CD56-CD16+ NK 
cells (22.46% and 21.28%) than all of the other subjects. 
 
4.1.10  Significantly Lower Number of CD4+ T cells in Active SLE Patients 
The absolute number of CD4+ T cells was significantly reduced in patients with active SLE 
(mean 1.36 x 106/ml, p<0.01) compared with healthy controls (mean 2.02 x 106/ml) (Figure 
4.9 (A)). Absolute number of CD4+ T cells was also lower in inactive SLE patients (mean 
1.62 x 106/ml) and disease controls (mean 1.80 x 106/ml) than healthy controls but this 
difference in number did not reach statistical significance. Proportions of CD45RO+ and 
CD45RO- CD4+ T cells, CD45RO+ and CD45RO- Tregs and CXCR3+ and CXCR3- 
CXCR5+PD-1+ Tfh cells were compared between SLE patient and control groups (Figure 4.9 
(B)). Overall, patients with SLE and other autoimmune conditions have a greater proportion 
of CD45RO+ CD4+ T cells and CD45RO+ Tregs than healthy controls. Active SLE patients 
have very few CXCR5+PD-1+ Tfh cells compared to patients with inactive SLE and control 
subjects. Differences in subsets of Tregs and Tfh cells will be discussed in separate sections 
below. 
 
 
Figure 4.9. Comparison of CD4+ T cells between SLE patients and disease and healthy 
control subjects. (A) The absolute number of total CD4+ T cells was compared between active 
SLE, inactive SLE, disease control and healthy control samples. (B) Proportions of CD45RO- 
and CD45RO+ CD4+ T cells, CD45RO- and CD45RO+ Tregs and CXCR3- and CXCR3+ 
CXCR5+PD-1+ Tfh cells were compared together between active SLE, inactive SLE, disease 
control and healthy control samples. A denotes active SLE, I denotes inactive SLE, D denotes 
disease control and H denotes healthy. (C) Representative plots depicting CD45RO vs. CD4 
expression by flow cytometry of active SLE, inactive SLE, disease control and healthy control 
samples. CD4+ T cells were compared for their expression of CD45RO. Percentages of cells 
within each gate are shown. (D) Proportions of CD45RO- and CD45RO+ CD4+ T cells 
expressed as a percentage of total CD4+ T cells were compared between active SLE, inactive 
SLE, disease control and healthy control samples. In (A) and (D), the horizontal bar 
represents the mean of each group. Statistical significance was calculated using the Kruskal-
Wallis test. * denotes p<0.05, ** denotes p<0.01 and *** denotes p<0.001. 
0 102 103 104 105
0
102
103
104
105
<B780_A-A>: CD4 PECy7
27.972.1
0 102 103 104 105
0
102
103
104
105
58.241.8
0 102 103 104 105
0
102
103
104
105
<B780_A-A>: CD4 PECy7
63.236.8
2
3
4
5
0 102 103 104 105
0
102
103
104
105
43.656.4
Severe
Moderate
Mild
To
ta
l C
D
4+
 T
 c
el
ls
 1
0^
6/
m
l
**
A
CXCR3- Tfh
CXCR3+ Tfh
CD45RO- Tregs
CD45RO+ Tregs
CD45RO- CD4+
CD45RO+ CD4+
B
A I D H
CD45RO
C
D
4
Active SLE Inactive SLE Disease control HealthyC
**** **** Severe
Moderate
Mild
D
CD45RO+CD45RO-
%
 C
D
4+
 T
 c
el
ls
%
 C
D
4+
 T
 c
el
ls
Chapter 4: Results  142 
 
 
Figure 4.9 (C) compares the expression of CD45RO on CD4+ T cells in SLE patients and 
control subjects. The proportion of CD45RO-expressing CD4+ T cells was significantly 
higher in patients with inactive SLE (mean 54.24%, p<0.001) and disease controls (mean 
51.72%, p<0.05) than in healthy controls (mean 41.94%) (Figure 4.9 (D)). The proportion of 
CD45RO- CD4+ T cells was therefore significantly lower in inactive SLE patients (mean 
45.61%, p<0.001) and disease controls (mean 48.17%, p<0.05) compared with healthy 
controls (mean 57.92%). Active SLE patients had a higher percentage of CD45RO+ CD4+ T 
cells (mean 49.42%) and therefore lower percentage of CD45RO- CD4+ T cells (mean 
50.57%) than healthy controls, but the differences were not statistically significant. 
 
4.1.11  Significantly Increased Proportion of CD45RO+ Tregs in Patients with SLE and 
Other Autoimmune Conditions 
Figure 4.10 shows the comparison of Tregs as identified by the expression of CD25 and 
lower levels of CD127 (A) and the comparison of CD45RO expression on Tregs (B) in SLE 
patients and control subjects. The frequency of Tregs expressed as a percentage of total CD4+ 
T cells was similar across all groups (active SLE mean 9.37%, inactive SLE mean 8.85%, 
disease control mean 8.66%, healthy control mean 7.67%) (Figure 4.10 (C)). Patients with 
SLE and other autoimmune conditions had a significantly higher proportion of CD45RO+ 
Tregs (active SLE mean 76.49%, p<0.01, inactive SLE mean 76.75%, p<0.0001, disease 
control mean 75.15%, p<0.01) and therefore significantly lower proportion of CD45RO- 
Tregs (active SLE mean 23.47%, p<0.01, inactive SLE mean 23.09%, p<0.0001, disease 
 
 
Figure 4.10. Comparison of Tregs between SLE patients and disease and healthy control 
subjects. (A) Representative plots depicting CD127 vs. CD25 expression by flow cytometry of 
active SLE, inactive SLE, disease control and healthy control samples. CD4+ T cells were 
further gated for CD127loCD25+ Tregs. (B) Representative plots depicting CD45RO vs. CD4 
expression by flow cytometry of active SLE, inactive SLE, disease control and healthy control 
samples. Tregs were further compared for their expression of CD45RO. In (A) and (B), 
percentages of cells within each gate are shown. (C) Proportions of Tregs expressed as a 
percentage of total CD4+ T cells were compared between active SLE, inactive SLE, disease 
control and healthy control samples. (D) Proportions of CD45RO- and CD45RO+ Tregs 
expressed as a percentage of total Tregs were compared between active SLE, inactive SLE, 
disease control and healthy control samples. In (C) and (D), the horizontal bar represents the 
mean of each group. Statistical significance was calculated using the Kruskal-Wallis test. ** 
denotes p<0.01, *** denotes p<0.001 and **** denotes p<0.0001. 
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control mean 24.72%, p<0.01) compared with healthy controls (CD45RO+ mean 65.03%, 
CD45RO- mean 34.78%) (Figure 4.10 (D)). 
 
4.1.12  Significantly Decreased Tfh cells and Proportion of CXCR3+ Tfh cells in Active 
SLE 
Figure 4.11 shows the comparison of CXCR5+ CD4+ T cells (A) and CXCR5+PD-1+ Tfh 
cells (B) in SLE patients and control subjects. SLE patients had a significantly decreased 
frequency of CXCR5+ CD4+ T cells expressed as a percentage of total CD4+ T cells (active 
SLE mean 6.31%, p<0.0001, inactive SLE mean 10.09%, p<0.05) compared to healthy 
controls (mean 12.43%) (Figure 4.11 (C)). Patients with other autoimmune conditions also 
had a lower percentage of CXCR5+ CD4+ T cells (mean 10.67%) than healthy controls but 
the difference was not statistically significant. Furthermore, active SLE patients had a 
significantly lower percentage of CXCR5+PD-1+ Tfh cells (mean 3.03%, p<0.001) than 
healthy controls (mean 5.55%). Inactive SLE patients and disease controls also had a 
decreased frequency of CXCR5+PD-1+ Tfh cells (inactive SLE mean 4.95%, disease control 
mean 4.55%) compared to healthy controls but this decrease did not reach statistical 
significance. 
 
Figure 4.12 (A) shows the comparison of CXCR3 expression on CD45RO-expressing 
CXCR5+PD-1+ Tfh cells in SLE patients and control subjects. Patients with SLE and other 
autoimmune conditions had a significantly higher proportion of CXCR3- CXCR5+PD-1+ Tfh 
cells (active SLE mean 50.12%, p<0.0001, inactive SLE mean 46.66%, p<0.001, disease 
control mean 48.19%, p<0.001) than healthy controls (mean 38.87%) (Figure 4.12 (B)). 
 
 
Figure 4.11. Comparison of Tfh cells between SLE patients and disease and healthy control 
subjects. (A) Representative plots depicting CXCR5 vs. CD4 expression by flow cytometry of 
active SLE, inactive SLE, disease control and healthy control samples. CD4+ T cells were 
further gated for CXCR5+ Tfh cells. (B) Representative plots depicting CXCR5 vs. PD-1 
expression by flow cytometry of active SLE, inactive SLE, disease control and healthy control 
samples. CD4+ T cells were further gated for CXCR5+PD-1+ Tfh cells. In (A) and (B), 
percentages of cells within each gate are shown. (C) Proportions of CXCR5+ and 
CXCR5+PD-1+ Tfh cells expressed as a percentage of total CD4+ T cells were compared 
between active SLE, inactive SLE, disease control and healthy control samples. The 
horizontal bar represents the mean of each group. Statistical significance was calculated 
using the Kruskal-Wallis test. * denotes p<0.05, *** denotes p<0.001 and **** denotes 
p<0.0001. 
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Figure 4.12. Comparison of CXCR5+PD-1+ Tfh cell subsets between SLE patients and 
disease and healthy control subjects. (A) Representative plots depicting CD45RO vs. CXCR3 
expression by flow cytometry of active SLE, inactive SLE, disease control and healthy control 
samples. CXCR5+PD-1+ Tfh cells were further gated for CXCR3-CD45RO+ and 
CXCR3+CD45RO+ subsets. Percentages of cells within each gate are shown. (B) Proportions 
of CXCR3-CD45RO+ and CXCR3+CD45RO+ subsets expressed as a percentage of total 
CXCR5+PD-1+ Tfh cells were compared between active SLE, inactive SLE, disease control 
and healthy control samples. The horizontal bar represents the mean of each group. 
Statistical significance was calculated using the Kruskal-Wallis test. * denotes p<0.05, *** 
denotes p<0.001 and **** denotes p<0.0001. 
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Active SLE patients had a significantly reduced proportion of CXCR3+ CXCR5+PD-1+ Tfh 
cells (mean 25.75%, p<0.0001) compared to healthy controls (mean 39.90%). Inactive SLE 
patients and disease controls also had a lower proportion of CXCR3+ CXCR5+PD-1+ Tfh 
cells (inactive SLE mean 36.23%, disease control mean 34.85%) than healthy controls but 
the difference was not statistically significant. Interestingly, the proportion of CXCR3+ 
CXCR5+PD-1+ Tfh cells was significantly lower in active SLE patients than in inactive SLE 
patients (p<0.05). 
 
4.1.13  Similar Levels of Serum BAFF in SLE Patients and Control Subjects 
The demographic and disease characteristics of the samples included in the analysis of serum 
BAFF concentration are summarised on Table 4.4. Overall, 54 SLE samples, 20 disease 
control samples and 62 healthy control samples were included. Fewer subjects were included 
in the analysis of serum BAFF levels than in the analysis for peripheral blood cell 
populations as serum samples were not obtained from every patient in the study, because not 
enough volume of blood could be drawn from some patients. Figure 4.13 shows the 
comparison of serum BAFF concentration between SLE patients and control subjects. Serum 
BAFF concentration was slightly higher in SLE patients (active SLE mean 1201 pg/ml, 
inactive SLE mean 1118 pg/ml) compared to controls (disease control mean 1000 pg/ml, 
healthy control mean 928 pg/ml) but the difference was not statistically significant. Two of 
the inactive SLE patients had a much higher serum BAFF level (6620 pg/ml and 4075 pg/ml) 
than all the other subjects included in the analysis. 
 
Table 4.4. Demographic characteristics and disease activity of SLE patient, disease control 
and healthy control samples included in measurement of serum BAFF concentration. For SLE 
patients and disease control subjects who have contributed multiples samples to the study, 
only one sample per subject, selected at random, was included in the analysis. 
 
 SLE 
(n = 54) 
Disease control 
(n = 20) 
Healthy 
(n = 62) 
Age, mean years 40.5 54.8 40.6 
Female (%) 48 (89%) 18 (90%) 54 (87%) 
Male (%) 6 (11%) 2 (10%) 8 (13%) 
SLE disease activity    
Active (%) 19 (35%) - - 
Severe 3 - - 
Moderate 6 - - 
Mild 10 - - 
Inactive (%) 35 (65%) - - 
Disease control condition    
Drug-induced lupus - 1 - 
Lupus-like illness, undifferentiated 
autoimmune condition 
- 4 - 
Rheumatoid arthritis - 4 - 
Scleroderma - 1 - 
Sjögren’s syndrome - 9 - 
Vasculitis - 1 - 
  
 
 
 
 
Figure 4.13. Serum BAFF concentration was measured using the Quantikine® BAFF 
Immunoassay and was compared between active SLE, inactive SLE, disease control and 
healthy control samples. The horizontal bar represents the mean of each group. 
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4.2  Case Study of a Patient with Severely Active SLE 
Four samples from SLE Patient 2 were included in the present study. Three of the samples 
were collected over a period of three weeks in September 2008 when the patient was 
hospitalised with severely active SLE, with a SLEDAI score of 30. During these three weeks, 
the patient had musculoskeletal (arthritis and myositis), renal (urinary casts, hematuria, 
proteinuria) and cutaneous (alopecia and mucosal ulcers) symptoms, as well as low 
complement levels, increased DNA binding, fever and leukopenia. While in hospital, the 
patient had been administered prednisone, hydroxychloroquine, mycophenolate and 
intragram, and other medications which do not alter the immune system. The fourth sample 
was collected three years later in September 2011 when the patient had mildly active SLE 
with a SLEDAI score of 4. The patient no longer had any of the musculoskeletal, renal and 
cutaneous symptoms, but still had low complement levels and increased DNA binding. At the 
time of blood collection, the patient had been treated with mycophenolate, 
hydroxychloroquine, prednisone and intragram. 
 
Figure 4.14 (A) compares the lymphocyte population, as identified by forward and side 
scatter properties, in the four samples collected from Patient 2. This patient was leukopenic 
during the first three time points, and the white cell count had recovered by the last time 
point due to an increase of monocytes (Figure 4.14 (B)). The total lymphocyte population 
had further decreased at time point 4. Absolute numbers of NK cells and CD4+ T cells did 
not fluctuate much during the three years. There was an increase in B cell numbers during 
time point 2 but a reduction of B cells followed at subsequent time points. 
 
Figure 4.14. Four samples from SLE Patient 2 were collected over three years. The patient 
had severely active SLE in September 2008 and mildly active SLE in September 2011. (A) 
Representative plots depicting FSC-A vs. SSC-A of viable PBMCs by flow cytometry at 4 
different time points. Lymphocytes are contained within the gate, and the percentage of cells 
within the gate is shown. (B) White blood cell count performed before PBMC purification by 
density gradient centrifugation and the absolute number of monocytes, total lymphocytes, 
CD4+ T cells, NK cells and B cells determined by flow cytometry at 4 different time points 
were compared, and these were also compared to the mean and standard deviation 
(indicated by vertical bars) of the values for healthy control samples. 
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Figure 4.15 compares the B cell subsets in the four samples collected from Patient 2. Samples 
collected from the patient in 2008 had two CD19+ populations – one population expressing 
higher levels of CD19 than the other (A). There appears to be three different CD19+ 
populations in the sample collected in 2011, with different levels of expression of CD19. 
This was not seen in any of the patient or control samples included in our study, which all 
had a single, clearly identifiable CD19 population like the example shown in the final B cell 
gating strategy (Figure 3.6 (G)). All the CD19-expressing populations were included in a 
single gate and expression of CD27 and IgD were compared (Figure 4.15 (B)). Interestingly, 
all four samples from the patient had almost no CD27-IgD+ cells, which were naïve and 
transitional B cells (Figure 4.15 (B, C)). The majority of B cells in the samples from this 
patient were CD27+IgD- and CD27+IgD+ cells (Figure 4.15 (B)), which should correspond to 
switched and MZ or non-switched memory B cells respectively according to the gating 
strategy shown in Figure 3.1 (H). We also used the final B cell gating strategy as shown in 
Figure 3.6 (H, I) to further examine these memory B cell subsets and therefore also compared 
the expression of IgM in these four samples. Unexpectedly, the expression IgM was 
extremely high, and only slightly lower in the sample collected in 2011 (Figure 4.15 (D)). 
This was not due to any faults in the antibody used, staining process or flow cytometry 
acquisition because none of the other samples from other patients and controls stained on the 
same day had such high levels of IgM expression. 
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Figure 4.15. Four samples from SLE Patient 2 were collected over three years. The patient 
had severely active SLE in September 2008 and mildly active SLE in September 2011. (A) 
Representative plots depicting CD19 expression by flow cytometry at 4 different time points. 
B cells are CD19+ cells contained within the gate. (B) Representative plots depicting CD27 
vs. IgD expression by flow cytometry at 4 different time points. CD19+ B cells were further 
gated for CD27-IgD+ naïve and transitional B cells and CD27-IgD- atypical, CD27+IgD+ MZ or 
non-switched and CD27+IgD- switched memory B cells. (C) Representative plots depicting 
CD38 vs. IgD expression by flow cytometry at 4 different time points. CD27-IgD+ B cells were 
further gated for naïve (CD38+) and transitional (CD38hi) B cells. Percentages of cells within 
each gate are shown in (A-C). (D) Representative plots depicting IgM vs. IgD expression by 
flow cytometry at 4 different time points. (E-F) Proportions of B cell subsets at 4 different time 
points were compared together, and these were also compared to the mean and standard 
deviation (indicated by vertical bars) of the values for healthy control samples. (G-H) Absolute 
numbers of B cell subsets at 4 different time points were compared together, and these were 
also compared to the mean and standard deviation (indicated by vertical bars) of the values 
for healthy control samples. 
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The proportion and absolute number of naïve and transitional B cells recovered slightly as 
the patient’s condition improved in 2011 (E, F). There was a drop in atypical memory B cells 
from the first to second time points, and this memory cell subset also recovered as the 
patient’s condition improved. Switched memory B cells increased while MZ or non-switched 
memory B cells decreased as the patient recovered (G, H). 
 
The different levels of expression of CD19 on B cells were further investigated, as illustrated 
in Figure 4.16. We gated the populations from the first three samples of Patient 2 as CD19hi 
and CD19lo cells (A). By overlaying the CD27+IgD- switched and CD27+IgD+ MZ or non-
switched memory B cells, the two subsets which accounted for the majority of B cells in the 
first three samples, we found that the CD19hi population corresponded to MZ or non-
switched memory B cells and CD19lo cells corresponded to switched memory B cells (B, C). 
Similarly, we gated the populations from the fourth sample as CD19hi, CD19mid and CD19lo 
cells (D). Once again, overlaying the two memory B cell subsets showed that CD19hi cells 
corresponded to MZ or non-switched memory B cells, and both the CD19mid and CD19lo B 
cells corresponded to switched memory B cells (E, F). 
 
Figure 4.17 compares the monocyte subsets (A) and NK cell subsets (B) in the four samples 
collected from Patient 2. In contrast to B cells, there was not anything extremely unusual 
about the phenotype of monocyte or NK cell subsets. The total number of monocytes 
increased, although the proportion of CD14+CD16- and CD16+ monocytes remained mostly 
unchanged even as the patient’s condition improved (C, D). It can be seen in the flow 
 
Figure 4.16. Four samples from SLE Patient 2 were collected over three years. The patient 
had severely active SLE in September 2008 and mildly active SLE in September 2011. (A) 
Representative plot depicting CD19 expression by flow cytometry of the first sample collected 
from the patient. Two populations of B cells can be identified based on different levels of 
expression of CD19. Percentages of cells within each gate are shown. (B) Expression of 
CD19 was compared for switched and MZ or non-switched memory B cells. CD19hi B cells 
are mostly MZ or non-switched memory B cells and CD19lo B cells are mostly switched 
memory B cells. (C) Representative plot depicting CD27 and IgD expression of the first 
sample collected from the patient. Switched memory B cells were identified by the expression 
of CD27 but not IgD, and non-switched or MZ memory B cells were identified by the 
expression of both CD27 and IgD. (D) Representative plot depicting CD19 expression by flow 
cytometry of the fourth sample collected from the patient. Three populations of B cells can be 
identified based on different levels of expression of CD19. Percentages of cells within each 
gate are shown. (E) Expression of CD19 was compared for switched and MZ or non-switched 
memory B cells. CD19hi B cells are mostly MZ or non-switched memory B cells while CD19mid 
and CD19lo B cells are mostly switched memory B cells. (F) Representative plot depicting 
CD27 and IgD expression of the fourth sample collected from the patient. Switched memory B 
cells were identified by the expression of CD27 but not IgD, and non-switched or MZ memory 
B cells were identified by the expression of both CD27 and IgD. 
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Figure 4.17. Four samples from SLE Patient 2 were collected over three years. The patient 
had severely active SLE in September 2008 and mildly active SLE in September 2011. (A) 
Representative plots depicting CD14 vs. CD16 expression by flow cytometry at 4 different 
time points. NKp46- PBMCs with larger forward and side scatter properties were further gated 
for CD14+CD16-, CD16+ and CD14dim monocytes. (B) Representative plots depicting CD16 
vs. CD56 expression by flow cytometry at 4 different time points. NKp46+ lymphocytes were 
further gated for CD56dimCD16+, CD56briCD16- and CD56-CD16+ NK cell subsets. 
Percentages of cells within each gate are shown in (A) and (B). (C) Proportions of monocyte 
subsets at 4 different time points were compared together. (D) Absolute numbers of 
monocyte subsets at 4 different time points were compared together. (E) Proportions of NK 
cell subsets at 4 different time points were compared together, and these were also 
compared to the mean and standard deviation (indicated by vertical bars) of the values for 
healthy control samples. (F) Absolute numbers of NK cell subsets at 4 different time points 
were compared together, and these were also compared to the mean and standard deviation 
(indicated by vertical bars) of the values for healthy control samples. 
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cytometric plots that the CD14+CD16+ intermediate monocytes recovered with a relative 
decrease in CD14dim monocytes when the patient recovered (A). In contrast to what we had 
observed in other SLE patient samples in our study (Figure 4.8), there was an increase in the 
proportion of CD56briCD16- NK cells and relative decrease in CD56dimCD16+ NK cells as the 
patient’s condition improved (E). Overall, the absolute numbers of the NK cell subsets 
increased as the patient was recovering (F). 
 
Figure 4.18 compares the total CD4+ T cell population (A), CD45RO expression on CD4+ T 
cells (B), Tregs (C) and CD45RO expression on Tregs (D) in the four samples collected from 
Patient 2. The patient had fewer CD45RO+ CD4+ T cells than CD45RO- CD4+ T cells at all 
four time points. The percentage and number of Tregs recovered as the patient’s condition 
improved, and the majority of Tregs were CD45RO+ (E, F). Figure 4.19 compares the 
CXCR5+ CD4+ T cells (A), CXCR5+PD-1+ Tfh cells (B) and CXCR3 expression on Tfh cells 
(C) in the four samples collected from Patient 2. Overall, there was a reduction in CXCR5-
expressing populations as the patient’s condition improved (D, E), which is in contrast to 
what we had observed in the other SLE patient samples in our study (Figure 4.11). The 
patient had more CXCR3- than CXCR3+ Tfh cells at all four time points (D, E). 
 
4.3  Longitudinal Study of Four SLE Patients 
The samples from every time point of four other SLE patients were included in a longitudinal 
study to compare the changes in numbers and proportions of peripheral blood cell 
populations over time and during changes in disease activity. These four patients were 
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Figure 4.18. Four samples from SLE Patient 2 were collected over three years. The patient 
had severely active SLE in September 2008 and mildly active SLE in September 2011. (A) 
Representative plots depicting CD4 expression by flow cytometry at 4 different time points. 
CD4+ T cells are contained within the gate. (B) Representative plots depicting CD45RO vs. 
CD4 expression by flow cytometry at 4 different time points. CD4+ T cells were compared for 
their expression of CD45RO. (C) Representative plots depicting CD127 vs. CD25 expression 
by flow cytometry at 4 different time points. CD4+ T cells were further gated for CD127loCD25+ 
Tregs. (D) Representative plots depicting CD45RO vs. CD4 expression by flow cytometry at 4 
different time points. Tregs were further compared for their expression of CD45RO. 
Percentages of cells within each gate are shown in (A-D). (E) Frequencies of CD45RO+ and 
CD45RO- CD4+ T cells, CD45RO+ and CD45RO- Tregs and total Tregs expressed as a 
percentage of total CD4+ T cells at 4 different time points were compared together, and these 
were also compared to the mean and standard deviation (indicated by vertical bars) of the 
values for healthy control samples. (F) Absolute numbers of CD45RO+ and CD45RO- CD4+ T 
cells, CD45RO+ and CD45RO- Tregs and total Tregs at 4 different time points were compared 
together, and these were also compared to the mean and standard deviation (indicated by 
vertical bars) of the values for healthy control samples. 
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Figure 4.19. Four samples from SLE Patient 2 were collected over three years. The patient 
had severely active SLE in September 2008 and mildly active SLE in September 2011. (A) 
Representative plots depicting CXCR5 vs. CD4 expression by flow cytometry at 4 different 
time points. CD4+ T cells were further gated for CXCR5+ Tfh cells. (B) Representative plots 
depicting CXCR5 vs. PD-1 expression by flow cytometry at 4 different time points. CD4+ T 
cells were further gated for CXCR5+PD-1+ Tfh cells. (C) Representative plots depicting 
CD45RO vs. CXCR3 expression by flow cytometry of at 4 different time points. CXCR5+PD-1+ 
Tfh cells were further gated for CXCR3-CD45RO+ and CXCR3+CD45RO+ subsets. 
Percentages of cells within each gate are shown in (A-C). (D) Frequencies of CXCR5+, 
CXCR5+PD-1+, CXCR3+ CXCR5+PD-1+ and CXCR3- CXCR5+PD-1+ Tfh cells expressed as a 
percentage of total CD4+ T cells at 4 different time points were compared together, and these 
were also compared to the mean and standard deviation (indicated by vertical bars) of the 
values for healthy control samples. (E) Absolute numbers of CXCR5+, CXCR5+PD-1+, 
CXCR3+ CXCR5+PD-1+ and CXCR3- CXCR5+PD-1+ Tfh cells at 4 different time points were 
compared together, and these were also compared to the mean and standard deviation 
(indicated by vertical bars) of the values for healthy control samples. 
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selected for the longitudinal study as they had provided the most number of samples (7-8 
samples from each patient) and their disease activity fluctuated over the course of the study. 
Samples were collected from each patient over approximately 3.5 years. The dates at which 
these patients’ samples were collected and their SLEDAI scores at the time of sample 
collection are summarised on Table 4.5. Plots depicting the changes in absolute number and 
proportion of cell subsets and serum BAFF level are shown in Figures 4.20-4.23. 
 
Absolute counts for the sample collected at the second time point from Patient 5 could not be 
calculated because the whole blood count was not measured. The absolute number of 
leukocytes, total lymphocytes, NK cells and CD4+ T cells were mostly stable for the first six 
time points even though the patient experienced a huge increase in SLEDAI (Figure 4.20 
(A)). Monocyte numbers fell as SLEDAI increased, and vice versa. The changes in total B 
cell numbers followed a similar trend to changes in SLEDAI during all eight time points. 
Proportions of transitional B cells increased, with a relative reduction in naïve B cells, when 
the patient experienced a flare, and vice versa when the patient’s condition improved (Figure 
4.20 (B)). Proportions of memory B cell subsets fluctuated throughout the eight time points 
but did not appear to be associated with changes in SLEDAI. Numbers of plasmablasts and 
plasma cells remained mostly low except for the increase at time point 8. Monocyte 
proportions were similar throughout the eight time points except at time point 2 where there 
was an approximately 20% decrease in classical monocytes with a relative increase in CD16+ 
monocytes (Figure 4.20 (C)). Changes in total monocyte numbers were mostly attributed to 
changes in numbers of classical monocytes. There were minor fluctuations in percentages of 
Table 4.5. Dates at which samples were collected and SLEDAI scores at time of collection of 
samples from SLE Patients 5, 6, 8 and 40. 
 
SLE Patient Time point Date SLEDAI Treatment 
5 1 15 February 2008 2 AZA, PRED 
 2 7 April 2008 20 HCQ 
 3 16 April 2008 20 HCQ, PRED 
 4 10 November 2008 10 None 
 5 17 November 2008 14 MMF, PRED 
 6 22 June 2009 8 MMF, PRED 
 7 10 September 2010 0 MMF, PRED 
 8 1 December 2011 2 PRED 
6 1 11 February 2008 2 HCQ 
 2 20 July 2010 12 HCQ 
 3 27 August 2010 10 HCQ 
 4 19 October 2010 6 HCQ, PRED 
 5 2 November 2010 6 AZA, HCQ, PRED 
 6 16 November 2010 0 AZA, HCQ, PRED 
 7 20 November 2010 0 AZA, HCQ, PRED 
 8 5 September 2011 2 AZA, HCQ, PRED 
8 1 7 April 2008 8 HCQ, PRED 
 2 14 October 2008 6 HCQ, PRED 
 3 27 October 2008 6 HCQ, PRED 
 4 10 November 2008 6 HCQ, PRED 
 5 28 April 2009 4 AZA, HCQ, PRED 
 6 11 October 2010 4 AZA, HCQ, PRED 
 7 5 September 2011 4 AZA, HCQ, PRED 
40 1 10 April 2008 8 AZA, HCQ, PRED 
 2 3 December 2008 8 AZA, HCQ 
 3 2 June 2009 4 AZA, HCQ, PRED 
 4 8 September 2010 8 HCQ, PRED 
 5 7 June 2011 8 MMF, HCQ, PRED 
 6 18 July 2011 12 HCQ, PRED 
 7 22 August 2011 12 HCQ, PRED 
 
AZA – azathioprine; HCQ – hydroxychloroquine; MMF – mycophenolate; PRED – prednisone. 
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Figure 4.20. Eight samples from SLE Patient 5 were collected over 3 years and 10 months. Absolute number of cell populations at the second time point 
could not be calculated as whole blood count was not measured. The patient’s treatment at each time point is indicated under each graph. AZA – 
azathioprine; HCQ – hydroxychloroquine; MMF – mycophenolate; PRED – prednisone. (A) White blood cell count performed before PBMC purification by 
density gradient centrifugation and the absolute number of monocytes, total lymphocytes, CD4+ T cells, NK cells and B cells determined by flow cytometry at 
8 different time points were compared, and these were also compared to the mean and standard deviation (SD) of the values for healthy control samples. (B) 
Frequency and absolute number of B cell populations at 8 different time points were compared, and these were also compared to the mean and SD of the 
values for healthy control samples. (C) Frequency and absolute number of monocyte populations at 8 different time points were compared, and these were 
also compared to the mean and SD of the values for healthy control samples. (D) Frequency and absolute number of NK cell populations at 8 different time 
points were compared, and these were also compared to the mean and SD of the values for healthy control samples. (E) Frequency and absolute number of 
CD45RO+ and CD45RO- CD4+ T cells and Treg populations at 8 different time points were compared, and these were also compared to the mean and SD of 
the values for healthy control samples. (F) Frequency and absolute number of Tfh cell populations at 8 different time points were compared, and these were 
also compared to the mean and SD of the values for healthy control samples. (G) Serum BAFF concentration at 7 different time points were compared, and 
these were also compared to the mean and SD of the values for healthy control samples. BAFF concentration could not be determined at time point 7 as 
serum could not be obtained. Vertical bars on each plot depict the SD of the values for healthy control samples. 
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Figure 4.21. Eight samples from SLE Patient 6 were collected over 3 years and 7 months. The patient’s treatment at each time point is indicated under each 
graph. AZA – azathioprine; HCQ – hydroxychloroquine; MMF – mycophenolate; PRED – prednisone. (A) White blood cell count performed before PBMC 
purification by density gradient centrifugation and the absolute number of monocytes, total lymphocytes, CD4+ T cells, NK cells and B cells determined by 
flow cytometry at 8 different time points were compared, and these were also compared to the mean and standard deviation (SD) of the values for healthy 
control samples. (B) Frequency and absolute number of B cell populations at 8 different time points were compared, and these were also compared to the 
mean and SD of the values for healthy control samples. (C) Frequency and absolute number of monocyte populations at 8 different time points were 
compared, and these were also compared to the mean and SD of the values for healthy control samples. (D) Frequency and absolute number of NK cell 
populations at 8 different time points were compared, and these were also compared to the mean and SD of the values for healthy control samples. (E) 
Frequency and absolute number of CD45RO+ and CD45RO- CD4+ T cells and Treg populations at 8 different time points were compared, and these were 
also compared to the mean and SD of the values for healthy control samples. (F) Frequency and absolute number of Tfh cell populations at 8 different time 
points were compared, and these were also compared to the mean and SD of the values for healthy control samples. (G) Serum BAFF concentration at 6 
different time points were compared, and these were also compared to the mean and SD of the values for healthy control samples. BAFF concentration could 
not be determined at time points 3 and 8 as serum could not be obtained. Vertical bars on each plot depict the SD of the values for healthy control samples. 
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Figure 4.22. Seven samples from SLE Patient 8 were collected over 3 years and 5 months. The patient’s treatment at each time point is indicated under each 
graph. AZA – azathioprine; HCQ – hydroxychloroquine; MMF – mycophenolate; PRED – prednisone. (A) White blood cell count performed before PBMC 
purification by density gradient centrifugation and the absolute number of monocytes, total lymphocytes, CD4+ T cells, NK cells and B cells determined by 
flow cytometry at 7 different time points were compared, and these were also compared to the mean and standard deviation (SD) of the values for healthy 
control samples. (B) Frequency and absolute number of B cell populations at 7 different time points were compared, and these were also compared to the 
mean and SD of the values for healthy control samples. (C) Frequency and absolute number of monocyte populations at 7 different time points were 
compared, and these were also compared to the mean and SD of the values for healthy control samples. (D) Frequency and absolute number of NK cell 
populations at 7 different time points were compared, and these were also compared to the mean and SD of the values for healthy control samples. (E) 
Frequency and absolute number of CD45RO+ and CD45RO- CD4+ T cells and Treg populations at 7 different time points were compared, and these were 
also compared to the mean and SD of the values for healthy control samples. (F) Frequency and absolute number of Tfh cell populations at 7 different time 
points were compared, and these were also compared to the mean and SD of the values for healthy control samples. (G) Serum BAFF concentration at 6 
different time points were compared, and these were also compared to the mean and SD of the values for healthy control samples. BAFF concentration could 
not be determined at time point 7 as serum could not be obtained. Vertical bars on each plot depict the SD of the values for healthy control samples. 
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Figure 4.23. Seven samples from SLE Patient 40 were collected over 3 years and 4 months. The patient’s treatment at each time point is indicated under 
each graph. AZA – azathioprine; HCQ – hydroxychloroquine; MMF – mycophenolate; PRED – prednisone. (A) White blood cell count performed before 
PBMC purification by density gradient centrifugation and the absolute number of monocytes, total lymphocytes, CD4+ T cells, NK cells and B cells determined 
by flow cytometry at 7 different time points were compared, and these were also compared to the mean and standard deviation (SD) of the values for healthy 
control samples. (B) Frequency and absolute number of B cell populations at 7 different time points were compared, and these were also compared to the 
mean and SD of the values for healthy control samples. (C) Frequency and absolute number of monocyte populations at 7 different time points were 
compared, and these were also compared to the mean and SD of the values for healthy control samples. (D) Frequency and absolute number of NK cell 
populations at 7 different time points were compared, and these were also compared to the mean and SD of the values for healthy control samples. (E) 
Frequency and absolute number of CD45RO+ and CD45RO- CD4+ T cells and Treg populations at 7 different time points were compared, and these were 
also compared to the mean and SD of the values for healthy control samples. (F) Frequency and absolute number of Tfh cell populations at 7 different time 
points were compared, and these were also compared to the mean and SD of the values for healthy control samples. (G) Serum BAFF concentration at 7 
different time points were compared, and these were also compared to the mean and SD of the values for healthy control samples. Vertical bars on each plot 
depict the SD of the values for healthy control samples. 
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NK cell subsets in the first six time points, and then a 20% increase in CD56dimCD16+ NK 
cells with a relative decrease of CD56briCD16- NK cells at time point 7, when the patient 
became inactive again after a period of SLE flares (Figure 4.20 (D)). Proportions of 
CD45RO+ and CD45RO- CD4+ T cells fluctuated throughout the eight time points but did not 
appear to be associated with changes in SLEDAI (Figure 4.20 (E)). The patient had a higher 
percentage of CD45RO+ T cells at all eight time points. The majority of the patient’s Tregs 
were CD45RO+ Tregs, and changes in the frequency of Tregs also did not appear to be 
associated with changes in disease activity. Absolute numbers of CXCR5-expressing 
populations gradually increased during the first six time points, and then greatly increased at 
time point 7 before returning to the same levels as time point 6 at the last time point (Figure 
4.20 (F)). The patient had a greater proportion of CXCR3- Tfh cells than CXCR3+ Tfh cells 
at all time points. The patient’s serum BAFF concentration decreased from the first to the 
second time point but remained mostly at the same level afterwards (Figure 4.20 (G)). No 
serum sample was obtained at time point 7 therefore BAFF concentration could not be 
measured at that time point. 
 
The absolute numbers of leukocytes, total lymphocytes, monocytes, B cells and CD4+ T cells 
in the samples from Patient 6 fluctuated over time but the changes were not associated with 
changes in SLEDAI (Figure 4.21 (A)). NK cell numbers were mostly low and further 
decreased at time point 4. Proportions of naïve, atypical memory, switched memory and MZ 
memory B cells were mostly stable throughout the eight time points (Figure 4.21 (B)). 
Changes in total B cell numbers were mostly due to changes in numbers of naïve B cells. 
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There was a marked increase in the frequency and number of transitional B cells at the 
second and third time points, when the patient’s SLEDAI score was greatest out of all the 
time points. Numbers of plasmablasts and plasma cells remained low at all time points. Over 
90% of the patient’s monocytes were classical monocytes at all eight time points, and 
proportions of monocyte subsets remained stable throughout all time points (Figure 4.21 
(C)). Similarly, over 90% of the patient’s NK cells were CD56dimCD16+ NK cells at all eight 
time points and proportions of NK cells also remained stable throughout all time points 
(Figure 4.21 (D)). The number and proportion of CD45RO+ and CD45RO- CD4+ T cells 
fluctuated throughout the eight time points but changes did not appear to be associated to 
changes in disease activity (Figure 4.21 (E)). The majority of Tregs were CD45RO+ Tregs at 
all time points, and changes in Treg numbers also did not appear to be related to changes in 
SLEDAI. CXCR5+ cell numbers gradually fell from the first to the fifth time point, but 
increased at time point 6, when the patient became quiescent after a period of SLE flares 
(Figure 4.21 (F)). Although the total number of CXCR5+ CD4+ T cells fell after time point 6, 
CXCR5+PD-1+ Tfh numbers remained at similar levels. The patient had a higher proportion 
of CXCR3- Tfh cells than CXCR3+ Tfh cells at all time points. Changes in the patient’s 
serum BAFF levels were similar to changes in SLEDAI scores (Figure 4.21 (G)). BAFF 
concentrations could not be determined at time points 3 and 8 as serum samples were not 
obtained at these two time points. 
 
There was a huge dip in the numbers of all cell populations at time point 5 for Patient 8, 
which coincided with the introduction of azathioprine treatment (Figure 4.22 (A)). Apart 
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from time point 5, there were modest changes in the total numbers of white blood cells and 
lymphocytes. Numbers of NK cells fell and never recovered after time point 5. Monocytes 
increased while CD4+ T cells decreased as the patient’s condition improved. Fluctuations in 
total number of B cells did not appear to be related to changes in SLEDAI. Proportions of 
naïve and transitional B cells fell while MZ memory B cells increased as the patient’s 
SLEDAI scores decreased (Figure 4.22 (B)). The percentages of atypical and switched 
memory B cells were stable until an increase at the last two time points. The patient had 
almost no plasmablasts and plasma cells at all time points. Proportions of monocyte subsets 
were mostly similar at all time points, with over 80% of monocytes being classical 
monocytes (Figure 4.22 (C)). Proportions of NK cell subsets were similar during the first five 
time points (Figure 4.22 (D)). There was an increased percentage of CD56briCD16- and 
CD56-CD16+ NK cells with a relative decrease of CD56dimCD16+ NK cells at time point 6, 
and this is the only time point where the proportion of CD56briCD16- NK cells exceeded that 
of CD56dimCD16+ NK cells. Percentages of CD56briCD16- and CD56-CD16+ NK cells fell 
and CD56dimCD16+ NK cells increased at the last time point. Proportions of CD45RO+ and 
CD45RO- CD4+ T cells fluctuated over the eight time points but fluctuations were not related 
to changes in SLEDAI (Figure 4.22 (E)). The majority of the patient’s Tregs were CD45RO+ 
Tregs at all time points, and there were only minor changes in the frequency of Tregs 
throughout the eight time points. Frequency and number of CXCR5+ populations changed 
during the eight time points but changes did not appear to be associated with changes in 
SLEDAI (Figure 4.22 (F)). Overall, serum BAFF levels fell as the patient’s SLEDAI scores 
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decreased (Figure 4.22 (G)). BAFF concentration could not be determined at the last time 
point as serum could not be obtained. 
 
Absolute numbers of leukocytes, monocytes, and B cells changed throughout the seven time 
points in Patient 40 but changes in numbers did not appear to be related to changes in disease 
activity (Figure 4.23 (A)). Changes in the total numbers of lymphocytes, CD4+ T cells and 
NK cells followed a similar trend to the changes in the patient’s SLEDAI scores throughout 
all time points. There were huge fluctuations in the proportions of all B cell subsets except 
for MZ memory B cells (Figure 4.23 (B)). The frequency of transitional B cells sharply 
increased at time point four and decreased to almost zero at time point 5, and remained 
mostly low afterwards. Plasmablasts and plasma cell numbers were increased at time points 3 
and 4. The fluctuations in the number and frequency of B cell subsets were unrelated to 
changes in SLEDAI. Proportions of monocyte subsets were mostly similar throughout the 
seven time points except at time point 4, where there was a 30% decrease in classical 
monocytes and a relative increase in CD16+ monocytes (Figure 4.23 (C)). Proportions of NK 
cell subsets changed only slightly during the first five time points (Figure 4.23 (D)). There 
was a marked decrease of CD56dimCD16+ NK cells and a relative increase of CD56briCD16- 
NK cells at time point 6, where the percentage of CD56briCD16- NK cells was greater than 
that of CD56dimCD16+ NK cells. The percentage of CD56dimCD16+ NK cells then rose with a 
relative reduction of CD56briCD16- NK cells at the last time point. Changes in the 
percentages of monocyte and NK cell subsets did not appear to be related to changes in 
SLEDAI. Changes in the proportions of CD45RO+ and CD45RO- CD4+ T cells also did not 
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appear to be related to changes in disease severity (Figure 4.23 (E)). Most of the Tregs at all 
seven time points were CD45RO+ Tregs. Changes in Treg numbers followed a similar trend 
to changes in the patient’s SLEDAI scores. Fluctuations of CXCR5+ populations appear 
unrelated to changes in SLEDAI (Figure 4.23 (F)). The patient had almost no CXCR5+ cells 
at time point 4 and very few CXCR5+PD-1+ Tfh cells at time point 6. Changes in the 
patient’s serum BAFF concentration did not reflect changes in SLEDAI (Figure 4.23 (G)). 
 
4.4  Data Cleaning and Missing Data Imputation 
4.4.1  Summary of Numeric Variables Prior to Data Cleaning 
Serum BAFF concentration and the frequency and absolute number of B cell, monocyte, NK 
cell, Treg and Tfh cell populations of all SLE, disease control and healthy control samples 
determined by flow cytometry are summarised in Table 4.6. The missing values were due to 
not enough blood collected for a particular sample so certain measurements could not be 
performed, serum samples were not collected and therefore serum BAFF concentration could 
not be measured, or certain cell populations (e.g. CD14dim monocytes) were not clearly 
identifiable in samples. Full blood counts and other data collected on patient blood samples 
by RPA Department of Clinical Immunology are summarised in Table 4.7. Not all 
measurements were conducted each time a patient visited the clinic, accounting for the 
missing values. Also accounting for the missing values were healthy control samples. 
 
4.4.2  Results of Data Cleaning and Imputation 
Four SLE samples were identified as possible outliers and were removed from the analysis. 
Three of the samples removed correspond to an individual patient with a SLEDAI of 30, and 
Table 4.6. Summary of white cell count, serum BAFF concentration and flow cytometry measurements of all samples included in the statistical analysis of the 
complete data set prior to data cleaning. 
 
Variable Min 1st Quartile Median Mean 3rd Quartile Max Number missing 
BAFF 293 665 844 1082 1181 8466 43 
White cell count ^ 0.2 4.8 6.2 6.4 7.7 17.3 3 
Total B cells as % live cells 0.78 5.62 8.76 9.68 12.4 52.3  
Total B cells 106/ml 0.013 0.317 0.517 0.582 0.777 3.08 3 
Plasmablasts/plasma cells as % live cells 0.00089 0.026 0.0565 0.11388 0.1 1.7 4 
Plasmablasts/plasma cells 106/ml 0.000012 0.0016 0.0033 0.0069 0.0063 0.12 7 
Switched memory B cells as % total B cells 1.7 10 15.8 18.2 22.9 86.4  
Switched memory B cells as % live cells 0.084 0.69 1.21 1.861 2.062 37.4  
Switched memory B cells 106/ml 0.00022 0.03924 0.06885 0.10241 0.13274 1.0472 3 
MZ/non-switched memory B cells as % total B 
cells 1.6 6.7 12.8 15.5 21.1 87.5  
MZ/non-switched memory B cells as % live 
cells 0.029 0.52 1.035 1.416 1.72 13.8  
MZ/non-switched memory B cells 106/ml 0.0021 0.0279 0.0634 0.0814 0.1091 0.4954 3 
Atypical memory B cells as % total B cells 0.43 2.52 4.02 6.1 6.5 47.3  
Atypical memory B cells as % live cells 0.037 0.19 0.34 0.474 0.62 3.88  
Atypical memory B cells 106/ml 0.00044 0.01064 0.01972 0.02856 0.03575 0.23115 3 
Naïve B cells as % total B cells 0.23 40.2 58.3 53.83 69.33 93  
Naïve B cells as % live cells 0.035 2.373 4.455 5.315 7.405 19.5  
Naïve B cells 106/ml 0.0025 0.1299 0.2617 0.3384 0.471 2.4764 3 
Transitional B cells as % total B cells 0.019 1.12 3.025 5.4 6.447 48.6  
Transitional B cells as % live cells 0.001 0.07 0.26 0.553 0.613 14  
Transitional B cells 106/ml 0.000035 0.0044 0.016 0.028 0.038 0.35 3 
Total monocytes as % live cells 1.8 12.3 16.3 17.6 20.9 72.4  
Total monocytes 106/ml 0.01 0.63 0.99 1.17 1.42 4.49 3 
CD14+CD16- monocytes as % total monocytes 58 83 89 87 92 99  
CD14+CD16- monocytes as % live cells 1.7 10.7 13.9 15.5 18.6 71.4  
CD14+CD16- monocytes 106/ml 0.0087 0.5434 0.8624 1.0349 1.2928 4.4268 3 
CD16+ monocytes as % total monocytes 0.68 7.55 10.97 12.57 17.03 42.47  
CD16+ monocytes as % live cells 0.12 1.03 1.67 2.08 2.67 9.26  
CD16+ monocytes 106/ml 0.0017 0.0639 0.0975 0.1306 0.1664 0.6903 3 
CD14dim monocytes as % total monocytes 0.25 3.39 6.03 8.1 12 34.38 117 
CD14dim monocytes as % live cells 0.068 0.48 0.8 1.289 1.615 5.85 117 
CD14dim monocytes 106/ml 0 0.029 0.052 0.079 0.097 0.625 117 
Total NK cells as % live cells 0.16 2.97 5.6 7.17 8.94 39.26  
Total NK cells 106/ml 0.0032 0.1823 0.3386 0.4565 0.5583 4.7069 3 
CD56briCD16- NK cells as % total NK cells 0.25 5.44 9.46 14.92 19.01 80.92  
CD56briCD16- NK cells as % live cells 0.0064 0.3175 0.53 0.7443 0.835 5.71  
CD56briCD16- NK cells 106/ml 0.00045 0.01771 0.03015 0.04739 0.05031 0.43967 3 
CD56dimCD16+ NK cells as % total NK cells 18 77 87 82 92 99  
CD56dimCD16+ NK cells as % live cells 0.057 2.185 4.795 6.255 7.93 36.2  
CD56dimCD16+ NK cells 106/ml 0.002 0.141 0.278 0.399 0.474 4.34 3 
CD56-CD16+ NK cells as % total NK cells 0.19 1.11 1.84 2.85 3.49 22.46  
CD56-CD16+ NK cells as % live cells 0.0059 0.049 0.11 0.1715 0.1725 5.49  
CD56-CD16+ NK cells 106/ml 0.00004 0.00319 0.00637 0.00988 0.0108 0.26901 3 
Total CD4+ T cells as % live cells 0.52 19.57 26.6 27.14 35.83 52.1 4 
Total CD4+ T cells 106/ml 0.0087 1.0414 1.688 1.7369 2.3142 5.285 7 
CXCR5+ CD4+ T cells as % total CD4+ T cells 0.36 6.2 9.2 10.2 13.72 26.2 4 
CXCR5+ CD4+ T cells as % live cells 0.0036 1.3375 2.8 3.0033 4.0875 16.5 4 
CXCR5+ CD4+ T cells 106/ml 0.00018 0.07975 0.16402 0.18496 0.25866 0.75168 7 
CD45RO+ CD4+ T cells as % total CD4+ T cells 12 38 49 48 59 90 13 
CD45RO+ CD4+ T cells as % live cells 0.46 8.49 11.6 12.47 15 36.1 13 
CD45RO+ CD4+ T cells 106/ml 0.0051 0.4984 0.6778 0.783 1.0339 2.418 15 
CD45RO- CD4+ T cells as % total CD4+ T cells 10 41 51 52 62 88 13 
CD45RO- CD4+ T cells as % live cells 0.054 8.44 12.8 14.619 19.95 44.2 13 
CD45RO+ CD4+ T cells 106/ml 0.0035 0.4367 0.8068 0.9367 1.245 4.6357 15 
Tregs as % total CD4+ T cells 2.5 6.3 7.9 9.1 10.9 27.3 13 
Tregs as % live cells 0.14 1.53 2.2 2.29 2.96 6.77 13 
Tregs 106/ml 0.00098 0.08832 0.12948 0.14562 0.17875 0.58596 15 
CD45RO+ Tregs as % CD45RO+ CD4+ T cells 3.1 9.6 12.9 14.2 17.3 40.6 13 
CD45RO+ Tregs as % Tregs 34 63 73 72 80 96 13 
CD45RO+ Tregs as % total CD4+ T cells 1.8 4.3 5.6 6.6 7.9 25.9 13 
CD45RO+ Tregs as % live cells 0.13 1.1 1.5 1.6 2.02 4.19 13 
CD45RO+ Tregs 106/ml 0.00076 0.06016 0.08845 0.1015 0.124 0.4104 15 
CD45RO- Tregs as % Tregs 3.9 19.4 27.1 28.2 36.5 65.1 13 
CD45RO- Tregs as % total CD4+ T cells 0.3 1.5 2.2 2.5 3.1 8.2 13 
CD45RO- Tregs as % live cells 0.0072 0.31 0.61 0.685 0.935 2.96 13 
CD45RO- Tregs 106/ml 0.00022 0.01824 0.03519 0.0437 0.05799 0.19988 15 
CXCR3+ CXCR5+PD-1+ Tfh as % total CD4+ T 
cells 0 0.76 1.45 1.75 2.46 8.57 13 
CXCR3+ CXCR5+PD-1+ Tfh as % live cells 0 0.15 0.39 0.51 0.71 2.01 13 
CXCR3+ CXCR5+PD-1+ Tfh 106/ml 0 0.01 0.024 0.03 0.044 0.136 15 
CXCR3- CXCR5+PD-1+ Tfh as % total CD4+ T 
cells 0 1.2 1.7 2.1 2.7 8.1 13 
CXCR3- CXCR5+PD-1+ Tfh as % live cells 0 0.28 0.5 0.56 0.74 1.96 13 
CXCR3- CXCR5+PD-1+ Tfh 106/ml 0 0.016 0.029 0.034 0.048 0.151 15 
CXCR5+PD-1+ Tfh as % total CD4+ T cells 0 2.6 4.2 4.6 6.1 18 4 
CXCR5+PD-1+ Tfh as % live cells 0 0.56 1.2 1.29 1.84 4.48 4 
CXCR5+PD-1+ Tfh 106/ml 0 0.037 0.069 0.079 0.105 0.328 8 
CXCR3+ CXCR5+PD-1+ Tfh as % CXCR5+PD-
1+ Tfh 0 28 35 34 42 65 13 
CXCR3- CXCR5+PD-1+ Tfh as % CXCR5+PD-
1+ Tfh 0 38 44 46 52 100 13 
 
^ measured by the Sysmex automated haematology analyser at Centenary Institute prior to PBMC isolation by density centrifugation 
Table 4.7. Summary of full blood counts and other measurements of patient samples 
included in the statistical analysis of the complete data set prior to data cleaning. 
 
Variable Min 1st 
quartile 
Median Mean 3rd 
quartile 
Max Number 
missing 
Basophils 0.000 0.000 0.000 0.015 0.000 0.100 90 
C3 0.13 0.67 0.87 0.89 1.12 1.75 101 
C4 0.03 0.12 0.16 0.17 0.20 0.80 103 
CRP 0.0 1.1 2.8 9.8 8.1 206.3 132 
Anti-dsDNA 0 1 3 18 11 206 126 
Eosinophils 0.0 0.0 0.1 0.1 0.1 1.2 90 
ESR 2 11 24 32 46 118 130 
HB 8.1 11.9 12.9 12.8 13.9 16.6 91 
Lymphocytes 0.1 1.0 1.4 1.6 2.0 5.8 91 
Monocytes 0.10 0.30 0.40 0.47 0.60 1.10 91 
Neutrophils 1.4 3.1 4.4 4.8 6.1 13.4 91 
PLT 9 220 270 277 326 534 91 
RCC 2.7 4.0 4.3 4.3 4.6 6.0 91 
WCC 2.1 5.3 6.7 6.9 8.6 15.7 91 
 
CRP – C reactive protein; dsDNA – double-stranded DNA; ESR – erythrocyte sedimentation 
rate; HB – haemoglobin; PLT – platelets; RCC – red cell count; WCC – white cell count. 
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one of the three samples has values taking the maximum value for five variables. The other 
sample removed corresponds to another patient on rituximab treatment and therefore has 
unreliable measurements for B cell populations, and this sample has values taking the 
maximum value for five variables. After outlier removal there were a total of 232 samples 
and 139 variables, of which 95 are numeric. Approximately 8% of entries were missing, 89% 
of samples contain at least one missing value and 52% of the variables contain at least one 
missing value. The densities of the numeric variables we measured from all patient and 
control samples were compared before and after data cleaning and imputation, and these are 
shown in Figures 4.24-4.31. For some of the measurements (e.g. SLEDAI, shown in Figure 
4.24) the distribution of the data changed after imputation, but for most of the measurements 
the data were already normally distributed so distribution did change after imputation (e.g. 
absolute number of B cells, shown in Figure 4.25). 
 
4.5  Effect of Various Treatments on Variables Measured by Flow 
Cytometry, Blood Counts, Levels of BAFF, Anti-dsDNA Antibody, 
Complements, ESR and C-Reactive Protein in SLE Patients 
4.5.1  Significantly Reduced Levels of Total NK cells, CD56dimCD16+ NK cells and 
Transitional B cells in SLE Patients Treated with Azathioprine 
A linear model was fitted to determine the effect of various medications on the numeric 
variables we have measured in SLE patients, as described in 2.6.2.6 Methods Used for Data 
Analysis. Patients treated with azathioprine had significantly lower absolute number and 
frequency as a percentage of live cells of total NK cells and CD56dimCD16+ NK cells, and 
significantly lower frequency of transitional B cells as a percentage of live cells and total B 
 
Figure 4.24. Density plots of age at time of sample collection, age at onset of disease, 
duration of disease, SLEDAI scores, serum BAFF concentration and white cell count of all 
samples before (in black) and after (in red) data cleaning and imputation. Density did not 
differ before and after data cleaning and imputation in plots with red lines only. 
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Figure 4.25. Density plots of frequency and absolute number of B cell populations of all 
samples before (in black) and after (in red) data cleaning and imputation. Density did not 
differ before and after data cleaning and imputation in plots with red lines only. 
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Figure 4.26. Density plots of frequency and absolute number of monocyte populations of all 
samples before (in black) and after (in red) data cleaning and imputation. Density did not 
differ before and after data cleaning and imputation in plots with red lines only. 
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Figure 4.27. Density plots of frequency and absolute number of NK cell populations of all 
samples before (in black) and after (in red) data cleaning and imputation. Density did not 
differ before and after data cleaning and imputation in plots with red lines only. 
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Figure 4.28. Density plots of frequency and absolute number of the total CD4+ cell population 
and CD45RO+ and CD45RO- CD4+ cells of all samples before (in black) and after (in red) 
data cleaning and imputation. Density did not differ before and after data cleaning and 
imputation in plots with red lines only. 
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Figure 4.29. Density plots of frequency and absolute number of Tregs and CD45RO+ and 
CD45RO- Tregs of all samples before (in black) and after (in red) data cleaning and 
imputation. Density did not differ before and after data cleaning and imputation in plots with 
red lines only. 
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Figure 4.30. Density plots of frequency and absolute number of Tfh cell populations of all 
samples before (in black) and after (in red) data cleaning and imputation. Density did not 
differ before and after data cleaning and imputation in plots with red lines only. 
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Figure 4.31. Density plots of full blood counts, anti-dsDNA antibody levels, complement 
levels, C-reactive protein and ESR of patient samples before (in black) and after (in red) data 
cleaning and imputation. Density did not differ before and after data cleaning and imputation 
in plots with red lines only. 
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cells in SLE patients (all p<0.01), as shown in Figure 4.32. The coefficients, R2 values, 
standard error and F-test values of the variables affected by treatment with azathioprine are 
summarised on Table 4.8. 
 
4.5.2  Significantly Increased Neutrophil Count in SLE Patients Treated with 
Prednisone 
SLE patients treated with prednisone had a significantly higher neutrophil count as measured 
on an automated haemocytometer (p<0.01) (Figure 4.33). The coefficients, R2 values, 
standard error and F-test values of the effect of prednisone on neutrophil count are 
summarised on Table 4.9. 
 
4.5.3  Significantly Increased C4 Levels in SLE Patients Treated with Mycophenolate 
SLE patients treated with mycophenolate had significantly increased C4 levels (p<0.01), as 
shown in Figure 4.34. The coefficients, R2 values, standard error and F-test values of the 
effect of mycophenolate on C4 levels are summarised on Table 4.10. 
 
The effect of hydroxycholoroquine treatment on the variables we measured in SLE patients 
was also analysed but we did not find any significant changes in the variables that were 
linked to treatment with hydroxycholoroquine. 
 
 
Figure 4.32. A linear model was fitted to determine the effect of azathioprine (AZA) treatment 
on numeric variables in SLE patients. Plots depict the variables that were significantly 
affected by azathioprine treatment. 
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Table 4.8. Summary of coefficients, R2 values, standard error and F-test values of numeric variables that were significantly affected by azathioprine treatment 
in SLE patients. *** denotes p<0.01. 
 
 CD56dimCD16+ NK 
cells 106/ml 
y 
CD56dimCD16+ NK 
cells as % live cells 
y 
Total NK cells 
106/ml 
y 
Total NK cells as % 
live cells 
y 
Transitional B cells 
as % live cells 
y 
Transitional B cells 
as % total B cells 
y 
AZA -0.157*** 
(0.042) 
-0.710*** 
(0.127) 
-0.184*** 
(0.045) 
-0.727*** 
(0.122) 
-0.369*** 
(0.087) 
-1.044*** 
(0.187) 
No AZA 0.257*** 
(0.020) 
1.558*** 
(0.060) 
0.305*** 
(0.022) 
1.733*** 
(0.058) 
0.430*** 
(0.042) 
1.637*** 
(0.089) 
Observations 133 136 133 136 136 136 
R2 0.095 0.190 0.115 0.208 0.117 0.189 
Adjusted R2 0.088 0.184 0.108 0.202 0.111 0.183 
Residual Std. Error 0.207 
(df = 131) 
0.619 
(df = 134) 
0.217 
(df = 131) 
0.599 
(df = 134) 
0.428 
(df = 134) 
0.914 
(df = 134) 
F Statistic 13.739*** 
(df = 1; 131) 
31.490*** 
(df = 1; 134) 
16.955*** 
(df = 1; 131) 
35.263*** 
(df = 1; 134) 
17.833*** 
(df = 1; 134) 
31.245*** 
(df = 1; 134) 
 
AZA – azathioprine. 
 
Figure 4.33. A linear model was fitted to determine the effect of prednisone (PRED) 
treatment on numeric variables in SLE patients. The plot depicts the effect of prednisone on 
neutrophil count, the only variable significantly affected by prednisone treatment. 
 
 
 
Figure 4.34. A linear model was fitted to determine the effect of mycophenolate (MMF) 
treatment on numeric variables in SLE patients. The plot depicts the effect of mycophenolate 
on C4 levels, the only variable significantly affected by mycophenolate treatment. 
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Table 4.9. Summary of coefficients, R2 values, standard error and F-test values of the effect 
of prednisone on neutrophil count in SLE patients. *** denotes p<0.01. 
 
 Neutrophil count 
y 
PRED 0.264*** 
(0.067) 
No PRED 1.489*** 
(0.056) 
Observations 121 
R2 0.116 
Adjusted R2 0.108 
Residual Std. Error 0.333 
(df = 119) 
F Statistic 15.574*** 
(df = 1; 119) 
 
PRED – prednisone. 
 
 
Table 4.10. Summary of coefficients, R2 values, standard error and F-test values of the effect 
of mycophenolate on C4 levels in SLE patients. *** denotes p<0.01. 
 
 C4 
y 
MMF 0.090*** 
(0.024) 
No MMF 0.143*** 
(0.008) 
Observations 116 
R2 0.109 
Adjusted R2 0.101 
Residual Std. Error 0.085 
(df = 114) 
F Statistic 13.899*** 
(df = 1; 114) 
 
MMF – mycophenolate. 
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4.5.4  Slightly Higher Proportion of Switched Memory B cells and Significantly Lower 
Proportion of Transitional B cells in SLE Patients Treated with Both Azathioprine and 
Prednisone 
A linear model was fitted to determine the effect of various combinations of medications on 
the numeric variables we have measured in SLE patients, as described in 2.6.2.6 Methods 
Used for Data Analysis. As shown in Figure 4.35 and Table 4.11, SLE patients treated with 
azathioprine alone had a significantly increased proportion of switched memory B cells 
(p<0.01) and patients treated with prednisone alone had a slightly increased proportion of 
switched memory B cells but this increase was not significant. There was a significant 
interaction effect between treatment with azathioprine and treatment with prednisone 
(p<0.01), therefore patients treated with both medications had only a slightly higher 
proportion of switched memory B cells compared to patients who were not administered 
these two medications. The significant increase of switched memory B cells that was seen in 
patients treated with azathioprine only was not seen in patients treated with both azathioprine 
and prednisone. SLE patients treated with either azathioprine alone or prednisone alone had a 
significantly lower proportion of transitional B cells (azathioprine p<0.01, prednisone 
p<0.05). There was a significant interaction effect between treatment with azathioprine and 
treatment with prednisone (p<0.1), therefore patients treated with both medications had a 
smaller reduction in the proportion of transitional B cells than patients treated with 
azathioprine alone, but overall patients treated with azathioprine and prednisone had lower a 
proportion of transitional B cells than patients not treated with these two medications. 
 
 
Figure 4.35. A linear model was fitted to determine the effect of treatment with azathioprine 
(AZA) and prednisone (PRED) on numeric variables in SLE patients. Plots depict the 
variables that were significantly affected by treatment with azathioprine and prednisone. 
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Table 4.11. Summary of coefficients, R2 values, standard error and F-test values of numeric 
variables that were significantly affected by treatment with azathioprine and prednisone in 
SLE patients. * denotes p<0.1, ** denotes p<0.05 and *** denotes p<0.01. 
 
 Switched memory B 
cells as % total B 
cells 
y 
Transitional B cells 
as % total B cells 
y 
AZA only 1.030*** 
(0.287) 
-1.608*** 
(0.399) 
PRED only 0.030 
(0.135) 
-0.421** 
(0.188) 
AZA and PRED -1.151*** 
(0.324) 
0.767* 
(0.451) 
No AZA or PRED 2.700*** 
(0.111) 
1.922*** 
(0.155) 
Observations 136 136 
R2 0.103 0.223 
Adjusted R2 0.083 0.205 
Residual Std. Error 0.648 
(df = 132) 
0.901 
(df = 132) 
F Statistic 5.060*** 
(df = 3; 132) 
12.618*** 
(df = 3; 132) 
 
AZA – azathioprine; PRED – prednisone. 
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Other combinations of medications were also considered – azathioprine and mycophenolate, 
azathioprine and hydroxycholoroquine, prednisone and mycophenolate, prednisone and 
hydroxychloroquine, and hydroxychloroquine and mycophenolate. However there were few 
patients treated with these combinations of medications, therefore a reliable analysis on the 
effects of these pairs of medications on the variables we have measured in SLE patients could 
not be performed. 
 
4.5.5  Significantly Lower Number and Frequency of Total NK cells, CD56dimCD16+ NK 
cells and Transitional B cells in Both Active SLE and Inactive SLE Patients Treated 
with Azathioprine 
A linear model was fitted to compare the effects of medications on the numeric variables we 
have measured in patients with active SLE versus those with inactive SLE, as described in 
2.6.2.6 Methods Used for Data Analysis. As shown in Figure 4.36 and Table 4.12, active 
SLE patients had significantly lower frequencies of total NK cells (p<0.05) and 
CD56dimCD16+ NK cells (p<0.05) expressed as a percentage of live cells than inactive SLE 
patients, but absolute numbers of total NK cells were similar between active and inactive 
SLE patients. Inactive SLE patients treated with azathioprine had significantly lower 
frequencies of total NK cells (p<0.01) and CD56dimCD16+ NK cells (p<0.01) and absolute 
number of total NK cells (p<0.01) than patients not treated with azathioprine. When 
analysing the effect of azathioprine on the frequency of NK cells and subsets, we found a 
significant interaction effect between treatment with azathioprine and disease activity 
(p<0.1). Therefore the frequency of total NK cells and CD56dimCD16+ NK cells were 
reduced to a lesser extent in active SLE patients treated with azathioprine compared to 
 
 
Figure 4.36. A linear model was fitted to determine the effect of treatment with azathioprine 
(AZA) on numeric variables in active and inactive SLE patients. Plots depict the variables that 
were significantly affected by treatment with azathioprine. 
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Table 4.12. Summary of coefficients, R2 values, standard error and F-test values of numeric variables that were significantly affected by azathioprine 
treatment in active and inactive SLE patients. * denotes p<0.1, ** denotes p<0.05 and *** denotes p<0.01. 
 
 Total NK cells 
106/ml 
y 
CD56dimCD16+ NK 
cells as % live cells 
y 
Total NK cells as % 
live cells 
y 
Transitional B cells 
106/ml 
y 
Transitional B cells 
as % live cells 
y 
Transitional B cells 
as % total B cells 
y 
AZA, inactive SLE -0.218*** 
(0.062) 
-0.901*** 
(0.175) 
-0.926*** 
(0.169) 
-0.023* 
(0.013) 
-0.312** 
(0.120) 
-1.104*** 
(0.262) 
No AZA, active SLE -0.074 
(0.045) 
-0.263** 
(0.124) 
-0.256** 
(0.120) 
0.028*** 
(0.009) 
0.209** 
(0.086) 
0.168 
(0.186) 
AZA, active SLE 0.090 
(0.090) 
0.447* 
(0.253) 
0.462* 
(0.244) 
-0.025 
(0.018) 
-0.173 
(0.174) 
0.065 
(0.378) 
No AZA, inactive 
SLE 
0.331*** 
(0.027) 
1.653*** 
(0.075) 
1.837*** 
(0.072) 
0.026*** 
(0.005) 
0.355*** 
(0.052) 
1.577*** 
(0.112) 
Observations 133 136 136 133 136 136 
R2 0.133 0.221 0.240 0.143 0.156 0.197 
Adjusted R2 0.113 0.203 0.223 0.123 0.137 0.179 
Residual Std. Error 0.217 
(df = 129) 
0.612 
(df = 132) 
0.591 
(df = 132) 
0.044 
(df = 129) 
0.422 
(df = 132) 
0.916 
(df = 132) 
F Statistic 6.610*** 
(df = 3; 129) 
12.471*** 
(df = 3; 132) 
13.891*** 
(df = 3; 132) 
7.159*** 
(df = 3; 129) 
8.133*** 
(df = 3; 132) 
10.802*** 
(df = 3; 132) 
 
AZA – azathioprine. 
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inactive SLE patients treated with azathioprine. When analysing the effect of azathioprine on 
the absolute number of NK cells, we did not find a significant interaction effect between 
treatment with azathiopine and disease activity, therefore the absolute numbers of NK cells 
were reduced at similar levels in both active and inactive SLE patients who were treated with 
azathioprine. Patients with active SLE had a significantly higher absolute number (p<0.01) 
and frequency as a percentage of live cells (p<0.05) of transitional B cells than patients with 
inactive SLE, but there was no significant difference in the frequency of transitional B cells 
expressed as a percentage of total B cells between active SLE and inactive SLE. Inactive 
SLE patients treated with azathioprine had a significantly lower absolute number (p<0.1) and 
frequency of transitional B cells expressed as a percentage of live cells (p<0.05) and as a 
percentage of total B cells (p<0.01) than patients not treated with azathioprine. There was no 
significant interaction effect between treatment with azathioprine and disease activity, 
therefore active SLE patients treated with azathioprine had the same levels of reduction in 
transitional B cells compared to patients with inactive SLE treated with azathioprine.  
 
4.5.6  Increased Anti-dsDNA Antibody Levels But Decreased Haemoglobin Levels and 
Frequency of CXCR5+PD-1+ and CXCR3+ CXCR5+PD-1+ Tfh Cells in Active and 
Inactive SLE Patients Treated with Prednisone 
As shown in Figure 4.37 and Table 4.13, active SLE patients had lower levels of anti-dsDNA 
antibody than inactive SLE patients but the difference was not significant. Interestingly, 
inactive SLE patients treated with prednisone had slightly higher levels of anti-dsDNA 
antibody than patients not treated with prednisone, but the increase did not reach statistical 
significance. When analysing the effect of prednisone on anti-dsDNA antibody levels in 
 
 
Figure 4.37. A linear model was fitted to determine the effect of treatment with prednisone 
(PRED) on numeric variables in active and inactive SLE patients. Plots depict the variables 
that were significantly affected by treatment with prednisone. 
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Table 4.13. Summary of coefficients, R2 values, standard error and F-test values of numeric variables that were significantly affected by prednisone treatment 
in active and inactive SLE patients. * denotes p<0.1, ** denotes p<0.05 and *** denotes p<0.01. 
 
 Anti-dsDNA 
y 
Haemaglobin 
y 
CXCR5+ PD-1+ Tfh 
cells as % live cells 
y 
CXCR3+ CXCR5+ 
PD-1+ Tfh cells as 
% total CD4+ T cells 
y 
CXCR5+ PD-1+ Tfh 
cells as % total 
CD4+ T cells 
y 
Total B cells as % 
live cells 
y 
PRED, inactive SLE 0.419 
(0.393) 
-0.035 
(0.024) 
-0.146 
(0.096) 
-0.134 
(0.122) 
-0.124 
(0.143) 
-0.578*** 
(0.143) 
No PRED, active 
SLE 
-0.371 
(0.463) 
-0.005 
(0.029) 
0.049 
(0.118) 
0.120 
(0.153) 
0.183 
(0.176) 
-0.315* 
(0.179) 
PRED, active SLE 1.393** 
(0.580) 
-0.076** 
(0.034) 
-0.263* 
(0.141) 
-0.403** 
(0.183) 
-0.531** 
(0.212) 
0.728*** 
(0.216) 
No PRED, inactive 
SLE 
1.167*** 
(0.317) 
2.672*** 
(0.021) 
0.787*** 
(0.083) 
0.952*** 
(0.107) 
1.644*** 
(0.125) 
2.489*** 
(0.124) 
Observations 89 121 132 127 132 136 
R2 0.207 0.218 0.136 0.135 0.139 0.141 
Adjusted R2 0.179 0.198 0.116 0.114 0.119 0.122 
Residual Std. Error 1.308 
(df = 85) 
0.085 
(df = 117) 
0.364 
(df = 128) 
0.454 
(df = 123) 
0.544 
(df = 128) 
0.567 
(df = 132) 
F Statistic 7.398*** 
(df = 3; 85) 
10.869*** 
(df = 3; 117) 
6.723*** 
(df = 3; 128) 
6.381*** 
(df = 3; 123) 
6.876*** 
(df = 3; 128) 
7.233*** 
(df = 3; 132) 
 
PRED – prednisone. 
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active and inactive SLE patients, we found a significant interaction effect between treatment 
with prednisone and disease activity (p<0.05). Active SLE patients treated with prednisone 
had a greater increase in anti-dsDNA antibody level than inactive SLE patients treated with 
prednisone, and much higher levels of anti-dsDNA antibody than active and inactive SLE 
patients not on prednisone treatment. Active and inactive SLE patients had similar levels of 
haemoglobin. Inactive SLE patients treated with prednisone had lower levels of haemoglobin 
than patients not treated with prednisone, but the difference was not statistically significant. 
When analysing the effect of prednisone on anti-dsDNA antibody in active and inactive SLE 
patients, we found a significant interaction effect between prednisone treatment and disease 
activity (p<0.05). Active SLE patients treated with prednisone had an even greater reduction 
in haemoglobin levels compared to inactive SLE patients treated with prednisone. 
 
As shown in Figure 4.37 and Table 4.13, frequency expressed as a percentage of live cells of 
CXCR5+PD-1+ Tfh cells and frequency expressed as a percentage of total CD4+ T cells of 
CXCR5+PD-1+ and CXCR3+ CXCR5+PD-1+ Tfh cells were similar between active and 
inactive SLE patients. Inactive SLE patients treated with prednisone had lower percentages 
of CXCR5+PD-1+ and CXCR3+ CXCR5+PD-1+ Tfh cells, but the differences did not reach 
statistical significance. There was a significant interaction effect between prednisone 
treatment and disease activity (frequency as percentage of live cells of CXCR5+PD-1+ Tfh 
cells, p<0.1, frequency expressed as a percentage of total CD4+ T cells of CXCR5+PD-1+ and 
CXCR3+ CXCR5+PD-1+ Tfh cells, both p<0.05), resulting in a greater level of reduction in 
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the frequencies of CXCR5+PD-1+ and CXCR3+ CXCR5+PD-1+ Tfh cells in active SLE 
patients treated with prednisone than in inactive SLE patients treated with prednisone. 
 
4.5.7  Increased Frequency of B cells in Active SLE Patients Treated with Prednisone 
but Reduced Frequency of B cells in Inactive SLE Patients Treated with Prednisone 
As shown in Figure 4.37 and Table 4.13, active SLE patients had a significantly lower 
frequency of total B cells expressed as a percentage of live cells than inactive SLE patients 
(p<0.1). Inactive SLE patients treated with prednisone had a significantly lower frequency of 
total B cells (p<0.01). There was a significant interaction effect between treatment with 
prednisone and disease activity (p<0.01), resulting in a higher frequency of total B cells in 
active SLE patients treated with prednisone compared to inactive SLE patients treated with 
prednisone, and also compared to active SLE patients not on prednisone treatment. 
 
A reliable analysis to compare the effects of mycophenolate or hydroxychloroquine on the 
variables we have measured in active SLE and inactive SLE could not be performed due to 
an imbalance in the number of patients in each class (i.e. active SLE and inactive SLE) 
treated with these two medications. 
 
4.6  Development of Models for the Immune Profiling of SLE 
4.6.1  Low Levels of Within Sample Variance for Variables Measured by Flow 
Cytometry 
The sample-to-sample (or between sample) variance and within sample variance of the four 
samples obtained from the single healthy subject were calculated for each of the variables 
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measured by flow cytometry, as shown in Table 4.14. The sample-to-sample variance 
differed greatly between different variables, e.g. the frequency of atypical memory B cells 
expressed as a percentage of total B cells had a SD of 0.352, whereas the frequency of naïve 
B cells expressed as a percentage of total B cells had a SD of 4.398. The majority of the 
variables we measured had a low within sample variance (< 2 SD). 
 
4.6.2  Samples from SLE Patients and Healthy Controls Could Be Partially Separated 
by Principal Component Analysis 
PCA was performed on the complete data set after data cleaning and imputation. The first 12 
principal components explain 77.10% of the variance exhibited by the data, and the 
percentage of variance of each of the first 12 principal components is summarised on Table 
4.15. The variables and the largest coefficients used for the first two principal components 
are summarised on Table 4.16. Most of the variables were percentages of CD16+ monocytes 
and CXCR5+ populations, but also include transitional and atypical memory B cells, NK cells 
and CD45RO+ cells and measurements such as CRP, anti-dsDNA levels and ESR. PCA 
could partially separate samples from SLE patients and those from healthy controls (Figure 
4.38 (A)), but was unable to separate active SLE, inactive SLE, disease control and healthy 
control samples (B) or inactive, mildly, moderately or severely active SLE samples (C). PCA 
was also performed on data from samples from SLE patients only but could not separate 
samples from patients with musculoskeletal (Figure 4.39 (A)), neurologic (B), cutaneous (C) 
or renal symptoms (D) from those of patients who did not have these symptoms. 
 
Table 4.14. Measurement error calculated for white cell count and variables measured by 
flow cytometry. 
 
Variable Between sample 
SD 
Within sample 
SD 
White cell count ^ 5.741 0.000 
Total B cells as % live cells 0.998 0.370 
Total B cells 106/ml 0.069 0.034 
Switched memory B cells as % total B cells 1.931 0.898 
Switched memory B cells as % live cells 0.043 0.099 
Switched memory B cells 106/ml 0.000 0.009 
MZ/non-switched memory B cells as % total B cells 2.649 1.286 
MZ/non-switched memory B cells as % live cells 0.106 0.133 
MZ/non-switched memory B cells 106/ml 0.005 0.012 
Atypical memory B cells as % total B cells 0.352 0.581 
Atypical memory B cells as % live cells 0.000 0.049 
Atypical memory B cells 106/ml 0.001 0.005 
Naïve B cells as % total B cells 4.398 1.231 
Naïve B cells as % live cells 0.877 0.187 
Naïve B cells 106/ml 0.068 0.017 
Transitional B cells as % total B cells 0.961 0.756 
Transitional B cells as % live cells 0.100 0.057 
Transitional B cells 106/ml 0.009 0.005 
Total monocytes as % live cells 2.075 1.009 
Total monocytes 106/ml 0.154 0.094 
CD14+CD16- monocytes as % total monocytes 1.193 1.437 
CD14+CD16- monocytes as % live cells 2.126 0.943 
CD14+CD16- monocytes 106/ml 0.158 0.088 
CD16+ monocytes as % total monocytes 1.193 1.437 
CD16+ monocytes as % live cells 0.121 0.247 
CD16+ monocytes 106/ml 0.015 0.024 
CD14dim monocytes as % total monocytes 1.175 1.204 
CD14dim monocytes as % live cells 0.137 0.206 
CD14dim monocytes 106/ml 0.016 0.020 
Total NK cells as % live cells 0.715 0.245 
Total NK cells 106/ml 0.058 0.023 
CD56briCD16- NK cells as % total NK cells 1.421 0.680 
CD56briCD16- NK cells as % live cells 0.101 0.041 
CD56briCD16- NK cells 106/ml 0.010 0.004 
CD56dimCD16+ NK cells as % total NK cells 1.110 1.028 
CD56dimCD16+ NK cells as % live cells 0.708 0.258 
CD56dimCD16+ NK cells 106/ml 0.058 0.024 
CD56-CD16+ NK cells as % total NK cells 0.247 0.470 
CD56-CD16+ NK cells as % live cells 0.024 0.032 
CD56-CD16+ NK cells 106/ml 0.002 0.003 
Total CD4+ T cells as % live cells 1.745 1.090 
Total CD4+ T cells 106/ml 0.301 0.105 
CXCR5+CD4+ T cells as % total CD4+ T cells 1.625 0.507 
CXCR5+CD4+ T cells as % live cells 0.064 1.556 
CXCR5+CD4+ T cells 106/ml 0.051 0.149 
CD45RO+CD4+ T cells as % total CD4+ T cells 8.841 1.811 
CD45RO+CD4+ T cells as % live cells 3.575 0.403 
CD45RO+CD4+ T cells 106/ml 0.380 0.038 
CD45RO-CD4+ T cells as % total CD4+ T cells 8.857 1.791 
CD45RO-CD4+ T cells as % live cells 1.749 1.067 
CD45RO-CD4+ T cells 106/ml 0.104 0.103 
Tregs as % total CD4+ T cells 0.234 0.385 
Tregs as % live cells 0.136 0.164 
Tregs 106/ml 0.025 0.015 
CD45RO+ Tregs as % CD45RO+ CD4+ T cells 3.314 0.661 
CD45RO+ Tregs as % total Tregs 3.324 2.918 
CD45RO+ Tregs as % total CD4+ T cells 0.380 0.343 
CD45RO+ Tregs as % live cells 0.190 0.112 
CD45RO+ Tregs 106/ml 0.025 0.010 
CD45RO- Tregs as % total Tregs 3.302 2.935 
CD45RO- Tregs as % total CD4+ T cells 0.279 0.312 
CD45RO- Tregs as % live cells 0.039 0.116 
CD45RO- Tregs 106/ml 0.000 0.011 
CXCR3+ CXCR5+PD-1+ Tfh as % total CD4+ T cells 1.057 0.151 
CXCR3+ CXCR5+PD-1+ Tfh as % live cells 0.378 0.064 
CXCR3+ CXCR5+PD-1+ Tfh 106/ml 0.037 0.006 
CXCR3- CXCR5+PD-1+ Tfh as % total CD4+ T cells 0.408 0.157 
CXCR3- CXCR5+PD-1+ Tfh as % live cells 0.164 0.057 
CXCR3- CXCR5+PD-1+ Tfh 106/ml 0.018 0.005 
CXCR5+PD-1+ Tfh as % total CD4+ T cells 1.581 0.323 
CXCR5+PD-1+ Tfh as % live cells 0.591 0.132 
CXCR5+PD-1+ Tfh 106/ml 0.060 0.013 
CXCR3+ CXCR5+PD-1+ Tfh as % CXCR5+PD-1+ Tfh 6.751 2.011 
CXCR3- CXCR5+PD-1+ Tfh as % CXCR5+PD-1+ Tfh 4.217 1.509 
 
^ measured by the Sysmex automated haematology analyser at Centenary Institute prior to 
PBMC isolation by density centrifugation 
Table 4.15. Summary of the percentage of the variance explained by each of the first 12 
principal components. 
 
Principal component Eigenvalue Percent of variability explained Cumulative sum 
1 16.01 17.00 17.00 
2 10.22 10.90 27.90 
3 8.15 8.70 36.60 
4 6.92 7.40 43.90 
5 6.14 6.50 50.50 
6 5.37 5.70 56.20 
7 4.56 4.90 61.00 
8 3.98 4.20 65.30 
9 3.55 3.80 69.00 
10 2.93 3.10 72.20 
11 2.48 2.60 74.80 
12 2.21 2.30 77.10 
 
 
Table 4.16. Summary of the largest coefficients used for the first two principal components. 
 
Variable Component 1 Component 2 
Atypical memory B cells as % total B cells 0.10  
Transitional B cells as % total B cells  0.12 
Transitional B cells as % live cells  0.15 
CD16+ monocytes as % total monocytes  0.18 
CD16+ monocytes as % live cells  0.10 
CD14dim monocytes as % total monocytes  0.16 
CD14dim monocytes as % live cells  0.10 
Total NK cells as % live cells  0.11 
CD56-CD16+ NK cells as % live cells  0.14 
CXCR5+ CD4+ T cells as % total CD4+ T cells -0.17 0.15 
CXCR5+ CD4+ T cells as % live cells -0.21 0.10 
CD45RO+ CD4+ T cells as % total CD4+ T cells  0.13 
CD45RO+ Tregs as % Tregs  0.10 
CXCR3+ CXCR5+PD-1+ Tfh as % total CD4+ T cells -0.16 0.20 
CXCR3+ CXCR5+PD-1+ Tfh as % live cells -0.20 0.15 
CXCR3- CXCR5+PD-1+ Tfh as % total CD4+ T cells -0.12 0.16 
CXCR3- CXCR5+PD-1+ Tfh as % live cells -0.19 0.13 
CXCR5+PD-1+ Tfh as % total CD4+ T cells -0.15 0.18 
CXCR5+PD-1+ Tfh as % live cells -0.21 0.14 
CXCR3- CXCR5+PD-1+ Tfh as % CXCR5+PD-1+ Tfh 0.10  
C-reactive protein 0.10  
Anti-dsDNA antibody 0.10  
ESR 0.11  
 
 
 
Figure 4.38. Principal component analysis was performed on the entire data set after 
cleaning and imputation. (A) Plot depicting the first two principal components against the 
response types SLE and healthy (i.e. no SLE). (B) Plot depicting the first two principal 
components against the response types active SLE, inactive SLE, disease control (i.e. other 
autoimmune conditions) and healthy (i.e. no SLE). (C) Plot depicting the first two principal 
components against the response types inactive, mild, moderate and severe SLE. 
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Figure 4.39. Principal component analysis was performed data from SLE samples after 
cleaning and imputation. (A) Plot depicting the first two principal components against the 
response types musculoskeletal and no musculoskeletal involvement. (B) Plot depicting the 
first two principal components against the response types neurologic and no neurologic 
involvement. (C) Plot depicting the first two principal components against the response types 
cutaneous and no cutaneous involvement. (D) Plot depicting the first two principal 
components against the response types renal and no renal involvement. 
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4.6.3  Levels of NK cells, CD45RO+ CD4+ T cells, Tfh Subsets, Complement, 
Haemoglobin and Red Cell Count were Significantly Associated with SLEDAI Scores 
A complete case analysis was used to measure the associations between SLEDAI scores and 
numeric variables measured in our study. Samples from SLE patients from all time points 
were included in this analysis. Several approaches were considered when calculating the 
associations between the 94 numeric variables and SLEDAI based on different 
transformations of the data – classical, linear, exponential and regression. The false discovery 
rate adjusted p-values for these associations are listed on Table 4.17. The variables that were 
significantly associated with SLEDAI were absolute number of NK cells, absolute number 
and frequency as a percentage of live cells of CD56dimCD16+ NK cells, absolute number of 
CD45RO+ CD4+ T cells, absolute number of CXCR5+PD-1+, CXCR3+ CXCR5+PD-1+ and 
CXCR3- CXCR5+PD-1+ Tfh cells, C3 and C4 levels, haemoglobin and red cell count. All of 
these variables were inversely associated with SLEDAI, as illustrated in Figure 4.40. 
 
When the same analysis was conducted with only the first sample from each SLE patient, 
there were fewer variables that were significantly associated with SLEDAI – frequency as a 
percentage of total CD4+ cells of CD45RO+ CD4+ T cells, CXCR5+PD-1+ and CXCR3- 
CXCR5+PD-1+ Tfh cells and C3 and C4 levels. Frequency and number of NK cells were no 
longer associated with SLEDAI when only the samples from the first time point were 
analysed. The false discovery rate adjusted p-values for these associations are listed on Table 
4.18. All of these variables were inversely associated with SLEDAI, as shown in Figure 4.41. 
 
Table 4.17. Adjusted p-values for associations between SLEDAI and numeric variables of 
samples from SLE patients from all time points, where p<0.1 is considered to be significant (in 
bold). 
 
Variable Classical Linear Exponential Regression 
Age at time of sample collection 0.3937 0.3974 0.3938 0.7504 
Age at onset of disease 0.8604 0.8854 0.8571 0.9683 
Duration of disease 0.9028 0.9206 0.8928 0.9839 
BAFF 0.8315 0.811 0.8039 0.9839 
White cell count ^ 0.5795 0.5252 0.5548 0.6045 
Total B cells as % live cells 0.3987 0.3974 0.4173 0.3088 
Total B cells 106/ml 0.7028 0.7285 0.7605 0.5899 
Plasmablasts/plasma cells as % live cells 0.1875 0.1933 0.1583 0.4429 
Plasmablasts/plasma cells 106/ml 0.2219 0.2151 0.2091 0.8124 
Switched memory B cells as % total B 
cells 0.3987 0.413 0.3912 0.4121 
Switched memory B cells as % live cells 0.799 0.8048 0.8431 0.9839 
Switched memory B cells 106/ml 0.6006 0.5762 0.6222 0.5249 
MZ/non-switched memory B cells as % 
total B cells 0.2318 0.2819 0.2284 0.3471 
MZ/non-switched memory B cells as % 
live cells 0.8315 0.8536 0.8571 0.9839 
MZ/non-switched memory B cells 106/ml 0.7028 0.6955 0.6804 0.9839 
Atypical memory B cells as % total B cells 0.7578 0.7632 0.7605 0.5643 
Atypical memory B cells as % live cells 0.2318 0.2151 0.2485 0.1175 
Atypical memory B cells 106/ml 0.5643 0.6097 0.5548 0.4852 
Naïve B cells as % total B cells 0.7545 0.7632 0.7604 0.5643 
Naïve B cells as % live cells 0.8604 0.8536 0.8494 0.7504 
Naïve B cells 106/ml 0.9347 0.9206 0.9073 0.6338 
Transitional B cells as % total B cells 0.799 0.7632 0.7605 0.6045 
Transitional B cells as % live cells 0.5636 0.5762 0.5788 0.1175 
Transitional B cells 106/ml 0.6184 0.5762 0.5548 0.1175 
Total monocytes as % live cells 0.2318 0.2151 0.2091 0.1175 
Total monocytes 106/ml 0.2458 0.2627 0.2792 0.4852 
CD14+CD16- monocytes as % total 
monocytes 0.7545 0.7632 0.7605 0.8344 
CD14+CD16- monocytes as % live cells 0.1875 0.2151 0.2091 0.1175 
CD14+CD16- monocytes 106/ml 0.2578 0.3248 0.3188 0.5273 
CD16+ monocytes as % total monocytes 0.7545 0.7632 0.7605 0.9839 
CD16+ monocytes as % live cells 0.1871 0.2029 0.1973 0.3362 
CD16+ monocytes 106/ml 0.1798 0.1713 0.1583 0.543 
CD14dim monocytes as % total monocytes 0.1871 0.2151 0.2091 0.4852 
CD14dim monocytes as % live cells 0.1543 0.1544 0.1539 0.5249 
CD14dim monocytes 106/ml 0.1729 0.1571 0.1583 0.6045 
Total NK cells as % live cells 0.1729 0.1711 0.1583 0.1106 
Total NK cells 106/ml 0.1277 0.1372 0.1391 0.0712 
CD56briCD16- NK cells as % total NK cells 0.1277 0.1372 0.136 0.103 
CD56briCD16- NK cells as % live cells 0.9614 0.9206 0.9073 0.9839 
CD56briCD16- NK cells 106/ml 0.9614 0.8536 0.8571 0.8987 
CD56dimCD16+ NK cells as % total NK 
cells 0.1277 0.1361 0.136 0.1175 
CD56dimCD16+ NK cells as % live cells 0.1277 0.1361 0.136 0.0712 
CD56dimCD16+ NK cells 106/ml 0.1211 0.1361 0.0919 0.0524 
CD56-CD16+ NK cells as % total NK cells 0.1584 0.1711 0.1583 0.1175 
CD56-CD16+ NK cells as % live cells 0.8604 0.8536 0.8494 0.9839 
CD56-CD16+ NK cells 106/ml 0.9925 0.9675 0.9578 0.542 
Total CD4+ T cells as % live cells 0.8315 0.8536 0.8441 0.6045 
Total CD4+ T cells 106/ml 0.3987 0.4364 0.4293 0.5743 
CXCR5+ CD4+ T cells as % total CD4+ T 
cells 0.165 0.1544 0.1583 0.1175 
CXCR5+ CD4+ T cells as % live cells 0.2678 0.3126 0.2853 0.3362 
CXCR5+ CD4+ T cells 106/ml 0.1543 0.1571 0.1583 0.1175 
CD45RO+ CD4+ T cells as % total CD4+ T 
cells 0.1543 0.1713 0.1697 0.1106 
CD45RO+ CD4+ T cells as % live cells 0.1277 0.1372 0.136 0.1106 
CD45RO+ CD4+ T cells 106/ml 0.0761 0.0714 0.0656 0.0712 
CD45RO- CD4+ T cells as % total CD4+ T 
cells 0.1543 0.1571 0.1583 0.1086 
CD45RO- CD4+ T cells as % live cells 0.8668 0.896 0.8571 0.7504 
CD45RO+ CD4+ T cells 106/ml 0.8274 0.8536 0.8431 0.8439 
Tregs as % total CD4+ T cells 0.5102 0.554 0.5548 0.5643 
Tregs as % live cells 0.2404 0.2903 0.2421 0.3362 
Tregs 106/ml 0.1876 0.2134 0.1697 0.1691 
CD45RO+ Tregs as % CD45RO+ CD4+ T 
cells 0.6698 0.7282 0.6804 0.7826 
CD45RO+ Tregs as % Tregs 0.236 0.2365 0.2421 0.3243 
CD45RO+ Tregs as % total CD4+ T cells 0.3322 0.3125 0.3892 0.4006 
CD45RO+ Tregs as % live cells 0.1277 0.1361 0.136 0.149 
CD45RO+ Tregs 106/ml 0.1349 0.1372 0.136 0.102 
CD45RO- Tregs as % Tregs 0.2219 0.2134 0.2091 0.3632 
CD45RO- Tregs as % total CD4+ T cells 0.7545 0.7959 0.7605 0.9237 
CD45RO- Tregs as % live cells 0.9925 0.9784 0.9578 0.9839 
CD45RO- Tregs 106/ml 0.8315 0.8536 0.8494 0.8124 
CXCR3+ CXCR5+PD-1+ Tfh as % total 
CD4+ T cells 0.1349 0.1372 0.136 0.1423 
CXCR3+ CXCR5+PD-1+ Tfh as % live cells 0.1794 0.1713 0.1639 0.2928 
CXCR3+ CXCR5+PD-1+ Tfh 106/ml 0.1277 0.1372 0.136 0.082 
CXCR3- CXCR5+PD-1+ Tfh as % total 
CD4+ T cells 0.1277 0.1361 0.136 0.1175 
CXCR3- CXCR5+PD-1+ Tfh as % live cells 0.1794 0.1713 0.1583 0.293 
CXCR3- CXCR5+PD-1+ Tfh 106/ml 0.1277 0.1372 0.136 0.0712 
CXCR5+PD-1+ Tfh as % total CD4+ T cells 0.1277 0.1361 0.1017 0.1086 
CXCR5+PD-1+ Tfh as % live cells 0.165 0.1768 0.1648 0.2086 
CXCR5+PD-1+ Tfh 106/ml 0.1543 0.1457 0.1391 0.0712 
CXCR3+ CXCR5+PD-1+ Tfh as % 
CXCR5+PD-1+ Tfh 0.3169 0.3123 0.2889 0.5643 
CXCR3- CXCR5+PD-1+ Tfh as % 
CXCR5+PD-1+ Tfh 0.7994 0.811 0.8039 0.7859 
Basophil count * 0.8604 0.7726 0.7821 0.9839 
C3 0.0002 0.0002 0.0002 0.0001 
C4 0.0316 0.0424 0.0356 0.0065 
C-reactive protein 0.8668 0.8536 0.8571 0.9839 
Anti-dsDNA 0.6377 0.629 0.6514 0.3293 
Eosinophil count * 0.1349 0.1457 0.136 0.2086 
ESR 0.3987 0.4566 0.4863 0.6045 
Haemoglobin * 0.0527 0.0555 0.0656 0.0712 
Lymphocyte count * 0.3419 0.3282 0.3714 0.4177 
Monocyte count * 0.3957 0.3974 0.4138 0.5249 
Neutrophil count * 0.6714 0.7235 0.7072 0.6194 
Platelets * 0.8315 0.8536 0.8571 0.4177 
Red cell count * 0.0316 0.0504 0.0656 0.0204 
White cell count * 0.9925 0.9323 0.9552 0.9395 
 
* measured as part of full blood count at the Department of Clinical Immunology, RPA 
Hospital 
 
^ measured by the Sysmex automated haematology analyser at Centenary Institute prior to 
PBMC isolation by density centrifugation 
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Figure 4.40. Associations were measured between SLEDAI and numeric variables of 
samples from SLE patients from all time points. Plots depict the associations between 
SLEDAI and variables that were significantly associated with SLEDAI. 
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Table 4.18. Adjusted p-values for associations between SLEDAI and numeric variables of 
samples from SLE patients from the first time point only, where p<0.1 is considered to be 
significant (in bold). 
 
Variable Classical Linear Exponential Regression 
Age at time of sample collection 0.6468 0.6825 0.6748 0.733 
Age at onset of SLE 0.7922 0.7631 0.8033 0.9259 
Duration of SLE 0.551 0.5777 0.5741 0.62 
BAFF 0.2606 0.2129 0.2579 0.4189 
White cell count ^ 0.9483 0.9492 0.9774 0.828 
Total B cells as % live cells 0.2925 0.2869 0.2919 0.1649 
Total B cells 106/ml 0.2577 0.2129 0.2579 0.1547 
Plasmablasts/plasma cells as % live cells 0.3403 0.3302 0.3261 0.3729 
Plasmablasts/plasma cells 106/ml 0.2925 0.3 0.2919 0.1547 
Switched memory B cells as % total B cells 0.2606 0.2869 0.2662 0.1641 
Switched memory B cells as % live cells 0.7234 0.7374 0.7845 0.9332 
Switched memory B cells 106/ml 0.7522 0.7952 0.7716 0.757 
MZ/non-switched memory B cells as % 
total B cells 0.4791 0.4869 0.4564 0.5253 
MZ/non-switched memory B cells as % live 
cells 0.9536 0.9697 0.9853 0.71 
MZ/non-switched memory B cells 106/ml 0.7592 0.8115 0.8403 0.5253 
Atypical memory B cells as % total B cells 0.7952 0.8115 0.8533 0.828 
Atypical memory B cells as % live cells 0.4791 0.497 0.4892 0.4189 
Atypical memory B cells 106/ml 0.5346 0.5969 0.5738 0.4843 
Naïve B cells as % total B cells 0.526 0.5306 0.5627 0.953 
Naïve B cells as % live cells 0.4896 0.5022 0.4892 0.4189 
Naïve B cells 106/ml 0.3403 0.3302 0.3238 0.1739 
Transitional B cells as % total B cells 0.7592 0.7069 0.7023 0.9799 
Transitional B cells as % live cells 0.4896 0.5022 0.4892 0.5679 
Transitional B cells 106/ml 0.4191 0.3111 0.3028 0.1952 
Total monocytes as % live cells 0.2606 0.2129 0.2503 0.1469 
Total monocytes 106/ml 0.4191 0.3845 0.366 0.4276 
CD14+CD16- monocytes as % total 
monocytes 0.5346 0.5916 0.5855 0.5253 
CD14+CD16- monocytes as % live cells 0.1908 0.2129 0.2256 0.1446 
CD14+CD16- monocytes 106/ml 0.3403 0.3624 0.3653 0.4189 
CD16+ monocytes as % total monocytes 0.5426 0.6129 0.5627 0.4712 
CD16+ monocytes as % live cells 0.5521 0.6129 0.5882 0.757 
CD16+ monocytes 106/ml 0.5521 0.6057 0.5892 0.9812 
CD14dim monocytes as % total monocytes 0.2606 0.2869 0.2919 0.3895 
CD14dim monocytes as % live cells 0.2925 0.2869 0.2889 0.4189 
CD14dim monocytes 106/ml 0.4191 0.3741 0.3877 0.6596 
Total NK cells as % live cells 0.2925 0.2869 0.3028 0.1638 
Total NK cells 106/ml 0.3081 0.3302 0.345 0.1547 
CD56briCD16- NK cells as % total NK cells 0.2606 0.2869 0.2889 0.1739 
CD56briCD16- NK cells as % live cells 0.7522 0.7952 0.8155 0.9089 
CD56briCD16- NK cells 106/ml 0.7938 0.8115 0.8403 0.9799 
CD56dimCD16+ NK cells as % total NK cells 0.2925 0.3111 0.2919 0.4158 
CD56dimCD16+ NK cells as % live cells 0.2925 0.2869 0.2889 0.1469 
CD56dimCD16+ NK cells 106/ml 0.2925 0.2869 0.2919 0.1446 
CD56-CD16+ NK cells as % total NK cells 0.7592 0.7631 0.8147 0.9012 
CD56-CD16+ NK cells as % live cells 0.5279 0.5022 0.4892 0.6604 
CD56-CD16+ NK cells 106/ml 0.849 0.8384 0.8583 0.5874 
Total CD4+ T cells as % live cells 0.3403 0.3624 0.3653 0.2318 
Total CD4+ T cells 106/ml 0.5279 0.5777 0.5738 0.5253 
CXCR5+ CD4+ T cells as % total CD4+ T 
cells 0.4191 0.446 0.3908 0.3895 
CXCR5+ CD4+ T cells as % live cells 1 0.9543 0.9987 0.9875 
CXCR5+ CD4+ T cells 106/ml 0.7522 0.7069 0.7423 0.5253 
CD45RO+ CD4+ T cells as % total CD4+ T 
cells 0.1295 0.175 0.1487 0.0872 
CD45RO+ CD4+ T cells as % live cells 0.6468 0.7069 0.7046 0.828 
CD45RO+ CD4+ T cells 106/ml 0.4979 0.5022 0.4892 0.4843 
CD45RO- CD4+ T cells as % total CD4+ T 
cells 0.1295 0.175 0.1602 0.1446 
CD45RO- CD4+ T cells as % live cells 0.1295 0.1494 0.1487 0.1283 
CD45RO+ CD4+ T cells 106/ml 0.2925 0.2869 0.2919 0.1952 
Tregs as % total CD4+ T cells 0.4374 0.4869 0.3692 0.5253 
Tregs as % live cells 0.7594 0.7631 0.7819 0.6604 
Tregs 106/ml 0.9536 0.9697 0.9711 0.9259 
CD45RO+ Tregs as % CD45RO+ CD4+ T 
cells 0.9083 0.8584 0.9021 0.8152 
CD45RO+ Tregs as % Tregs 0.1908 0.2129 0.2194 0.1547 
CD45RO+ Tregs as % total CD4+ T cells 0.2606 0.2869 0.2919 0.3134 
CD45RO+ Tregs as % live cells 0.8905 0.891 0.8583 0.9799 
CD45RO+ Tregs 106/ml 0.6395 0.6883 0.6821 0.6604 
CD45RO- Tregs as % Tregs 0.1908 0.2129 0.2503 0.1547 
CD45RO- Tregs as % total CD4+ T cells 0.5603 0.6129 0.6224 0.5253 
CD45RO- Tregs as % live cells 0.2925 0.3302 0.3028 0.1952 
CD45RO- Tregs 106/ml 0.5279 0.5022 0.5545 0.5253 
CXCR3+ CXCR5+PD-1+ Tfh as % total 
CD4+ T cells 0.1908 0.1888 0.1959 0.1446 
CXCR3+ CXCR5+PD-1+ Tfh as % live cells 0.4791 0.5022 0.4892 0.4261 
CXCR3+ CXCR5+PD-1+ Tfh 106/ml 0.3889 0.3553 0.3653 0.1547 
CXCR3- CXCR5+PD-1+ Tfh as % total CD4+ 
T cells 0.1295 0.1124 0.0953 0.0872 
CXCR3- CXCR5+PD-1+ Tfh as % live cells 0.4859 0.497 0.4773 0.4189 
CXCR3- CXCR5+PD-1+ Tfh 106/ml 0.4791 0.5022 0.4518 0.1649 
CXCR5+PD-1+ Tfh as % total CD4+ T cells 0.1295 0.1124 0.0953 0.0872 
CXCR5+PD-1+ Tfh as % live cells 0.4791 0.5022 0.4773 0.4717 
CXCR5+PD-1+ Tfh 106/ml 0.5186 0.5022 0.4892 0.1846 
CXCR3+ CXCR5+PD-1+ Tfh as % 
CXCR5+PD-1+ Tfh 0.4191 0.3624 0.3877 0.4189 
CXCR3- CXCR5+PD-1+ Tfh as % 
CXCR5+PD-1+ Tfh 0.7228 0.7069 0.7423 0.7521 
Basophil count * 0.6351 0.8115 0.8202 0.5253 
C3 0.1067 0.0586 0.0953 0.0665 
C4 0.1295 0.1759 0.1487 0.0665 
C-reactive protein 0.9522 0.902 0.9272 0.997 
Anti-dsDNA 0.5279 0.5777 0.5627 0.4189 
Eosinophil count * 0.4896 0.5022 0.4892 0.5253 
ESR 0.6395 0.686 0.7023 0.6591 
Haemoglobin * 0.4191 0.4732 0.4444 0.4326 
Lymphocyte count * 0.6351 0.6825 0.6677 0.8137 
Monocyte count * 0.5521 0.6507 0.6442 0.757 
Neutrophil count * 0.6351 0.704 0.6748 0.6591 
Platelets * 0.7522 0.7631 0.7886 0.4883 
Red cell count * 0.3403 0.3553 0.3653 0.2452 
White cell count * 0.7788 0.7952 0.8155 0.71 
 
* measured as part of full blood count at the Department of Clinical Immunology, RPA 
Hospital 
 
^ measured by the Sysmex automated haematology analyser at Centenary Institute prior to 
PBMC isolation by density centrifugation 
 
 
 
Figure 4.41. Associations were measured between SLEDAI and numeric variables of 
samples from SLE patients from the first time point only. Plots depict the associations 
between SLEDAI and variables that were significantly associated with SLEDAI. 
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4.6.4  Levels of Atypical Memory B cells, NK cells, CD45RO- CD4+ T cells and Tfh 
Subsets Could Significantly Discriminate Between SLE Patients and Healthy Subjects 
Logistic regression was used to measure the associations between the binary variable of the 
response types SLE and healthy (i.e. no SLE) and numeric variables measured in our study. 
Samples from SLE patients and healthy controls from all time points were included in this 
analysis. The adjusted p-values for these associations are listed on Table 4.19. Over half of 
the numeric variables were able to significantly discriminate between SLE patients and 
healthy controls, but the most significant of these variables (p<10-6) were frequency as a 
percentage of total B cells of atypical memory B cells, frequency as a percentage of live cells 
of total NK cells and CD56dimCD16+ NK cells, frequency as a percentage of total NK cells of 
CD56briCD16- NK cells, frequency as a percentage of live cells of CD4+ T cells, CD45RO- 
CD4+ T cells, CXCR5+ CD4+ T cells, CXCR5+PD-1+ Tfh cells and CXCR3+ CXCR5+PD-1+ 
Tfh cells, and frequency as a percentage of CXCR5+PD-1+ Tfh cells of CXCR3- CXCR5+PD-
1+ Tfh cells. These variables were all inversely associated with the probability of SLE except 
for the frequency of atypical memory B cells, CD56briCD16- NK cells and CXCR3- 
CXCR5+PD-1+ Tfh cells, as shown in Figure 4.42. 
 
When the same analysis was conducted with only the first sample from each SLE patient and 
healthy control, there were still many variables that could significantly discriminate between 
SLE patients and healthy controls, as indicated by the adjusted p-values listed on Table 4.20. 
The most significant of these variables (p<10-5) were frequency as a percentage of live cells 
of CD45RO- CD4+ T cells, CD45RO- Tregs, CXCR5+ CD4+ T cells, CXCR5+PD-1+ Tfh 
cells, CXCR3+ CXCR5+PD-1+ Tfh cells and frequency as a percentage of Tregs of CD45RO- 
Table 4.19. Adjusted p-values for associations between the response types of SLE and 
healthy (no SLE) and numeric variables of samples from all time points. Variables above the 
line in the table (p<0.05) are considered to be able to significantly discriminate between the 
two response types. 
 
Variable Logistic regression t-test 
CD56dimCD16+ NK cells as % live cells 1.91E-08 3.89E-16 
Total NK cells as % live cells 5.85E-08 3.23E-14 
CXCR5+PD-1+ Tfh cells as % live cells 8.44E-08 6.74E-14 
CD56briCD16- NK cells as % total NK cells 1.04E-07 1.11E-13 
CXCR3+ CXCR5+PD-1+ Tfh cells as % live cells 1.04E-07 1.48E-11 
CXCR5+ CD4+ T cells as % live cells 1.04E-07 3.23E-14 
CD45RO- CD4+ T cells as % live cells 1.18E-07 6.74E-14 
CXCR3- CXCR5+PD-1+ Tfh cells as % CXCR5+PD-1+ Tfh 
cells 2.43E-07 3.43E-12 
Atypical memory B cells as % total B cells 7.02E-07 1.98E-12 
Total CD4+ T cells as % live cells 7.02E-07 4.83E-13 
CD56dimCD16+ NK cells as % total NK cells 1.37E-06 5.81E-13 
CD56dimCD16+ NK cells 106/ml 3.61E-06 8.85E-09 
CD45RO- Tregs as % Tregs 9.13E-06 4.27E-09 
CD45RO- Tregs as % live cells 1.14E-05 4.11E-08 
CXCR5+ CD4+ T cells as % total CD4+ T cells 1.25E-05 1.09E-09 
CXCR3+ CXCR5+PD-1+ Tfh cells 106/ml 1.54E-05 3.57E-07 
Total NK cells 106/ml 1.77E-05 1.07E-07 
CXCR5+ CD4+ T cells 106/ml 1.77E-05 1.07E-07 
CXCR5+PD-1+ Tfh cells 106/ml 2.01E-05 3.27E-07 
CXCR3+ CXCR5+PD-1+ Tfh cells as % total CD4+ T cells 2.19E-05 9.19E-08 
CXCR3- CXCR5+PD-1+ Tfh cells as % live cells 2.63E-05 2.76E-07 
MZ memory B cells as % live cells 3.34E-05 1.04E-06 
CXCR3+ CXCR5+PD-1+ Tfh cells as % CXCR5+PD-1+ Tfh 
cells 3.97E-05 4.15E-06 
Atypical memory B cells as % live cells 4.57E-05 1.97E-08 
CD45RO+ Tregs as % Tregs 4.58E-05 2.95E-06 
Atypical memory B cells 106/ml 7.27E-05 1.07E-07 
CD45RO- CD4+ T cells 106/ml 1.08E-04 3.00E-06 
CD45RO+ Tregs as % total CD4+ T cells 1.10E-04 8.65E-07 
MZ memory B cells as % total B cells 1.10E-04 8.57E-06 
CXCR5+PD-1+ Tfh cells as % total CD4+ T cells 1.17E-04 5.49E-07 
CD45RO- CD4+ T cells as % total CD4+ T cells 5.68E-04 1.77E-05 
Total CD4+ T cells 106/ml 7.21E-04 2.59E-05 
CD45RO+ CD4+ T cells as % live cells 8.67E-04 2.12E-05 
CD16+ monocytes as % total monocytes 8.83E-04 1.44E-05 
MZ memory B cells 106/ml 1.36E-03 6.85E-04 
Tregs as % live cells 2.15E-03 6.19E-05 
CD14+CD16- monocytes 106/ml 2.21E-03 1.62E-04 
CD56-CD16+ NK cells as % total NK cells 2.68E-03 2.46E-04 
Total monocytes 106/ml 3.52E-03 3.55E-04 
CD45RO+ CD4+ T cells as % total CD4+ T cells 7.37E-03 1.61E-03 
Tregs as % total CD4+ T cells 8.29E-03 8.95E-04 
CXCR3- CXCR5+PD-1+ Tfh cells 106/ml 8.90E-03 2.15E-03 
Plasmablasts/plasma cells as % live cells 1.78E-02 5.02E-04 
CD45RO- Tregs 106/ml 2.71E-02 8.45E-03 
CD14+CD16- monocytes as % live cells 2.71E-02 7.08E-03 
Plasmablasts/plasma cells 106/ml 3.43E-02 1.50E-03 
Total monocytes as % live cells 4.87E-02 1.52E-02 
CD45RO+ Tregs as % CD45RO+ CD4+ T cells 6.49E-02 2.16E-02 
CD45RO- Tregs as % total CD4+ T cells 6.71E-02 2.55E-02 
CD14dim monocytes as % total monocytes 7.87E-02 3.89E-02 
CD14+CD16- monocytes as % total monocytes 9.40E-02 3.44E-02 
CXCR3- CXCR5+PD-1+ Tfh cells as % total CD4+ T cells 9.96E-02 3.90E-02 
CD56-CD16+ NK cells as % live cells 9.96E-02 5.24E-02 
Total B cells as % live cells 1.11E-01 4.28E-02 
Switched memory B cells as % live cells 1.38E-01 6.64E-02 
Naïve B cells as % live cells 1.41E-01 6.64E-02 
CD45RO+ Tregs as % live cells 1.45E-01 5.94E-02 
CD56briCD16- NK cells 106/ml 1.45E-01 4.04E-02 
CD56-CD16+ NK cells 106/ml 1.54E-01 8.74E-02 
CD45RO+ CD4+ T cells 106/ml 1.55E-01 8.24E-02 
Transitional B cells as % total B cells 2.49E-01 1.06E-01 
Naïve B cells as % total B cells 2.56E-01 1.24E-01 
White cell count ^ 3.36E-01 1.98E-01 
CD16+ monocytes as % live cells 3.86E-01 2.21E-01 
CD14dim monocytes 106/ml 5.09E-01 3.48E-01 
Switched memory B cells as % total B cells 5.12E-01 3.49E-01 
CD56briCD16- NK cells as % live cells 5.14E-01 3.27E-01 
CD45RO+ Tregs 106/ml 5.76E-01 3.63E-01 
Transitional B cells 106/ml 6.12E-01 3.66E-01 
Age at time of sample collection 7.03E-01 5.79E-01 
CD16+ monocytes 106/ml 7.17E-01 5.23E-01 
Tregs 106/ml 7.98E-01 5.84E-01 
Total B cells 106/ml 9.01E-01 7.12E-01 
BAFF 9.01E-01 7.12E-01 
Switched memory B cells 106/ml 9.01E-01 7.18E-01 
Transitional B cells as % live cells 1.00E+00 8.12E-01 
Naïve B cells 106/ml 1.00E+00 9.79E-01 
CD14dim monocytes as % live cells 1.00E+00 9.85E-01 
 
^ measured by the Sysmex automated haematology analyser at Centenary Institute prior to 
PBMC isolation by density centrifugation 
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Figure 4.42. Associations were measured between the response types SLE and healthy (no 
SLE) and numeric variables of samples from all time points. Plots depict the associations 
between the two response types and the top 10 most highly significant variables. 
Table 4.20. Adjusted p-values for associations between the response types of SLE and 
healthy (no SLE) and numeric variables of samples from the first time point only. Variables 
above the line in the table (p<0.05) are considered to be able to significantly discriminate 
between the two response types. 
 
Variable Logistic regression t-test 
CXCR5+PD-1+ Tfh cells as % live cells 9.56E-06 4.02E-09 
CD45RO- Tregs as % live cells 9.91E-06 3.00E-08 
CXCR5+ CD4+ T cells as % live cells 9.91E-06 1.94E-08 
CD45RO- CD4+ T cells as % live cells 9.91E-06 5.24E-08 
CXCR3+ CXCR5+PD-1+ Tfh cells as % live cells 9.91E-06 5.24E-08 
CD45RO- Tregs as % Tregs 9.91E-06 1.14E-07 
CD56dimCD16+ NK cells as % live cells 2.38E-05 2.80E-07 
CD45RO+ Tregs as % Tregs 3.07E-05 6.06E-07 
Total CD4+ T cells as % live cells 3.24E-05 9.10E-07 
Total NK cells as % live cells 4.12E-05 1.28E-06 
CXCR5+ CD4+ T cells as % total CD4+ T cells 4.40E-05 2.93E-06 
Atypical memory B cells as % total B cells 4.40E-05 1.40E-06 
CXCR3- CXCR5+PD-1+ Tfh cells as % CXCR5+PD-1+ Tfh 
cells 4.40E-05 2.72E-06 
CXCR3- CXCR5+PD-1+ Tfh cells as % live cells 6.31E-05 2.83E-06 
CD56briCD16- NK cells as % total NK cells 1.85E-04 2.53E-05 
CXCR3+ CXCR5+PD-1+ Tfh cells as % total CD4+ T cells 1.85E-04 3.97E-05 
CXCR5+PD-1+ Tfh cells as % total CD4+ T cells 2.65E-04 5.56E-05 
MZ memory B cells as % live cells 2.65E-04 5.15E-05 
CXCR5+ CD4+ T cells 106/ml 2.75E-04 5.56E-05 
Atypical memory B cells 106/ml 3.92E-04 7.58E-04 
CD56dimCD16+ NK cells as % total NK cells 3.92E-04 3.32E-04 
CXCR5+PD-1+ Tfh cells 106/ml 5.32E-04 1.36E-04 
Tregs as % live cells 5.32E-04 2.34E-04 
CD45RO- CD4+ T cells as % total CD4+ T cells 5.32E-04 1.68E-04 
CD45RO- CD4+ T cells 106/ml 5.46E-04 1.95E-04 
CD45RO- Tregs as % total CD4+ T cells 6.55E-04 2.63E-04 
Atypical memory B cells as % live cells 6.55E-04 2.96E-04 
CXCR3+ CXCR5+PD-1+ Tfh cells 106/ml 7.90E-04 2.19E-04 
MZ memory B cells as % total B cells 8.72E-04 3.01E-04 
CD45RO+ CD4+ T cells as % total CD4+ T cells 8.72E-04 3.31E-04 
CD45RO- Tregs 106/ml 1.06E-03 3.01E-04 
CXCR3+ CXCR5+PD-1+ Tfh cells as % CXCR5+PD-1+ Tfh 
cells 3.82E-03 6.61E-03 
CD56dimCD16+ NK cells 106/ml 4.79E-03 2.84E-03 
CD45RO+ Tregs as % total CD4+ T cells 4.93E-03 3.54E-03 
MZ memory B cells 106/ml 8.89E-03 3.54E-03 
Total NK 106/ml 1.10E-02 7.34E-03 
CD14+CD16- monocytes 106/ml 1.45E-02 1.16E-02 
CD16+ monocytes as % total monocytes 1.53E-02 1.15E-02 
Total CD4+ T cells 106/ml 1.88E-02 1.54E-02 
Total monocytes 106/ml 1.88E-02 1.55E-02 
CXCR3- CXCR5+PD-1+ Tfh cells 106/ml 1.88E-02 1.30E-02 
Switched memory B cells as % live cells 2.05E-02 1.51E-02 
Plasmablasts/plasma cells as % live cells 2.91E-02 1.68E-02 
CD45RO+ CD4+ T cells as % live cells 4.32E-02 3.90E-02 
Plasmablasts/plasma cells 106/ml 5.00E-02 3.11E-02 
CXCR3- CXCR5+PD-1+ Tfh cells as % total CD4+ T cells 6.72E-02 5.88E-02 
CD14dim monocytes as % total monocytes 7.36E-02 5.90E-02 
White cell count ^ 7.45E-02 6.55E-02 
CD56-CD16+ NK cells as % total NK cells 9.25E-02 7.81E-02 
CD14+CD16- monocytes as % total monocytes 1.00E-01 8.21E-02 
CD45RO+ Tregs as % live cells 1.02E-01 9.88E-02 
CD56briCD16- NK cells 106/ml 1.31E-01 1.07E-01 
BAFF 1.39E-01 1.46E-01 
Transitional B cells as % total B cells 1.44E-01 1.27E-01 
Total B cells as % live cells 1.44E-01 1.27E-01 
CD56-CD16+ NK cells as % live cells 1.46E-01 1.17E-01 
CD14+CD16- monocytes as % live cells 2.14E-01 1.87E-01 
Switched memory B cells as % total B cells 2.43E-01 2.10E-01 
CD16+ monocytes 106/ml 2.43E-01 2.18E-01 
CD56-CD16+ NK cells 106/ml 2.77E-01 2.26E-01 
Switched memory B cells 106/ml 2.83E-01 2.34E-01 
Total mononcytes as % live cells 3.00E-01 2.62E-01 
Tregs as % total CD4+ T cells 3.10E-01 2.86E-01 
CD14dim monocytes 106/ml 3.31E-01 3.69E-01 
Tregs 106/ml 3.46E-01 3.22E-01 
Naïve B cells as % live cells 4.36E-01 3.79E-01 
Transitional B cells 106/ml 4.73E-01 4.03E-01 
CD16+ monocytes as % live cells 5.96E-01 5.11E-01 
CD45RO+ Tregs 106/ml 6.10E-01 5.32E-01 
Naïve B cells 106/ml 6.10E-01 5.28E-01 
Transitional B cells as % live cells 6.10E-01 5.28E-01 
CD56briCD16- NK cells as % live cells 6.42E-01 5.48E-01 
Naïve B cells as % total B cells 8.11E-01 6.85E-01 
CD14dim monocytes as % live cells 1.00E+00 8.92E-01 
Total B cells 106/ml 1.00E+00 9.23E-01 
CD45RO+ Tregs as % CD45RO+ CD4+ T cells 1.00E+00 9.23E-01 
Age at time of sample collection 1.00E+00 9.23E-01 
CD45RO+ CD4+ T cells 106/ml 1.00E+00 9.81E-01 
 
^ measured by the Sysmex automated haematology analyser at Centenary Institute prior to 
PBMC isolation by density centrifugation 
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Figure 4.43. Associations were measured between the response types SLE and healthy (no 
SLE) and numeric variables of samples from the first time point only. Plots depict the 
associations between the two response types and the top 14 most highly significant variables. 
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Tregs. As shown in Figure 4.43, these variables were all inversely associated with the 
probability of SLE. 
 
4.6.5  Age at Time of Sample Collection and Levels of NK Cell Subsets Could 
Significantly Discriminate Between SLE Patients and Patients with Other Autoimmune 
Conditions 
Logistic regression was used to measure the associations between the binary variable of the 
response types SLE and other autoimmune condition and numeric variables measured in our 
study. Samples from SLE patients and disease control subjects from all time points were 
included in this analysis. The adjusted p-values for these associations are listed on Table 
4.21. The variables that could significantly (p<0.1) discriminate between SLE patients and 
patients with other autoimmune conditions were age at time of sample collection, absolute 
number of total NK cells and CD56dimCD16+ NK cells, frequency as a percentage of live 
cells of total NK cells and CD56dimCD16+ NK cells, and frequency as a percentage of total 
NK cells of CD56briCD16- NK cells and CD56dimCD16+ NK cells. As shown in Figure 4.44, 
these variables were all inversely associated with the probability of SLE except for frequency 
as a percentage of total NK cells of CD56briCD16- NK cells. When the same analysis was 
conducted with only the first sample from each SLE patient and disease control subject, the 
only variable that could discriminate between the two response types was age at time of 
sample collection. 
 
A similar analysis was performed only with SLE samples from all time points to measure the 
associations between the binary variable of the response types active SLE and inactive SLE 
Table 4.21. Adjusted p-values for associations between the response types of SLE and other 
autoimmune condition and numeric variables of samples from all time points. Variables above 
the line in the table are considered to be able to significantly discriminate between the two 
response types. 
 
Variable Logistic regression t-test 
Age at time of sample collection 2.69E-04 3.31E-05 
CD56dimCD16+ NK cells as % live cells 4.12E-03 2.91E-03 
CD56briCD16- NK cells as % live cells 4.12E-03 7.26E-04 
Total NK cells as % live cells 7.67E-03 8.44E-03 
CD56dimCD16+ NK cells 106/ml 7.75E-03 1.02E-02 
Total NK cells 106/ml 9.54E-03 1.54E-02 
CD56dimCD16+ NK cells as % total NK cells 2.93E-02 3.35E-06 
CD16+ monocytes 106/ml 1.71E-01 6.83E-02 
Plasmablasts/plasma cells as % live cells 1.71E-01 3.44E-05 
CD16+ monocytes as % live cells 1.85E-01 5.45E-02 
C3 1.85E-01 1.38E-01 
CD56-CD16+ NK cells 106/ml 2.32E-01 4.49E-01 
C-reactive protein 3.10E-01 3.99E-01 
Basophils * 3.19E-01 4.25E-01 
CD56-CD16+ NK cells as % live cells 3.19E-01 4.49E-01 
Plasmablasts/plasma cells 106/ml 3.19E-01 5.91E-03 
CD16+ monocytes as % total monocytes 3.19E-01 2.02E-01 
Total CD4+ T cells 106/ml 3.19E-01 1.77E-01 
Age at onset of disease 3.19E-01 6.27E-01 
CD45RO+ CD4+ T cells 106/ml 3.86E-01 3.52E-01 
Switched memory B cells as % total B cells 3.86E-01 3.99E-01 
Total monocytes 106/ml 3.86E-01 3.99E-01 
Total CD4+ T cells as % live cells 3.86E-01 1.30E-01 
CD45RO+ CD4+ T cells as % live cells 3.86E-01 2.02E-01 
CXCR5+ CD4+ T cells 106/ml 3.86E-01 3.99E-01 
CXCR5+ CD4+ T cells as % total CD4+ T cells 3.86E-01 3.52E-01 
Naïve B cells 106/ml 3.93E-01 3.99E-01 
CXCR5+ CD4+ T cells as % live cells 3.93E-01 3.52E-01 
Duration of disease 4.37E-01 6.01E-01 
White cell count ^ 4.37E-01 3.99E-01 
CD14+CD16- monocytes 106/ml 4.37E-01 4.71E-01 
Naïve B cells as % live cells 5.19E-01 4.71E-01 
CD45RO+ Tregs as % CD45RO+ CD4+ T cells 5.19E-01 4.71E-01 
CD14dim monocytes as % total monocytes 5.30E-01 4.71E-01 
CD14+CD16- monocytes as % total monocytes 5.34E-01 4.71E-01 
Atypical memory B cells as % total B cells 5.34E-01 3.99E-01 
Total B cells 106/ml 5.34E-01 4.81E-01 
Neutrophils * 5.34E-01 4.95E-01 
Total monocytes as % live cells 5.34E-01 4.49E-01 
Switched memory B cells as % live cells 5.34E-01 4.71E-01 
Platelets * 5.34E-01 4.25E-01 
CD14dim monocytes as % live cells 5.34E-01 4.71E-01 
Tregs as % total CD4+ T cells 5.34E-01 4.95E-01 
White cell count * 5.35E-01 4.81E-01 
CD45RO- CD4+ T cells as % live cells 6.03E-01 4.81E-01 
C4 6.03E-01 4.71E-01 
CD45RO+ Tregs as % total CD4+ T cells 6.03E-01 4.95E-01 
CD45RO- Tregs as % total CD4+ T cells 6.21E-01 7.09E-01 
Atypical memory B cells as % live cells 6.41E-01 4.81E-01 
Anti-dsDNA antibody 6.53E-01 6.50E-01 
CD14+CD16- monocytes as % live cells 6.54E-01 5.42E-01 
MZ memory B cells 106/ml 6.65E-01 6.59E-01 
Red cell count * 6.65E-01 7.61E-01 
CXCR3+ CXCR5+PD-1+ Tfh cells as % CXCR5+PD-1+ Tfh 
cells 7.08E-01 4.95E-01 
CXCR3+ CXCR5+PD-1+ Tfh cells as % live cells 7.38E-01 7.37E-01 
Naïve B cells as % total B cells 7.52E-01 8.20E-01 
CD45RO- CD4+ T cells 106/ml 7.55E-01 6.59E-01 
CD45RO- Tregs as % Tregs 7.80E-01 8.30E-01 
Haemoglobin * 7.80E-01 8.70E-01 
CXCR3- CXCR5+PD-1+ Tfh cells 106/ml 7.80E-01 7.58E-01 
CXCR3+ CXCR5+PD-1+ Tfh cells as % total CD4+ T cells 7.80E-01 8.20E-01 
CXCR3- CXCR5+PD-1+ Tfh cells as % live cells 7.80E-01 7.58E-01 
CD56-CD16+ NK cells as % total NK cells 7.89E-01 8.30E-01 
CXCR3+ CXCR5+PD-1+ Tfh cells 106/ml 8.33E-01 8.20E-01 
Total B cells as % live cells 8.33E-01 8.30E-01 
CD45RO+ Tregs as % live cells 8.36E-01 8.33E-01 
CXCR5+PD-1+ Tfh cells 106/ml 8.36E-01 8.30E-01 
Tregs as % live cells 8.81E-01 8.70E-01 
CD14dim monocytes 106/ml 8.81E-01 8.34E-01 
Monocytes * 8.84E-01 8.70E-01 
CD56briCD16- NK cells as % live cells 8.84E-01 8.70E-01 
CXCR5+PD-1+ Tfh cells as % live cells 8.84E-01 8.70E-01 
CXCR3- CXCR5+PD-1+ Tfh cells as % total CD4+ T cells 8.96E-01 8.70E-01 
MZ memory B cells as % live cells 9.02E-01 8.70E-01 
CD45RO+ CD4+ T cells as % total CD4+ T cells 9.02E-01 8.70E-01 
CD45RO+ Tregs 106/ml 9.02E-01 8.70E-01 
Tregs 106/ml 9.02E-01 8.70E-01 
MZ memory B cells as % total B cells 9.34E-01 9.25E-01 
Transitional B cells as % live cells 9.34E-01 8.97E-01 
Switched memory B cells 106/ml 9.34E-01 9.19E-01 
Atypical memory B cells 106/ml 9.34E-01 9.07E-01 
Lymphocytes * 9.34E-01 8.97E-01 
CD56briCD16- NK cells 106/ml 9.34E-01 9.39E-01 
CD45RO- Tregs 106/ml 9.34E-01 9.39E-01 
Transitional B cells 106/ml 9.34E-01 9.25E-01 
ESR 9.34E-01 9.39E-01 
Eosinophils * 9.34E-01 9.39E-01 
CD45RO- CD4+ T cells as % total CD4+ T cells 9.34E-01 9.39E-01 
BAFF 9.66E-01 9.50E-01 
CD45RO- Tregs as % live cells 9.71E-01 9.78E-01 
CD45RO+ Tregs as % Tregs 9.71E-01 9.78E-01 
CXCR3- CXCR5+PD-1+ Tfh cells as % CXCR5+PD-1+ Tfh 
cells 9.71E-01 9.78E-01 
CXCR5+PD-1+ Tfh cells as % total CD4+ T cells 9.93E-01 9.92E-01 
Transitional B cells as % total B cells 9.93E-01 9.92E-01 
 
* measured as part of full blood count at the Department of Clinical Immunology, RPA 
Hospital 
^ measured by the Sysmex automated haematology analyser at Centenary Institute prior to 
PBMC isolation by density centrifugation 
 
Figure 4.44. Associations were measured between the response types SLE and other 
autoimmune condition and numeric variables of samples from all time points. Plots depict the 
associations between the two response types and the variables that significantly discriminate 
between the two response types. 
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(as determined by PGA) and numeric variables measured in our study. Mildly, moderately 
and severely active SLE were included together as active SLE. None of the variables could 
significantly discriminate between active SLE and inactive SLE. 
 
4.6.6  Levels of Transitional B cells, CD14dim monocytes, CD56-CD16+ NK cells and 
Basophils Could Significantly Discriminate Between SLE Patients with Neurologic 
Symptoms and Those Without Neurologic Symptoms 
Logistic regression was used to measure the associations between the binary variable of SLE 
patients with neurologic symptoms and SLE patients without neurologic symptoms and 
numeric variables measured in our study. Samples from SLE patients from all time points 
were included in this analysis. The adjusted p-values for these associations are listed on 
Table 4.22. The variables that could significantly (p<0.1) discriminate between patients with 
neurologic symptoms and those without neurologic symptoms were absolute numbers of 
transitional B cells, CD14dim monocytes and CD56-CD16+ NK cells, frequency as a 
percentage of live cells of transitional B cells and CD56-CD16+ NK cells, and basophil count. 
As shown in Figure 4.45, these variables were all inversely associated with the probability of 
developing neurologic symptoms. 
 
4.6.7  Frequency of CD45RO+ CD4+ T cells Could Significantly Discriminate Between 
SLE Patients with Renal Symptoms and Those Without Renal Symptoms 
Logistic regression was used to measure the associations between the binary variable of SLE 
patients with renal symptoms and SLE patients without renal symptoms and numeric 
variables measured in our study. Samples from SLE patients from all time points were 
included in this analysis. The adjusted p-values for these associations are listed on Table 
Table 4.22. Adjusted p-values for associations between the response types of neurologic or 
no neurologic involvement and numeric variables of samples from SLE patients from all time 
points. Variables above the line in the table are considered to be able to significantly 
discriminate between the two response types. 
 
Variable Logistic regression t-test 
CD56-CD16+ NK cells as % live cells 9.20E-01 1.29E-08 
Transitional B cells as % live cells 9.20E-01 1.31E-06 
Transitional B cells 106/ml 9.20E-01 4.88E-05 
CD56-CD16+ NK cells 106/ml 9.20E-01 1.08E-04 
CD14dim monocytes 106/ml 9.20E-01 7.81E-04 
Basophils * 9.95E-01 7.81E-04 
Transitional B cells as % total B cells 9.20E-01 1.69E-01 
CD14dim monocytes as % live cells 9.20E-01 1.76E-01 
Lymphocytes * 9.20E-01 2.86E-01 
Total NK cells as % live cells 9.20E-01 2.86E-01 
Total NK cells 106/ml 9.20E-01 2.86E-01 
CD56briCD16- NK cells 106/ml 9.20E-01 2.86E-01 
CD56dimCD16+ NK cells as % live cells 9.20E-01 2.86E-01 
Atypical memory B cells 106/ml 9.20E-01 2.86E-01 
CD56dimCD16+ NK cells 106/ml 9.20E-01 3.52E-01 
Atypical memory B cells as % live cells 9.20E-01 3.52E-01 
Eosinophils * 9.20E-01 4.13E-01 
CD56briCD16- NK cells as % live cells 9.20E-01 4.74E-01 
CD45RO- Tregs 106/ml 9.20E-01 5.37E-01 
Tregs 106/ml 9.20E-01 9.54E-01 
Atypical memory B cells as % total B cells 9.20E-01 9.54E-01 
CD45RO+ Tregs as % Tregs 9.20E-01 9.54E-01 
Duration of disease 9.20E-01 9.54E-01 
CD45RO+ Tregs 106/ml 9.20E-01 9.54E-01 
CD45RO- Tregs as % total CD4+ T cells 9.20E-01 9.54E-01 
C4 9.20E-01 9.54E-01 
CXCR5+ CD4+ T cells as % total CD4+ T cells 9.20E-01 9.54E-01 
CXCR5+PD-1+ Tfh cells as % total CD4+ T cells 9.20E-01 9.54E-01 
CXCR3- CXCR5+PD-1+ Tfh cells as % total CD4+ T cells 9.20E-01 9.54E-01 
CD16+ monocytes as % live cells 9.20E-01 9.54E-01 
Naïve B cells as % live cells 9.20E-01 9.54E-01 
CD45RO+ CD4+ T cells 106/ml 9.20E-01 9.54E-01 
Age at time of sample collection 9.20E-01 9.54E-01 
CD56-CD16+ NK cells as % total NK cells 9.20E-01 9.54E-01 
MZ memory B cells as % live cells 9.20E-01 9.54E-01 
CD45RO- Tregs as % Tregs 9.20E-01 9.54E-01 
Naïve B cells as % total B cells 9.20E-01 9.54E-01 
Monocytes * 9.20E-01 9.54E-01 
MZ memory B cells 106/ml 9.20E-01 9.54E-01 
CD45RO+ Tregs as % CD45RO+ CD4+ T cells 9.20E-01 9.54E-01 
CD14dim monocytes as % total monocytes 9.20E-01 9.54E-01 
CXCR3- CXCR5+PD-1+ Tfh cells as % live cells 9.20E-01 9.54E-01 
Plasmablasts/plasma cells as % live cells 9.20E-01 9.54E-01 
CD16+ monocytes as % total monocytes 9.20E-01 9.54E-01 
CD56dimCD16+ NK cells as % total NK cells 9.20E-01 9.54E-01 
MZ memory B cells as % total B cells 9.20E-01 9.54E-01 
White cell count ^ 9.20E-01 9.54E-01 
CD14+CD16- monocytes as % total monocytes 9.20E-01 9.54E-01 
CD45RO- CD4+ T cells as % total CD4+ T cells 9.20E-01 9.54E-01 
CD56briCD16- NK cells as % total NK cells 9.20E-01 9.54E-01 
Total CD4+ T cells 106/ml 9.20E-01 9.54E-01 
CXCR3+ CXCR5+PD-1+ Tfh cells as % total CD4+ T cells 9.20E-01 9.54E-01 
White cell count * 9.20E-01 9.54E-01 
CD45RO+ Tregs as % total CD4+ T cells 9.20E-01 9.54E-01 
CXCR5+PD-1+ Tfh cells as % live cells 9.20E-01 9.54E-01 
CD14+CD16- monocytes 106/ml 9.20E-01 9.54E-01 
Naïve B cells 106/ml 9.20E-01 9.54E-01 
C-reactive protein 9.20E-01 9.54E-01 
Haemoglobin * 9.20E-01 9.54E-01 
CXCR3- CXCR5+PD-1+ Tfh cells 106/ml 9.20E-01 9.54E-01 
Anti-dsDNA antibody 9.20E-01 9.54E-01 
CD45RO- Tregs as % live cells 9.20E-01 9.54E-01 
Red cell count * 9.20E-01 9.54E-01 
CD45RO+ CD4+ T cells as % total CD4+ T cells 9.20E-01 9.54E-01 
Total monocytes 106/ml 9.20E-01 9.54E-01 
Switched memory B cells 106/ml 9.20E-01 9.54E-01 
Total B cells 106/ml 9.20E-01 9.54E-01 
CXCR5+ CD4+ T cells as % live cells 9.20E-01 9.54E-01 
Plasmablasts/plasma cells 106/ml 9.54E-01 9.54E-01 
CXCR3+ CXCR5+PD-1+ Tfh cells as % live cells 9.20E-01 9.54E-01 
CD45RO+ CD4+ T cells as % live cells 9.20E-01 9.54E-01 
CD45RO+ Tregs as % live cells 9.29E-01 9.54E-01 
Tregs as % total CD4+ T cells 9.20E-01 9.54E-01 
Platelets * 9.20E-01 9.54E-01 
Switched memory B cells as % total B cells 9.20E-01 9.54E-01 
CXCR3+ CXCR5+PD-1+ Tfh cells as % CXCR5+PD-1+ Tfh 
cells 9.54E-01 9.54E-01 
CXCR5+PD-1+ Tfh cells 106/ml 9.20E-01 9.54E-01 
Total B cells as % live cells 9.46E-01 9.54E-01 
CXCR3- CXCR5+PD-1+ Tfh cells as % CXCR5+PD-1+ Tfh 
cells 9.46E-01 9.54E-01 
CD16+ monocytes 106/ml 9.20E-01 9.54E-01 
BAFF 9.46E-01 9.54E-01 
ESR 9.20E-01 9.54E-01 
CD45RO- CD4+ T cells as % live cells 9.46E-01 9.54E-01 
CXCR3+ CXCR5+PD-1+ Tfh cells 106/ml 9.25E-01 9.54E-01 
CD45RO- CD4+ T cells 106/ml 9.46E-01 9.59E-01 
Switched memory B cells as % live cells 9.46E-01 9.59E-01 
Total monocytes as % live cells 9.20E-01 9.60E-01 
Neutrophils * 9.46E-01 9.60E-01 
Total CD4+ T cells as % live cells 9.55E-01 9.62E-01 
CXCR5+ CD4+ T cells 106/ml 9.55E-01 9.62E-01 
C3 9.55E-01 9.62E-01 
CD14+CD16- monocytes as % live cells 9.46E-01 9.62E-01 
Tregs as % live cells 9.76E-01 9.69E-01 
Age at onset of disease 9.76E-01 9.71E-01 
 
* measured as part of full blood count at the Department of Clinical Immunology, RPA 
Hospital 
^ measured by the Sysmex automated haematology analyser at Centenary Institute prior to 
PBMC isolation by density centrifugation 
 
 
Figure 4.45. Associations were measured between the response types of neurologic or no 
neurologic involvement and numeric variables of samples from SLE patients from all time 
points. Plots depict the associations between the two response types and the variables that 
significantly discriminate the two response types. 
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4.23. Only the frequency of CD45RO+ CD4+ T cells expressed as a percentage of live cells 
could significantly discriminate between patients with renal symptoms and those without 
renal symptoms (Figure 4.46). Furthermore, none of the variables we measured could 
significantly discriminate between SLE patients with musculoskeletal or cutaneous 
symptoms from those without these symptoms. 
 
4.6.8  Model for the Prediction of SLEDAI 
Penalised regression was used to select models for predicting SLEDAI in SLE patients using 
the variables we measured. The boxplots of the log Mean Square Error (MSE) of the models 
considered for the prediction of SLEDAI are shown in Figure 4.47. Several of the models had 
a log(MSE) that was lower than that for the intercept model, which was -2.6. The estimated 
coefficients and log(MSE) for the best three models for predicting SLEDAI are summarised 
on Table 4.24. Therefore, the best model for predicting log(1+SLEDAI) was determined to 
be: 
log(1+SLEDAI) =  
– 0.188 + 0.004 x “frequency of transitional B cells as percentage of live cells”  
+ 0.199 x “absolute number of transitional B cells” 
– 0.275 x “frequency of CD56dimCD16+ NK cells as percentage of live cells”  
– 0.090 x “frequency of CD45RO+ CD4+ T cells as percentage of live cells”  
– 0.200 x “absolute number of CXCR3- CXCR5+PD-1+ Tfh cells” 
where each of the variables is assumed to be transformed via log(1+x) and standardised. This 
model had a log(MSE) of -2.64, which was the lowest log(MSE) for the top three candidate 
models. 
Table 4.23. Adjusted p-values for associations between the response types of renal or no 
renal involvement and numeric variables of samples from SLE patients from all time points. 
Variables above the line in the table are considered to be able to significantly discriminate 
between the two response types. 
 
Variable Logistic regression t-test 
CD45RO+ CD4+ T cells as % live cells 7.67E-02 1.80E-01 
CD45RO+ CD4+ T cells 106/ml 1.89E-01 2.00E-01 
CXCR3+ CXCR5+PD-1+ Tfh cells 106/ml 3.18E-01 2.57E-01 
CD45RO+ Tregs as % live cells 1.89E-01 2.57E-01 
CD45RO- CD4+ T cells as % total CD4+ T cells 2.39E-01 2.57E-01 
CD45RO+ CD4+ T cells as % total CD4+ T cells 1.30E-01 2.57E-01 
MZ memory B cells as % live cells 3.18E-01 2.82E-01 
Red cell count * 2.39E-01 2.82E-01 
CXCR3+ CXCR5+PD-1+ Tfh cells as % live cells 3.18E-01 2.82E-01 
Haemoglobin * 3.18E-01 2.82E-01 
CD56briCD16- NK cells as % total NK cells 3.18E-01 2.82E-01 
Transitional B cells 106/ml 1.51E-01 2.82E-01 
CD45RO+ Tregs 106/ml 3.35E-01 2.87E-01 
Transitional B cells as % live cells 1.51E-01 2.87E-01 
CD56dimCD16+ NK cells 106/ml 4.58E-01 2.87E-01 
CD16+ monocytes as % live cells 3.35E-01 2.87E-01 
CD16+ monocytes 106/ml 4.00E-01 2.87E-01 
Transitional B cells as % total B cells 3.18E-01 2.87E-01 
CXCR3+ CXCR5+PD-1+ Tfh cells as % total CD4+ T cells 3.18E-01 2.87E-01 
Tregs as % live cells 3.18E-01 3.00E-01 
MZ memory B cells 106/ml 4.00E-01 3.00E-01 
White cell count * 3.53E-01 3.08E-01 
MZ memory B cells as % total B cells 3.18E-01 3.11E-01 
CXCR5+PD-1+ Tfh cells 106/ml 4.00E-01 3.11E-01 
CXCR5+PD-1+ Tfh cells as % total CD4+ T cells 3.18E-01 3.13E-01 
CXCR5+PD-1+ Tfh cells as % live cells 3.53E-01 3.36E-01 
C3 3.35E-01 3.36E-01 
CXCR5+ CD4+ T cells as % live cells 3.53E-01 3.36E-01 
CXCR5+ CD4+ T cells as % total CD4+ T cells 3.18E-01 3.65E-01 
Total NK cells 106/ml 5.26E-01 4.00E-01 
CD45RO+ Tregs as % CD45RO+ CD4+ T cells 5.07E-01 4.02E-01 
CXCR5+ CD4+ T cells 106/ml 4.74E-01 4.02E-01 
Atypical memory B cells 106/ml 3.18E-01 4.02E-01 
CXCR3- CXCR5+PD-1+ Tfh cells 106/ml 4.74E-01 4.02E-01 
Atypical memory B cells as % live cells 3.18E-01 4.02E-01 
CXCR3+ CXCR5+PD-1+ Tfh cells as % CXCR5+PD-1+ Tfh 
cells 3.18E-01 4.02E-01 
CD56dimCD16+ NK cells as % live cells 4.88E-01 4.07E-01 
CD45RO+ Tregs as % total CD4+ T cells 4.08E-01 4.07E-01 
CD56-CD16+ NK cells 106/ml 6.05E-01 4.07E-01 
White cell count ^ 4.88E-01 4.21E-01 
CD45RO+ Tregs as % Tregs 4.00E-01 4.28E-01 
CXCR3- CXCR5+PD-1+ Tfh cells as % live cells 4.58E-01 4.55E-01 
CXCR3- CXCR5+PD-1+ Tfh cells as % total CD4+ T cells 4.00E-01 4.59E-01 
Plasmablasts/plasma cells as % live cells 4.88E-01 4.84E-01 
Neutrophils * 4.88E-01 4.84E-01 
CD56dimCD16+ NK cells as % total NK cells 4.58E-01 4.84E-01 
Total CD4+ T cells as % live cells 4.00E-01 4.84E-01 
Tregs 106/ml 5.19E-01 4.84E-01 
CD16+ monocytes as % total monocytes 4.88E-01 4.90E-01 
Tregs as % total CD4+ T cells 5.19E-01 5.04E-01 
CD14dim monocytes as % total monocytes 5.07E-01 5.52E-01 
Lymphocytes * 5.19E-01 5.55E-01 
CD45RO- CD4+ T cells 106/ml 4.58E-01 5.62E-01 
CD45RO- Tregs as % Tregs 5.19E-01 5.64E-01 
Total NK cells as % live cells 6.75E-01 5.64E-01 
Atypical memory B cells as % total B cells 5.19E-01 5.80E-01 
BAFF 6.97E-01 6.90E-01 
Monocytes * 7.15E-01 6.90E-01 
Basophils * 6.42E-01 6.90E-01 
Switched memory B cells 106/ml 7.77E-01 6.90E-01 
CD14dim monocytes as % live cells 6.75E-01 7.10E-01 
Age at time of sample collection 7.86E-01 7.16E-01 
CD14+CD16- monocytes as % total monocytes 7.15E-01 7.16E-01 
CD56-CD16+ NK cells as % total NK cells 7.15E-01 7.16E-01 
Plasmablasts/plasma cells 106/ml 7.86E-01 7.16E-01 
Total monocytes as % live cells 7.66E-01 7.31E-01 
Eosinophils * 7.61E-01 7.34E-01 
CD56briCD16- NK cells as % live cells 8.10E-01 7.41E-01 
CD56briCD16- NK cells 106/ml 8.10E-01 7.41E-01 
Anti-dsDNA antibody 8.10E-01 8.19E-01 
CD14+CD16- monocytes as % live cells 8.18E-01 8.19E-01 
CD14dim monocytes 106/ml 8.10E-01 8.19E-01 
Switched memory B cells as % total B cells 8.53E-01 8.19E-01 
CD14+CD16- monocytes 106/ml 8.18E-01 8.19E-01 
ESR 8.18E-01 8.38E-01 
CD56-CD16+ NK cells as % live cells 8.53E-01 8.38E-01 
CD45RO- Tregs as % live cells 8.30E-01 8.38E-01 
C4 8.57E-01 8.38E-01 
Switched memory B cells as % live cells 8.57E-01 8.40E-01 
Age at onset of disease 8.57E-01 8.63E-01 
Total B cells 106/ml 8.57E-01 8.76E-01 
Total monocytes 106/ml 8.81E-01 8.86E-01 
Naïve B cells as % total B cells 9.08E-01 8.99E-01 
CD45RO- Tregs 106/ml 8.85E-01 8.99E-01 
Platelets * 8.57E-01 9.00E-01 
CXCR3- CXCR5+PD-1+ Tfh cells as % CXCR5+PD-1+ Tfh 
cells 9.08E-01 9.04E-01 
Duration of disease 9.08E-01 9.04E-01 
Naïve B cells 106/ml 9.49E-01 9.63E-01 
Total B cells as % live cells 9.56E-01 9.63E-01 
CD45RO- Tregs as % total CD4+ T cells 9.75E-01 9.78E-01 
CD45RO- CD4+ T cells as % live cells 9.75E-01 9.78E-01 
Naïve B cells as % live cells 9.75E-01 9.78E-01 
Total CD4+ T cells 106/ml 9.75E-01 9.78E-01 
C-reactive protein 9.75E-01 9.78E-01 
 
* measured as part of full blood count at the Department of Clinical Immunology, RPA 
Hospital 
 
^ measured by the Sysmex automated haematology analyser at Centenary Institute prior to 
PBMC isolation by density centrifugation 
 
 
Figure 4.46. Associations were measured between the response types of renal or no renal 
involvement and numeric variables of samples from SLE patients from all time points. The 
plot depicts the associations between the two response types and the only variable 
(frequency of CD45RO+ CD4+ T cells as a percentage of live cells) that significantly 
discriminates the two response types. 
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Figure 4.47. Penalised regression was performed to determine if previously identified 
associated variables could predict SLEDAI scores of SLE patients. Boxplots of the log Mean 
Square Error (MSE) for all of the considered predictors for SLEDAI are shown.  
 
 
Table 4.24. Summary of the estimated coefficients and log(MSE) for the top three models for 
predicting SLEDAI. 
 
Variable AIC BIC AIC (sig) 
Intercept -0.188 -0.174 -0.174 
Transitional B cells as % live cells -0.004 0.196 0.196 
Transitional B cells 106/ml 0.199   
CD56dimCD16+ NK cells as % live cells -0.275 -0.311 -0.311 
CD45RO+ CD4+ T cells as % live cells -0.090 -0.195 -0.195 
CXCR3- CXCR5+PD-1+ Tfh 106/ml -0.200   
log(MSE) -2.640 -2.628 -2.611 
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4.6.9  Model for Predicting Whether an Individual has SLE or Not 
Penalised logistic regression was used to select models for predicting whether an individual 
has SLE or is healthy using the variables we measured. The boxplots of the classification 
rates of the models considered for predicting if an individual has SLE are shown in Figure 
4.48 (A). All the candidate models had an average cross-validation error that was lower than 
that for the majority vote classifier, which was 32%. The receiver operating characteristic 
(ROC) curves for the best three models for predicting if an individual has SLE are shown in 
Figure 4.48 (B) and the estimated coefficients, cross-validation errors and area under curve 
(AUC) for these three models are summarised on Table 4.25. Therefore, the best model for 
predicting whether an individual has SLE or not was determined to be: 
P(SLE) = exp(η)/(1+exp(η)), which maps η to a probability between 0 and 1, where 
η = 2.479 – 0.15 x “BAFF” 
 – 0.22 x “absolute number of MZ memory B cells” 
 – 0.078 x “frequency of plasmablasts and plasma cells as percentage of live cells” 
 – 0.375 x “frequency of switched memory B cells as percentage of B cells” 
 – 0.438 x “frequency of MZ memory B cells as percentage of live cells” 
 + 0.711 x “frequency of atypical memory B cells as percentage of B cells” 
 + 0.054 x “frequency of atypical memory B cells as percentage of live cells” 
 + 0.378 x “absolute number of atypical memory B cells” 
 – 0.277 x “frequency of CD16+ monocytes as percentage of total monocytes” 
 – 0.659 x “frequency of CD56dimCD16+ NK cells as percentage of NK cells” 
 – 1.626 x “frequency of CD56dimCD16+ NK cells as percentage of live cells” 
A 
 
 
B 
 
 
Figure 4.48. Penalised logistic regression was performed to determine if previously identified 
associated variables could classify whether an individual had SLE or not. (A) Boxplots of the 
classification rates for all of the considered classifiers for the binary variable SLE or healthy 
(no SLE). (B) The ROC curve for the top three classifiers for the binary variable SLE or 
healthy (no SLE). 
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Table 4.25. Summary of the estimated coefficients, cross-validation error and area under 
curve for the top three models for the binary variable SLE or healthy (no SLE). 
 
Variable LASSO LASSO (refit) SCAD (refit) 
Intercept 2.479 6.678 5.433 
Age at time of sample collection   -0.512 
BAFF -0.150 -1.473  
Plasmablasts/plasma cells as % live cells 0.078 0.257  
Switched memory B cells as % total B cells -0.375 -1.919  
MZ/non-switched memory B cells as % live cells -0.438 -1.079 -1.369 
Atypical memory B cells as % total B cells 0.711 2.638  
Atypical memory B cells as % live cells 0.054 -0.329 2.085 
Atypical memory B cells 106/ml 0.378 1.230  
CD16+ monocytes as % total monocytes -0.277 -1.340  
CD56dimCD16+ NK cells as % total NK cells -0.659 -3.658  
CD56dimCD16+ NK cells as % live cells -1.626 -3.266 -3.700 
CXCR5+ CD4+ T cells as % live cells -0.954 -3.208  
CD45RO- CD4+ T cells as % CD4+ T cells -0.191 0.761  
CXCR5+ CD4+ T cells as % CD4+ T cells   -4.681 
CD45RO- CD4+ T cells as % live cells -0.894 -3.565 -5.580 
CD45RO- Tregs as % Tregs -0.514 -1.549  
CXCR5+PD-1+ Tfh as % live cells -0.673 -0.174  
CXCR3- CXCR5+PD-1+ Tfh as % CXCR5+PD-1+ Tfh 0.354 0.115  
Average cross-validation error 9.36% 10.64% 10.87% 
Area under curve 0.9907 0.9933 0.9872 
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 – 0.954 x “frequency of CXCR5+ CD4+ T cells as percentage of live cells” 
 – 0.191 x “frequency of CD45RO- CD4+ T cells as percentage of CD4+ T cells” 
 – 0.894 x “frequency of CD45RO- CD4+ T cells as percentage of live cells” 
 – 0.514 x “frequency of CD45RO- Tregs as percentage of Tregs” 
– 0.673 x “frequency of CXCR5+PD-1+ Tfh cells as percentage of live cells” 
+ 0.354 x “frequency of CXCR3- CXCR5+PD-1+ Tfh cells as percentage of 
CXCR5+PD-1+ Tfh cells” 
where each of the variables is assumed to be transformed via log(1+x) and standardised. This 
model had an AUC of 0.9907 and a cross-validation error of 9.36%, which was the lowest 
cross-validation error among the top three candidate models. The pairs of the top variables 
separating the response types SLE or healthy (no SLE) were compared against each other, as 
depicted by the plots in Figure 4.49. The plots indicate a clear separation between SLE and 
healthy. 
 
4.6.10  Model for Predicting if a Patient with SLE has Renal Symptoms 
Penalised logistic regression was used to select the model for predicting whether an SLE 
patient has renal symptoms or not using the variables we measured. The boxplots of the 
classification rates of the models considered for predicting if an SLE patient has renal 
symptoms are shown in Figure 4.50 (A). Several models had an average cross-validation 
error that was lower than that for the majority vote classifier, which was 22%. The ROC 
curves for the best three models for predicting the presence of renal symptoms are shown in 
Figure 4.50 (B) and the estimated coefficients, cross-validation errors and AUC for these 
 Healthy
SLE 
−2 −1 0 1 2
−1
0
1
2
3
4
Age at time of sample collection
M
Z 
m
em
or
y 
B
 c
el
ls
as
 %
 li
ve
 c
el
ls
 
 
 
   
 
 
 
  
 
 
 
 
 
  
   
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
   
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0 
−2 −1 0 1 2
−1
0
1
2
3
4
5
A
ty
pi
ca
l m
em
or
y 
B
 c
el
ls
as
 %
 li
ve
 c
el
ls
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
   
 
 
 
 0 
 0 
−2 −1 0 1 2
−2
−1
0
1
2
C
D
56
di
m
 C
D
16
+ 
N
K
 c
el
ls
as
 %
 li
ve
 c
el
ls
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 0 
−2 −1 0 1 2
−3
−2
−1
0
1
C
X
C
R
5+
 C
D
4+
 T
 c
el
ls
as
 %
 to
ta
l C
D
4+
 T
 c
el
ls
 
   
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 0 
−2 −1 0 1 2
−2
−1
0
1
2
C
D
45
R
O
- C
D
4+
 T
 c
el
ls
as
 %
 li
ve
 c
el
ls
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0 
−1 0 1 2 3 4
−1
0
1
2
3
4
5
MZ memory B cells as % live cells
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 0 
−1 0 1 2 3 4
−2
−1
0
1
2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 0 
−1 0 1 2 3 4
−3
−2
−1
0
1
 
   
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 0 
Age at time of sample collection
Age at time of sample collection Age at time of sample collection
Age at time of sample collection
A
ty
pi
ca
l m
em
or
y 
B
 c
el
ls
as
 %
 li
ve
 c
el
ls
MZ memory B cells as % live cells
C
D
56
di
m
 C
D
16
+ 
N
K
 c
el
ls
as
 %
 li
ve
 c
el
ls
MZ memory B cells as % live cells
C
X
C
R
5+
 C
D
4+
 T
 c
el
ls
as
 %
 to
ta
l C
D
4+
 T
 c
el
ls
 
 
Figure 4.49. Logistic regression and penalised logistic regression were performed to 
determine if previously identified associated variables could classify whether an individual had 
SLE or not.  Plots depict the pairs of top variables separating the binary variable SLE or 
healthy (no SLE). 
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Figure 4.50. Penalised logistic regression was performed to determine if previously identified 
associated variables could classify SLE patients as having renal or no renal symptoms. (A) 
Boxplots of the classification rates for all of the considered classifiers for the binary variable 
renal or no renal involvement. (B) The ROC curve for the top three classifiers for the binary 
variable renal or no renal involvement. 
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three models are summarised on Table 4.26. Therefore, the best model for predicting whether 
a patient with SLE has renal symptoms or not was determined to be: 
P(renal) = exp(η)/(1+exp(η)), which maps η to a probability between 0 and 1, where 
η = 1.410 + 0.605 x “frequency of transitional B cells as percentage of live cells” 
 – 0.760 x “frequency of CD45RO+ CD4+ T cells as percentage of CD4+ T cells” 
where each of the variables is assumed to be transformed via log(1+x) and standardised. This 
model had a cross-validation error of 19.07%, which was the lowest cross-validation error for 
the top three candidate models. Interestingly, all three models had the same AUC of 0.744.
Table 4.26. Summary of the estimated coefficients, cross-validation error and area under 
curve for the top three models for the binary variable renal or no renal involvement. 
 
Variable BIC AIC (Sig) BIC (Sig) 
Intercept -1.410 -1.410 -1.410 
Transitional B cells as % live cells 0.605 0.605 0.605 
CD45RO+ CD4+ T cells as % total CD4+ T cells -0.760 -0.760 -0.760 
Average cross-validation error 19.07% 19.25% 19.25% 
Area under curve 0.744 0.744 0.744 
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CHAPTER 5:  DISCUSSION 
SLE is a multi-organ, antibody-mediated autoimmune condition in which the exact aetiology 
is as yet unknown. It has been suggested in studies with animal models and lupus patients 
that SLE could be driven by a T-independent pathway through the overexpression of BAFF, 
which may promote the survival of autoreactive B cells, leading to the production of 
pathogenic autoantibodies. Alternatively, a T-dependent mechanism has also been suggested, 
where the abnormal expansion of Tfh cells could also result in the production of 
autoantibodies involved in the development of SLE. Other cell populations, including Tregs, 
monocytes, and NK cells, have also been implicated in the immune dysregulation in SLE. 
What remains to be determined is whether or not these mechanisms occur in tandem in SLE 
patients, which is the main goal of the study here. 
 
The cell populations and measurements that were found to be significantly different between 
SLE patients and controls in the first part of this study are summarised on Table 5.1. A 
number of retrospective and prospective studies have reported leukopenia in approximately 
50% of SLE cases (Dubois and Tuffanelli, 1964, Worrall et al., 1990, Estes and Christian, 
1971, Grigor et al., 1978, Tan et al., 1982). In our study, we found that healthy individuals 
had a slightly lower white cell count than patients with SLE and other autoimmune 
conditions, but this difference was not significant (Figure 4.2 (A)). However, we did find that 
SLE patients had significantly lower numbers of lymphocytes than both control groups 
(Figure 4.2 (B) and (D)), in agreement with previous studies (Rivero et al., 1978, Wouters et 
al., 2004, Worrall et al., 1990, Grigor et al., 1978). 
Table 5.1. Summary of cell populations and measurements that were significantly different between SLE patients and controls in this study. 
 
Cell population or measurement Phenotype Patient group Comments 
Decreased number of lymphocytes Forward and side scatter typical of 
lymphocytes 
Active and 
inactive SLE 
 
    
Increased frequency of transitional B cells CD19+ CD27- CD38hi IgD+ Subset of SLE Active SLE n=1, inactive SLE n=3 
Two of the inactive SLE have 
increased BAFF 
Increased frequency of atypical memory B cells CD19+ CD27- IgD- Active and 
inactive SLE 
 
Presence of IgM-only memory B cells CD19+ CD27+ IgM+ IgD- Subset of SLE Active SLE n=1, inactive SLE n=4 
Increased number of plasmablasts and plasma cells CD19lo CD27hi IgD- CD38hi Subset of SLE Active SLE n=6, inactive SLE n=4 
    
Decreased total number of NK cells NKp46+ lymphocytes Active and 
inactive SLE 
 
Increased proportion of CD56bri NK cells and 
decreased proportion of CD56dim NK cells 
CD56bri CD16- and CD56dim CD16+ Active and 
inactive SLE 
 
Decreased total number of CD4+ T cells CD4+ lymphocytes Active SLE  
    
Increased proportion of CD45RO+ and decreased 
proportion of CD45RO- CD4+ T cells 
CD45RO+ CD4+ and CD45RO- CD4+ Inactive SLE  
Increased proportion of CD45RO+ and decreased 
proportion of CD45RO- Tregs 
CD45RO+ CD25+ CD127lo CD4+ and 
CD45RO- CD25+ CD127lo CD4+  
Active and 
inactive SLE 
 
    
Decreased frequency of CXCR5+ CD4+ T cells CXCR5+ CD4+ Active and 
inactive SLE 
 
Decreased frequency of CXCR5+ PD-1+ Tfh cells CXCR5+ PD-1+ CD4+ Active SLE  
Increased frequency of CXCR3- Tfh cells CXCR3- CXCR5+ PD-1+ CD4+ Active and 
inactive SLE 
 
Decreased frequency of CXCR3+ Tfh cells CXCR3+ CXCR5+ PD-1+ CD4+ Active SLE Only population that was significantly 
different between active and inactive 
SLE 
    
Increased serum BAFF n/a Subset of SLE Active SLE n=1, inactive SLE n=2 
Inactive SLE also have increased 
transitional B cells 
 
CD – cluster of differentiation; n/a – not applicable; SLE – systemic lupus erythematosus. 
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SLE is characterised by the production of autoantibodies due to the loss of B cell regulation. 
Recent studies have reported perturbations in the number and proportion of B cell subsets 
and an increase in the presence of abnormal B cell populations in the peripheral blood of 
lupus patients, as summarised on Table 1.11. Some studies have reported a reduction of B 
cell numbers in SLE patients (Messner et al., 1973, Glinski et al., 1976, Odendahl et al., 
2000, Arce et al., 2001). While numbers of B cells were similar between SLE patients and 
controls in our study (Figure 4.3 (A)), proportions of B cell subsets varied across all groups, 
in particular the memory B cell subsets. We found that SLE patients had a significantly 
higher percentage of atypical memory B cells than healthy controls (Figure 4.4 (B)). Other 
groups have previously reported an increase in atypical memory B cells in active SLE 
patients (Jacobi et al., 2008b, Anolik et al., 2004, Wei et al., 2007a), but the percentages of 
atypical memory B cells were similar between active and inactive patients in our cohort. 
Wehr et al. (Wehr et al., 2004) found a decrease in non-switched memory B cells in SLE 
patients. However in our cohort, only inactive SLE patients had a significantly lower 
proportion of MZ or non-switched memory B cells than healthy controls, whereas active SLE 
patients had similar levels of this subset as healthy controls, but the difference between active 
and inactive SLE patients was not significant (Figure 4.4 (C)). The frequency of switched 
memory B cells was similar between SLE patients and healthy controls in our study (Figure 
4.4 (D)). Interestingly, we found a distinct population of IgM-only memory B cells in five 
SLE patients (Figure 4.5 (B)). These IgM-only cells were clearly distinguishable from 
switched IgD-IgM- and MZ or non-switched IgD+IgM+ memory B cells (Figure 4.5 (A)). 
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IgM-only memory B cells were reportedly increased in a study of Sjögren Syndrome patients 
(Abdulahad et al., 2011), but we do not have enough patients in our cohort to make any 
conclusions about IgM-only memory B cells in relation to SLE. Further work is required to 
fully elucidate the function of these cells and find better methods to distinguish this 
population from the other memory B cell subsets. 
 
There were also differences in the proportions of other B cell subsets between SLE patients 
and controls but these differences were insignificant, in contrast to what has been reported in 
the literature. Sims et al. (Sims et al., 2005) and Wehr et al. (Wehr et al., 2004) found an 
increase in transitional B cells in SLE patients while Lee at al. (Lee et al., 2009) reported an 
increase in pre-naïve B cells in only active SLE patients. We found that transitional and pre-
naïve B cells could not be distinguished using differences in the level of expression of either 
or both of CD38 and CD10 (Figure 3.2 (A)), in contrast to what Lee et al. (Lee et al., 2009) 
showed in their study. Therefore we have included pre-naïve B cells in our calculation of 
transitional B cells. Overall, we found that the frequency of transitional B cells was similar 
between SLE patients and controls, although several SLE patients had a much higher 
percentage of this population compared to all other subjects in the cohort (Figure 4.3 (E)). In 
addition, we found that SLE patients treated with azathioprine alone or in combination with 
prednisone had a lower frequency of transitional B cells compared to patients not treated with 
azathioprine (Figures 4.24 and 4.27). Approximately 13% of SLE patients were treated with 
azathioprine and 70% with prednisone (Table 2.7). It is possible that treatment with these two 
medications could counteract the expansion of transitional B cells in SLE patients in our 
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study, but it seems more plausible that the few patients with increased transitional B cells 
may represent a subtype of SLE because only a small percentage of patients were treated 
with azathioprine in our study. 
 
Several groups have found that active SLE patients had significantly fewer naïve B cells than 
controls (Anolik et al., 2004, Jacobi et al., 2003). We also found a decrease in the percentage 
of naïve B cells in both active and inactive SLE patients compared to controls but the 
decrease was not significant (Figure 4.3 (D)). Although many reports have recognised the 
presence of increased plasmablasts and plasma cells as a distinguishing feature of active SLE 
(Jacobi et al., 2010, Jacobi et al., 2003, Odendahl et al., 2000, Anolik et al., 2004), only a 
subset of SLE patients in our cohort have elevated numbers of plasmablasts and plasma cells 
while other patients had similar or even fewer plasmablasts and plasma cells than control 
subjects (Figure 4.5 (D)). The findings here support the concept of the existence of different 
subtypes of SLE, that perhaps patients with elevated transitional B cells represent one 
subtype while patients with an increased number of plasmablasts and plasma cells are another 
subtype. 
 
Elevated Tfh cell numbers were believed to drive spontaneous GC formation and the 
consequent overproduction of high-affinity autoantibodies in sanroque mice, which develop 
a lupus-like disease (Linterman et al., 2009, Vinuesa et al., 2005), prompting investigators to 
test whether this particular cell type has a role in human SLE. Overall, a number of groups 
have shown an increase in peripheral Tfh or Tfh-like cells in active (Simpson et al., 2010, 
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Kawamoto et al., 2006) or both active and inactive SLE patients (Yang et al., 2005, Dolff et 
al., 2011, Terrier et al., 2012, Feng et al., 2012), although different groups have used 
different combinations of the Tfh-associated markers CD4, CXCR5, ICOS, PD-1, Bcl-6 and 
IL-21 to identify Tfh cells, as summarised in 1.3.1.3 Evidence for Increased Tfh Cells in 
SLE Patients. Because the phenotype for human cTfh cells had not been definitively 
determined, we had tested various combinations of markers used by these groups, and also 
markers used by groups investigating differences in Tfh cell subsets after influenza A 
vaccination (Bentebibel et al., 2013) and in HIV patients (Locci et al., 2013), as discussed in 
3.6 Treg and Tfh Cell Panel Development. Surprisingly, we found that the frequency of 
CXCR5-expressing CD4+ T cells was significantly lower in both active and inactive SLE 
patients compared to healthy controls (Figure 4.11 (C)). Tfh cells, defined as CXCR5+PD-1+ 
CD4+ T cells, were also significantly decreased in active SLE patients compared with healthy 
controls (Figure 4.11 (C)). Inactive SLE patients had a slightly lower percentage of 
CXCR5+PD-1+ Tfh cells but this difference was not significant. Feng et al. (Feng et al., 2012) 
found that CXCR5+PD-1+ Tfh cells in SLE patients were significantly decreased after 
methylprednisone treatment. In our study, we found that patients with active SLE treated 
with prednisone had a more profound decrease in the frequency of CXCR5+PD-1+ Tfh cells 
than inactive SLE patients treated with prednisone (Figure 4.29). Therefore the reduction of 
Tfh cells in active SLE patients could be attributed to treatment with prednisone as the 
majority of patients in our study were treated with prednisone (Table 2.7). 
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We also observed differences in Tfh cell subsets based on the differential expression of 
CXCR3 between SLE patients and controls. SLE patients, as well as disease control subjects, 
had significantly higher percentages of CXCR3- CXCR5+PD-1+ Tfh cells than healthy 
controls (Figure 4.12 (B)). Active SLE patients had a significantly lower proportion of 
CXCR3+ CXCR5+PD-1+ Tfh cells than inactive SLE patients and healthy controls. 
Interestingly, the percentage CXCR3+ CXCR5+PD-1+ Tfh cells was the only significant 
difference between active and inactive SLE patients in our study. The smaller percentage of 
CXCR3+ CXCR5+PD-1+ Tfh cells in active SLE could also be attributed to prednisone 
treatment, as we found that active SLE patients treated with prednisone had a greater 
decrease in the frequency of CXCR3+ CXCR5+PD-1+ Tfh cells expressed as a percentage of 
total CD4+ T cells than inactive SLE patients treated with prednisone (Figure 4.29). 
Bentebibel et al. (Bentebibel et al., 2013) reported an increase of CXCR3+ICOS+CXCR5+ T 
helper cells after influenza vaccination and found that these cells were efficient at helping 
memory B cells differentiate into plasma cells. These CXCR3+ICOS+CXCR5+ T helper cells 
also expressed high levels of PD-1. In contrast, Locci et al. (Locci et al., 2013) found that 
CXCR3-PD-1+CXCR5+ memory Tfh cells more closely resembled GC Tfh cells, and were 
more efficient at providing help to B cells than CXCR3+ CXCR5+ CD4+ T cells, a finding 
also reported previously by Morita et al (Morita et al., 2011). The findings by Locci et al. 
(2013) and Morita et al. (2011) are in line with the fact that CXCR3 expression is associated 
with a Th1 but not Th2 response (Yamamoto et al., 2000, Kim et al., 2001a). As efficient B 
cell helpers it is conceivable that CXCR3- CXCR5+PD-1+ Tfh cells could be the main players 
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in the T-dependent mechanism of B cell autoimmunity in SLE, which could also explain the 
increased CXCR3- CXCR5+PD-1+ Tfh cells in SLE in our study, especially in active SLE. 
 
Although a reduction in Tregs has been shown in animal models of lupus (Wu and Staines, 
2004, Hsu et al., 2006), the evidence in human SLE is not clear, as different studies have 
reported conflicting data with regards to frequency and number of Tregs in SLE patients 
compared with controls. Most studies found a decrease in Tregs in active SLE (Crispin et al., 
2003, Vargas-Rojas et al., 2008, Bonelli et al., 2008a, Bonelli et al., 2008b, Miyara et al., 
2005, Zhang et al., 2008a, Mellor-Pita et al., 2006, Lee et al., 2006, Barreto et al., 2009, 
Habibagahi et al., 2011, Lee et al., 2008, Liu et al., 2004a, Barath et al., 2007a, Barath et al., 
2007b, Yan et al., 2008, Suen et al., 2009, Kim et al., 2012, Ma et al., 2013), while others 
reported an increase in Tregs in SLE (Suarez et al., 2006, Azab et al., 2008, Zhang et al., 
2008b, Vigna-Perez et al., 2006, Yan et al., 2008, Cepika et al., 2007, Ma et al., 2013, 
Vallerskog et al., 2007, Lin et al., 2007a). Some studies found no difference in the level of 
Tregs between SLE patients and controls (Alvarado-Sanchez et al., 2006, Yates et al., 2008, 
Vargas-Rojas et al., 2008, Venigalla et al., 2008, Zhang et al., 2008b, Prado et al., 2013, 
Mesquita et al., 2011). In our study, although active SLE patients had significantly lower 
numbers of CD4+ T cells than healthy controls (Figure 4.9 (A)), patients and controls had 
similar proportions of Tregs (Figure 4.10 (C)), therefore active SLE patients also had 
significantly lower numbers of Tregs. This finding is in line with that in lupus mouse models 
(Wu and Staines, 2004, Hsu et al., 2006) and also the concept that the depletion of Tregs 
results in immune dysregulation and autoimmunity (Bennett et al., 2001, Brunkow et al., 
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2001, Wildin et al., 2001, Fontenot et al., 2003). Several groups subfractionated Tregs into 
naïve and activated subsets. Miyara et al. (Miyara et al., 2009) and Pan et al. (Pan et al., 
2012) found an increase in naïve Tregs in patients with active SLE but Kim et al. (Kim et al., 
2012) found no difference in the ratio of naïve and activated Tregs in patients with SLE 
compared to controls. In contrast, we found that both active and inactive SLE patients had 
significantly lower proportions of naïve Tregs than healthy controls (Figure 4.10 (D)). In 
addition, inactive SLE patients had a significantly lower percentage of naïve CD4+ T cells 
than healthy controls, and active SLE patients also had a smaller proportion of naïve CD4+ T 
cells than healthy controls, but the difference did not reach statistical significance (Figure 4.9 
(D)). A possibility for the contrast in findings in the levels of Tregs in studies with SLE 
patients could be due to the different gating strategies used for identification of Tregs. All of 
the studies from other groups mentioned above identified Tregs as CD25+/hi and/or FoxP3+ 
CD4+ cells, except for Mesquita et al. (Mesquita et al., 2011), who also included the low 
level of expression of CD127 in their definition of Tregs. We identified Tregs as 
CD25+CD127lo CD4+ cells. The groups who have used only CD25 in combination with CD4 
may have included CD25+ conventional CD4+ T cells in their calculation Treg numbers, as 
up to 20% of CD4+ T cells express CD25 (Baecher-Allan et al., 2001, Seddiki et al., 2006b). 
We did not use FoxP3 for the detection of Tregs to avoid fixation and permeabilisation of 
cells and compromising cell number and quality because in some of the patient samples, we 
barely had enough cell numbers for all the cell populations we wanted to study.  
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BAFF has been shown to play an important role in mediating SLE, first suggested by the 
overexpression of BAFF in spontaneous lupus mouse models (Gross et al., 2000, Kahn et al., 
2008) as well as in BAFF-Tg mice (Mackay et al., 1999, Khare et al., 2000). BAFF promotes 
the survival of B cells beyond the transitional T1 stage and allows self-reactive B cells to 
migrate to the normally forbidden follicular and marginal zones, where they are 
inappropriately activated and produce autoantibody (Thien et al., 2004). The evidence for the 
role of BAFF in human SLE is also convincing with numerous studies showing increased 
levels of serum BAFF (Lin et al., 2007b, Pers et al., 2005, Zhang et al., 2001, Cheema et al., 
2001, Stohl et al., 2003, Becker-Merok et al., 2006) and blood BAFF mRNA (Ju et al., 2006, 
Lin et al., 2007b, Stohl et al., 2003) in patients with SLE. It was therefore surprising to find 
that in our study, serum BAFF levels were only slightly elevated in SLE patients compared to 
control subjects, with only three SLE patients having a much higher level of serum BAFF 
than all the other subjects (Figure 4.13). It is possible that these three SLE patients represent 
a separate subset of patients where disease is caused by the excess production of BAFF, 
whereas the immune dysregulation found in the other SLE patients are due to other causes. It 
had been suggested that serum BAFF levels could be reduced with corticosteroid treatment 
(Stohl et al., 2003), which could be the reason for the lack of patients with increased BAFF in 
our cohort. However we found no correlation between serum BAFF levels and dosage of 
prednisone in our study. The data here further promotes the idea that distinct subtypes of SLE 
exist in different patients, with the overproduction of BAFF representing one of the subtypes. 
Interestingly, the two inactive SLE patients with the highest serum BAFF concentration 
(6620pg/ml and 4075 pg/ml, mean inactive SLE 1118 pg/ml) also had the highest and fourth 
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highest frequency of transitional B cells (44.3% and 23.2%, mean inactive SLE 5.7%), 
respectively (Figure 4.3 (E)). This reflects the concept that excess BAFF could provide 
inappropriate survival signals to B cells, promoting the survival of autoreactive B cells. 
 
Several studies have suggested a role for monocytes in the pathogenesis of SLE, but these 
studies have reported contrasting findings in the differences in monocyte subsets in lupus 
patients. Sumegi et al. (Sumegi et al., 2005) found that monocytes expressing CD16 were 
increased in both active and inactive SLE patients. In contrast, Cairns et al. (Cairns et al., 
2002) did not find a difference in the frequency of CD16+ monocytes between SLE patients 
and controls. More recently, Burbano et al. (Burbano et al., 2014) reported an increase in 
classical monocytes, a decrease in non-classical monocytes but no difference in intermediate 
monocytes in active SLE patients. In our study, we observed only minor differences in the 
total number of monocytes and proportion of monocyte subsets between SLE patients and 
control subjects. Approximately half of the samples in our study did not have a clearly 
identifiable CD14dim monocyte population so CD14dim monocytes were included in the 
CD16+ monocyte population in our calculations. Healthy individuals had fewer monocytes 
overall than patients with SLE and other autoimmune conditions (Figure 4.6 (A)), and active 
SLE patients have a higher proportion of classical monocytes and relatively fewer CD16+ 
monocytes than inactive SLE patients and controls, but these differences were not significant 
(Figure 4.6 (C) and (D)). A decrease in CD14dim monocytes was also observed in active SLE 
patients but not inactive SLE patients and controls, and once again, the decrease was not 
significant (Figure 4.7 (B)). Sumegi et al. (Sumegi et al., 2005) found that glucocorticoid 
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treatment caused a decrease in non-classical monocytes and an increase in classical moncytes 
in SLE patients. However, we found no correlation between dosage of prednisone and 
percentages of any of the monocyte subsets in our study. Yoshimoto et al. (Yoshimoto et al., 
2007) found an increased infiltration of CD16+ monocytes in the glomerular vessels of active 
lupus nephritis patients. Similarly in our study, the minor reduction of CD16+ monocytes, 
which includes CD14dim monocytes, in active SLE patients could be explained by the 
possibility that in active SLE patients with renal manifestations (30% of all active SLE 
patients included in this analysis), CD16+ monocytes may have exited the periphery and these 
patients could have a higher proportion of CD16+ monocytes in the sites of tissue damage. 
 
Most studies have found a decrease in NK cells (Hervier et al., 2011, Henriques et al., 2013, 
Schleinitz et al., 2009, Puxeddu et al., 2012, Park et al., 2009, Riccieri et al., 2000, Erkeller-
Yuksel et al., 1997, Erkeller-Yusel et al., 1993) but no differences in the proportion of NK 
cells subsets in SLE patients (Hervier et al., 2011, Henriques et al., 2013, Schleinitz et al., 
2009). In contrast, Schepis et al. (Schepis et al., 2009) reported that overall there were no 
differences in total number of NK cells but the proportion of CD56briCD16- NK cells were 
increased in patients with SLE. It has been suggested that CD56briCD16- NK cells could be 
considered to be a regulatory subset because of their ability to secrete IL-10 (Deniz et al., 
2008) and their involvement in enhancing the function of cells (Roncarolo et al., 1991, 
Zingoni et al., 2004, Hanna et al., 2004, Byrne et al., 2004, Morandi et al., 2006, Martin-
Fontecha et al., 2004, Gerosa et al., 2002, Piccioli et al., 2002, Della Chiesa et al., 2003) and 
the inhibition of autoreactive cells (Della Chiesa et al., 2003, Takeda and Dennert, 1993, Lu 
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et al., 2007). Therefore, any aberrations in the number or function of CD56briCD16- NK cells 
could potentially result in the development of autoimmunity. Similar to most of the previous 
investigations of NK cells in SLE, we found that the total number of NK cells was 
significantly lower in SLE patients compared to healthy controls (Figure 4.8 (B)), but we also 
found that SLE patients had a significantly higher proportion of CD56briCD16- NK cells and 
relatively fewer CD56dimCD16+ NK cells than healthy controls (Figure 4.8 (C) and (D)). 
Although we found that SLE patients treated with azathioprine had a significant reduction in 
total NK cells and the CD56dimCD16+ NK subset (Figure 4.24), azathioprine treatment could 
not fully account for the decrease in CD56dimCD16+ NK cells and relative increase in 
CD56briCD16- NK cells because only 13% of SLE patients in our study were treated with 
azathioprine (Table 2.7). An increase in CD56briCD16- NK cells could possibly lead to 
enhanced SLE autoantibody production, as the excess CD56briCD16- NK cells could promote 
autoantigen presentation by DCs. However, this contradicts the notion that CD56briCD16- 
NK cells act as a regulatory subset that prevents autoimmunity through the killing of 
autoreactive cells. Further research is required to understand the role of CD56briCD16- NK 
cells in SLE. In addition, there were very low percentages of the rare CD56-CD16+ NK cell 
subset in all of the subjects as expected, with the exception of two patients with Sjögren’s 
Syndrome (Figure 4.8 (E)). It would be interesting to review the clinical history of these two 
patients and see if they have had any viral infections or other conditions which could have 
led to the expansion of the CD56-CD16+ NK cell subset, and also extend the investigation to 
a larger cohort of patients to see if this phenomenon occurs in any other patients with 
Sjögren’s Syndrome. 
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We collected four samples from SLE Patient 2. Three of the samples were from September 
2008, when the patient was hospitalised with severely active SLE. The patient had a SLEDAI 
score of 30 at those three time points. The last sample collected from this patient was from 
September 2011, when the patient’s condition had markedly improved. The patient’s 
SLEDAI at the fourth time point was 4. We reviewed this patient’s medical records again and 
found that he had been treated with epratuzumab, a humanised anti-CD22 mAb, in addition 
to prednisone, hydroxychloroquine, mycophenolate and intragram. The unusual appearance 
of the patient’s B cell profile, consisting of several distinct B cell populations with different 
levels of expression of CD19 (Figure 4.16), as well as the expansion of the switched and MZ 
memory B cell subsets and the depletion of the naïve and transitional memory B cells (Figure 
4.15) were attributed to treatment with epratuzumab, which preferentially targets CD27- B 
cells (Jacobi et al., 2008a). The CD27- subsets, which includes transitional, naïve and 
atypical memory B cells, started to reappear while the MZ memory B cells decreased as the 
patient’s condition improved.  
 
The proportion of CD14+CD16- monocytes in Patient 2 remained almost unchanged during 
the three years (Figure 4.17 (C)). Although the proportion of CD16+ monocytes was similar 
in the three years, there was a reduction in the CD14dim subset with a relative increase in the 
CD14+CD16+ subset at the fourth time point (Figure 4.17 (A)). The total number of 
monocytes was replenished at the fourth time point (Figure 4.17 (D)), accounting for the 
increase in leukocyte numbers and correlating with a decrease in disease activity. The 
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frequency of CD56briCD16- NK cells increased, with a relative decrease of the 
CD56dimCD16+ NK subset, as the patient’s condition improved (Figure 4.17 (E)). This 
finding is opposite to what we would have expected. We found that proportion of 
CD56briCD16- NK cells was significantly higher in SLE patients than disease controls and 
healthy controls and vice versa in our analysis with all other SLE patients (Figure 4.8 (C) and 
(D)), therefore we would have expected a decrease in CD56briCD16- NK cells as Patient 2 
improved.  
 
There were small fluctuations in the absolute number of CD4+ T cells in Patient 2 over the 
three years (Figure 4.14 (B)), with a higher proportion of CD45RO- than CD45RO+ cells at 
all four time points (Figure 4.18 (E)). This was opposite to what we observed in the other 
SLE patients in our cohort as they had significantly higher proportions of CD45RO+ cells 
compared to healthy controls (Figure 4.9 (D)). The majority of Tregs in Patient 2’s samples 
were CD45RO+ (Figure 4.18 (E)), which is what we found in the other SLE patients in our 
study (Figure 4.10 (D)). There was a slight increase in Tregs at the fourth time point when 
the patient’s condition improved (Figure 4.18 (E) and (F)). Unexpectedly, there was a 
reduction of all CXCR5-expressing populations at the last time point when the patient’s 
disease activity decreased (Figure 4.19 (D) and (E)). This is in contrast to what we observed 
overall in the other SLE patients, where active SLE patients had significantly fewer CXCR5+ 
cells than healthy controls, and also fewer compared with inactive SLE and disease controls 
although the difference was not significant (Figure 4.11 (C)). This unexpected finding 
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supports the idea that the overabundant Tfh cells drive the B cell dysregulation and 
autoimmunity in Patient 2, representing one of the many subtypes of SLE. 
 
Longitudinal studies were conducted on the samples from four other SLE patients. Some 
expected findings were observed in some patients. For example, changes in the frequency of 
switched memory B cells were inversely proportional to changes SLEDAI score in Patients 5 
(Figure 4.20 (B)), 6 (Figure 4.21 (B)) and 8 (Figure 4.22 (B)) but not 40 (Figure 4.23 (B)). 
We had previously observed that the proportion of switched memory B cells was higher in 
inactive SLE (mean 19.09%) than active SLE (mean 17.08%) in our analysis of samples from 
every patient (Figure 4.4 (D)). The increase in the percentage of CD56briCD16- NK cells and 
a relative reduction in CD56dimCD16+ NK cells with a higher SLEDAI score was seen only 
in Patient 5 (Figure 4.20 (D)) but not Patients 6 (Figure 4.21 (D)), 8 (Figure 4.22 (D)) or 40 
(Figure 4.23 (D)). The proportion of CD56briCD16- NK cells was higher and CD56dimCD16+ 
NK cells lower in patients with active SLE (CD56briCD16- mean 18.99%, CD56dimCD16+ 
mean 78.60%) compared with inactive SLE (CD56briCD16- mean 16.23%, CD56dimCD16+ 
mean 81.15%) in our analysis with samples from every patient (Figure 4.8 (C, D)). The 
absolute number of transitional B cells and total NK cells were greatly decreased at time 
points 5 to 7 in Patient 8 (Figure 4.22 (A, B)), which were the three time points when the 
patient was treated with azathioprine. We found that SLE patients treated with azathioprine 
had significantly fewer transitional B cells and NK cells when analysing the effects of 
different medications on peripheral blood cell populations and other variables we measured 
in the study (Figure 4.24). 
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However, most of the fluctuations in number and percentage of peripheral cell subsets and 
serum BAFF levels did not reflect what we had found in our analysis of samples from every 
patient, and these fluctuations did not correspond to changes in SLEDAI or treatment. For 
example, we would have expected the frequency of Tregs to remain mostly unchanged 
regardless of changes in SLEDAI (Figure 4.10 (C)), but we observed increases and decreases 
in the frequency of Tregs in Patient 5 over the 8 time points (Figure 4.20 (E)). There was an 
increase in disease activity in the patient from time points 2 to 6, but the changes in Treg 
percentage did not correspond to the changes in SLEDAI scores. The SLEDAI score of 
Patient 5 increased from 2 to 20 from the first to the second time point, and there was a huge 
increase in the proportion of all CXCR5+ populations at the second time point (Figure 4.20 
(F)). Based on our analysis with samples from all SLE patients, we would have expected a 
reduction of CXCR5+ CD4+ T cells and CXCR5+PD-1+ Tfh cells with an increase in disease 
activity (Figure 4.11 (C)), but the opposite occurred with Patient 5. The increase in the 
frequency of Tfh cells in Patient 5 at the second time point could be because the patient was 
not treated with prednisone. However there was a gradual increase in Tfh cells at time points 
3 to 7 even though the patient was taking prednisone throughout these time points, which is 
in contrast to our finding that patients treated with prednisone have a lower frequency of Tfh 
cells (Figure 4.29). Patient 40 had a low number of NK cells and a low proportion of 
transitional B cells during the first three time points (Figure 4.23 (A, B)), which was when 
the patient was medicated with azathioprine. This was followed by an increase in NK cell 
number and a huge increase in the percentage of transitional B cells at time point 4, when the 
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patient was no longer on azathioprine. The changes in NK cells and transitional B cells were 
expected in relation to treatment with azathioprine during the first four time points, as we 
found that azathioprine treatment significantly lowers NK cell number and frequency of 
transitional B cells as a percentage of total B cells (Figure 4.24). However, there was massive 
reduction in the frequency of transitional B cells at time point 5 and the frequency remained 
low for the remaining time points even though the patient was not treated with azathioprine 
from time point 4 onwards. Even though plasmablasts and plasma cell numbers were greatly 
increased at time point 8 in Patient 5, plasmablast and plasma cell numbers were similar 
when Patient 5 was not treated with mycophenolate (time points 1-4) compared to when the 
patient was treated with mycophenolate (time points 5-7) (Figure 4.20 (B)). Patient 40 had 
very low numbers of plasmablasts and plasma cells at time points 1-2, when the patient was 
not treated with mycophenolate, and similarly low numbers of plasmablasts and plasma cells 
at time points 5-6 (during and after mycophenolate treatment) (Figure 4.23 (B)). Therefore 
we cannot conclude that mycophenolate treatment led to the reduction of plasmablast and 
plasma cell numbers. 
 
It is important to note that we had not considered the differences in organ involvement of 
each patient in our initial analysis, which could possibly explain the differences in the 
perturbations of peripheral cell subsets seen in different patients. This will be addressed later 
in this section. 
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There was a massive reduction in the absolute number of all cell populations at time point 5 
for Patient 8 (Figure 4.22). Although it appeared that the introduction of azathioprine 
treatment could account for the decrease in cell number at time point 5, this massive 
reduction in cell number was not seen in Patient 6, who was also treated with azathioprine 
(Figure 4.21). Instead, we believe the decrease in cell number was due to a problem with an 
older model of the Sysmex automated haematology analyser, which unfortunately gave us an 
inaccurate full blood count reading. The white cell count for Patient 8 at all other time points 
ranged from 5.5-7.2 x 106/ml but at time point 5 it was only 0.2 x 106/ml. 
 
To determine whether or not different subtypes of SLE exist, statistical analyses with the 
complete data set were performed. Briefly, differences in the levels of peripheral blood cell 
populations and serum BAFF we had found in SLE were considered together with SLEDAI 
scores, organ involvement and other clinical measurements including the levels of anti-
dsDNA antibody, complement, ESR, CRP and full blood count. Every sample collected from 
every patient and control subject were included, and any data we had not collected at any 
time point were imputed. Although previous studies had investigated differences in the 
number or phenotype of a particular cell population in SLE, few groups have studied B cells, 
monocytes, NK cells, Tregs and Tfh cells altogether in relation to other aspects of SLE in a 
single study. 
 
PCA was performed on the complete data set. The first two principal components consisted 
of many of the cell populations which we found were different in frequency or absolute 
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number between SLE patients and controls when only one sample per subject was included 
in the analysis. These were atypical memory B cells, total NK cells, CD45RO+ CD4+ T cells, 
CD45RO+ Tregs and the CXCR5+ cell populations (Table 4.7). The inclusion of transitional 
B cells, CD56-CD16+ NK cells and the CD16-expressing monocyte subsets was unexpected 
because we found that the percentages of these populations were similar between SLE 
patients and controls in our previous analysis. There were three variables included in the first 
two principal components were not measured by flow cytometry – anti-dsDNA antibody, 
CRP and ESR. It is not surprising that these variables were included because the presence of 
anti-dsDNA antibody is specific to SLE (Pisetsky, 2000) while elevated CRP and ESR are 
non-specific markers of inflammation (Pepys and Baltz, 1983, ICSH, 1988). Samples from 
SLE patients could be separated from healthy control samples using PCA (Figure 4.30 (A)). 
When patient and control samples were grouped in the same manner as our previous analysis, 
i.e. active SLE, inactive SLE, disease controls and healthy controls, or when SLE patients 
were grouped according to different degrees of disease severity as determined by the PGA 
(Figure 1.1), i.e. inactive, mild, moderate or severe activity, PCA could not separate samples 
from these groups (Figure 4.30 (B) and (C)). Furthermore, PCA was unable to separate 
patient samples based on organ involvement (Figure 4.31). The findings from the PCA 
analysis strongly suggests that although the composition of peripheral blood cells is different 
between SLE patients and those without SLE, there are no different subtypes of SLE as we 
had hypothesised based on the findings from our previous analysis including one sample per 
subject only. 
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Although we could not distinguish between inactive, mildly, moderately or severely active 
SLE patients using PCA, we found that a number of the variables we had measured were 
associated with SLEDAI scores, a quantifiable measure of disease activity based on the 
symptoms experienced by a patient at any one time. When including samples from SLE 
patients from all time points, the numbers of total NK cells and CD56dimCD16+ NK cell 
subset, CD45RO+ CD4+ T cells, CXCR5+PD-1+ Tfh cells and subsets, C3 and C4 levels, 
haemaglobin and red cell count were significantly associated with SLEDAI scores (Figure 
4.32). The flow cytometric variables identified here were what we had previously observed to 
be significantly different between SLE patients and controls (Figures 4.8, 4.9, 4.11 and 4.12). 
Low complement levels and haemolytic anaemia have been included many of the lists of 
diagnostic criteria or disease activity assessment for SLE (Figure 1.1, Tables 1.2, 1.3, 1.4, 
1.5, 1.7), so it is not surprising that C3 and C4 levels, haemoglobin and red cell count were 
found to be associated with SLEDAI scores. When including only the first sample from each 
SLE patient in the analysis, there were fewer variables that were significantly associated with 
SLEDAI as expected, because of a smaller sample size. These variables were the frequency 
as a percentage of total CD4+ T cells of CD45RO+ CD4+ T cells, CXCR5+PD-1+ Tfh cells 
and CXCR3- CXCR5+PD-1+ Tfh cells and C3 and C4 levels (Figure 4.33). As we had found 
a number of variables that were significantly associated with SLEDAI scores, we then 
performed penalised regression on the complete data set and proposed a model for the 
prediction of SLEDAI, as described in 4.5.8 Model for the Prediction of SLEDAI. 
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Over half of the variables that we have measured were able to significantly discriminate 
between SLE patients and healthy controls, whether we included samples from all time 
points or only samples from the first time point in our analysis (Tables 4.10 and 4.11). This 
was not an unexpected finding because PCA could only separate samples from SLE patients 
and those from healthy controls but could not distinguish between any of the other response 
types. Likewise, none of the variables we have measured could significantly differentiate 
active and inactive SLE patients. When including samples from all time points, the variables 
that were most able to distinguish between SLE patients and healthy controls were mostly the 
variables of the first two components in the PCA – percentages of atypical memory B cells, 
total NK cells and the two main NK cell subsets, CD4+ T cells and CD45RO- CD4+ T cells, 
and Tfh cells and subsets (Figure 4.34). When including samples only from the first time 
point, only the percentages of CD45RO- populations and CXCR5+ cells could separate SLE 
patients and healthy controls at a similar level of significance (Figure 4.35), the fewer 
variables explained by the fewer samples in total included in the analysis. As PCA and many 
of the variables we have measured were able to distinguish the response types SLE and 
healthy (i.e. no SLE), we then performed penalised logistic regression on the complete data 
set and proposed a model to predict if an individual has SLE or not, as described in 4.5.9 
Model for Predicting Whether an Individual has SLE or Not. 
 
Although PCA could not separate SLE patients from patients with other autoimmune 
conditions, we found that the numbers and proportions of NK cell subsets could significantly 
discriminate between these two response types (Figure 4.36), which was similar to what we 
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had found in our previous analysis (Figure 4.8). It must be noted that SLE patients were not 
age-matched with disease control subjects in this study as indicated on Table 2.1 (SLE mean 
age 39.9 years, disease control mean age 54.9 years), therefore the finding that the age at 
time of sample collection could discriminate between these two groups simply reflects the 
age difference between these two groups. 
 
As we found that PCA could not separate SLE patients based on organ involvement, we did 
not expect any of the variables we have measured to be able to distinguish between patients 
based on organ involvement either. Indeed, none of the variables could identify patients with 
musculoskeletal or cutaneous symptoms from those who did not experience these symptoms. 
This is most likely due to class imbalance, as few patients in our cohort had musculoskeletal 
or cutaneous symptoms (Table 2.10). Surprisingly, we found that the numbers of several rare 
cell populations – transitional B cells, CD14dim monocytes, CD56-CD16+ NK cells and 
basophils – could significantly discriminate patients with neurologic symptoms and those 
without neurologic symptoms (Figure 4.37). However, we interpret this finding with caution 
because of the very small number of patients with neurologic involvement in our cohort. In 
addition, we found one variable which could significantly separate SLE patients with renal 
symptoms from those who did not – frequency of CD45RO+ CD4+ T cells expressed as a 
percentage of live cells (Figure 4.38). We subsequently performed penalised logistic 
regression on the complete data set and proposed a model to predict if a patient with SLE has 
renal symptoms or not, as described in 4.5.10 Model for Predicting if a Patient with SLE 
has Renal Symptoms. 
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Overall, the findings from our study do not support the concept that there are different 
subtypes of human SLE based on the immune process driving the disease. Although our 
initial analysis of the differences in the peripheral blood cell populations between SLE 
patients and controls suggested the possibility of several subtypes, namely increased 
transitional B cells, increased plasmblasts and plasma cells and a third subtype with increased 
serum BAFF, subsequent analyses with the complete data set taking into account SLEDAI, 
organ involvement and other clinical measures showed that there are no individual signatures 
of SLE as indicated by perturbations of a particular cell population. We could classify which 
subjects had SLE or not with the variables we have measured but these variables were not 
able to distinguish SLE patients with different degrees of disease severity as determined by 
the PGA, nor were any the variables associated with musculoskeletal, neurologic or 
cutaneous symptoms. However, we were able to propose a model to predict whether a patient 
with SLE has renal or symptoms or not that incorporates the measurement of percentages of 
transitional B cells and CD45RO+ CD4+ T cells. We have also developed models 
incorporating many of the variables we have measured to predict a patient’s SLEDAI score, 
and whether an individual has SLE or not. The current study could possibly be strengthened 
with a higher number of active SLE patients and more patients with different organ 
involvement and other autoimmune conditions to remove the problem of class imbalance and 
to validate trends observed in this study. The models we have developed for predicting if an 
individual has SLE, predicting if an SLE patient has renal involvement and predicting 
SLEDAI form a basis for improved methods for the diagnosis and assessment of the severity 
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of SLE in the future. The design of future antibody panels would reflect the advances in flow 
cytometry and mass cytometry technology, such as the Cytometry by Time of Flight 
(CyTOF), which would enable, at present, the detection of 40 markers simultaneously. The 
three eight-colour panels we have used in the present study could be combined into one, and 
we could even include additional markers to improve the discrimination of certain cell 
populations (e.g. the inclusion of CD138 to distinguish between plasmablasts and plasma 
cells) and markers of cell populations we were not able to investigate in the present study as 
we did not have enough PBMCs from patient samples, e.g. NKT cells. A reduction of NKT 
cells and defects in NKT cell function has been reported in SLE patients (Cho et al., 2011, 
van der Vliet et al., 2001, Kojo et al., 2001, Oishi et al., 2001) while NKT cell numbers were 
found to be correlated with SLEDAI in one study (Cho et al., 2011), and there is increasing 
evidence that NKT cells have a role in immunoregulation in SLE, including maintaining the 
balance between Th1 and Th2 responses and the suppression of autoantibody production, 
which is highlighted in the review by Chen et al. (Chen et al., 2015). Improvement in data 
analysis software would allow for the automated analysis of cell populations which would be 
beneficial in increasing efficiency and accuracy in the diagnosis and assessment of SLE. 
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